[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is also known as:\n1. Acrokeratosis paraneoplastic syndrome\n2. Acrokeratosis of the nipple\n3. Benign acrokeratosis\n4. Benign acrokeratosis of the nipple\n5. Paraneoplastic acrokeratosis\n6. Paraneoplastic acrokeratosis of the nipple\n7. Paget's acrokeratosis\n8. Paget's acrokeratosis of the nipple\nPlease note that these synonyms may not be mutually exclusive, and there may be other synonyms or alternative terms used in different contexts or by different authors.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastic syndrome is a synonym for Acrokeratosis paraneoplastica.\n2. Acrokeratosis of the nipple is a synonym for Acrokeratosis paraneoplastica.\n3. Benign acrokeratosis is a synonym for Acrokeratosis paraneoplastica.\n4. Paraneoplastic acrokeratosis is a synonym for Acrokeratosis paraneoplastica.\n5. Paget's acrokeratosis is a synonym for Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastic syndrome is a synonym for Acrokeratosis paraneoplastica.",
      "Acrokeratosis of the nipple is a synonym for Acrokeratosis paraneoplastica.",
      "Benign acrokeratosis is a synonym for Acrokeratosis paraneoplastica.",
      "Paraneoplastic acrokeratosis is a synonym for Acrokeratosis paraneoplastica.",
      "Paget's acrokeratosis is a synonym for Acrokeratosis paraneoplastica."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Acrokeratosis of the nipple is not a synonym for Acrokeratosis paraneoplastica. It is a distinct condition also known as nipple eczema or dermatitis of the nipple.\n3. FALSE [correction]: Benign acrokeratosis, also known as acrokeratosis verruciformis, is a different condition from Acrokeratosis paraneoplastica.\n4. TRUE\n5. FALSE [correction]: Paget's acrokeratosis is not a recognized medical term. Paget's disease is a separate condition affecting the bones, and there is also extramammary Paget's disease, which is a rare skin condition. Neither should be confused with Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both rare genetic disorders that can cause developmental delays and intellectual disability, among other symptoms. However, they are distinct conditions with some differences in their clinical features and genetic causes.\nSimilarities between Weaver syndrome and Sotos syndrome:\n1. Developmental delays and intellectual disability: Both conditions can cause delays in cognitive and motor development, as well as intellectual disability.\n2. Growth retardation: Children with both conditions may experience slowed growth and short stature.\n3. Distinctive facial features: Both conditions can cause distinctive facial features, such as a small head, narrow eyes, and a flat nasal bridge.\nDifferences between Weaver syndrome and Sotos syndrome:\n1. Genetic cause: Weaver syndrome is caused by mutations in the PHACTR1 gene, while Sotos syndrome is caused by mutations in the NSD1 gene.\n2. Prevalence: Sotos syndrome is much more common than Weaver syndrome, with an estimated prevalence of 1 in 100,000 to 1 in 20,000, while Weaver syndrome is much less common, with an estimated prevalence of 1 in 100,000 to 1 in 50,000.\n3. Age of onset: The symptoms of Weaver syndrome typically become apparent in the first year of life, while Sotos syndrome can be diagnosed at any age, but typically becomes apparent in the first few years of life.\n4. Additional symptoms: Weaver syndrome can also cause additional symptoms such as congenital heart defects, hearing loss, and vision problems, while Sotos syndrome can cause a wider range of symptoms, including seizures, delayed speech and language development, and behavioral problems.\nIn summary, while Weaver syndrome and Sotos syndrome share some similarities, they are distinct conditions with different genetic causes, prevalence, age of onset, and clinical features. A thorough clinical evaluation and genetic testing are necessary for accurate diagnosis and appropriate management of these rare genetic disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome and Sotos syndrome are both rare genetic disorders that can cause developmental delays and intellectual disability.\n2. Weaver syndrome is caused by mutations in the PHACTR1 gene, while Sotos syndrome is caused by mutations in the NSD1 gene.\n3. Sotos syndrome has an estimated prevalence of 1 in 100,000 to 1 in 20,000, which is more common than Weaver syndrome's estimated prevalence of 1 in 100,000 to 1 in 50,000.\n4. Symptoms of Weaver syndrome typically become apparent in the first year of life, whereas Sotos syndrome symptoms typically become apparent in the first few years of life.\n5. Weaver syndrome can cause additional symptoms such as congenital heart defects, hearing loss, and vision problems, while Sotos syndrome can cause symptoms including seizures, delayed speech and language development, and behavioral problems.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome and Sotos syndrome are both rare genetic disorders that can cause developmental delays and intellectual disability.",
      "Weaver syndrome is caused by mutations in the PHACTR1 gene, while Sotos syndrome is caused by mutations in the NSD1 gene.",
      "Sotos syndrome has an estimated prevalence of 1 in 100,000 to 1 in 20,000, which is more common than Weaver syndrome's estimated prevalence of 1 in 100,000 to 1 in 50,000.",
      "Symptoms of Weaver syndrome typically become apparent in the first year of life, whereas Sotos syndrome symptoms typically become apparent in the first few years of life.",
      "Weaver syndrome can cause additional symptoms such as congenital heart defects, hearing loss, and vision problems, while Sotos syndrome can cause symptoms including seizures, delayed speech and language development, and behavioral problems."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Weaver syndrome is caused by mutations in the EZH2 gene, not the PHACTR1 gene.\n3. UNKNOWN: Without specific prevalence data for Weaver syndrome, it's difficult to confirm the accuracy of the comparison.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Joint Annotation Symphony Protein-Protein Annotation Resource) is a database of protein-protein interaction (PPI) networks that has been released in several versions over the years. Here are the releases of the JASPAR database:\n1. JASPAR Release 1.0 (2003): This was the first release of the JASPAR database, which contained protein-protein interaction data for 1,321 proteins from 12 organisms.\n2. JASPAR Release 2.0 (2006): This release expanded the database to include interactions for 3,157 proteins from 24 organisms, and introduced a new scoring function for predicting protein-protein interactions.\n3. JASPAR Release 3.0 (2010): This release added data for an additional 1,500 proteins, bringing the total number of proteins in the database to 4,657. It also introduced a new algorithm for predicting protein-protein interactions.\n4. JASPAR Release 4.0 (2013): This release added data for 2,300 proteins from 30 organisms, and improved the accuracy of the interaction predictions using a new scoring function.\n5. JASPAR Release 5.0 (2016): This release added data for 3,000 proteins from 40 organisms, and introduced a new feature for predicting protein-protein interactions in complexes.\n6. JASPAR Release 6.0 (2019): This release added data for 4,000 proteins from 50 organisms, and improved the accuracy of the interaction predictions using a new scoring function.\n7. JASPAR Release 7.0 (2022): This is the latest release of the JASPAR database, which contains data for 5,000 proteins from 60 organisms. It also includes a new feature for predicting protein-protein interactions in the context of disease.\nEach release of the JASPAR database has improved upon the previous one in terms of the number of proteins included, the accuracy of the interaction predictions, and the features available for analyzing protein-protein interactions.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR Release 1.0 was released in 2003 with protein-protein interaction data for 1,321 proteins from 12 organisms.\n2. JASPAR Release 2.0 was released in 2006 and included interactions for 3,157 proteins from 24 organisms.\n3. JASPAR Release 3.0 was released in 2010 and added data for an additional 1,500 proteins, totaling 4,657 proteins in the database.\n4. JASPAR Release 4.0 was released in 2013 and added data for 2,300 proteins from 30 organisms.\n5. JASPAR Release 7.0 was released in 2022 and contains data for 5,000 proteins from 60 organisms.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR Release 1.0 was released in 2003 with protein-protein interaction data for 1,321 proteins from 12 organisms.",
      "JASPAR Release 2.0 was released in 2006 and included interactions for 3,157 proteins from 24 organisms.",
      "JASPAR Release 3.0 was released in 2010 and added data for an additional 1,500 proteins, totaling 4,657 proteins in the database.",
      "JASPAR Release 4.0 was released in 2013 and added data for 2,300 proteins from 30 organisms.",
      "JASPAR Release 7.0 was released in 2022 and contains data for 5,000 proteins from 60 organisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: JASPAR is a database of transcription factor binding profiles, not protein-protein interaction data. Release 1.0 was released in 2004, not 2003.\n2. UNKNOWN: While JASPAR Release 2.0 was indeed released, the statement about the number of proteins and organisms is not verifiable without specific reference to JASPAR's content, which primarily deals with transcription factor DNA-binding motifs, not protein interactions.\n3. UNKNOWN: The release year and the specific details about the number of proteins added in JASPAR Release 3.0 cannot be verified without the correct reference. Additionally, JASPAR focuses on transcription factor binding profiles, not protein-protein interactions.\n4. UNKNOWN: The release year and the details about the number of proteins and organisms for JASPAR Release 4.0 cannot be verified without the correct reference. JASPAR's focus is on transcription factor binding profiles.\n5. UNKNOWN: The release year and the details about the number of proteins and organisms for JASPAR Release 7.0 cannot be verified without the correct reference. Additionally, the focus of JASPAR is on transcription factor binding profiles, not protein-protein interactions.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a protein that is encoded by the KP4 gene in the human genome. It is a viral protein that is produced by certain viruses, including the human T-lymphotropic virus type 1 (HTLV-1) and the human immunodeficiency virus type 1 (HIV-1).\nThe KP4 protein has been shown to have a number of different functions, including:\n1. Inhibition of immune cell activation: The KP4 protein can inhibit the activation of immune cells, such as T cells and macrophages, which are important in the immune response.\n2. Inhibition of interferon production: The KP4 protein can inhibit the production of interferon, a protein that is produced by cells in response to the presence of viruses. Interferon plays a key role in the immune response by activating immune cells and inducing the production of antiviral proteins.\n3. Inhibition of apoptosis: The KP4 protein can inhibit the programmed cell death (apoptosis) of infected cells, which allows the virus to persist and continue to replicate.\n4. Modulation of the immune response: The KP4 protein can modulate the immune response by suppressing the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), and increasing the production of anti-inflammatory cytokines, such as interleukin-10 (IL-10).\n5. Inhibition of viral replication: The KP4 protein can also inhibit the replication of certain viruses, including HIV-1, by interacting with viral proteins and preventing their assembly or integration into host cells.\nOverall, the KP4 protein is an important viral protein that plays a key role in the replication and survival of certain viruses by modulating the immune response and inhibiting the production of antiviral proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is encoded by the KP4 gene in the human genome.\n2. The KP4 protein is produced by viruses such as the human T-lymphotropic virus type 1 (HTLV-1) and the human immunodeficiency virus type 1 (HIV-1).\n3. The KP4 protein can inhibit the activation of immune cells like T cells and macrophages.\n4. The KP4 protein can inhibit the production of interferon, which is involved in the immune response to viruses.\n5. The KP4 protein can inhibit the programmed cell death (apoptosis) of infected cells.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is encoded by the KP4 gene in the human genome.",
      "The KP4 protein is produced by viruses such as the human T-lymphotropic virus type 1 (HTLV-1) and the human immunodeficiency virus type 1 (HIV-1).",
      "The KP4 protein can inhibit the activation of immune cells like T cells and macrophages.",
      "The KP4 protein can inhibit the production of interferon, which is involved in the immune response to viruses.",
      "The KP4 protein can inhibit the programmed cell death (apoptosis) of infected cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The KP4 protein is not encoded by the human genome; it is a fungal protein produced by Ustilago maydis, a type of smut fungus.\n2. FALSE [correction]: The KP4 protein is not produced by viruses such as HTLV-1 or HIV-1; it is produced by the Ustilago maydis fungus.\n3. UNKNOWN: Without specific context or scientific literature, it is unclear whether the KP4 protein from Ustilago maydis has the ability to inhibit the activation of immune cells like T cells and macrophages in humans.\n4. UNKNOWN: Similarly, it is unclear whether the KP4 protein can inhibit the production of interferon without additional context or references to scientific studies.\n5. UNKNOWN: There is no clear information provided about the KP4 protein's ability to inhibit apoptosis of infected cells, so this statement cannot be confirmed or corrected without further context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (1,1-diethyl-2,3-bis(methylsulfonyl)propane) is a thyroid hormone analog that has been utilized in both experimental and clinical studies. DITPA is a synthetic compound that mimics the action of triiodothyronine (T3), a thyroid hormone that plays a crucial role in regulating metabolism, growth, and development.\nExperimental studies have shown that DITPA can stimulate the uptake and oxidation of glucose in various tissues, including the liver, muscle, and adipose tissue, leading to increased glucose metabolism and improved insulin sensitivity. DITPA has also been shown to improve cardiovascular function in animal models of heart failure and to reduce body weight in obese animals.\nIn clinical studies, DITPA has been investigated as a potential treatment for various metabolic disorders, including type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). For example, a phase II clinical trial published in 2017 found that DITPA treatment improved glucose tolerance and insulin sensitivity in patients with type 2 diabetes. Another study published in 2020 found that DITPA reduced body weight and improved metabolic parameters in patients with NAFLD.\nHowever, it is important to note that DITPA has also been associated with potential side effects, including an increased risk of heart problems and bone loss. As a result, DITPA is typically used in clinical settings under close medical supervision, and its long-term safety and efficacy are still being studied.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA (1,1-diethyl-2,3-bis(methylsulfonyl)propane) is a thyroid hormone analog used in experimental and clinical studies.\n2. DITPA mimics the action of triiodothyronine (T3), a thyroid hormone.\n3. A phase II clinical trial published in 2017 found that DITPA treatment improved glucose tolerance and insulin sensitivity in patients with type 2 diabetes.\n4. A study published in 2020 found that DITPA reduced body weight and improved metabolic parameters in patients with non-alcoholic fatty liver disease (NAFLD).\n5. DITPA has been associated with potential side effects, including an increased risk of heart problems and bone loss.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA (1,1-diethyl-2,3-bis(methylsulfonyl)propane) is a thyroid hormone analog used in experimental and clinical studies.",
      "DITPA mimics the action of triiodothyronine (T3), a thyroid hormone.",
      "A phase II clinical trial published in 2017 found that DITPA treatment improved glucose tolerance and insulin sensitivity in patients with type 2 diabetes.",
      "A study published in 2020 found that DITPA reduced body weight and improved metabolic parameters in patients with non-alcoholic fatty liver disease (NAFLD).",
      "DITPA has been associated with potential side effects, including an increased risk of heart problems and bone loss."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific references to the clinical trials and studies mentioned in statements 3, 4, and 5, it is not possible to verify the accuracy of these claims. Therefore, the truthfulness of these statements remains unknown based on the information provided.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "COUGER (COmputational UniVerse Gene Regulatory) is a computational tool used in bioinformatics and systems biology to predict the regulatory elements in a given DNA sequence. It is designed to identify potential transcription factor binding sites, enhancers, and other regulatory elements that can affect gene expression.\nCOUGER uses a combination of machine learning algorithms and structural bioinformatics techniques to analyze the DNA sequence and predict the presence of regulatory elements. It can be used to analyze genomic sequences from a wide range of organisms, including humans, and can be applied to a variety of research questions, including understanding the regulation of gene expression, identifying potential drug targets, and developing personalized medicine approaches.\nSome of the key features of COUGER include:\n1. Prediction of transcription factor binding sites: COUGER can predict the binding sites of transcription factors based on their DNA-binding domain sequences and the local chromatin structure.\n2. Enhancer prediction: COUGER can identify potential enhancer elements based on their proximity to promoters and other regulatory elements.\n3. Chromatin structure prediction: COUGER can predict the three-dimensional structure of chromatin, which can help identify regulatory elements that are in close proximity to each other.\n4. Integration with other tools: COUGER can be integrated with other bioinformatics tools and databases, such as ChIP-seq and ENCODE data, to improve the accuracy of regulatory element prediction.\nOverall, COUGER is a powerful tool for understanding the regulatory elements in a given DNA sequence and can be used to identify potential drug targets, develop personalized medicine approaches, and improve our understanding of the regulation of gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. COUGER is a computational tool used in bioinformatics and systems biology.\n2. The tool is designed to predict regulatory elements such as transcription factor binding sites and enhancers in DNA sequences.\n3. COUGER uses machine learning algorithms and structural bioinformatics techniques for analysis.\n4. It can analyze genomic sequences from a wide range of organisms, including humans.\n5. COUGER can be integrated with other bioinformatics tools and databases to improve prediction accuracy.",
    "llama-2-7b-chat-hf_fact": [
      "COUGER is a computational tool used in bioinformatics and systems biology.",
      "The tool is designed to predict regulatory elements such as transcription factor binding sites and enhancers in DNA sequences.",
      "COUGER uses machine learning algorithms and structural bioinformatics techniques for analysis.",
      "It can analyze genomic sequences from a wide range of organisms, including humans.",
      "COUGER can be integrated with other bioinformatics tools and databases to improve prediction accuracy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about a computational tool named \"COUGER,\" it is not possible to verify the accuracy of these statements. The statements could be true if there is a tool with that name that performs the functions described, but without additional context or reference to such a tool, the truthfulness of the statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available to treat tick-borne encephalitis (TBE). The most common treatment for TBE is antiviral medication, which can help reduce the severity of symptoms and shorten the duration of the illness. The specific drug used will depend on the severity of the infection and the patient's overall health.\nHere are some of the drugs commonly used to treat TBE:\n1. Ribavirin: This drug is an antiviral medication that is effective against TBE virus. It is usually given in combination with other medications to help reduce the severity of symptoms.\n2. Aztreonam: This drug is an antibiotic that is sometimes used to treat TBE, particularly in cases where there is a secondary bacterial infection.\n3. Penicillamine: This drug is an antibiotic that is sometimes used to treat TBE, particularly in cases where there is a secondary bacterial infection.\n4. Corticosteroids: These drugs, such as prednisone, can help reduce inflammation in the brain and spinal cord, which can occur in some cases of TBE.\n5. Immunoglobulin: This is a preparation of antibodies that can help reduce the severity of TBE by providing the body with a boost of antibodies to fight the virus. It is usually given intravenously and can be effective in reducing the severity of symptoms.\nIt's important to note that these drugs may not be effective in all cases of TBE, and the best treatment approach will depend on the severity of the infection and the patient's overall health. In some cases, hospitalization may be necessary to provide supportive care, such as oxygen therapy and fluid replacement.\nIt's also important to note that prevention is the best way to avoid TBE, by avoiding tick habitats, using insect repellents, and checking for ticks after spending time outdoors. If you think you may have been exposed to TBE, it's important to seek medical attention as soon as possible.",
    "llama-2-7b-chat-hf_fact_raw": "1. Antiviral medication is used to treat tick-borne encephalitis (TBE).\n2. Ribavirin is an antiviral medication that is effective against the TBE virus.\n3. Aztreonam is an antibiotic sometimes used to treat TBE, especially in cases with a secondary bacterial infection.\n4. Corticosteroids, such as prednisone, can help reduce inflammation in the brain and spinal cord in some cases of TBE.\n5. Immunoglobulin, a preparation of antibodies, can be given intravenously to reduce the severity of TBE symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "Antiviral medication is used to treat tick-borne encephalitis (TBE).",
      "Ribavirin is an antiviral medication that is effective against the TBE virus.",
      "Aztreonam is an antibiotic sometimes used to treat TBE, especially in cases with a secondary bacterial infection.",
      "Corticosteroids, such as prednisone, can help reduce inflammation in the brain and spinal cord in some cases of TBE.",
      "Immunoglobulin, a preparation of antibodies, can be given intravenously to reduce the severity of TBE symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Antiviral medications are not typically used to treat tick-borne encephalitis (TBE) because there are no specific antiviral treatments for TBE. Treatment is mainly supportive.\n2. FALSE [correction]: Ribavirin is an antiviral medication, but it is not effective against the TBE virus.\n3. TRUE: Aztreonam is an antibiotic, and while it would not be used to treat TBE itself, it could be used in cases where there is a secondary bacterial infection.\n4. UNKNOWN: While corticosteroids are used to reduce inflammation in various neurological conditions, their use in TBE is not standard and would depend on individual cases and clinical judgment. There is no clear consensus or widely accepted guideline for their use in TBE treatment.\n5. TRUE: Immunoglobulin therapy can be used as a post-exposure prophylaxis for TBE, and in some cases, it might be used to reduce the severity of symptoms, although its effectiveness in altering the course of the disease once symptoms have developed is not well established.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers available for DNA shape annotations, but some of the most popular ones include:\n1. DNase-seq: This is a database of DNA shape annotations generated from DNase I footprinting data. It provides information on the accessibility of different regions of the genome to the DNase I enzyme, which can be used to infer the structure of the chromatin.\n2. Chromatin Hub: This is a database of chromatin structure data generated from a variety of techniques, including chromatin immunoprecipitation sequencing (ChIP-seq) and DNase-seq. It provides information on the occupancy of different proteins and nucleosomes at different regions of the genome.\n3. 4D-Nucleosome: This is a database of 4D nucleosome mapping data, which provides information on the dynamics of nucleosome positioning and movement in the genome.\n4. Hi-C: This is a database of chromosome conformation capture (Hi-C) data, which provides information on the spatial proximity of different regions of the genome. It can be used to infer the 3D structure of the chromatin and to identify regions of the genome that are in close proximity to each other.\n5. Chromosome Conformation and Remodeling (CCR): This is a database of chromosome conformation capture (Hi-C) data, which provides information on the spatial proximity of different regions of the genome. It can be used to infer the 3D structure of the chromatin and to identify regions of the genome that are in close proximity to each other.\n6. Topologically Associating Domains (TADs): This is a database of chromatin structure data generated from a variety of techniques, including Hi-C and DNase-seq. It provides information on the 3D organization of the genome and the boundaries of different topological domains.\n7. Chromatin Interaction Map (ChIA-Map): This is a database of chromatin interaction data generated from a variety of techniques, including Hi-C and DNase-seq. It provides information on the interactions between different regions of the genome and can be used to infer the 3D structure of the chromatin.\n8. Genome-wide Chromatin Conformation Capture (",
    "llama-2-7b-chat-hf_fact_raw": "1. DNase-seq is a database that provides DNA shape annotations generated from DNase I footprinting data.\n2. Chromatin Hub is a database that offers chromatin structure data from techniques such as chromatin immunoprecipitation sequencing (ChIP-seq) and DNase-seq.\n3. 4D-Nucleosome is a database that provides information on nucleosome positioning and movement dynamics in the genome.\n4. Hi-C is a database that contains chromosome conformation capture data to infer the 3D structure of chromatin.\n5. Topologically Associating Domains (TADs) is a database that provides data on the 3D organization of the genome and the boundaries of topological domains.",
    "llama-2-7b-chat-hf_fact": [
      "DNase-seq is a database that provides DNA shape annotations generated from DNase I footprinting data.",
      "Chromatin Hub is a database that offers chromatin structure data from techniques such as chromatin immunoprecipitation sequencing (ChIP-seq) and DNase-seq.",
      "4D-Nucleosome is a database that provides information on nucleosome positioning and movement dynamics in the genome.",
      "Hi-C is a database that contains chromosome conformation capture data to infer the 3D structure of chromatin.",
      "Topologically Associating Domains (TADs) is a database that provides data on the 3D organization of the genome and the boundaries of topological domains."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: DNase-seq is not a database; it is a genomic technique used to identify regions of DNA that are accessible to the enzyme DNase I, which often correspond to regulatory elements.\n2. FALSE [correction]: Chromatin Hub is not a specific database; the statement seems to refer to various databases and resources that offer chromatin structure data. ChIP-seq and DNase-seq are techniques used to study chromatin structure and DNA accessibility, respectively.\n3. UNKNOWN: Without more context, it is unclear whether \"4D-Nucleosome\" refers to a specific database or is a conceptual term. There are databases that provide information on nucleosome positioning, but without specific reference, the existence of a database named \"4D-Nucleosome\" cannot be confirmed.\n4. FALSE [correction]: Hi-C is not a database; it is a chromosome conformation capture technique that allows researchers to study the 3D architecture of the genome.\n5. FALSE [correction]: Topologically Associating Domains (TADs) are not a database; they are genomic regions within which DNA sequences are more frequently interacting with each other than with sequences outside the TAD. There are databases and tools that provide data on TADs, but TADs themselves are not a database.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene has been associated with several syndromes, including:\n1. Rubinstein-Taybi Syndrome (RTBT): This is a rare genetic disorder characterized by intellectual disability, growth delays, facial dysmorphism, and various other physical abnormalities. EZH2 mutations are found in approximately 50% of individuals with RTBT.\n2. Pallister-Hall Syndrome (PHS): This is a rare genetic disorder characterized by intellectual disability, growth delays, facial dysmorphism, and various other physical abnormalities. EZH2 mutations are found in approximately 20% of individuals with PHS.\n3. Gorlin Syndrome: This is a rare genetic disorder characterized by multiple cysts on the ovaries, testes, or other organs, as well as various other physical abnormalities. EZH2 mutations have been identified in some cases of Gorlin Syndrome.\n4. Myotonic Dystrophy Type 1 (DM1): This is a rare genetic disorder characterized by muscle weakness and wasting, as well as various other physical and cognitive abnormalities. EZH2 mutations have been identified in some cases of DM1.\n5. Charcot-Marie-Tooth Disease Type 1A (CMT1A): This is a rare genetic disorder characterized by progressive damage to the nerves in the feet and legs, leading to muscle weakness and wasting. EZH2 mutations have been identified in some cases of CMT1A.\nIt's worth noting that EZH2 mutations can also be found in other genetic disorders and cancers, but the above syndromes are the most commonly associated with EZH2 mutations.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rubinstein-Taybi Syndrome is associated with mutations in the EZH2 gene, with approximately 50% of individuals with the syndrome having such mutations.\n2. Pallister-Hall Syndrome is associated with mutations in the EZH2 gene, with approximately 20% of individuals with the syndrome having such mutations.\n3. Some cases of Gorlin Syndrome have been identified with mutations in the EZH2 gene.\n4. Mutations in the EZH2 gene have been identified in some cases of Myotonic Dystrophy Type 1.\n5. Charcot-Marie-Tooth Disease Type 1A has been associated with mutations in the EZH2 gene in some cases.",
    "llama-2-7b-chat-hf_fact": [
      "Rubinstein-Taybi Syndrome is associated with mutations in the EZH2 gene, with approximately 50% of individuals with the syndrome having such mutations.",
      "Pallister-Hall Syndrome is associated with mutations in the EZH2 gene, with approximately 20% of individuals with the syndrome having such mutations.",
      "Some cases of Gorlin Syndrome have been identified with mutations in the EZH2 gene.",
      "Mutations in the EZH2 gene have been identified in some cases of Myotonic Dystrophy Type 1.",
      "Charcot-Marie-Tooth Disease Type 1A has been associated with mutations in the EZH2 gene in some cases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Rubinstein-Taybi Syndrome is associated with mutations in the CREBBP and EP300 genes, not the EZH2 gene.\n2. FALSE [correction]: Pallister-Hall Syndrome is associated with mutations in the GLI3 gene, not the EZH2 gene.\n3. FALSE [correction]: Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is associated with mutations in the PTCH1 gene, not the EZH2 gene.\n4. FALSE [correction]: Myotonic Dystrophy Type 1 is associated with an expansion of the CTG trinucleotide repeat in the DMPK gene, not mutations in the EZH2 gene.\n5. FALSE [correction]: Charcot-Marie-Tooth Disease Type 1A is most commonly associated with a duplication of the PMP22 gene, not mutations in the EZH2 gene.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "There are several human proteins that undergo a dimer-to-tetramer transition, which means they exist as dimers (two identical proteins bound together) under normal conditions but can form higher-order oligomers (tetramers, in this case) upon binding to specific ligands or undergoing certain cellular processes. Here are some examples:\n1. G-protein-coupled receptors (GPCRs): Many GPCRs, such as the β-adrenergic receptor, undergo a dimer-to-tetramer transition in response to ligand binding. This transition activates the receptor and triggers downstream signaling pathways.\n2. Ion channels: Some ion channels, like the voltage-gated calcium channel, can form dimers in their resting state but transition to tetramers upon depolarization. This allows for an influx of calcium ions into the cell, which can trigger various cellular responses.\n3. Kinases: The protein kinase A (PKA) regulatory subunit can form a dimer in the absence of ligand but transition to a tetramer upon binding to cAMP. This tetrameric structure is important for the activation of PKA and its downstream signaling pathways.\n4. Transcription factors: The retinoblastoma protein (Rb) is a tumor suppressor that can exist as a monomer or a dimer in unphosphorylated states. Upon phosphorylation, Rb can transition to a tetramer, which is important for the regulation of transcription and cell cycle progression.\n5. Chaperone proteins: HSP90, a chaperone protein involved in protein folding and degradation, can exist as a dimer in its resting state but transition to a tetramer upon binding to its client proteins. This tetrameric structure allows for more efficient protein folding and degradation.\nThese are just a few examples of human proteins that undergo a dimer-to-tetramer transition. This type of conformational change is a common mechanism used by proteins to regulate their activity, localization, and interactions with other molecules.",
    "llama-2-7b-chat-hf_fact_raw": "1. G-protein-coupled receptors (GPCRs), such as the β-adrenergic receptor, can undergo a dimer-to-tetramer transition in response to ligand binding.\n2. Some ion channels, like the voltage-gated calcium channel, transition from dimers to tetramers upon depolarization.\n3. The protein kinase A (PKA) regulatory subunit transitions from a dimer to a tetramer upon binding to cAMP.\n4. The retinoblastoma protein (Rb) can transition to a tetramer upon phosphorylation.\n5. HSP90, a chaperone protein, can transition from a dimer to a tetramer upon binding to its client proteins.",
    "llama-2-7b-chat-hf_fact": [
      "G-protein-coupled receptors (GPCRs), such as the β-adrenergic receptor, can undergo a dimer-to-tetramer transition in response to ligand binding.",
      "Some ion channels, like the voltage-gated calcium channel, transition from dimers to tetramers upon depolarization.",
      "The protein kinase A (PKA) regulatory subunit transitions from a dimer to a tetramer upon binding to cAMP.",
      "The retinoblastoma protein (Rb) can transition to a tetramer upon phosphorylation.",
      "HSP90, a chaperone protein, can transition from a dimer to a tetramer upon binding to its client proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about G-protein-coupled receptors (GPCRs) such as the β-adrenergic receptor undergoing a dimer-to-tetramer transition in response to ligand binding is not a widely established fact in the scientific literature. GPCRs are known to form dimers, but their oligomerization state beyond dimerization is still a topic of research and debate.\n\n2. FALSE [correction]: Voltage-gated calcium channels are known to exist as tetramers in their functional state, but there is no widely accepted evidence that they transition from dimers to tetramers upon depolarization. They are composed of four subunits that come together to form a functional channel, but this assembly is not typically described as a transition from a dimeric to a tetrameric state upon depolarization.\n\n3. FALSE [correction]: The protein kinase A (PKA) regulatory subunit does not transition from a dimer to a tetramer upon binding to cAMP. Instead, cAMP binding to the regulatory subunits of PKA leads to the dissociation of the tetrameric holoenzyme into two regulatory subunit dimers and two catalytic subunits, which are then active.\n\n4. UNKNOWN: The statement about the retinoblastoma protein (Rb) transitioning to a tetramer upon phosphorylation is not a standard description of Rb function. Rb is known to be phosphorylated, which leads to a change in its activity and the release of E2F transcription factors, but the specific oligomerization state of Rb upon phosphorylation is not commonly described in this manner.\n\n5. UNKNOWN: HSP90 is indeed a chaperone protein that can form dimers, but whether it transitions to a tetramer upon binding to client proteins is not a well-established fact. The oligomerization state of HSP90 can be influenced by various factors, including co-chaperones and nucleotides, but the specific transition from dimer to tetramer upon client protein binding is not universally recognized in the literature.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Phospholamban (PLN) is a protein that plays a critical role in regulating the activity of the sarcoplasmic reticulum (SR) Ca2+-ATPase pump in cardiac muscle cells. PLN inhibits the activity of the Ca2+-ATPase pump by binding to the enzyme and blocking its active site.\nOne protein that has been found to interact with PLN and is also an anti-apoptotic protein is Bcl-2. Bcl-2 is a member of the Bcl-2 family of proteins, which are involved in regulating programmed cell death (apoptosis). Bcl-2 and PLN have been shown to interact in cardiac muscle cells, and Bcl-2 has been shown to inhibit the pro-apoptotic effects of PLN in these cells. This suggests that Bcl-2 may play a role in protecting cardiac muscle cells from apoptosis by inhibiting the activity of PLN.\nOther proteins that have been found to interact with PLN and are involved in regulating cardiac function include:\n* CaMKII (Calcium/Calmodulin-dependent Protein Kinase II): PLN and CaMKII have been shown to interact in cardiac muscle cells, and CaMKII has been shown to phosphorylate and activate PLN.\n* RyR2 (Ryanodine Receptor 2): PLN and RyR2 have been shown to interact in the SR of cardiac muscle cells, and PLN has been shown to regulate the activity of RyR2.\n* ATP2A1 (SERCA2A): PLN and ATP2A1 have been shown to interact in cardiac muscle cells, and PLN has been shown to regulate the activity of ATP2A1.\nOverall, these proteins play important roles in regulating cardiac function and may be involved in the regulation of PLN activity and its effects on cardiac muscle cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Phospholamban (PLN) regulates the activity of the sarcoplasmic reticulum (SR) Ca2+-ATPase pump in cardiac muscle cells.\n2. Bcl-2 is a protein that interacts with PLN and is an anti-apoptotic protein.\n3. Bcl-2 has been shown to inhibit the pro-apoptotic effects of PLN in cardiac muscle cells.\n4. CaMKII has been shown to phosphorylate and activate PLN in cardiac muscle cells.\n5. PLN has been shown to regulate the activity of RyR2 and ATP2A1 in cardiac muscle cells.",
    "llama-2-7b-chat-hf_fact": [
      "Phospholamban (PLN) regulates the activity of the sarcoplasmic reticulum (SR) Ca2+-ATPase pump in cardiac muscle cells.",
      "Bcl-2 is a protein that interacts with PLN and is an anti-apoptotic protein.",
      "Bcl-2 has been shown to inhibit the pro-apoptotic effects of PLN in cardiac muscle cells.",
      "CaMKII has been shown to phosphorylate and activate PLN in cardiac muscle cells.",
      "PLN has been shown to regulate the activity of RyR2 and ATP2A1 in cardiac muscle cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Phospholamban (PLN) indeed regulates the activity of the sarcoplasmic reticulum (SR) Ca2+-ATPase (also known as SERCA) pump in cardiac muscle cells, which is crucial for calcium homeostasis and cardiac muscle relaxation.\n2. FALSE [correction]: Bcl-2 is an anti-apoptotic protein, but it is not known for interacting with PLN. Bcl-2 primarily interacts with proteins in the apoptotic pathways, such as Bax and Bak, to regulate cell death.\n3. FALSE [correction]: Bcl-2 is an anti-apoptotic protein that inhibits cell death, but there is no established evidence that it directly inhibits the pro-apoptotic effects of PLN in cardiac muscle cells, as PLN is not typically described as a pro-apoptotic protein.\n4. TRUE: CaMKII (Calcium/Calmodulin-dependent protein kinase II) has been shown to phosphorylate PLN, which leads to the activation of the SR Ca2+-ATPase pump in cardiac muscle cells.\n5. UNKNOWN: While PLN is known to regulate the activity of the SR Ca2+-ATPase pump, its direct regulation of RyR2 (Ryanodine receptor 2) and ATP2A1 (another name for SERCA) is more complex and may not be solely regulated by PLN. The statement is vague without specifying the nature of the regulation, and the literature on this topic may have varying findings.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, several clinical trials have shown that vitamin D supplementation can reduce the incidence of falls in older people. Here are some examples:\n1. A 2010 Cochrane review of 13 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults. The review included over 15,000 participants and found that the risk of falls decreased by 19% in the groups receiving vitamin D supplements compared to the placebo groups.\n2. A 2012 randomized controlled trial published in the Journal of the American Geriatrics Society found that vitamin D and calcium supplementation reduced the risk of falls in older adults with low baseline vitamin D levels. The study included 1,121 participants aged 65 years and older and found that the risk of falls decreased by 43% in the vitamin D and calcium group compared to the placebo group.\n3. A 2014 randomized controlled trial published in the Journal of Gerontology found that vitamin D supplementation reduced the risk of falls in older adults with cognitive impairment. The study included 240 participants aged 70 years and older with cognitive impairment and found that the risk of falls decreased by 56% in the vitamin D group compared to the placebo group.\n4. A 2017 systematic review and meta-analysis published in the Journal of the American Medical Association found that vitamin D supplementation was associated with a reduced risk of falls in older adults. The review included 17 randomized controlled trials and found that the risk of falls decreased by 13% in the vitamin D groups compared to the placebo groups.\nIt is important to note that while these studies suggest a potential benefit of vitamin D supplementation in reducing the incidence of falls in older people, the results may not be generalizable to all older adults. The effects of vitamin D supplementation on falls may depend on various factors, such as baseline vitamin D levels, age, sex, and underlying health conditions. Further research is needed to confirm these findings and to determine the optimal dosage and duration of vitamin D supplementation for fall prevent",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2010 Cochrane review of 13 randomized controlled trials found that vitamin D supplementation decreased the risk of falls by 19% in older adults compared to placebo groups.\n2. A 2012 randomized controlled trial published in the Journal of the American Geriatrics Society showed a 43% reduction in the risk of falls with vitamin D and calcium supplementation in older adults with low baseline vitamin D levels.\n3. A 2014 randomized controlled trial published in the Journal of Gerontology indicated a 56% decrease in the risk of falls in older adults with cognitive impairment who received vitamin D supplementation.\n4. A 2017 systematic review and meta-analysis published in the Journal of the American Medical Association associated vitamin D supplementation with a 13% reduced risk of falls in older adults.\n5. The 2012 study included 1,121 participants aged 65 years and older.",
    "llama-2-7b-chat-hf_fact": [
      "A 2010 Cochrane review of 13 randomized controlled trials found that vitamin D supplementation decreased the risk of falls by 19% in older adults compared to placebo groups.",
      "A 2012 randomized controlled trial published in the Journal of the American Geriatrics Society showed a 43% reduction in the risk of falls with vitamin D and calcium supplementation in older adults with low baseline vitamin D levels.",
      "A 2014 randomized controlled trial published in the Journal of Gerontology indicated a 56% decrease in the risk of falls in older adults with cognitive impairment who received vitamin D supplementation.",
      "A 2017 systematic review and meta-analysis published in the Journal of the American Medical Association associated vitamin D supplementation with a 13% reduced risk of falls in older adults.",
      "The 2012 study included 1,121 participants aged 65 years and older."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe responses to statements 2, 3, 4, and 5 are marked as UNKNOWN because, without access to the specific studies mentioned, I cannot verify the exact percentages or details provided in these statements. The first statement is considered true as it references a specific Cochrane review from 2010, which is a reputable source for systematic reviews in healthcare. However, for the other statements, without the actual studies or additional context, it is not possible to confirm their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that Jarid2 (Jumonji AT-rich interactive domain 2) is associated with miR-155 (microRNA-155) in Th17 cells.\nTh17 cells are a subtype of T cells that play a key role in the immune response, and they are characterized by the production of the cytokine interleukin-17 (IL-17). miR-155 is a microRNA that has been shown to play a critical role in the regulation of Th17 cell differentiation and function.\nStudies have shown that Jarid2 is a direct target of miR-155 in Th17 cells. miR-155 binds to the 3' untranslated region (UTR) of the Jarid2 mRNA and represses its expression. This repression of Jarid2 expression by miR-155 is important for the proper differentiation and function of Th17 cells.\nIn addition, Jarid2 has been shown to play a role in the regulation of the expression of genes involved in the Th17 cell response. For example, Jarid2 has been shown to repress the expression of the transcription factor retinoic acid-related orphan receptor gamma t (Rorgt), which is a key regulator of Th17 cell differentiation.\nOverall, the association between Jarid2 and miR-155 in Th17 cells suggests that miR-155 may play a key role in regulating the expression of genes involved in the Th17 cell response, and that Jarid2 may be an important factor in this process.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is associated with miR-155 in Th17 cells.\n2. Th17 cells are characterized by the production of the cytokine interleukin-17 (IL-17).\n3. miR-155 plays a critical role in the regulation of Th17 cell differentiation and function.\n4. miR-155 binds to the 3' untranslated region (UTR) of the Jarid2 mRNA and represses its expression.\n5. Jarid2 represses the expression of the transcription factor retinoic acid-related orphan receptor gamma t (Rorgt), which is a key regulator of Th17 cell differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is associated with miR-155 in Th17 cells.",
      "Th17 cells are characterized by the production of the cytokine interleukin-17 (IL-17).",
      "miR-155 plays a critical role in the regulation of Th17 cell differentiation and function.",
      "miR-155 binds to the 3' untranslated region (UTR) of the Jarid2 mRNA and represses its expression.",
      "Jarid2 represses the expression of the transcription factor retinoic acid-related orphan receptor gamma t (Rorgt), which is a key regulator of Th17 cell differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding Jarid2, miR-155, and their specific interactions or regulatory mechanisms are highly specific and would require access to current scientific literature or specific studies to verify. Without the specific context or references, it is not possible to determine the truthfulness of statements 1, 4, and 5. However, statements 2 and 3 are general knowledge about Th17 cells and miR-155, respectively, and are considered true based on current scientific understanding.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 12 genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 12 genes.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 12 genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9 genes.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein Kinase 1 (CK1) is a serine/threonine protein kinase that plays a crucial role in various cellular processes, including cell signaling, metabolism, and gene expression. CK1 has multiple phosphorylation sites, and the consensus motifs for these sites are as follows:\n1. Thr-Ser-Thr (TST): This is the most common phosphorylation consensus motif for CK1, found in the activation loop of the kinase domain.\n2. Ser-Thr-Pro (STP): This motif is also found in the activation loop of the kinase domain and is important for the stability and activity of CK1.\n3. Thr-Gly-Thr (TGT): This motif is located in the substrate binding site of the kinase domain and is involved in the binding of phosphorylated substrates.\n4. Ser-Gly-X-X-Ser (SXXS): This motif is found in the carboxy-terminal region of CK1 and is involved in the binding of regulatory proteins.\n5. Thr-X-X-Thr (TXT): This motif is found in the amino-terminal region of CK1 and is involved in the binding of regulatory proteins.\nIt's worth noting that the consensus motifs for CK1 phosphorylation can vary depending on the specific isoform of the enzyme and the cellular context in which it is active.",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein Kinase 1 (CK1) is a serine/threonine protein kinase.\n2. The consensus phosphorylation motif Thr-Ser-Thr (TST) is found in the activation loop of CK1's kinase domain.\n3. The consensus phosphorylation motif Ser-Thr-Pro (STP) is important for the stability and activity of CK1.\n4. The consensus phosphorylation motif Thr-Gly-Thr (TGT) is involved in the binding of phosphorylated substrates to CK1.\n5. The consensus phosphorylation motifs Ser-Gly-X-X-Ser (SXXS) and Thr-X-X-Thr (TXT) are involved in the binding of regulatory proteins to CK1.",
    "llama-2-7b-chat-hf_fact": [
      "Casein Kinase 1 (CK1) is a serine/threonine protein kinase.",
      "The consensus phosphorylation motif Thr-Ser-Thr (TST) is found in the activation loop of CK1's kinase domain.",
      "The consensus phosphorylation motif Ser-Thr-Pro (STP) is important for the stability and activity of CK1.",
      "The consensus phosphorylation motif Thr-Gly-Thr (TGT) is involved in the binding of phosphorylated substrates to CK1.",
      "The consensus phosphorylation motifs Ser-Gly-X-X-Ser (SXXS) and Thr-X-X-Thr (TXT) are involved in the binding of regulatory proteins to CK1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The consensus phosphorylation motif for CK1 is not Thr-Ser-Thr (TST); instead, it is often Ser-Xxx-Ser/Thr (S/T-X-S/T), where \"Xxx\" can be any amino acid residue.\n3. TRUE\n4. FALSE [correction]: The consensus phosphorylation motif Thr-Gly-Thr (TGT) is not specifically known to be involved in the binding of phosphorylated substrates to CK1. The actual motifs involved in substrate recognition by CK1 typically include basic amino acids surrounding the phosphorylation site.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes multiple isoforms of the ASPH protein, which are produced through alternative splicing. Here are the different isoforms/proteins encoded by the ASPH gene:\n1. ASPH: This is the full-length isoform of the ASPH protein, which contains all of the protein's functional domains.\n2. ASPH-A: This isoform lacks the N-terminal domain of the full-length ASPH protein and contains a shorter C-terminal domain.\n3. ASPH-B: This isoform is similar to ASPH-A but has an additional 100 amino acids at the C-terminus.\n4. ASPH-C: This isoform is a truncated form of the full-length ASPH protein that lacks the N-terminal domain and a portion of the C-terminal domain.\n5. ASPH-D: This isoform is similar to ASPH-C but has an additional 100 amino acids at the C-terminus.\n6. ASPH-E: This isoform is a splice variant of ASPH that lacks the C-terminal domain and contains a shorter N-terminal domain.\n7. ASPH-F: This isoform is a splice variant of ASPH that lacks the N-terminal domain and contains a shorter C-terminal domain.\n8. ASPH-G: This isoform is a splice variant of ASPH that lacks the C-terminal domain and contains a shorter N-terminal domain.\n9. ASPH-H: This isoform is a splice variant of ASPH that lacks the N-terminal domain and contains a shorter C-terminal domain.\n10. ASPH-I: This isoform is a splice variant of ASPH that lacks the C-terminal domain and contains a shorter N-terminal domain.\nIt's worth noting that the exact functions of each isoform are not yet fully understood and are still being studied, but they are thought to play roles in various cellular processes, including cell signaling, cytoskeleton organization, and protein degradation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene in humans encodes multiple isoforms of the ASPH protein through alternative splicing.\n2. The full-length isoform of the ASPH protein is known as ASPH and contains all of the protein's functional domains.\n3. The ASPH-A isoform lacks the N-terminal domain of the full-length ASPH protein and contains a shorter C-terminal domain.\n4. The ASPH-B isoform is similar to ASPH-A but has an additional 100 amino acids at the C-terminus.\n5. The ASPH-C isoform is a truncated form of the full-length ASPH protein that lacks the N-terminal domain and a portion of the C-terminal domain.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene in humans encodes multiple isoforms of the ASPH protein through alternative splicing.",
      "The full-length isoform of the ASPH protein is known as ASPH and contains all of the protein's functional domains.",
      "The ASPH-A isoform lacks the N-terminal domain of the full-length ASPH protein and contains a shorter C-terminal domain.",
      "The ASPH-B isoform is similar to ASPH-A but has an additional 100 amino acids at the C-terminus.",
      "The ASPH-C isoform is a truncated form of the full-length ASPH protein that lacks the N-terminal domain and a portion of the C-terminal domain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about the ASPH gene and its protein isoforms are highly specific and would require detailed knowledge of the gene's splicing variants and the structure of the resulting proteins. Without access to specific scientific literature or databases that provide information on the ASPH gene and its isoforms, it is not possible to verify the details about the isoforms' structure and nomenclature. Therefore, while the first two statements are generally true for many genes and their proteins, the details in statements 3, 4, and 5 cannot be confirmed without additional context or reference material.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin was approved by the US Food and Drug Administration (FDA) on July 8, 2014, for the treatment of type 2 diabetes. It was approved under the brand name Jardiance.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was approved by the US Food and Drug Administration on July 8, 2014.\n2. Empagliflozin is used for the treatment of type 2 diabetes.\n3. The brand name under which empagliflozin was approved is Jardiance.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was approved by the US Food and Drug Administration on July 8, 2014.",
      "Empagliflozin is used for the treatment of type 2 diabetes.",
      "The brand name under which empagliflozin was approved is Jardiance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Empagliflozin was approved by the US Food and Drug Administration on August 1, 2014.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Loss of the protein Lon1 in the plant Arabidopsis thaliana has been shown to have several phenotypic effects. Here are some of the results of Lon1 loss-of-function mutations in Arabidopsis:\n1. Increased sensitivity to oxidative stress: Lon1 is involved in the repair of DNA damage caused by reactive oxygen species (ROS), which are highly reactive molecules that can damage cellular components. Mutants lacking Lon1 are more sensitive to oxidative stress, as they are unable to repair DNA damage efficiently.\n2. Enhanced cell death: Lon1 plays a role in preventing cell death in response to various stresses, including oxidative stress. Mutants lacking Lon1 exhibit increased cell death, particularly in the roots and shoots.\n3. Altered root architecture: Lon1 regulates the expression of genes involved in root growth and development. Mutants lacking Lon1 have altered root architectures, including reduced root length and branching.\n4. Delayed seed germination: Lon1 regulates the expression of genes involved in seed germination. Mutants lacking Lon1 have delayed seed germination, likely due to impaired seedling establishment.\n5. Reduced plant height: Lon1 regulates the expression of genes involved in stem elongation. Mutants lacking Lon1 have reduced plant height, likely due to impaired stem elongation.\n6. Altered flowering time: Lon1 regulates the expression of genes involved in flowering time. Mutants lacking Lon1 have altered flowering times, with some exhibiting early flowering and others exhibiting late flowering.\n7. Reduced seed production: Lon1 regulates the expression of genes involved in seed production. Mutants lacking Lon1 have reduced seed production, likely due to impaired ovule development.\n8. Altered hormone levels: Lon1 regulates the levels of various hormones, including auxin and cytokinin. Mutants lacking Lon1 have altered hormone levels, which may contribute to the observed phenotypes.\nThese results demonstrate that Lon1 plays a critical role in maintaining the integrity of the genome and in regulating various physi",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutants of Arabidopsis thaliana lacking Lon1 are more sensitive to oxidative stress.\n2. Lon1 loss-of-function mutations in Arabidopsis result in increased cell death, especially in roots and shoots.\n3. Arabidopsis mutants without Lon1 exhibit altered root architectures, such as reduced root length and branching.\n4. Loss of Lon1 in Arabidopsis leads to delayed seed germination.\n5. Arabidopsis plants lacking Lon1 have reduced plant height.",
    "llama-2-7b-chat-hf_fact": [
      "Mutants of Arabidopsis thaliana lacking Lon1 are more sensitive to oxidative stress.",
      "Lon1 loss-of-function mutations in Arabidopsis result in increased cell death, especially in roots and shoots.",
      "Arabidopsis mutants without Lon1 exhibit altered root architectures, such as reduced root length and branching.",
      "Loss of Lon1 in Arabidopsis leads to delayed seed germination.",
      "Arabidopsis plants lacking Lon1 have reduced plant height."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nWithout specific scientific studies or data to reference, it is difficult to confirm the accuracy of these statements. However, they are consistent with the types of phenotypic changes that might be expected in plants with a mutation in a gene involved in stress responses or cellular maintenance, such as Lon1. Lon1 is known to be a mitochondrial ATP-dependent protease that plays a role in protein quality control, and its dysfunction could lead to various phenotypic alterations in plants. If these statements are derived from experimental findings, they would likely be true, but without the specific context or sources, they cannot be verified beyond reasonable assumptions based on general knowledge of plant genetics and molecular biology.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Yes, a linker histone called H3K4me3 (histone H3 lysine 4 trimethylation at position 3) is present in the yeast genome. H3K4me3 is a type of epigenetic marker that plays a crucial role in the regulation of gene expression and chromatin structure in yeast. It is known to be involved in the recruitment of RNA polymerase II and other transcription factors to the promoter region of genes, and is also involved in the maintenance of gene silencing.\nIn yeast, H3K4me3 is established and maintained by the action of the enzyme histone methyltransferase, GCN5. GCN5 is a histone methyltransferase that specifically methylates histone H3 on lysine 4, leading to the formation of H3K4me3. This modification is known to be important for the regulation of gene expression, particularly for the activation of gene expression during the cell cycle.\nIt is worth noting that while H3K4me3 is the most well-studied linker histone in yeast, other linker histones such as H3K27me3 and H3K36me3 also play important roles in the regulation of gene expression and chromatin structure in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. H3K4me3 is a linker histone present in the yeast genome.\n2. H3K4me3 plays a role in the regulation of gene expression and chromatin structure in yeast.\n3. H3K4me3 is involved in the recruitment of RNA polymerase II to the promoter region of genes in yeast.\n4. The enzyme histone methyltransferase GCN5 establishes and maintains H3K4me3 by methylating histone H3 on lysine 4.\n5. Other linker histones such as H3K27me3 and H3K36me3 also contribute to the regulation of gene expression and chromatin structure in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "H3K4me3 is a linker histone present in the yeast genome.",
      "H3K4me3 plays a role in the regulation of gene expression and chromatin structure in yeast.",
      "H3K4me3 is involved in the recruitment of RNA polymerase II to the promoter region of genes in yeast.",
      "The enzyme histone methyltransferase GCN5 establishes and maintains H3K4me3 by methylating histone H3 on lysine 4.",
      "Other linker histones such as H3K27me3 and H3K36me3 also contribute to the regulation of gene expression and chromatin structure in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: H3K4me3 is not a linker histone; it is a histone modification where the fourth lysine (K) of histone H3 is trimethylated (me3).\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The enzyme that establishes H3K4me3 by methylating histone H3 on lysine 4 is not GCN5; it is typically set1 in yeast (Set1/COMPASS complex).\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is some evidence to suggest that tomato juice may help lower cholesterol levels. Tomatoes are a rich source of a compound called lycopene, which has been shown to have a number of potential health benefits, including reducing cholesterol levels.\nSome studies have found that drinking tomato juice can help lower LDL (bad) cholesterol levels, which is the type of cholesterol that can build up in the arteries and increase the risk of heart disease. For example, a study published in the Journal of Nutrition in 2003 found that drinking 8 ounces of tomato juice per day for 12 weeks lowered LDL cholesterol levels by 10% in healthy adults.\nOther studies have also suggested that tomato juice may help lower cholesterol levels by reducing the absorption of dietary cholesterol from food. For example, a study published in the American Journal of Clinical Nutrition in 2000 found that drinking tomato juice reduced the absorption of cholesterol from a high-cholesterol meal by 20%.\nIt's important to note that while these findings are promising, the evidence for the cholesterol-lowering effects of tomato juice is still limited and more research is needed to fully understand its effects. Additionally, tomato juice is just one part of a healthy diet and lifestyle that can help lower cholesterol levels and reduce the risk of heart disease. Other factors, such as a diet rich in fruits, vegetables, and whole grains, regular physical activity, and maintaining a healthy weight, are also important for overall heart health.\nIn summary, while there is some evidence to suggest that tomato juice may help lower cholesterol levels, more research is needed to fully understand its effects and to determine its potential as a cholesterol-lowering agent. As with any dietary intervention, it's important to talk to a healthcare provider before making significant changes to your diet.",
    "llama-2-7b-chat-hf_fact_raw": "1. Tomatoes are a source of a compound called lycopene, which may have health benefits including reducing cholesterol levels.\n2. A study published in the Journal of Nutrition in 2003 found that drinking 8 ounces of tomato juice per day for 12 weeks lowered LDL cholesterol levels by 10% in healthy adults.\n3. A study published in the American Journal of Clinical Nutrition in 2000 found that drinking tomato juice reduced the absorption of cholesterol from a high-cholesterol meal by 20%.\n4. The evidence for the cholesterol-lowering effects of tomato juice is still limited and more research is needed.\n5. Factors such as a diet rich in fruits, vegetables, and whole grains, regular physical activity, and maintaining a healthy weight are important for overall heart health.",
    "llama-2-7b-chat-hf_fact": [
      "Tomatoes are a source of a compound called lycopene, which may have health benefits including reducing cholesterol levels.",
      "A study published in the Journal of Nutrition in 2003 found that drinking 8 ounces of tomato juice per day for 12 weeks lowered LDL cholesterol levels by 10% in healthy adults.",
      "A study published in the American Journal of Clinical Nutrition in 2000 found that drinking tomato juice reduced the absorption of cholesterol from a high-cholesterol meal by 20%.",
      "The evidence for the cholesterol-lowering effects of tomato juice is still limited and more research is needed.",
      "Factors such as a diet rich in fruits, vegetables, and whole grains, regular physical activity, and maintaining a healthy weight are important for overall heart health."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Heat shock proteins (HSPs) are a family of proteins that play a crucial role in protecting cells against stress, including changes in temperature, pH, and the accumulation of toxic molecules. Two members of the HSP family, Hsp70 and Hsp110, have been shown to play a role in mRNA stability.\nHsp70 is a chaperone protein that helps to fold and stabilize proteins, and it has been shown to play a role in mRNA stability by binding to the 3' untranslated region (UTR) of specific mRNAs and protecting them from degradation. Hsp70 can also interact with the RNA-binding protein HuR, which is involved in mRNA stability and translation, and the two proteins work together to stabilize mRNAs.\nHsp110, on the other hand, is a molecular chaperone that is involved in protein folding and degradation. It has been shown to play a role in mRNA stability by interacting with the 3' UTR of mRNAs and preventing the degradation of these molecules. Hsp110 can also interact with the RNA-binding protein FUS, which is involved in mRNA metabolism and degradation, and the two proteins work together to stabilize mRNAs.\nBoth Hsp70 and Hsp110 have been shown to play a role in protecting mRNAs from degradation in response to stress, and these proteins may play a role in maintaining the stability of specific mRNAs under normal conditions as well. Dysregulation of HSP70 and HSP110 has been implicated in a number of diseases, including cancer, neurodegeneration, and neurodevelopmental disorders, and further research is needed to fully understand the role of these proteins in mRNA stability and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 is a chaperone protein that binds to the 3' untranslated region (UTR) of specific mRNAs to protect them from degradation.\n2. Hsp70 interacts with the RNA-binding protein HuR to stabilize mRNAs.\n3. Hsp110 is a molecular chaperone involved in protein folding and degradation and plays a role in mRNA stability by interacting with the 3' UTR of mRNAs.\n4. Hsp110 can interact with the RNA-binding protein FUS to stabilize mRNAs.\n5. Dysregulation of HSP70 and HSP110 has been implicated in diseases such as cancer, neurodegeneration, and neurodevelopmental disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 is a chaperone protein that binds to the 3' untranslated region (UTR) of specific mRNAs to protect them from degradation.",
      "Hsp70 interacts with the RNA-binding protein HuR to stabilize mRNAs.",
      "Hsp110 is a molecular chaperone involved in protein folding and degradation and plays a role in mRNA stability by interacting with the 3' UTR of mRNAs.",
      "Hsp110 can interact with the RNA-binding protein FUS to stabilize mRNAs.",
      "Dysregulation of HSP70 and HSP110 has been implicated in diseases such as cancer, neurodegeneration, and neurodevelopmental disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hsp70 is a chaperone protein that primarily assists in the folding of nascent polypeptides and the refolding of misfolded proteins, rather than binding to the 3' untranslated region (UTR) of specific mRNAs to protect them from degradation.\n2. TRUE\n3. FALSE [correction]: Hsp110 is a molecular chaperone involved in protein folding and preventing protein aggregation. It is not typically known for interacting with the 3' UTR of mRNAs to play a role in mRNA stability.\n4. UNKNOWN: Without specific literature to confirm or deny this interaction, the relationship between Hsp110 and the RNA-binding protein FUS in the context of mRNA stabilization cannot be determined.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "There are two types of deiodinases present in skeletal muscle:\n1. Type 1 deiodinase (D1): D1 is the primary deiodinase isoform in skeletal muscle, and it is responsible for the conversion of T4 to T3. T3 is then released into the circulation and binds to T3 receptors in muscle cells, where it stimulates the uptake and utilization of glucose and fatty acids for energy production.\n2. Type 2 deiodinase (D2): D2 is also present in skeletal muscle, although at lower levels than D1. D2 converts T4 and T3 into the inactive metabolite T2, which is then secreted into the circulation.\nIt's worth noting that the activity of these deiodinases can be influenced by various factors, such as thyroid hormone status, exercise, and nutrient availability, which can affect the regulation of muscle metabolism and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Type 1 deiodinase (D1) is present in skeletal muscle and is responsible for converting T4 to T3.\n2. Type 2 deiodinase (D2) is also present in skeletal muscle and converts T4 and T3 into the inactive metabolite T2.\n3. T3 is released into the circulation and binds to T3 receptors in muscle cells.\n4. T3 stimulates the uptake and utilization of glucose and fatty acids in muscle cells for energy production.\n5. The activity of deiodinases in skeletal muscle can be influenced by factors such as thyroid hormone status, exercise, and nutrient availability.",
    "llama-2-7b-chat-hf_fact": [
      "Type 1 deiodinase (D1) is present in skeletal muscle and is responsible for converting T4 to T3.",
      "Type 2 deiodinase (D2) is also present in skeletal muscle and converts T4 and T3 into the inactive metabolite T2.",
      "T3 is released into the circulation and binds to T3 receptors in muscle cells.",
      "T3 stimulates the uptake and utilization of glucose and fatty acids in muscle cells for energy production.",
      "The activity of deiodinases in skeletal muscle can be influenced by factors such as thyroid hormone status, exercise, and nutrient availability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Type 1 deiodinase (D1) is not predominantly present in skeletal muscle; it is primarily found in the liver and kidneys and is responsible for converting T4 to T3.\n2. FALSE [correction]: Type 2 deiodinase (D2) is present in skeletal muscle and is responsible for converting T4 to T3, not T4 and T3 into the inactive metabolite T2.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Inflammatory caspase proteins are a family of proteins that play a role in the regulation of inflammation. Here are some of the inflammatory caspase proteins found in humans:\n1. Caspase-1 (also known as interleukin-1 beta converting enzyme, or ICE): This caspase is involved in the processing and activation of pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α).\n2. Caspase-2 (also known as cytosolic factor X): This caspase is involved in the regulation of inflammation in the brain and is activated in response to microglia activation.\n3. Caspase-3 (also known as apoptosis-related cysteine peptidase 1, or ARC1): This caspase is involved in the regulation of apoptosis (cell death) and is activated in response to pro-inflammatory cytokines.\n4. Caspase-4 (also known as cytosolic factor Y): This caspase is involved in the regulation of inflammation in the brain and is activated in response to microglia activation.\n5. Caspase-5 (also known as cytosolic factor Z): This caspase is involved in the regulation of inflammation in the brain and is activated in response to microglia activation.\n6. Caspase-6 (also known as cytosolic factor A): This caspase is involved in the regulation of inflammation in the brain and is activated in response to microglia activation.\n7. Caspase-7 (also known as apoptosis-related cysteine peptidase 2, or ARC2): This caspase is involved in the regulation of apoptosis (cell death) and is activated in response to pro-inflammatory cytokines.\n8. Caspase-8 (also known as Fas-associated death domain protein, or FADD): This caspase is involved in the regulation of apoptosis (cell death) and is activated in response to the",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α).\n2. Caspase-2 is involved in the regulation of inflammation in the brain and is activated in response to microglia activation.\n3. Caspase-3 is involved in the regulation of apoptosis and is activated in response to pro-inflammatory cytokines.\n4. Caspase-4 is involved in the regulation of inflammation in the brain and is activated in response to microglia activation.\n5. Caspase-8 is involved in the regulation of apoptosis and is activated in response to the Fas-associated death domain protein (FADD).",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is involved in the processing and activation of pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α).",
      "Caspase-2 is involved in the regulation of inflammation in the brain and is activated in response to microglia activation.",
      "Caspase-3 is involved in the regulation of apoptosis and is activated in response to pro-inflammatory cytokines.",
      "Caspase-4 is involved in the regulation of inflammation in the brain and is activated in response to microglia activation.",
      "Caspase-8 is involved in the regulation of apoptosis and is activated in response to the Fas-associated death domain protein (FADD)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-2 is known for its role in apoptosis and DNA repair, not specifically for the regulation of inflammation in the brain in response to microglia activation.\n3. TRUE\n4. FALSE [correction]: Caspase-4 is known for its role in the non-canonical inflammasome pathway, which is involved in the response to bacterial infections, rather than being activated in response to microglia activation in the brain.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between the Aurora B kinase and the Polycomb protein Ring1B. Both proteins have been shown to play important roles in regulating chromatin structure and gene expression, particularly during cell division.\nAurora B is a serine/threonine kinase that is involved in the regulation of mitotic progression and chromosome segregation. It is activated during mitosis and plays a key role in the proper separation of chromosomes during cell division.\nRing1B is a member of the Polycomb protein family, which are transcriptional repressors that play a crucial role in the maintenance of gene silencing during cell differentiation and development. Ring1B is specifically involved in the repression of genes involved in the G1/S checkpoint and the maintenance of cell proliferation.\nStudies have shown that Aurora B and Ring1B interact and co-localize at specific sites on the chromatin during mitosis. This interaction is thought to play a role in the regulation of chromatin structure and gene expression during cell division. For example, Aurora B has been shown to phosphorylate and activate Ring1B, leading to the repression of target genes involved in the G1/S checkpoint.\nIn addition, Ring1B has been shown to be involved in the regulation of the mitotic spindle checkpoint, which is a critical step in the proper separation of chromosomes during cell division. Ring1B has been shown to interact with the Aurora B kinase and to be required for the proper activation of the mitotic spindle checkpoint.\nIn summary, there is a clear link between the Aurora B kinase and the Polycomb protein Ring1B, as they interact and co-localize at specific sites on the chromatin during mitosis and play important roles in regulating chromatin structure and gene expression during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase is a serine/threonine kinase involved in the regulation of mitotic progression and chromosome segregation.\n2. Ring1B is a member of the Polycomb protein family and is involved in the repression of genes related to the G1/S checkpoint and cell proliferation.\n3. Aurora B kinase and Ring1B interact and co-localize at specific sites on the chromatin during mitosis.\n4. Aurora B kinase has been shown to phosphorylate and activate Ring1B.\n5. Ring1B is involved in the regulation of the mitotic spindle checkpoint and is required for its proper activation.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase is a serine/threonine kinase involved in the regulation of mitotic progression and chromosome segregation.",
      "Ring1B is a member of the Polycomb protein family and is involved in the repression of genes related to the G1/S checkpoint and cell proliferation.",
      "Aurora B kinase and Ring1B interact and co-localize at specific sites on the chromatin during mitosis.",
      "Aurora B kinase has been shown to phosphorylate and activate Ring1B.",
      "Ring1B is involved in the regulation of the mitotic spindle checkpoint and is required for its proper activation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Ring1B is not directly involved in the regulation of the mitotic spindle checkpoint; it is involved in histone modification and gene repression as part of the Polycomb group (PcG) protein complex.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Non-canonical sequence motifs at splice sites refer to sequences that are not the standard GT/AG or UG/AC dinucleotides found in the consensus splice site sequences. These non-canonical motifs can be found in both the donor and acceptor splice sites. Here are some of the most frequent non-canonical sequence motifs found in vertebrate splice sites:\nDonor splice sites:\n1. GU-rich sequences: GU-rich sequences are found in the donor splice sites of many vertebrate genes. These sequences are rich in guanine and uracil nucleotides and can be found in the vicinity of the splice site.\n2. AU-rich sequences: AU-rich sequences are also found in the donor splice sites of some vertebrate genes. These sequences are rich in adenine and uracil nucleotides.\n3. G/C-rich sequences: G/C-rich sequences are found in the donor splice sites of some vertebrate genes. These sequences are rich in guanine and cytosine nucleotides.\n4. T-rich sequences: T-rich sequences are found in the donor splice sites of some vertebrate genes. These sequences are rich in thymine nucleotides.\nAcceptor splice sites:\n1. GT-rich sequences: GT-rich sequences are found in the acceptor splice sites of many vertebrate genes. These sequences are rich in guanine and thymine nucleotides and can be found in the vicinity of the splice site.\n2. AG-rich sequences: AG-rich sequences are found in the acceptor splice sites of some vertebrate genes. These sequences are rich in adenine and guanine nucleotides.\n3. UG-rich sequences: UG-rich sequences are found in the acceptor splice sites of some vertebrate genes. These sequences are rich in uracil and guanine nucleotides.\n4. AU-rich sequences: AU-rich sequences are found in the acceptor splice sites of some vertebrate genes. These sequences are rich in adenine and uracil nucleotides.\nIt's worth noting",
    "llama-2-7b-chat-hf_fact_raw": "1. GU-rich sequences are found in the donor splice sites of many vertebrate genes.\n2. AU-rich sequences are found in the donor splice sites of some vertebrate genes.\n3. GT-rich sequences are found in the acceptor splice sites of many vertebrate genes.\n4. AG-rich sequences are found in the acceptor splice sites of some vertebrate genes.\n5. UG-rich sequences are found in the acceptor splice sites of some vertebrate genes.",
    "llama-2-7b-chat-hf_fact": [
      "GU-rich sequences are found in the donor splice sites of many vertebrate genes.",
      "AU-rich sequences are found in the donor splice sites of some vertebrate genes.",
      "GT-rich sequences are found in the acceptor splice sites of many vertebrate genes.",
      "AG-rich sequences are found in the acceptor splice sites of some vertebrate genes.",
      "UG-rich sequences are found in the acceptor splice sites of some vertebrate genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: AU-rich sequences are typically found in the 3' untranslated regions (UTRs) of many eukaryotic mRNAs, not in the donor splice sites.\n3. FALSE [correction]: GT-rich sequences are found in the donor splice sites, not the acceptor splice sites of many vertebrate genes. The consensus sequence at the donor splice site is often characterized by the presence of a GU at the 5' end of the intron.\n4. TRUE\n5. FALSE [correction]: The consensus sequence at the acceptor splice site is characterized by the presence of an AG at the 3' end of the intron, not UG-rich sequences.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "The event that results in the acetylation of S6K1 is the activation of the mTORC1 signaling pathway. S6K1 is a key downstream target of mTORC1, and its acetylation is a critical step in the regulation of protein synthesis and cell growth. When mTORC1 is activated, it phosphorylates and activates S6K1, which then becomes acetylated by the enzyme histone acetyltransferase (HAT). The acetylation of S6K1 leads to its activation and the initiation of protein synthesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The acetylation of S6K1 is a result of the activation of the mTORC1 signaling pathway.\n2. S6K1 is a downstream target of mTORC1.\n3. The acetylation of S6K1 is involved in the regulation of protein synthesis and cell growth.\n4. When mTORC1 is activated, it phosphorylates and activates S6K1.\n5. S6K1 is acetylated by the enzyme histone acetyltransferase (HAT).",
    "llama-2-7b-chat-hf_fact": [
      "The acetylation of S6K1 is a result of the activation of the mTORC1 signaling pathway.",
      "S6K1 is a downstream target of mTORC1.",
      "The acetylation of S6K1 is involved in the regulation of protein synthesis and cell growth.",
      "When mTORC1 is activated, it phosphorylates and activates S6K1.",
      "S6K1 is acetylated by the enzyme histone acetyltransferase (HAT)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe statements regarding the acetylation of S6K1 and its relationship with mTORC1 signaling pathway are specific to molecular biology and would require specific scientific evidence to confirm or refute. While it is true that S6K1 is a downstream target of mTORC1 and that its phosphorylation is involved in the regulation of protein synthesis and cell growth, the details of its acetylation, such as the enzyme responsible for this modification, would need to be verified with current scientific literature.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that is caused by mutations in the CACNA1A gene. This gene encodes a subunit of a complex called the calcium channel alpha-1A subunit, which is involved in the transmission of signals in the brain and nervous system. The mutations that cause EA6 lead to a dysfunction of this complex, resulting in episodes of ataxia (loss of coordination and balance) and other neurological symptoms. The disorder is usually inherited in an autosomal dominant pattern, meaning that a single copy of the mutated gene is enough to cause the condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is caused by mutations in the CACNA1A gene.\n2. The CACNA1A gene encodes a subunit of the calcium channel alpha-1A subunit complex.\n3. The calcium channel alpha-1A subunit complex is involved in the transmission of signals in the brain and nervous system.\n4. Mutations in the CACNA1A gene lead to dysfunction of the calcium channel alpha-1A subunit complex.\n5. Episodic ataxia type 6 is usually inherited in an autosomal dominant pattern.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is caused by mutations in the CACNA1A gene.",
      "The CACNA1A gene encodes a subunit of the calcium channel alpha-1A subunit complex.",
      "The calcium channel alpha-1A subunit complex is involved in the transmission of signals in the brain and nervous system.",
      "Mutations in the CACNA1A gene lead to dysfunction of the calcium channel alpha-1A subunit complex.",
      "Episodic ataxia type 6 is usually inherited in an autosomal dominant pattern."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add a methyl group to specific residues on histone proteins, which are the chief components of chromatin, the complex of DNA and proteins that make up the chromosomes. Histone methylation is a common epigenetic modification that plays a crucial role in regulating gene expression, chromatin structure, and cellular processes.\nIn animals, chromomethylases are involved in a variety of biological processes, including:\n1. Gene silencing: Chromomethylases can methylate histones to repress gene expression, particularly in the context of repetitive DNA elements.\n2. Chromatin remodeling: Chromomethylases can work with other chromatin-modifying enzymes to alter the structure of chromatin, allowing for more or less access to the DNA for transcriptional activators and repressors.\n3. Cellular differentiation: Chromomethylases have been implicated in the regulation of cellular differentiation, with specific patterns of histone methylation associated with different cell types.\n4. Cancer: Chromomethylases have been implicated in cancer, with altered patterns of histone methylation observed in cancer cells.\nSome examples of chromomethylases found in animal genomes include:\n1. Histone methyltransferases (HMTs): HMTs are the most well-studied class of chromomethylases in animals. They catalyze the transfer of a methyl group from S-adenosylmethionine to specific residues on histone proteins, leading to histone methylation.\n2. Lysine-specific demethylases (KDMs): KDMs are enzymes that remove methyl groups from histone lysine residues. They are involved in the demethylation of histones, which can lead to changes in chromatin structure and gene expression.\n3. Arginine methyltransferases (RMTs): RMTs are enzymes that add a methyl group to arginine residues on histone proteins. They are involved in the regulation of chromatin structure and gene expression.\n4.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are enzymes that add a methyl group to specific residues on histone proteins.\n2. Histone methylation is an epigenetic modification that plays a role in regulating gene expression and chromatin structure.\n3. In animals, chromomethylases are involved in gene silencing, particularly in the context of repetitive DNA elements.\n4. Histone methyltransferases (HMTs) are a class of chromomethylases that catalyze the transfer of a methyl group to histone proteins.\n5. Lysine-specific demethylases (KDMs) are enzymes that remove methyl groups from histone lysine residues.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are enzymes that add a methyl group to specific residues on histone proteins.",
      "Histone methylation is an epigenetic modification that plays a role in regulating gene expression and chromatin structure.",
      "In animals, chromomethylases are involved in gene silencing, particularly in the context of repetitive DNA elements.",
      "Histone methyltransferases (HMTs) are a class of chromomethylases that catalyze the transfer of a methyl group to histone proteins.",
      "Lysine-specific demethylases (KDMs) are enzymes that remove methyl groups from histone lysine residues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chromomethylases are enzymes that add a methyl group to specific residues on DNA, not histone proteins.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Histone methyltransferases (HMTs) are a class of enzymes that catalyze the transfer of a methyl group to histone proteins, but they are not referred to as chromomethylases.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "There are several packages available in R/Bioconductor for the analysis of transcription factor binding sites (TFBS). Here are some of the most popular ones:\n1. TFBS: This package provides a comprehensive set of tools for the analysis of TFBS, including the detection of TFBS motifs, prediction of TF-DNA interactions, and visualization of TFBS profiles.\n2. TRANSFAC: This package is a widely used tool for the analysis of TFBS. It provides a comprehensive database of TFBS motifs and their corresponding transcription factors, as well as tools for the prediction of TF-DNA interactions and the analysis of ChIP-seq data.\n3. ChIPseek: This package provides a simple and efficient way to identify TFBS in ChIP-seq data. It uses a probabilistic model to predict the binding sites of transcription factors and can be used to identify both known and novel TFBS.\n4. TFBS-tools: This package provides a collection of tools for the analysis of TFBS, including the detection of TFBS motifs, prediction of TF-DNA interactions, and visualization of TFBS profiles.\n5. TF-Pick: This package provides a tool for the prediction of TFBS in a given DNA sequence. It uses a machine learning approach to identify the most likely TFBS motifs and can be used to identify both known and novel TFBS.\n6. TF-Watch: This package provides a tool for the real-time monitoring of TFBS in a given DNA sequence. It uses a dynamic programming approach to identify the most likely TFBS motifs and can be used to identify both known and novel TFBS.\n7. TF-Rank: This package provides a tool for the ranking of TFBS in a given DNA sequence. It uses a machine learning approach to identify the most likely TFBS motifs and can be used to identify both known and novel TFBS.\n8. TF-Predict: This package provides a tool for the prediction of TFBS in a given DNA sequence. It uses a machine learning approach to identify the most likely TFBS motifs and can be used to identify both known and novel TFBS.\n9. TF-Profiler: This package provides a tool for the profiling",
    "llama-2-7b-chat-hf_fact_raw": "1. The TFBS package in R/Bioconductor provides tools for the detection of TFBS motifs, prediction of TF-DNA interactions, and visualization of TFBS profiles.\n2. The TRANSFAC package in R/Bioconductor includes a database of TFBS motifs and transcription factors, and tools for TF-DNA interaction prediction and ChIP-seq data analysis.\n3. ChIPseek is a package in R/Bioconductor that predicts TFBS in ChIP-seq data using a probabilistic model.\n4. TFBS-tools is a collection of tools in R/Bioconductor for TFBS analysis, including detection of motifs, prediction of interactions, and visualization.\n5. TF-Pick is a package in R/Bioconductor that uses machine learning to predict TFBS in DNA sequences.",
    "llama-2-7b-chat-hf_fact": [
      "The TFBS package in R/Bioconductor provides tools for the detection of TFBS motifs, prediction of TF-DNA interactions, and visualization of TFBS profiles.",
      "The TRANSFAC package in R/Bioconductor includes a database of TFBS motifs and transcription factors, and tools for TF-DNA interaction prediction and ChIP-seq data analysis.",
      "ChIPseek is a package in R/Bioconductor that predicts TFBS in ChIP-seq data using a probabilistic model.",
      "TFBS-tools is a collection of tools in R/Bioconductor for TFBS analysis, including detection of motifs, prediction of interactions, and visualization.",
      "TF-Pick is a package in R/Bioconductor that uses machine learning to predict TFBS in DNA sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The TRANSFAC package itself is not part of R/Bioconductor. TRANSFAC is a database of transcription factors and their DNA binding sites, but it is not a package within R/Bioconductor. However, there may be R/Bioconductor packages that interface with the TRANSFAC database or include similar data.\n3. UNKNOWN: Without specific information about a package named \"ChIPseek\" in R/Bioconductor, it is not possible to confirm the accuracy of this statement. There is a package called \"ChIPseeker\" which is used for annotating ChIP-seq data and identifying TFBS, but it does not specifically mention a probabilistic model for TFBS prediction.\n4. UNKNOWN: The name \"TFBS-tools\" does not correspond to a known package in R/Bioconductor. However, the functionalities described are common in various R/Bioconductor packages related to TFBS analysis. The statement could be referring to a hypothetical collection of tools or a specific package not officially recognized under that name.\n5. UNKNOWN: There is no information available about a package called \"TF-Pick\" in R/Bioconductor. It is possible that the package exists and uses machine learning for predicting TFBS, but without further information, the accuracy of this statement cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Sarcopenia is the progressive loss of muscle mass and strength that occurs with aging. While there are currently no FDA-approved treatments for sarcopenia, several clinical trials are underway to evaluate the effectiveness of various interventions in preventing or slowing the progression of this condition. Here are some of the ongoing clinical trials for the prevention of sarcopenia:\n1. Resistance Training and Nutritional Interventions to Prevent Sarcopenia (RRNS): This randomized controlled trial is evaluating the effectiveness of resistance training and nutritional interventions in preventing sarcopenia in older adults.\n2. Sarcopenia Prevention with Omega-3 Fatty Acids (SPO3): This randomized controlled trial is investigating the effectiveness of omega-3 fatty acid supplementation in preventing sarcopenia in older adults.\n3. Vitamin D and Omega-3 Fatty Acid Supplementation to Prevent Sarcopenia (VITALS): This randomized controlled trial is evaluating the effectiveness of vitamin D and omega-3 fatty acid supplementation in preventing sarcopenia in older adults.\n4. Resveratrol for Sarcopenia Prevention (RESPOND): This randomized controlled trial is investigating the effectiveness of resveratrol supplementation in preventing sarcopenia in older adults.\n5. Exercise and Nutrition Interventions to Prevent Sarcopenia (ENIGMA): This randomized controlled trial is evaluating the effectiveness of exercise and nutrition interventions in preventing sarcopenia in older adults.\n6. Sarcopenia Prevention with Plant-Based Nutrition (SPRINT): This randomized controlled trial is investigating the effectiveness of a plant-based nutrition intervention in preventing sarcopenia in older adults.\n7. Tai Chi for Sarcopenia Prevention (TaiSP): This randomized controlled trial is evaluating the effectiveness of tai chi exercise in preventing sarcopenia in older adults.\n8. Music Intervention for Sarcopenia Prevention (MUSIC): This randomized controlled trial",
    "llama-2-7b-chat-hf_fact_raw": "1. The RRNS trial is a randomized controlled trial evaluating resistance training and nutritional interventions for preventing sarcopenia in older adults.\n2. The SPO3 trial is a randomized controlled trial investigating the effectiveness of omega-3 fatty acid supplementation in preventing sarcopenia in older adults.\n3. The VITALS trial is a randomized controlled trial evaluating the effectiveness of vitamin D and omega-3 fatty acid supplementation in preventing sarcopenia in older adults.\n4. The RESPOND trial is a randomized controlled trial investigating the effectiveness of resveratrol supplementation in preventing sarcopenia in older adults.\n5. The ENIGMA trial is a randomized controlled trial evaluating the effectiveness of exercise and nutrition interventions in preventing sarcopenia in older adults.",
    "llama-2-7b-chat-hf_fact": [
      "The RRNS trial is a randomized controlled trial evaluating resistance training and nutritional interventions for preventing sarcopenia in older adults.",
      "The SPO3 trial is a randomized controlled trial investigating the effectiveness of omega-3 fatty acid supplementation in preventing sarcopenia in older adults.",
      "The VITALS trial is a randomized controlled trial evaluating the effectiveness of vitamin D and omega-3 fatty acid supplementation in preventing sarcopenia in older adults.",
      "The RESPOND trial is a randomized controlled trial investigating the effectiveness of resveratrol supplementation in preventing sarcopenia in older adults.",
      "The ENIGMA trial is a randomized controlled trial evaluating the effectiveness of exercise and nutrition interventions in preventing sarcopenia in older adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the trials mentioned, it is not possible to determine the accuracy of these statements. The names of the trials (RRNS, SPO3, VITALS, RESPOND, ENIGMA) do not provide enough context to verify the claims made about their focus and interventions.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins that provide information on the structural and functional properties of these proteins. Here are some of the most popular databases:\n1. Membrane Protein Databank (MPDB): This is a comprehensive database of membrane proteins, including their structures, functions, and interactions. It contains information on the molecular recognition features of membrane proteins, such as transmembrane helices, loops, and binding sites.\n2. Protein Data Bank (PDB): This is a database of 3D structures of proteins, including membrane proteins. It provides information on the structure and function of membrane proteins, as well as their molecular recognition features.\n3. Membrane Protein Structural Database (MPSD): This database contains the structural information of membrane proteins, including their three-dimensional structures, functional sites, and binding sites. It also provides information on the molecular recognition features of membrane proteins.\n4. Membrane Protein Interaction Database (MPID): This database contains information on the interactions between membrane proteins and other molecules, including ligands, substrates, and other proteins. It provides information on the molecular recognition features of membrane proteins and their interactions with other molecules.\n5. Membrane Protein Functional Site Database (MPFS): This database contains information on the functional sites of membrane proteins, including binding sites, active sites, and transport sites. It provides information on the molecular recognition features of membrane proteins and their functional properties.\n6. Membrane Protein-Ligand Interaction Database (MP-LIB): This database contains information on the interactions between membrane proteins and ligands, including small molecules, peptides, and proteins. It provides information on the molecular recognition features of membrane proteins and their interactions with ligands.\n7. Membrane Protein-Protein Interaction Database (MP-PIB): This database contains information on the interactions between membrane proteins and other proteins, including protein-protein interactions and protein-ligand interactions. It provides information on the molecular recognition features of membrane proteins and their interactions with other proteins.\nThese databases are valuable resources for researchers studying membrane proteins and their mole",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Databank (MPDB) is a database that includes structures, functions, and interactions of membrane proteins.\n2. The Protein Data Bank (PDB) is a database that provides 3D structures of proteins, including membrane proteins.\n3. The Membrane Protein Structural Database (MPSD) contains structural information of membrane proteins, including their three-dimensional structures and functional sites.\n4. The Membrane Protein Interaction Database (MPID) provides information on interactions between membrane proteins and other molecules.\n5. The Membrane Protein Functional Site Database (MPFS) contains information on the functional sites of membrane proteins, such as binding sites and active sites.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Databank (MPDB) is a database that includes structures, functions, and interactions of membrane proteins.",
      "The Protein Data Bank (PDB) is a database that provides 3D structures of proteins, including membrane proteins.",
      "The Membrane Protein Structural Database (MPSD) contains structural information of membrane proteins, including their three-dimensional structures and functional sites.",
      "The Membrane Protein Interaction Database (MPID) provides information on interactions between membrane proteins and other molecules.",
      "The Membrane Protein Functional Site Database (MPFS) contains information on the functional sites of membrane proteins, such as binding sites and active sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about the Membrane Protein Structural Database (MPSD), Membrane Protein Interaction Database (MPID), and Membrane Protein Functional Site Database (MPFS) cannot be verified as true or false without specific knowledge about these databases. These names do not correspond to well-known databases in the field of bioinformatics, and without additional context or information, it is not possible to determine the accuracy of these statements. If these databases exist and the descriptions provided are accurate, then the statements would be true. However, without further information, their status must remain UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys. Rivaroxaban is a direct oral anticoagulant (DOAC) that is metabolized by the liver and kidneys. The main metabolic pathway of rivaroxaban involves the enzyme CYP2C9, which is primarily found in the liver, and to a lesser extent in the kidneys. The kidneys also play a role in the elimination of rivaroxaban, as the drug is excreted primarily in the urine.\nApproximately 70% of the administered dose of rivaroxaban is recovered in the urine as the parent drug or as metabolites. The main metabolite of rivaroxaban, which accounts for approximately 40% of the total drug content in the urine, is the 3-hydroxy-rivaroxaban metabolite. Other metabolites of rivaroxaban include the 3-carboxy-rivaroxaban metabolite and the 3-glucuronide-rivaroxaban metabolite.\nThe kidneys play a critical role in the elimination of rivaroxaban, particularly in patients with impaired liver function. In these patients, the kidneys may be responsible for a larger proportion of drug elimination, which can affect the efficacy and safety of the drug. Therefore, it is important to monitor renal function in patients taking rivaroxaban and to adjust the dose or discontinue the drug if renal function is compromised.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized by the liver and kidneys.\n2. The enzyme CYP2C9, which is primarily found in the liver, is involved in the main metabolic pathway of rivaroxaban.\n3. The kidneys are responsible for the elimination of rivaroxaban, with the drug being excreted primarily in the urine.\n4. Approximately 70% of the administered dose of rivaroxaban is recovered in the urine as the parent drug or as metabolites.\n5. The main metabolite of rivaroxaban in the urine is the 3-hydroxy-rivaroxaban metabolite, accounting for about 40% of the total drug content.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized by the liver and kidneys.",
      "The enzyme CYP2C9, which is primarily found in the liver, is involved in the main metabolic pathway of rivaroxaban.",
      "The kidneys are responsible for the elimination of rivaroxaban, with the drug being excreted primarily in the urine.",
      "Approximately 70% of the administered dose of rivaroxaban is recovered in the urine as the parent drug or as metabolites.",
      "The main metabolite of rivaroxaban in the urine is the 3-hydroxy-rivaroxaban metabolite, accounting for about 40% of the total drug content."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The enzyme CYP3A4, not CYP2C9, is involved in the main metabolic pathway of rivaroxaban.\n3. TRUE\n4. FALSE [correction]: Approximately one-third of the administered dose of rivaroxaban is recovered in the urine as the parent drug or as metabolites.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRalpha2 (Throughfall Receptor Alpha 2) is a G protein-coupled receptor that is primarily expressed in the heart, where it plays a crucial role in regulating cardiac function. The activation of TRalpha2 by its endogenous ligand, atrial natriuretic peptide (ANP), leads to the activation of downstream signaling pathways that regulate a variety of cardiac functions, including:\n1. Cardiac hypertrophy: TRalpha2 activation has been shown to inhibit cardiac hypertrophy by reducing the expression of genes involved in hypertrophy, such as ANF (atrial natriuretic factor) and BNP (brain natriuretic peptide).\n2. Contractility: TRalpha2 activation can increase the contractility of the heart by upregulating genes involved in the contractile apparatus, such as MYH7 (myosin heavy chain 7) and TNNI3 (troponin I3).\n3. Autophagy: TRalpha2 activation has been shown to promote autophagy in the heart, which is a cellular process that helps to maintain cardiac function by removing damaged or dysfunctional organelles and proteins.\n4. Inflammation: TRalpha2 activation can reduce inflammation in the heart by suppressing the expression of pro-inflammatory genes, such as NFKB1 (nuclear factor kappa B 1).\n5. Cardiac remodeling: TRalpha2 activation can reduce cardiac remodeling by inhibiting the expression of genes involved in fibrosis and hypertrophy, such as TGFBR1 (transforming growth factor receptor 1).\nSome of the genes that are directly regulated by TRalpha2 in the heart include:\n* ANF (atrial natriuretic factor)\n* BNP (brain natriuretic peptide)\n* MYH7 (myosin heavy chain 7)\n* TNNI3 (troponin I3)\n* NFKB1 (nuclear factor kappa B 1)\n* TGFBR1 (transforming growth factor receptor 1)\nIt'",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 is primarily expressed in the heart and regulates cardiac function.\n2. TRalpha2 activation inhibits cardiac hypertrophy by reducing the expression of genes such as ANF and BNP.\n3. TRalpha2 activation can increase the contractility of the heart by upregulating genes like MYH7 and TNNI3.\n4. TRalpha2 activation promotes autophagy in the heart, a process for removing damaged organelles and proteins.\n5. TRalpha2 activation can reduce inflammation in the heart by suppressing the expression of pro-inflammatory genes such as NFKB1.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 is primarily expressed in the heart and regulates cardiac function.",
      "TRalpha2 activation inhibits cardiac hypertrophy by reducing the expression of genes such as ANF and BNP.",
      "TRalpha2 activation can increase the contractility of the heart by upregulating genes like MYH7 and TNNI3.",
      "TRalpha2 activation promotes autophagy in the heart, a process for removing damaged organelles and proteins.",
      "TRalpha2 activation can reduce inflammation in the heart by suppressing the expression of pro-inflammatory genes such as NFKB1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific to the field of molecular biology and concern the role of TRalpha2, a thyroid hormone receptor isoform, in cardiac function. Without access to the specific scientific literature or studies that these statements are based on, it is not possible to accurately verify their truthfulness. These statements would require expert knowledge in molecular cardiology and an understanding of the current research on thyroid hormone receptors and their impact on heart physiology.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Here are some of the available biomedical question answering systems:\n1. PubMedQA: This is a biomedical question answering system that uses natural language processing and machine learning techniques to answer questions based on the PubMed database of biomedical literature.\n2. BioASQ: This is a benchmark dataset and evaluation tool for biomedical question answering systems. It contains a collection of questions and answers related to various biomedical topics.\n3. Med2RDF: This is a biomedical question answering system that uses a knowledge graph to represent biomedical knowledge and answer questions.\n4. BioPortal: This is a question answering system that uses a combination of natural language processing and machine learning techniques to answer biomedical questions.\n5. Biomedical Information Retrieval System (BIRS): This is a question answering system that uses a combination of natural language processing and machine learning techniques to answer biomedical questions.\n6. Biomedical Question Answering System (BQAS): This is a question answering system that uses a combination of natural language processing and machine learning techniques to answer biomedical questions.\n7. Medical Information Retrieval System (MIRS): This is a question answering system that uses a combination of natural language processing and machine learning techniques to answer medical questions.\n8. Biomedical Text Mining System (BTMS): This is a question answering system that uses natural language processing and machine learning techniques to mine biomedical text and answer questions.\n9. Biomedical Knowledge Graph Embedding (BKGE): This is a question answering system that uses a knowledge graph to represent biomedical knowledge and answer questions.\n10. Biomedical Question Answering with Deep Learning (BQADL): This is a question answering system that uses deep learning techniques to answer biomedical questions.\nThese are just a few examples of the many biomedical question answering systems available. Each system has its own strengths and limitations, and the choice of which system to use will depend on the specific needs and goals of the user.",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMedQA is a biomedical question answering system that utilizes natural language processing and machine learning to answer questions from the PubMed database.\n2. BioASQ is a benchmark dataset and evaluation tool for biomedical question answering systems, containing a collection of biomedical questions and answers.\n3. Med2RDF is a biomedical question answering system that employs a knowledge graph to represent and answer biomedical questions.\n4. BioPortal is a question answering system that uses natural language processing and machine learning to answer biomedical questions.\n5. Biomedical Information Retrieval System (BIRS) uses natural language processing and machine learning to answer biomedical questions.",
    "llama-2-7b-chat-hf_fact": [
      "PubMedQA is a biomedical question answering system that utilizes natural language processing and machine learning to answer questions from the PubMed database.",
      "BioASQ is a benchmark dataset and evaluation tool for biomedical question answering systems, containing a collection of biomedical questions and answers.",
      "Med2RDF is a biomedical question answering system that employs a knowledge graph to represent and answer biomedical questions.",
      "BioPortal is a question answering system that uses natural language processing and machine learning to answer biomedical questions.",
      "Biomedical Information Retrieval System (BIRS) uses natural language processing and machine learning to answer biomedical questions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PubMedQA is a dataset for biomedical question answering research, not a question answering system itself.\n2. TRUE\n3. FALSE [correction]: Med2RDF is not a question answering system; it is a framework to convert biomedical information into RDF (Resource Description Framework) format, which can be used to create knowledge graphs.\n4. FALSE [correction]: BioPortal is not a question answering system; it is a repository of biomedical ontologies that provides access via web services and web browsers for browsing and querying.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The transcription factor that activates the betalain pathway is ABSCISIC ACID INSENSITIVE 3 (ABI3). ABI3 is a transcription factor that regulates the expression of genes involved in the biosynthesis of betalains, which are a class of plant secondary metabolites that are involved in various physiological processes, including defense against pathogens and insects. ABI3 is a key regulator of the betalain pathway and is activated in response to various abiotic and biotic stress signals, leading to the upregulation of betalain biosynthesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. ABSCISIC ACID INSENSITIVE 3 (ABI3) is a transcription factor that activates the betalain pathway.\n2. ABI3 regulates the expression of genes involved in the biosynthesis of betalains.\n3. Betalains are a class of plant secondary metabolites.\n4. Betalains are involved in various physiological processes, including defense against pathogens and insects.\n5. ABI3 is activated in response to various abiotic and biotic stress signals.",
    "llama-2-7b-chat-hf_fact": [
      "ABSCISIC ACID INSENSITIVE 3 (ABI3) is a transcription factor that activates the betalain pathway.",
      "ABI3 regulates the expression of genes involved in the biosynthesis of betalains.",
      "Betalains are a class of plant secondary metabolites.",
      "Betalains are involved in various physiological processes, including defense against pathogens and insects.",
      "ABI3 is activated in response to various abiotic and biotic stress signals."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ABSCISIC ACID INSENSITIVE 3 (ABI3) is a transcription factor, but it is not known to activate the betalain pathway. ABI3 is primarily involved in seed development and response to abscisic acid.\n2. FALSE [correction]: ABI3 does not regulate the expression of genes involved in the biosynthesis of betalains. It is involved in the regulation of genes during seed maturation and germination.\n3. TRUE: Betalains are indeed a class of red and yellow indole-derived pigments found in the Caryophyllales group of plants.\n4. TRUE: Betalains are involved in various physiological processes, including defense against pathogens and insects, as well as attracting pollinators and acting as antioxidants.\n5. TRUE: ABI3 is known to be activated in response to various abiotic stresses such as drought, salinity, and cold, and it plays a role in plant response to these stresses. However, its role in biotic stress responses is less clear, so this statement could be considered vague without specific context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "There are several technologies that are commonly used for enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses. Here are some of the preferred technologies:\n1. TiO2-based enrichment: This method uses titanium dioxide (TiO2) to selectively bind phosphorylated peptides based on their charge and hydrophilicity. The phosphorylated peptides are first labeled with a fluorescent dye, and then incubated with TiO2 beads. The beads are then washed and analyzed using mass spectrometry.\n2. IMAC (Immobilized Metal Affinity Chromatography): This method uses metal ions (e.g. copper or nickel) to selectively bind phosphorylated peptides based on their charge and hydrophilicity. The phosphorylated peptides are first labeled with a metal-specific tag, and then incubated with an immobilized metal ion affinity matrix. The matrix is then washed and analyzed using mass spectrometry.\n3. Cation exchange (CE) chromatography: This method uses a cation exchange resin to selectively bind phosphorylated peptides based on their charge. The phosphorylated peptides are first labeled with a cation-specific tag, and then incubated with a cation exchange resin. The resin is then washed and analyzed using mass spectrometry.\n4. Hydrophilic interaction liquid chromatography (HILIC): This method uses a hydrophilic interaction resin to selectively bind phosphorylated peptides based on their hydrophilicity. The phosphorylated peptides are first labeled with a hydrophilic tag, and then incubated with a hydrophilic interaction resin. The resin is then washed and analyzed using mass spectrometry.\n5. Reversed-phase HPLC: This method uses a reversed-phase column to separate phosphorylated peptides based on their hydrophobicity. The phosphorylated peptides are first labeled with a hydrophobic tag, and then separated using a",
    "llama-2-7b-chat-hf_fact_raw": "1. Titanium dioxide (TiO2)-based enrichment is used to selectively bind phosphorylated peptides for global quantitative phosphoproteomic analyses.\n2. Immobilized Metal Affinity Chromatography (IMAC) uses metal ions to bind phosphorylated peptides for enrichment in phosphoproteomic studies.\n3. Cation exchange (CE) chromatography is a method that uses a cation exchange resin to bind phosphorylated peptides based on their charge.\n4. Hydrophilic interaction liquid chromatography (HILIC) is used to selectively bind phosphorylated peptides based on their hydrophilicity.\n5. Reversed-phase High-Performance Liquid Chromatography (HPLC) separates phosphorylated peptides based on their hydrophobicity.",
    "llama-2-7b-chat-hf_fact": [
      "Titanium dioxide (TiO2)-based enrichment is used to selectively bind phosphorylated peptides for global quantitative phosphoproteomic analyses.",
      "Immobilized Metal Affinity Chromatography (IMAC) uses metal ions to bind phosphorylated peptides for enrichment in phosphoproteomic studies.",
      "Cation exchange (CE) chromatography is a method that uses a cation exchange resin to bind phosphorylated peptides based on their charge.",
      "Hydrophilic interaction liquid chromatography (HILIC) is used to selectively bind phosphorylated peptides based on their hydrophilicity.",
      "Reversed-phase High-Performance Liquid Chromatography (HPLC) separates phosphorylated peptides based on their hydrophobicity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll the statements provided are true and accurately describe various methods and principles used in phosphoproteomic analyses for the enrichment and separation of phosphorylated peptides.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "The Palmini classification is used to rate the severity of symptoms in patients with multiple system atrophy (MSA), which is a rare, progressive neurodegenerative disorder that affects both the central and autonomic nervous systems. The Palmini classification system categorizes MSA into four subtypes based on the distribution and severity of symptoms, including cerebellar, cerebral, autonomic, and pure cerebellar types.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Palmini classification is used to rate the severity of symptoms in patients with multiple system atrophy (MSA).\n2. Multiple system atrophy is a progressive neurodegenerative disorder.\n3. Multiple system atrophy affects both the central and autonomic nervous systems.\n4. The Palmini classification system categorizes MSA into four subtypes.\n5. The subtypes of MSA according to the Palmini classification include cerebellar, cerebral, autonomic, and pure cerebellar types.",
    "llama-2-7b-chat-hf_fact": [
      "The Palmini classification is used to rate the severity of symptoms in patients with multiple system atrophy (MSA).",
      "Multiple system atrophy is a progressive neurodegenerative disorder.",
      "Multiple system atrophy affects both the central and autonomic nervous systems.",
      "The Palmini classification system categorizes MSA into four subtypes.",
      "The subtypes of MSA according to the Palmini classification include cerebellar, cerebral, autonomic, and pure cerebellar types."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Palmini classification is not used for multiple system atrophy (MSA); it is used for classifying types of epilepsy, particularly focal cortical dysplasia. The severity of symptoms in MSA is often rated using scales such as the Unified Multiple System Atrophy Rating Scale (UMSARS).\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Palmini classification does not categorize MSA into subtypes as it is not used for MSA. MSA is typically categorized into two subtypes based on the predominant symptoms: MSA with predominant parkinsonism (MSA-P) and MSA with predominant cerebellar ataxia (MSA-C).\n5. FALSE [correction]: The subtypes mentioned are not part of the Palmini classification for MSA. As previously stated, the Palmini classification is related to epilepsy, not MSA. The subtypes of MSA are MSA-P and MSA-C, as mentioned above.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory condition of the thyroid gland that can cause pain, swelling, and difficulty swallowing. While the exact cause of subacute thyroiditis is not fully understood, there is evidence to suggest that viral infections play a role in its development.\nSeveral viruses have been linked to the development of subacute thyroiditis, including:\n1. Viruses that infect the thyroid gland directly: Some viruses, such as the thyroid gland-specific virus (TGSV), have been shown to directly infect the thyroid gland and cause inflammation and damage to the gland.\n2. Viruses that infect other parts of the body: Viruses that infect other parts of the body, such as the respiratory or gastrointestinal tracts, can also cause systemic inflammation and spread to the thyroid gland, leading to subacute thyroiditis.\n3. Herpesviruses: Herpesviruses, such as herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6), have been implicated in the development of subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viruses have been implicated in the etiology of human subacute thyroiditis.\n2. Subacute thyroiditis is an inflammatory condition of the thyroid gland that can cause pain, swelling, and difficulty swallowing.\n3. There is evidence to suggest that viral infections play a role in the development of subacute thyroiditis.\n4. The thyroid gland-specific virus (TGSV) has been shown to directly infect the thyroid gland.\n5. Herpesviruses, such as herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6), have been implicated in the development of subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact": [
      "Viruses have been implicated in the etiology of human subacute thyroiditis.",
      "Subacute thyroiditis is an inflammatory condition of the thyroid gland that can cause pain, swelling, and difficulty swallowing.",
      "There is evidence to suggest that viral infections play a role in the development of subacute thyroiditis.",
      "The thyroid gland-specific virus (TGSV) has been shown to directly infect the thyroid gland.",
      "Herpesviruses, such as herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6), have been implicated in the development of subacute thyroiditis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Viruses have been implicated in the etiology of human subacute thyroiditis, with several studies suggesting a link between viral infections and the condition.\n2. TRUE: Subacute thyroiditis, also known as de Quervain's thyroiditis, is indeed an inflammatory condition of the thyroid gland that can cause symptoms such as pain, swelling, and difficulty swallowing.\n3. TRUE: There is scientific evidence to support the idea that viral infections can trigger subacute thyroiditis in some individuals.\n4. FALSE [correction]: There is no known virus called the \"thyroid gland-specific virus (TGSV)\" that has been shown to directly infect the thyroid gland. This statement appears to be incorrect or based on a misunderstanding.\n5. TRUE: Herpesviruses, including herpes simplex virus (HSV) and human herpesvirus 6 (HHV-6), have been implicated in the development of various thyroid conditions, including subacute thyroiditis, although the exact mechanisms and the strength of the association may vary.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Yes, STAT3 (Signal Transducer and Activator of Transcription 3) is involved in EIF2AK2-dependent suppression of autophagy. EIF2AK2 (Eukaryotic Translation Initiation Factor 2-Associated Kinase 2) is a kinase that phosphorylates and inhibits the translation initiation factor eIF2α, leading to suppression of global protein synthesis. STAT3 is a transcription factor that is involved in many cellular processes, including the regulation of autophagy.\nRecent studies have shown that STAT3 and EIF2AK2 interact and cooperate to suppress autophagy. EIF2AK2 phosphorylates and inhibits STAT3, leading to its nuclear exclusion and inactivation. This inactivation of STAT3 prevents it from activating the expression of genes involved in autophagy, such as ATG5 and ATG7. As a result, the suppression of autophagy is maintained, and cells are more susceptible to stress and survive under conditions of limited nutrients or oxidative stress.\nIn summary, EIF2AK2-dependent suppression of autophagy involves the inhibition of STAT3, which is a key transcription factor that regulates the expression of genes involved in autophagy.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is involved in EIF2AK2-dependent suppression of autophagy.\n2. EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2α.\n3. STAT3 is a transcription factor that regulates the expression of genes involved in autophagy.\n4. Recent studies have indicated that STAT3 and EIF2AK2 interact to suppress autophagy.\n5. EIF2AK2 phosphorylates and inhibits STAT3, leading to its nuclear exclusion and inactivation.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is involved in EIF2AK2-dependent suppression of autophagy.",
      "EIF2AK2 phosphorylates and inhibits the translation initiation factor eIF2α.",
      "STAT3 is a transcription factor that regulates the expression of genes involved in autophagy.",
      "Recent studies have indicated that STAT3 and EIF2AK2 interact to suppress autophagy.",
      "EIF2AK2 phosphorylates and inhibits STAT3, leading to its nuclear exclusion and inactivation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: EIF2AK2 (also known as PKR) does not phosphorylate and inhibit STAT3. Instead, EIF2AK2 phosphorylates the translation initiation factor eIF2α, which can lead to the inhibition of general protein synthesis under stress conditions. STAT3's activity is regulated by different kinases, such as JAK2, which phosphorylates STAT3, leading to its dimerization, nuclear translocation, and activation of gene transcription.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool designed for genomic analysis, particularly for the analysis of next-generation sequencing (NGS) data. It is used to visualize and interpret the results of high-throughput sequencing experiments, such as RNA-seq, ChIP-seq, and DNA sequencing. Here are some of the key usage scenarios for Theatre:\n1. Data visualization: Theatre allows users to visualize large-scale genomic data sets, such as gene expression profiles, DNA methylation patterns, or chromatin structure. It provides a variety of visualization tools, including heat maps, scatter plots, and 3D visualizations, to help researchers identify patterns and trends in the data.\n2. Data analysis: Theatre includes a range of analytical tools for processing and interpreting NGS data. For example, it can be used to identify differentially expressed genes between different samples, to detect novel transcripts or splice variants, or to identify regions of the genome with altered methylation patterns.\n3. Data integration: Theatre can be used to integrate data from multiple sources, such as RNA-seq and DNA sequencing data, to gain a more comprehensive understanding of the genome. It can also be used to integrate data from different experimental conditions, such as comparing gene expression between healthy and diseased tissues.\n4. Collaboration: Theatre allows researchers to share and collaborate on genomic analysis projects. It provides a web-based platform for data sharing, annotation, and discussion, making it easier for researchers to work together on large-scale genomic projects.\n5. Education: Theatre can be used as a teaching tool for genomics courses, providing a user-friendly platform for students to explore and analyze genomic data.\n6. Data storage: Theatre can be used to store and manage large-scale genomic data sets, providing a centralized repository for researchers to access and analyze data.\n7. Data sharing: Theatre can be used to share genomic data with other researchers, providing a platform for data sharing and collaboration.\n8. Data reproducibility: Theatre provides a platform for researchers to document and share their analysis pipelines, making it easier for others to reproduce and validate their results.\n9. Data mining: Theatre can be used to mine large-scale genomic data sets for novel insights and discoveries, such as identifying",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool used for the analysis of next-generation sequencing (NGS) data.\n2. Theatre provides visualization tools like heat maps, scatter plots, and 3D visualizations for genomic data sets.\n3. The software includes analytical tools to identify differentially expressed genes and detect novel transcripts or splice variants.\n4. Theatre allows for the integration of data from multiple sources, such as RNA-seq and DNA sequencing data.\n5. Theatre offers a web-based platform for researchers to share, annotate, and collaborate on genomic analysis projects.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool used for the analysis of next-generation sequencing (NGS) data.",
      "Theatre provides visualization tools like heat maps, scatter plots, and 3D visualizations for genomic data sets.",
      "The software includes analytical tools to identify differentially expressed genes and detect novel transcripts or splice variants.",
      "Theatre allows for the integration of data from multiple sources, such as RNA-seq and DNA sequencing data.",
      "Theatre offers a web-based platform for researchers to share, annotate, and collaborate on genomic analysis projects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The statement is too vague to determine its truthfulness without additional context. \"Theatre\" is not a commonly recognized software tool for NGS data analysis; however, it could be a specific or proprietary tool not widely known. More commonly recognized tools include Galaxy, IGV, or GATK.\n2. UNKNOWN: Without specific information about the software tool \"Theatre,\" it is not possible to confirm the types of visualization tools it provides.\n3. UNKNOWN: Similar to the previous statement, without specific information about \"Theatre,\" it is not possible to confirm the analytical tools it includes.\n4. UNKNOWN: The ability to integrate data from multiple sources is a feature of many NGS data analysis tools, but without specific information about \"Theatre,\" the truthfulness of this statement cannot be determined.\n5. UNKNOWN: The provision of a web-based platform for collaboration is a feature of some genomic analysis tools, but without specific information about \"Theatre,\" it is not possible to confirm this feature.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the specific implementation and the size of the sequences. However, here are some general guidelines on the complexity of the Smith-Waterman algorithm:\n* Time complexity: The time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence. This is because the algorithm scans through the shorter sequence once for each position in the longer sequence, and the number of positions in the longer sequence is proportional to n.\n* Space complexity: The space complexity of the Smith-Waterman algorithm is O(n), where n is the length of the shorter sequence. This is because the algorithm only needs to store the shorter sequence and the corresponding scores for each position in the longer sequence.\n* Worst-case time complexity: The worst-case time complexity of the Smith-Waterman algorithm can be O(n^3) for certain types of input sequences. This occurs when the sequences are perfectly complementary, meaning that every position in one sequence has a perfect match with a position in the other sequence. In this case, the algorithm needs to compare every position in the shorter sequence with every position in the longer sequence, which leads to a worst-case time complexity of O(n^3).\n* Average-case time complexity: The average-case time complexity of the Smith-Waterman algorithm is typically much faster than the worst-case time complexity, with a time complexity of O(n^2) or O(n^2 log n) for most input sequences. This is because the sequences are typically not perfectly complementary, so the algorithm can use heuristics to reduce the number of comparisons needed.\n* Practical time complexity: In practice, the time complexity of the Smith-Waterman algorithm can be much faster than the worst-case time complexity, especially for longer sequences. Modern computers have a large number of cores and a large amount of memory, which allows for parallelization and the use of more efficient algorithms. For example, the time complexity of the Smith-Waterman algorithm for aligning two sequences of length 1000 can be around 1-10 seconds on a modern computer.\nIn summary, the execution time of the Smith-Waterman algorithm for the alignment of two sequences depends on the size of the sequences and the specific implementation, but",
    "llama-2-7b-chat-hf_fact_raw": "1. The time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\n2. The space complexity of the Smith-Waterman algorithm is O(n), where n is the length of the shorter sequence.\n3. The worst-case time complexity of the Smith-Waterman algorithm can be O(n^3) for certain types of input sequences.\n4. The average-case time complexity of the Smith-Waterman algorithm is typically O(n^2) or O(n^2 log n) for most input sequences.\n5. The practical time complexity of the Smith-Waterman algorithm for aligning two sequences of length 1000 can be around 1-10 seconds on a modern computer.",
    "llama-2-7b-chat-hf_fact": [
      "The time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.",
      "The space complexity of the Smith-Waterman algorithm is O(n), where n is the length of the shorter sequence.",
      "The worst-case time complexity of the Smith-Waterman algorithm can be O(n^3) for certain types of input sequences.",
      "The average-case time complexity of the Smith-Waterman algorithm is typically O(n^2) or O(n^2 log n) for most input sequences.",
      "The practical time complexity of the Smith-Waterman algorithm for aligning two sequences of length 1000 can be around 1-10 seconds on a modern computer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The space complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\n3. FALSE [correction]: The worst-case time complexity of the Smith-Waterman algorithm is O(n^2), not O(n^3), where n is the length of the shorter sequence.\n4. FALSE [correction]: The average-case time complexity of the Smith-Waterman algorithm is typically O(n^2), not O(n^2 log n), for most input sequences.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 (Flavocyclin-like 1) is a member of the Solute Carrier (SLC) family of transmembrane transporters. Specifically, FLVCR1 is a member of the SLC16 subfamily, which is also known as the ATP-binding cassette (ABC) transporter superfamily.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 stands for Flavocyclin-like 1.\n2. FLVCR1 is a member of the Solute Carrier (SLC) family of transmembrane transporters.\n3. FLVCR1 is part of the SLC16 subfamily.\n4. The SLC16 subfamily is also known as the ATP-binding cassette (ABC) transporter superfamily.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 stands for Flavocyclin-like 1.",
      "FLVCR1 is a member of the Solute Carrier (SLC) family of transmembrane transporters.",
      "FLVCR1 is part of the SLC16 subfamily.",
      "The SLC16 subfamily is also known as the ATP-binding cassette (ABC) transporter superfamily."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 stands for Feline leukemia virus subgroup C cellular receptor 1.\n2. FALSE [correction]: FLVCR1 is a member of the Major Facilitator Superfamily (MFS) of transporters, not the Solute Carrier (SLC) family.\n3. FALSE [correction]: FLVCR1 is not part of the SLC16 subfamily; it is part of the Major Facilitator Superfamily (MFS).\n4. FALSE [correction]: The SLC16 subfamily is known as the Monocarboxylate Transporter (MCT) family, not the ATP-binding cassette (ABC) transporter superfamily. The ABC transporter superfamily is a different group of transporters.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "GATA-1 is a transcription factor that plays a crucial role in regulating gene expression during erythropoiesis and lymphocyte development. The biotinylation tagging approach has been used to identify GATA-1 interacting partners, including:\n1. HMG-CoA reductase: GATA-1 was shown to interact with HMG-CoA reductase, a key enzyme involved in cholesterol biosynthesis, and this interaction was found to be important for GATA-1-mediated erythroid cell differentiation.\n2. KAT2A: GATA-1 was found to interact with the histone acetyltransferase KAT2A, which is involved in regulating chromatin structure and gene expression.\n3. TFIIA: GATA-1 was shown to interact with TFIIA, a general transcription factor that plays a role in the initiation of transcription.\n4. TFIIB: GATA-1 was found to interact with TFIIB, another general transcription factor that is involved in the initiation of transcription.\n5. RNA polymerase II: GATA-1 was shown to interact with RNA polymerase II, the primary enzyme responsible for transcribing DNA into RNA during transcription.\n6. CBX3: GATA-1 was found to interact with CBX3, a chromodomain-containing protein that is involved in regulating chromatin structure and gene expression.\n7. BTG2: GATA-1 was shown to interact with BTG2, a zinc finger protein that is involved in regulating gene expression and cellular differentiation.\n8. KRAB-ZNF: GATA-1 was found to interact with KRAB-ZNF, a family of zinc finger proteins that are involved in regulating gene expression and chromatin structure.\n9. SUV39H1: GATA-1 was shown to interact with SUV39H1, a histone methyltransferase that is involved in regulating chromatin structure and gene expression.\n10. H3K27 demethylase: GATA-1 was found to interact with H3K27 demethylase, an enzym",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 interacts with HMG-CoA reductase, which is involved in cholesterol biosynthesis.\n2. GATA-1 interacts with the histone acetyltransferase KAT2A.\n3. GATA-1 interacts with TFIIA, a general transcription factor.\n4. GATA-1 interacts with TFIIB, another general transcription factor.\n5. GATA-1 interacts with RNA polymerase II, which is responsible for transcribing DNA into RNA.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 interacts with HMG-CoA reductase, which is involved in cholesterol biosynthesis.",
      "GATA-1 interacts with the histone acetyltransferase KAT2A.",
      "GATA-1 interacts with TFIIA, a general transcription factor.",
      "GATA-1 interacts with TFIIB, another general transcription factor.",
      "GATA-1 interacts with RNA polymerase II, which is responsible for transcribing DNA into RNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GATA-1 does not interact with HMG-CoA reductase; it is a transcription factor involved in the regulation of erythroid and megakaryocytic cell development.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 (TATA-binding protein-associated factor 10) is a protein that plays a crucial role in the regulation of transcription, specifically in the initiation of transcription by RNA polymerase II (RNAPII). GATA1 is a transcription factor that is involved in the regulation of gene expression in various cell types, including hematopoietic cells.\nWhen TAF10 interacts with GATA1, it enhances the ability of GATA1 to bind to its target DNA sequences and recruit RNAPII to initiate transcription. TAF10 acts as a bridge between GATA1 and the RNAPII complex, facilitating the interaction between these two proteins and allowing GATA1 to recruit RNAPII to the promoter region of the gene it regulates.\nThis interaction between TAF10 and GATA1 is important for the regulation of gene expression in hematopoietic cells, as it allows GATA1 to control the expression of genes involved in the development and differentiation of these cells. Disruptions in this interaction have been implicated in the development of certain hematopoietic disorders, such as myelodysplastic syndromes and acute myeloid leukemia.\nIn summary, the outcome of TAF10 interacting with GATA1 is the enhancement of GATA1's ability to regulate gene expression by recruiting RNAPII to the promoter region of target genes, which is essential for the proper development and function of hematopoietic cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 (TATA-binding protein-associated factor 10) plays a role in the regulation of transcription by RNA polymerase II.\n2. GATA1 is a transcription factor involved in the regulation of gene expression in hematopoietic cells.\n3. The interaction between TAF10 and GATA1 enhances GATA1's ability to bind to its target DNA sequences.\n4. TAF10 acts as a bridge between GATA1 and the RNA polymerase II complex.\n5. Disruptions in the interaction between TAF10 and GATA1 have been implicated in the development of hematopoietic disorders such as myelodysplastic syndromes and acute myeloid leukemia.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 (TATA-binding protein-associated factor 10) plays a role in the regulation of transcription by RNA polymerase II.",
      "GATA1 is a transcription factor involved in the regulation of gene expression in hematopoietic cells.",
      "The interaction between TAF10 and GATA1 enhances GATA1's ability to bind to its target DNA sequences.",
      "TAF10 acts as a bridge between GATA1 and the RNA polymerase II complex.",
      "Disruptions in the interaction between TAF10 and GATA1 have been implicated in the development of hematopoietic disorders such as myelodysplastic syndromes and acute myeloid leukemia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. A DSS is a computer-based system that provides healthcare professionals with clinical decision-making support and helps them make informed decisions based on patient-specific data. Here are some examples of DSS for chronic pain management:\n1. Chronic Pain Management Decision Support System (CPM-DSS): This DSS is designed to help primary care physicians manage chronic pain in adults. It provides clinical decision-making support based on the latest evidence-based guidelines and recommendations.\n2. PainCare Decision Support System (PCDSS): This DSS is designed to help healthcare professionals manage chronic non-cancer pain in adults. It provides clinical decision-making support based on the latest evidence-based guidelines and recommendations.\n3. Pain Management Decision Support System (PMDSS): This DSS is designed to help healthcare professionals manage chronic pain in adults and children. It provides clinical decision-making support based on the latest evidence-based guidelines and recommendations.\n4. Chronic Pain Management (CPM) Decision Support System: This DSS is designed to help healthcare professionals manage chronic pain in adults. It provides clinical decision-making support based on the latest evidence-based guidelines and recommendations.\n5. Pain-Q: This DSS is designed to help healthcare professionals manage chronic pain in adults. It provides clinical decision-making support based on the latest evidence-based guidelines and recommendations.\n6. Pain-Q: This DSS is designed to help healthcare professionals manage chronic pain in adults. It provides clinical decision-making support based on the latest evidence-based guidelines and recommendations.\n7. Chronic Pain Management (CPM) Decision Support System: This DSS is designed to help healthcare professionals manage chronic pain in adults. It provides clinical decision-making support based on the latest evidence-based guidelines and recommendations.\n8. Pain Management Decision Support System (PMDSS): This DSS is designed to help healthcare professionals manage chronic pain in adults and children. It provides clinical decision-making support based on the latest evidence-",
    "llama-2-7b-chat-hf_fact_raw": "1. Decision support systems (DSS) are available for chronic pain management.\n2. The Chronic Pain Management Decision Support System (CPM-DSS) is designed to help primary care physicians manage chronic pain in adults.\n3. The PainCare Decision Support System (PCDSS) is intended for managing chronic non-cancer pain in adults.\n4. The Pain Management Decision Support System (PMDSS) is designed to assist in managing chronic pain in both adults and children.\n5. Pain-Q is a decision support system aimed at helping healthcare professionals manage chronic pain in adults.",
    "llama-2-7b-chat-hf_fact": [
      "Decision support systems (DSS) are available for chronic pain management.",
      "The Chronic Pain Management Decision Support System (CPM-DSS) is designed to help primary care physicians manage chronic pain in adults.",
      "The PainCare Decision Support System (PCDSS) is intended for managing chronic non-cancer pain in adults.",
      "The Pain Management Decision Support System (PMDSS) is designed to assist in managing chronic pain in both adults and children.",
      "Pain-Q is a decision support system aimed at helping healthcare professionals manage chronic pain in adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the Pain Management Decision Support System (PMDSS) and Pain-Q, it is not possible to confirm the accuracy of statements 4 and 5. These systems may exist and have the described functions, but without additional context or sources, their details cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a protein that is localized primarily in the cytoplasm of cells, but it can also be found in the nucleus of some cells. Specifically, angiogenin is a secreted protein that is involved in the regulation of angiogenesis, the process of blood vessel formation, and it can act as a cytoplasmic and nuclear protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is a protein that is primarily localized in the cytoplasm of cells.\n2. Angiogenin can also be found in the nucleus of some cells.\n3. Angiogenin is a secreted protein.\n4. Angiogenin is involved in the regulation of angiogenesis.\n5. Angiogenesis is the process of blood vessel formation.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is a protein that is primarily localized in the cytoplasm of cells.",
      "Angiogenin can also be found in the nucleus of some cells.",
      "Angiogenin is a secreted protein.",
      "Angiogenin is involved in the regulation of angiogenesis.",
      "Angiogenesis is the process of blood vessel formation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine is a medication that is primarily used to treat angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart muscle. While its primary mechanism of action is through the inhibition of ion channels, ranolazine has been shown to also affect kinase signaling activation in the heart.\nKinase signaling is a complex pathway that plays a crucial role in regulating various cellular processes, including cell survival, proliferation, and differentiation. In the heart, kinase signaling is involved in the regulation of cardiac contractility, excitability, and hypertrophy. Dysregulation of kinase signaling can lead to various cardiac diseases, including heart failure.\nRanolazine has been shown to activate the protein kinase B (Akt) pathway in the heart, which is a key regulator of cell survival and metabolism. Activation of Akt by ranolazine can lead to increased phosphorylation of downstream targets, including glycogen synthase kinase-3 (GSK-3) and forkhead box protein O (FOXO). These phosphorylation events can lead to increased glucose metabolism, reduced oxidative stress, and improved cardiac function.\nRanolazine has also been shown to inhibit the activity of the mitogen-activated protein kinase (MAPK) pathway in the heart. The MAPK pathway is involved in the regulation of cell proliferation and differentiation, and its dysregulation can lead to various cardiac diseases. Inhibition of the MAPK pathway by ranolazine can reduce inflammation and oxidative stress in the heart, which can contribute to improved cardiac function.\nIn addition, ranolazine has been shown to increase the expression of the potassium channel subunit KCNQ1 in the heart. KCNQ1 is involved in the regulation of the cardiac action potential duration and refractoriness, and its upregulation by ranolazine can lead to improved cardiac function and reduced risk of arrhythmias.\nOverall, the activation of Akt and inhibition of the MAPK pathway by ranolazine can lead to improved cardiac function and reduced risk of cardiac diseases, such as heart",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine is primarily used to treat angina pectoris.\n2. Ranolazine inhibits ion channels as its primary mechanism of action.\n3. Ranolazine activates the protein kinase B (Akt) pathway in the heart.\n4. Ranolazine inhibits the activity of the mitogen-activated protein kinase (MAPK) pathway in the heart.\n5. Ranolazine increases the expression of the potassium channel subunit KCNQ1 in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine is primarily used to treat angina pectoris.",
      "Ranolazine inhibits ion channels as its primary mechanism of action.",
      "Ranolazine activates the protein kinase B (Akt) pathway in the heart.",
      "Ranolazine inhibits the activity of the mitogen-activated protein kinase (MAPK) pathway in the heart.",
      "Ranolazine increases the expression of the potassium channel subunit KCNQ1 in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Ranolazine is primarily used to treat chronic angina pectoris.\n2. TRUE: Ranolazine's mechanism of action involves the inhibition of the late phase of the inward sodium channel during cardiac repolarization, which is an ion channel.\n3. UNKNOWN: The effect of ranolazine on the protein kinase B (Akt) pathway in the heart is not well-established in the literature, and without specific context or reference, it's difficult to determine the truth of this statement.\n4. UNKNOWN: Similar to statement 3, the effect of ranolazine on the mitogen-activated protein kinase (MAPK) pathway in the heart is not clearly established, and without additional context, the truth of this statement cannot be determined.\n5. UNKNOWN: The statement regarding ranolazine's effect on the expression of the potassium channel subunit KCNQ1 in the heart is specific and would require a reference to the scientific literature to verify. Without such a reference, the truth of this statement is unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Yes, the regulation of Vsr endonuclease is independent of the growth phase of bacteria. Vsr endonuclease is a key enzyme involved in the SOS response of E. coli, which is a DNA damage response mechanism that helps the bacteria to repair DNA damage caused by various factors, including oxidative stress, UV radiation, and certain antibiotics.\nThe SOS response is a global regulatory program that is activated in response to DNA damage, and it involves a complex series of events that ultimately lead to the activation of Vsr endonuclease. The activation of Vsr endonuclease is not directly linked to the growth phase of the bacteria, but rather to the presence of DNA damage.\nIn fact, studies have shown that Vsr endonuclease is active in both stationary and exponential phases of growth, suggesting that it is not specifically regulated by the growth phase of the bacteria. Instead, it appears to be constitutively expressed and actively involved in the SOS response, regardless of the growth phase.\nThis is thought to be due to the fact that DNA damage can occur at any time during the cell cycle, and the SOS response is an important mechanism for protecting the bacteria against DNA damage. Therefore, the regulation of Vsr endonuclease is independent of the growth phase of the bacteria, and it is constantly active in order to monitor and repair DNA damage.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is independent of the growth phase of bacteria.\n2. Vsr endonuclease is involved in the SOS response of E. coli.\n3. The SOS response is activated in response to DNA damage in bacteria.\n4. Vsr endonuclease is active in both stationary and exponential phases of bacterial growth.\n5. The SOS response is a mechanism for protecting bacteria against DNA damage.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is independent of the growth phase of bacteria.",
      "Vsr endonuclease is involved in the SOS response of E. coli.",
      "The SOS response is activated in response to DNA damage in bacteria.",
      "Vsr endonuclease is active in both stationary and exponential phases of bacterial growth.",
      "The SOS response is a mechanism for protecting bacteria against DNA damage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins. Here are some of the commonly used tools:\n1. BepiPred: This tool uses a combination of sequence analysis and machine learning algorithms to predict the presence of beta-barrel transmembrane domains in proteins. It can also predict the number of beta-barrels and their orientation in the membrane.\n2. TMHMM: This tool uses a hidden Markov model to predict the transmembrane helices in a protein sequence. It can also predict the orientation of the helices and the type of transmembrane domain (e.g., beta-barrel, alpha-helix, etc.).\n3. PredictBAR: This tool uses a machine learning algorithm to predict the presence of beta-barrel transmembrane domains in proteins. It can also predict the number of beta-barrels and their orientation in the membrane.\n4. TMPro: This tool uses a combination of sequence analysis and machine learning algorithms to predict the transmembrane helices in a protein sequence. It can also predict the orientation of the helices and the type of transmembrane domain (e.g., beta-barrel, alpha-helix, etc.).\n5. BarrelFinder: This tool uses a machine learning algorithm to predict the presence of beta-barrel transmembrane domains in proteins. It can also predict the number of beta-barrels and their orientation in the membrane.\n6. TM-Align: This tool uses a hidden Markov model to predict the transmembrane helices in a protein sequence. It can also predict the orientation of the helices and the type of transmembrane domain (e.g., beta-barrel, alpha-helix, etc.).\n7. Transmembrane Predictor: This tool uses a machine learning algorithm to predict the presence of transmembrane helices in a protein sequence. It can also predict the number of helices and their orientation in the membrane.\n8. PredictTMB: This tool uses a machine learning algorithm to predict the presence of beta-barrel transmembrane domains in proteins. It can also predict the number of beta-barrels and their orientation in the membrane.\n9. TM-Profiler: This tool uses a machine learning algorithm to predict the transmembrane",
    "llama-2-7b-chat-hf_fact_raw": "1. BepiPred uses sequence analysis and machine learning algorithms to predict beta-barrel transmembrane domains in proteins.\n2. TMHMM uses a hidden Markov model to predict transmembrane helices and their orientation in protein sequences.\n3. PredictBAR employs a machine learning algorithm to predict beta-barrel transmembrane domains in proteins.\n4. TMPro combines sequence analysis and machine learning algorithms to predict transmembrane helices in protein sequences.\n5. BarrelFinder uses a machine learning algorithm to predict the presence of beta-barrel transmembrane domains in proteins.",
    "llama-2-7b-chat-hf_fact": [
      "BepiPred uses sequence analysis and machine learning algorithms to predict beta-barrel transmembrane domains in proteins.",
      "TMHMM uses a hidden Markov model to predict transmembrane helices and their orientation in protein sequences.",
      "PredictBAR employs a machine learning algorithm to predict beta-barrel transmembrane domains in proteins.",
      "TMPro combines sequence analysis and machine learning algorithms to predict transmembrane helices in protein sequences.",
      "BarrelFinder uses a machine learning algorithm to predict the presence of beta-barrel transmembrane domains in proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first two statements are true as BepiPred and TMHMM are known bioinformatics tools for predicting protein domains. BepiPred is indeed used for predicting beta-barrel transmembrane domains, and TMHMM uses a hidden Markov model to predict transmembrane helices. However, without specific information about PredictBAR, TMPro, and BarrelFinder, it is not possible to confirm the accuracy of statements 3, 4, and 5. These tools could exist and perform the functions described, but without additional context or information, their descriptions cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "The Galassi classification is used to diagnose and classify brain tumors, specifically gliomas. It is a system used to categorize gliomas based on their histological features, including the type of glial cell that the tumor arises from, the degree of differentiation, and the presence of certain characteristics such as necrosis or mitotic activity. The Galassi classification system is used to help guide treatment and prognosis for patients with gliomas.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Galassi classification is used to diagnose and classify gliomas.\n2. This classification system categorizes gliomas based on their histological features.\n3. The Galassi classification considers the type of glial cell the tumor arises from.\n4. The degree of differentiation is a factor in the Galassi classification system.\n5. The presence of characteristics such as necrosis or mitotic activity is included in the Galassi classification.",
    "llama-2-7b-chat-hf_fact": [
      "The Galassi classification is used to diagnose and classify gliomas.",
      "This classification system categorizes gliomas based on their histological features.",
      "The Galassi classification considers the type of glial cell the tumor arises from.",
      "The degree of differentiation is a factor in the Galassi classification system.",
      "The presence of characteristics such as necrosis or mitotic activity is included in the Galassi classification."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification is used to classify arachnoid cysts, not gliomas.\n2. FALSE [correction]: While the statement about categorizing based on histological features could be true for a classification system for gliomas, it is not accurate for the Galassi classification, which is for arachnoid cysts.\n3. FALSE [correction]: The Galassi classification does not consider the type of glial cell because it is not a system for classifying gliomas.\n4. FALSE [correction]: The degree of differentiation is a factor in glioma classification systems, but not in the Galassi classification, which is for arachnoid cysts.\n5. FALSE [correction]: The presence of characteristics such as necrosis or mitotic activity might be considered in glioma classification systems, but the Galassi classification does not include these factors as it is for arachnoid cysts.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Omenn syndrome, is a rare genetic disorder characterized by a combination of symptoms that affect various systems of the body. Here are some common features of Shapiro syndrome:\n1. Developmental Delays: Children with Shapiro syndrome often experience delays in reaching developmental milestones, such as sitting, standing, and walking.\n2. Intellectual Disability: Intellectual disability is a common feature of Shapiro syndrome, ranging in severity from mild to severe.\n3. Distinctive Facial Appearance: People with Shapiro syndrome often have a distinctive facial appearance, including a small head, narrow eyes, and a flat nasal bridge.\n4. Short Stature: Short stature is a common feature of Shapiro syndrome, with affected individuals typically growing to be shorter than their peers.\n5. Skeletal Abnormalities: Shapiro syndrome can cause various skeletal abnormalities, including joint contractures, scoliosis, and other skeletal deformities.\n6. Neurological Problems: Affected individuals may experience a range of neurological problems, including seizures, ataxia, and problems with coordination and balance.\n7. Vision Loss: Shapiro syndrome can cause vision loss, including cataracts, glaucoma, and other eye problems.\n8. Hearing Loss: Hearing loss is another common feature of Shapiro syndrome, and may affect one or both ears.\n9. Respiratory Problems: Affected individuals may experience respiratory problems, including bronchiectasis, chronic cough, and sleep apnea.\n10. Increased Risk of Infections: People with Shapiro syndrome may be at increased risk of infections, particularly respiratory infections, due to their immune system dysfunction.\n11. Autoimmune Disorders: Some individuals with Shapiro syndrome may develop autoimmune disorders, such as thyroiditis or type 1 diabetes.\n12. Gastrointestinal Problems: Shapiro syndrome can cause gastrointestinal problems, including constipation",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by developmental delays in children, affecting milestones such as sitting, standing, and walking.\n2. Intellectual disability, ranging from mild to severe, is a common feature of Shapiro syndrome.\n3. Individuals with Shapiro syndrome often have distinctive facial features, including a small head, narrow eyes, and a flat nasal bridge.\n4. Short stature is a typical characteristic of Shapiro syndrome, with affected individuals being shorter than their peers.\n5. Shapiro syndrome can lead to various skeletal abnormalities, such as joint contractures, scoliosis, and other deformities.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is characterized by developmental delays in children, affecting milestones such as sitting, standing, and walking.",
      "Intellectual disability, ranging from mild to severe, is a common feature of Shapiro syndrome.",
      "Individuals with Shapiro syndrome often have distinctive facial features, including a small head, narrow eyes, and a flat nasal bridge.",
      "Short stature is a typical characteristic of Shapiro syndrome, with affected individuals being shorter than their peers.",
      "Shapiro syndrome can lead to various skeletal abnormalities, such as joint contractures, scoliosis, and other deformities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is characterized by the triad of recurrent episodes of spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum, not developmental delays affecting milestones such as sitting, standing, and walking.\n2. UNKNOWN: Intellectual disability is not a primary feature of Shapiro syndrome as defined by its characteristic triad, but since agenesis of the corpus callosum can be associated with a range of neurological impairments, intellectual disability could be a related issue. However, without specific information linking intellectual disability as a common feature of Shapiro syndrome, this statement remains unclear.\n3. FALSE [correction]: Distinctive facial features are not a typical characteristic of Shapiro syndrome. The syndrome is primarily defined by hypothermia, hyperhidrosis, and agenesis of the corpus callosum.\n4. UNKNOWN: Short stature is not one of the primary characteristics of Shapiro syndrome. Without specific information linking short stature as a typical characteristic of Shapiro syndrome, this statement cannot be confirmed.\n5. UNKNOWN: Skeletal abnormalities such as joint contractures, scoliosis, and other deformities are not among the primary features of Shapiro syndrome. Without specific information linking these skeletal abnormalities as common features of Shapiro syndrome, this statement cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "Mutations within the BRAG1 gene have been linked to a rare genetic disorder called Bragg-Gettiers Syndrome. This is a multisystem disorder that affects various parts of the body, including the brain, eyes, and skeleton. The main features of Bragg-Gettiers Syndrome include:\n1. Intellectual disability: Individuals with Bragg-Gettiers Syndrome typically have mild to moderate intellectual disability, which can range from mild to moderate.\n2. Distinctive facial features: People with Bragg-Gettiers Syndrome often have distinctive facial features, such as a small head, narrow eyes, and a short nose.\n3. Brain abnormalities: Imaging studies have shown that individuals with Bragg-Gettiers Syndrome may have abnormalities in the structure and function of certain brain regions, including the cerebral cortex and basal ganglia.\n4. Skeletal abnormalities: Bragg-Gettiers Syndrome can also cause skeletal abnormalities, such as short stature, joint deformities, and bone fragility.\n5. Eye abnormalities: Individuals with Bragg-Gettiers Syndrome may have eye abnormalities, including microphthalmia (small eyes) and cataracts.\n6. Other features: Other features of Bragg-Gettiers Syndrome can include delayed speech and language development, seizures, and hearing loss.\nIt is important to note that Bragg-Gettiers Syndrome is a rare disorder, and each individual with the condition may have a different combination of symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations within the BRAG1 gene are linked to Bragg-Gettiers Syndrome.\n2. Bragg-Gettiers Syndrome is a multisystem disorder that affects the brain, eyes, and skeleton.\n3. Individuals with Bragg-Gettiers Syndrome typically have mild to moderate intellectual disability.\n4. People with Bragg-Gettiers Syndrome may have distinctive facial features, such as a small head, narrow eyes, and a short nose.\n5. Bragg-Gettiers Syndrome can cause skeletal abnormalities, such as short stature, joint deformities, and bone fragility.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations within the BRAG1 gene are linked to Bragg-Gettiers Syndrome.",
      "Bragg-Gettiers Syndrome is a multisystem disorder that affects the brain, eyes, and skeleton.",
      "Individuals with Bragg-Gettiers Syndrome typically have mild to moderate intellectual disability.",
      "People with Bragg-Gettiers Syndrome may have distinctive facial features, such as a small head, narrow eyes, and a short nose.",
      "Bragg-Gettiers Syndrome can cause skeletal abnormalities, such as short stature, joint deformities, and bone fragility."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided refer to Bragg-Gettiers Syndrome and its associated gene, BRAG1. However, without specific scientific literature or medical references to confirm the existence of this syndrome and its characteristics, it is not possible to determine the truthfulness of these statements. They could be fictional or based on less commonly known medical conditions. Therefore, the response to each statement is \"UNKNOWN\".",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "The main inhibitor of protein phosphatase 1 (PP1) is the protein called PP1-specific inhibitor (PPI). PPI is a regulatory subunit that binds to the catalytic subunit of PP1 and inhibits its activity. PPI is a negative regulator of PP1 and plays a crucial role in regulating the activity of PP1 in various cellular processes, including cell signaling, metabolism, and gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. The main inhibitor of protein phosphatase 1 (PP1) is called PP1-specific inhibitor (PPI).\n2. PPI binds to the catalytic subunit of PP1 to inhibit its activity.\n3. PPI is a negative regulator of PP1.\n4. PPI regulates the activity of PP1 in various cellular processes such as cell signaling, metabolism, and gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "The main inhibitor of protein phosphatase 1 (PP1) is called PP1-specific inhibitor (PPI).",
      "PPI binds to the catalytic subunit of PP1 to inhibit its activity.",
      "PPI is a negative regulator of PP1.",
      "PPI regulates the activity of PP1 in various cellular processes such as cell signaling, metabolism, and gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The main inhibitor of protein phosphatase 1 (PP1) is not called PP1-specific inhibitor (PPI); it is known as Inhibitor-1 (I-1) when phosphorylated, and Inhibitor-2 (I-2) is another protein that can inhibit PP1.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria increase their genetic diversity during the stationary phase of growth. In Bacillus subtilis, several mechanisms underlie adaptive mutagenesis:\n1. DNA damage and repair: During the stationary phase, bacteria experience DNA damage due to various factors, such as oxidative stress, DNA replication stress, and exposure to antibiotics. To cope with this damage, bacteria have evolved DNA repair mechanisms, such as nucleotide excision repair and base excision repair, which can introduce mutations into the genome.\n2. MutS and MutL homologs: B. subtilis has two mutS homologs, BsmI and BsmII, and two mutL homologs, Bsm3 and Bsm4. These proteins are involved in DNA mismatch repair, which can introduce mutations into the genome.\n3. RecA-mediated recombination: RecA is a DNA recombinase that plays a key role in homologous recombination, a process that can introduce mutations into the genome. During the stationary phase, RecA is upregulated, leading to increased recombination and mutation.\n4. Transposon mutagenesis: Transposons are mobile genetic elements that can insert into different locations within the genome, leading to mutations. During the stationary phase, transposons are more active, leading to increased mutation rates.\n5. Rho-independent recombination: Rho-independent recombination is a process that can introduce mutations into the genome without the need for RecA. This process is more active during the stationary phase and can lead to the formation of chimeric genes and mutations.\n6. DNA shuffling: DNA shuffling is a process that involves the random recombination of genetic material, leading to the creation of new genetic combinations. This process can occur during the stationary phase and can lead to the formation of mutations.\n7. Horizontal gene transfer: Horizontal gene transfer, also known as gene transfer agents (GTAs), are mobile genetic elements that can transfer genetic material between different species. During the stationary phase, GTAs are more active, leading to the",
    "llama-2-7b-chat-hf_fact_raw": "1. In Bacillus subtilis, DNA repair mechanisms such as nucleotide excision repair and base excision repair can introduce mutations into the genome during the stationary phase.\n2. Bacillus subtilis has two mutS homologs (BsmI and BsmII) and two mutL homologs (Bsm3 and Bsm4) that are involved in DNA mismatch repair, which can introduce mutations.\n3. RecA-mediated recombination, which can introduce mutations into the genome, is upregulated during the stationary phase in Bacillus subtilis.\n4. Transposons in Bacillus subtilis are more active during the stationary phase, leading to increased mutation rates.\n5. Rho-independent recombination, which can introduce mutations into the genome, is more active during the stationary phase in Bacillus subtilis.",
    "llama-2-7b-chat-hf_fact": [
      "In Bacillus subtilis, DNA repair mechanisms such as nucleotide excision repair and base excision repair can introduce mutations into the genome during the stationary phase.",
      "Bacillus subtilis has two mutS homologs (BsmI and BsmII) and two mutL homologs (Bsm3 and Bsm4) that are involved in DNA mismatch repair, which can introduce mutations.",
      "RecA-mediated recombination, which can introduce mutations into the genome, is upregulated during the stationary phase in Bacillus subtilis.",
      "Transposons in Bacillus subtilis are more active during the stationary phase, leading to increased mutation rates.",
      "Rho-independent recombination, which can introduce mutations into the genome, is more active during the stationary phase in Bacillus subtilis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: DNA repair mechanisms such as nucleotide excision repair and base excision repair are generally designed to correct mutations, not introduce them. However, any DNA repair mechanism can potentially introduce mutations as a result of errors, but this is not their primary function.\n2. FALSE [correction]: Bacillus subtilis has homologs to the E. coli mutS and mutL genes, known as mutS and mutL, not BsmI, BsmII, Bsm3, or Bsm4. These genes are involved in DNA mismatch repair, which is a process that generally serves to reduce mutations, not introduce them.\n3. TRUE: RecA-mediated recombination is a process that can introduce mutations into the genome, and it is known to be upregulated during the stationary phase in Bacillus subtilis as a part of the stress response.\n4. TRUE: Transposons, which are mobile genetic elements, can indeed be more active during the stationary phase, leading to increased mutation rates in Bacillus subtilis.\n5. FALSE [correction]: Rho-independent termination is a mechanism for terminating transcription in bacteria and is not directly involved in recombination. The statement seems to confuse recombination with transcription termination. There is no known process called \"Rho-independent recombination.\"",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erucic acid syndrome, is a rare but potentially life-threatening condition that can occur in individuals who consume large amounts of rutabaga or other cruciferous vegetables, such as cabbage, broccoli, and cauliflower.\nThe main cause of erucism is the consumption of excessive amounts of rutabaga or other cruciferous vegetables, which contain a toxic compound called erucic acid. Erucic acid is a cyclic dextranucleotide that can accumulate in the body and cause damage to the liver, kidneys, and other organs.\nOther factors that may contribute to the development of erucism include:\n1. Genetic predisposition: Some people may be more susceptible to the toxic effects of erucic acid due to genetic variations in their genome.\n2. Age: Erucism is more common in older adults, as they may be more likely to consume larger amounts of cruciferous vegetables or have a weaker digestive system that is less able to break down the toxin.\n3. Nutrient deficiencies: A diet that is deficient in certain nutrients, such as vitamin C or selenium, may increase the risk of developing erucism.\n4. Gastrointestinal disorders: Certain gastrointestinal disorders, such as irritable bowel syndrome or inflammatory bowel disease, may increase the risk of developing erucism.\n5. Medications: Certain medications, such as chemotherapy drugs, can increase the risk of developing erucism by interfering with the body's ability to break down erucic acid.\nIt is important to note that erucism is a rare condition, and the risk of developing it can be minimized by consuming cruciferous vegetables in moderation and maintaining a balanced diet. If you have any concerns about erucism or any other health condition, it is always best to consult with a healthcare professional.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is a condition that can occur from consuming large amounts of rutabaga or other cruciferous vegetables.\n2. The toxic compound associated with erucism is called erucic acid.\n3. Erucic acid can accumulate in the body and cause damage to the liver, kidneys, and other organs.\n4. Genetic predisposition may make some individuals more susceptible to the toxic effects of erucic acid.\n5. Older adults are more commonly affected by erucism.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is a condition that can occur from consuming large amounts of rutabaga or other cruciferous vegetables.",
      "The toxic compound associated with erucism is called erucic acid.",
      "Erucic acid can accumulate in the body and cause damage to the liver, kidneys, and other organs.",
      "Genetic predisposition may make some individuals more susceptible to the toxic effects of erucic acid.",
      "Older adults are more commonly affected by erucism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Erucism is not a condition caused by consuming large amounts of rutabaga or other cruciferous vegetables; it is a type of poisoning that results from contact with the hairs or spines of certain caterpillars.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide is a medication that is used to treat a variety of conditions related to fluid and electrolyte balance in the body. Some of the indications for hydrochlorothiazide include:\n1. Hypertension (high blood pressure): Hydrochlorothiazide is commonly used to treat mild to moderate hypertension, as it can help to lower blood pressure by increasing urine production and reducing the amount of fluid in the body.\n2. Heart failure: Hydrochlorothiazide can help to reduce the workload on the heart by removing excess fluid from the body, which can help to improve symptoms of heart failure.\n3. Congestive heart failure: Hydrochlorothiazide can help to reduce the workload on the heart by removing excess fluid from the body, which can help to improve symptoms of congestive heart failure.\n4. Nephrotic syndrome: Hydrochlorothiazide can help to reduce the amount of protein in the urine, which can help to manage nephrotic syndrome.\n5. Diabetes insipidus: Hydrochlorothiazide can help to treat diabetes insipidus by increasing urine production and reducing the amount of fluid in the body.\n6. Edema: Hydrochlorothiazide can help to reduce the amount of fluid in the body, which can help to manage edema (swelling) caused by various conditions, such as heart failure, liver disease, or kidney disease.\n7. Renal impairment: Hydrochlorothiazide can help to reduce the amount of fluid in the body, which can help to manage renal impairment (kidney disease) by reducing the amount of fluid that the kidneys have to process.\n8. Hyperkalemia: Hydrochlorothiazide can help to reduce the level of potassium in the blood, which can help to manage hyperkalemia (high potassium levels) caused by various conditions, such as kidney disease or certain medications.\nIt's important to note that hydrochlorothiazide can have side effects, especially if taken in high doses or for a long time. Therefore, it's important to use this",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used to treat mild to moderate hypertension by increasing urine production and reducing fluid in the body.\n2. Hydrochlorothiazide is used to improve symptoms of heart failure by removing excess fluid from the body.\n3. Hydrochlorothiazide is used to manage nephrotic syndrome by reducing the amount of protein in the urine.\n4. Hydrochlorothiazide is used to treat diabetes insipidus by increasing urine production and reducing fluid in the body.\n5. Hydrochlorothiazide can help manage edema caused by conditions such as heart failure, liver disease, or kidney disease by reducing fluid in the body.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used to treat mild to moderate hypertension by increasing urine production and reducing fluid in the body.",
      "Hydrochlorothiazide is used to improve symptoms of heart failure by removing excess fluid from the body.",
      "Hydrochlorothiazide is used to manage nephrotic syndrome by reducing the amount of protein in the urine.",
      "Hydrochlorothiazide is used to treat diabetes insipidus by increasing urine production and reducing fluid in the body.",
      "Hydrochlorothiazide can help manage edema caused by conditions such as heart failure, liver disease, or kidney disease by reducing fluid in the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Hydrochlorothiazide is used to manage nephrotic syndrome by reducing fluid retention in the body, not by reducing the amount of protein in the urine.\n4. FALSE [correction]: Hydrochlorothiazide is not typically used to treat diabetes insipidus; it is a condition characterized by large amounts of dilute urine and increased thirst, and the treatment usually involves a different type of medication called desmopressin.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of urinary incontinence. Silicon-based materials have been used to create various medical devices that can help manage urinary incontinence, including:\n1. Urinary incontinence pessaries: These are devices that are inserted into the vagina to support the urethra and bladder, helping to prevent leakage. Silicon is often used as the material for these pessaries due to its flexibility, durability, and biocompatibility.\n2. Artificial urinary sphincters: These devices are implanted in the urethra to help control urine flow and prevent leakage. Silicon is used as the material for the sphincter, which is designed to mimic the natural muscle function of the urethral sphincter.\n3. Urinary incontinence slings: These are mesh devices that are placed under the urethra and bladder to support the urethra and prevent leakage. Silicon-coated mesh is sometimes used for these slings to provide additional support and prevent tissue growth.\n4. Urinary incontinence catheters: Silicon-coated catheters are sometimes used for urinary catheterization, particularly for long-term catheterization. The silicon coating can help reduce irritation and discomfort.\nIt's important to note that these devices are typically used as a last resort for treating urinary incontinence, and other non-surgical treatments such as pelvic floor exercises, bladder training, and medications should be tried first. Additionally, the use of silicon in medical devices is tightly regulated, and the safety and efficacy of these devices must be carefully evaluated before they are approved for use in clinical practice.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon-based materials are used to create medical devices for managing urinary incontinence.\n2. Urinary incontinence pessaries made of silicon are inserted into the vagina to support the urethra and bladder.\n3. Artificial urinary sphincters made of silicon are implanted in the urethra to control urine flow.\n4. Silicon-coated mesh is sometimes used in urinary incontinence slings to support the urethra.\n5. Silicon-coated catheters are used for long-term urinary catheterization to reduce irritation and discomfort.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon-based materials are used to create medical devices for managing urinary incontinence.",
      "Urinary incontinence pessaries made of silicon are inserted into the vagina to support the urethra and bladder.",
      "Artificial urinary sphincters made of silicon are implanted in the urethra to control urine flow.",
      "Silicon-coated mesh is sometimes used in urinary incontinence slings to support the urethra.",
      "Silicon-coated catheters are used for long-term urinary catheterization to reduce irritation and discomfort."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Artificial urinary sphincters are typically made of silicone, not silicon, and are implanted around the urethra to control urine flow.\n4. FALSE [correction]: It is silicone that is used for coating mesh in urinary incontinence slings, not silicon. Silicone is a more biocompatible material for medical applications.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "There is a popular belief that the moon cycle can affect the rupture risk of intracranial aneurysms, but there is limited scientific evidence to support this claim.\nIntracranial aneurysms are abnormal bulges or balloon-like pouches that can occur in the blood vessels of the brain. They can rupture, leading to bleeding in the brain and potentially life-threatening complications. While the exact causes of intracranial aneurysms are not fully understood, several factors have been identified as increasing the risk of rupture, including:\n1. Family history: Having a family history of intracranial aneurysms increases the risk of developing one.\n2. Age: The risk of rupture increases with age, with most cases occurring in people over the age of 40.\n3. Gender: Women are more likely to develop intracranial aneurysms than men.\n4. High blood pressure: High blood pressure is the most common risk factor for intracranial aneurysms, as it can increase the pressure on the blood vessels in the brain.\n5. Smoking: Smoking can increase the risk of intracranial aneurysms by damaging the blood vessels in the brain.\nThere have been some studies that have suggested a possible association between the moon cycle and the rupture risk of intracranial aneurysms. One study published in the Journal of Neurosurgery found that the rupture rate of intracranial aneurysms was higher during the full moon than during other phases of the moon cycle. However, this study had a small sample size and the results were not statistically significant, so more research is needed to confirm these findings.\nAnother study published in the journal Stroke found that the rupture rate of intracranial aneurysms was higher in the summer months than in other seasons, which some researchers have suggested may be due to the increased solar radiation during this time. However, this study did not control for the lunar cycle, so it is not clear whether the association between the solar cycle and aneurysm rupture is due to the lunar cycle or other factors.\nOverall, while there is some evidence to suggest that the moon cycle may play a role in the rupture risk of intracran",
    "llama-2-7b-chat-hf_fact_raw": "1. Intracranial aneurysms are abnormal bulges or balloon-like pouches that can occur in the blood vessels of the brain.\n2. Having a family history of intracranial aneurysms increases the risk of developing one.\n3. The risk of intracranial aneurysm rupture increases with age, particularly in people over the age of 40.\n4. Women are more likely to develop intracranial aneurysms than men.\n5. High blood pressure is the most common risk factor for intracranial aneurysms.",
    "llama-2-7b-chat-hf_fact": [
      "Intracranial aneurysms are abnormal bulges or balloon-like pouches that can occur in the blood vessels of the brain.",
      "Having a family history of intracranial aneurysms increases the risk of developing one.",
      "The risk of intracranial aneurysm rupture increases with age, particularly in people over the age of 40.",
      "Women are more likely to develop intracranial aneurysms than men.",
      "High blood pressure is the most common risk factor for intracranial aneurysms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, the HuR protein (also known as ELAVL1) has been shown to regulate the splicing process in various cell types. HuR is a member of the ELAVL1 family of RNA-binding proteins, which are involved in the regulation of mRNA metabolism, including splicing, transport, and stability.\nHuR has been shown to bind to the introns and exons of target mRNAs and regulate their splicing in several ways:\n1. Enhancing splicing: HuR can enhance the splicing of specific exons by binding to their introns and recruiting the splicing machinery. This can result in the inclusion of specific exons that are normally skipped, leading to the production of alternative splice variants.\n2. Inhibiting splicing: HuR can also inhibit the splicing of certain exons by blocking the access of the splicing machinery to the introns. This can result in the skipping of specific exons, leading to the production of a shorter mRNA transcript.\n3. Regulating splicing factor expression: HuR can also regulate the expression of splicing factors, such as SR proteins and U2AF65, which are essential for the splicing process. By modulating the expression of these factors, HuR can influence the efficiency of splicing and the inclusion of specific exons.\nOverall, HuR plays a complex role in the regulation of the splicing process, and its specific functions can vary depending on the cell type and the specific mRNA being regulated. Dysregulation of HuR has been implicated in various diseases, including cancer and neurodegenerative disorders, highlighting its importance in the regulation of mRNA metabolism.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HuR protein, also known as ELAVL1, regulates the splicing process in various cell types.\n2. HuR is a member of the ELAVL1 family of RNA-binding proteins involved in mRNA metabolism regulation.\n3. HuR can enhance the splicing of specific exons by recruiting the splicing machinery.\n4. HuR can inhibit the splicing of certain exons by blocking the access of the splicing machinery.\n5. HuR can regulate the expression of splicing factors, such as SR proteins and U2AF65.",
    "llama-2-7b-chat-hf_fact": [
      "The HuR protein, also known as ELAVL1, regulates the splicing process in various cell types.",
      "HuR is a member of the ELAVL1 family of RNA-binding proteins involved in mRNA metabolism regulation.",
      "HuR can enhance the splicing of specific exons by recruiting the splicing machinery.",
      "HuR can inhibit the splicing of certain exons by blocking the access of the splicing machinery.",
      "HuR can regulate the expression of splicing factors, such as SR proteins and U2AF65."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HuR protein, also known as ELAVL1, is involved in various aspects of mRNA metabolism including stability and translation, but it is not primarily known for regulating the splicing process.\n2. TRUE\n3. UNKNOWN: While HuR is known to influence alternative splicing, the specific mechanism by which it may enhance the splicing of specific exons by recruiting the splicing machinery is not well-defined and can vary depending on the context.\n4. UNKNOWN: Similarly, the exact mechanisms by which HuR might inhibit the splicing of certain exons are complex and context-dependent, and a definitive statement cannot be made without specific evidence.\n5. UNKNOWN: HuR is known to interact with various components of the mRNA processing machinery, but whether it directly regulates the expression of splicing factors like SR proteins and U2AF65 is not clearly established and would require specific references to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha (ProT) is a small protein that plays a multifaceted role in various cellular processes, including protein synthesis, cell signaling, and immune response. The c-terminal peptide of ProT, also known as ProT-CT, has been shown to have several distinct functions:\n1. Protein synthesis: ProT-CT has been shown to stimulate protein synthesis in various cell types, including T cells and macrophages. It does this by binding to the ribosome and enhancing the translation of mRNAs into proteins.\n2. Cell signaling: ProT-CT has been shown to activate several signaling pathways, including the PI3K/Akt and MAPK pathways, which are involved in cell survival, proliferation, and migration.\n3. Immune response: ProT-CT has been shown to play a role in the regulation of the immune response, particularly in the activation of T cells and the production of cytokines. It does this by interacting with the T cell receptor (TCR) and the CD28 co-stimulatory molecule, leading to the activation of T cells and the production of pro-inflammatory cytokines.\n4. Cancer: ProT-CT has been shown to be overexpressed in various types of cancer, including breast, lung, and colon cancer. It has been suggested that ProT-CT may play a role in cancer progression and metastasis by promoting cell migration and invasion.\n5. Neurodegeneration: ProT-CT has been shown to be involved in the regulation of neurodegeneration, particularly in the context of Alzheimer's disease. It has been suggested that ProT-CT may play a role in the clearance of amyloid-β, a protein that accumulates in the brain in Alzheimer's disease.\nOverall, ProT-CT is a multifunctional protein that plays a complex role in various cellular processes, including protein synthesis, cell signaling, immune response, cancer, and neurodegeneration. Further research is needed to fully understand the mechanisms by which ProT-CT functions and its potential as a therapeutic target for various diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha c-terminal peptide (ProT-CT) stimulates protein synthesis in various cell types by binding to the ribosome and enhancing mRNA translation.\n2. ProT-CT activates several cell signaling pathways, including the PI3K/Akt and MAPK pathways, which are involved in cell survival, proliferation, and migration.\n3. ProT-CT plays a role in the regulation of the immune response, particularly in T cell activation and cytokine production, by interacting with the T cell receptor and CD28 co-stimulatory molecule.\n4. ProT-CT is overexpressed in various types of cancer, such as breast, lung, and colon cancer, and may contribute to cancer progression and metastasis.\n5. ProT-CT is involved in the regulation of neurodegeneration and may play a role in the clearance of amyloid-β in Alzheimer's disease.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha c-terminal peptide (ProT-CT) stimulates protein synthesis in various cell types by binding to the ribosome and enhancing mRNA translation.",
      "ProT-CT activates several cell signaling pathways, including the PI3K/Akt and MAPK pathways, which are involved in cell survival, proliferation, and migration.",
      "ProT-CT plays a role in the regulation of the immune response, particularly in T cell activation and cytokine production, by interacting with the T cell receptor and CD28 co-stimulatory molecule.",
      "ProT-CT is overexpressed in various types of cancer, such as breast, lung, and colon cancer, and may contribute to cancer progression and metastasis.",
      "ProT-CT is involved in the regulation of neurodegeneration and may play a role in the clearance of amyloid-β in Alzheimer's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The specific role of Prothymosin alpha c-terminal peptide (ProT-CT) in stimulating protein synthesis by binding to the ribosome and enhancing mRNA translation is not a widely established fact and would require specific scientific evidence to confirm.\n2. UNKNOWN: The activation of cell signaling pathways such as PI3K/Akt and MAPK by ProT-CT is a specific claim that requires scientific evidence to verify its accuracy.\n3. UNKNOWN: The role of ProT-CT in the regulation of the immune response, particularly in T cell activation and cytokine production, is a detailed biological function that would need to be supported by scientific research to determine its truthfulness.\n4. UNKNOWN: The statement that ProT-CT is overexpressed in various types of cancer and may contribute to cancer progression and metastasis is a scientific claim that requires empirical evidence from research studies for validation.\n5. UNKNOWN: The involvement of ProT-CT in the regulation of neurodegeneration and its potential role in the clearance of amyloid-β in Alzheimer's disease is a specific scientific assertion that would need to be substantiated by research findings.\n\nNote: The responses to these statements are marked as UNKNOWN because they are specific scientific claims that require access to relevant research literature to verify their accuracy. Without such access or specific knowledge up to the knowledge cutoff date, it is not possible to determine the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Cystatin C is a protein that is involved in the regulation of protein degradation in the body, and it can form fibrils under certain conditions. The peptide that plays a pivotal role in human cystatin C fibrillization is the amino acid sequence RRARRRR. This sequence is located in the N-terminal region of the cystatin C protein and is responsible for the formation of fibrils.\nStudies have shown that the RRARRRR sequence in cystatin C is highly conserved across different species, and mutations in this sequence can disrupt the formation of fibrils and reduce the aggregation of cystatin C. The fibrillization of cystatin C is thought to play a role in the pathogenesis of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.\nIt is worth noting that the fibrillization of cystatin C is a complex process that involves the interaction of multiple factors, including the protein itself, metal ions, and other molecules. The RRARRRR sequence is just one of the many factors that can contribute to the formation of fibrils in cystatin C.",
    "llama-2-7b-chat-hf_fact_raw": "1. The peptide sequence RRARRRR plays a pivotal role in human cystatin C fibrillization.\n2. The RRARRRR sequence is located in the N-terminal region of the cystatin C protein.\n3. Mutations in the RRARRRR sequence can disrupt the formation of fibrils and reduce the aggregation of cystatin C.\n4. The fibrillization of cystatin C is associated with the pathogenesis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.\n5. The RRARRRR sequence in cystatin C is highly conserved across different species.",
    "llama-2-7b-chat-hf_fact": [
      "The peptide sequence RRARRRR plays a pivotal role in human cystatin C fibrillization.",
      "The RRARRRR sequence is located in the N-terminal region of the cystatin C protein.",
      "Mutations in the RRARRRR sequence can disrupt the formation of fibrils and reduce the aggregation of cystatin C.",
      "The fibrillization of cystatin C is associated with the pathogenesis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.",
      "The RRARRRR sequence in cystatin C is highly conserved across different species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The peptide sequence RRARRRR is indeed known to play a pivotal role in human cystatin C fibrillization.\n2. FALSE [correction]: The RRARRRR sequence is located in the C-terminal region of the cystatin C protein, not the N-terminal region.\n3. TRUE: Mutations in the RRARRRR sequence can disrupt the formation of fibrils and are known to reduce the aggregation of cystatin C, which is a characteristic of certain mutations that lead to less aggregation-prone forms of the protein.\n4. TRUE: The fibrillization of cystatin C is associated with the pathogenesis of neurodegenerative diseases, including cerebral amyloid angiopathy, which is related to Alzheimer's disease.\n5. UNKNOWN: Without specific information on the conservation of the RRARRRR sequence across different species, it is not possible to determine the truth of this statement. Conservation can vary depending on the protein and the species being compared.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Yes, the concentration of protein HIF-1α (Hypoxia-Inducible Factor-1 alpha) has been shown to increase after the administration of the cytoprotective prodrug amifostine (ethyol).\nAmifostine is a prodrug that is converted into the active compound ethylhydroxylaurate (EHLA) in the body. EHLA has been shown to have cytoprotective effects against various types of tissue damage, including oxidative stress, inflammation, and radiation injury.\nStudies have shown that amifostine can increase the expression of HIF-1α in various cell types, including cancer cells, immune cells, and endothelial cells. HIF-1α is a transcription factor that plays a critical role in response to hypoxia, and its activation can lead to the expression of genes involved in adaptive responses to stress, such as angiogenesis, glucose metabolism, and cell survival.\nFor example, a study published in the journal Cancer Research in 2003 found that amifostine increased the expression of HIF-1α in human lung cancer cells under normoxic conditions, and that this increase was associated with increased resistance to oxidative stress. Another study published in the journal Radiation Research in 2010 found that amifostine increased HIF-1α expression in mouse brain endothelial cells after exposure to ionizing radiation.\nOverall, these studies suggest that amifostine can increase the concentration of protein HIF-1α in various cell types, which may contribute to its cytoprotective effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug amifostine (ethyol).\n2. Amifostine is converted into the active compound ethylhydroxylaurate (EHLA) in the body.\n3. EHLA has cytoprotective effects against tissue damage such as oxidative stress, inflammation, and radiation injury.\n4. A study published in the journal Cancer Research in 2003 found that amifostine increased the expression of HIF-1α in human lung cancer cells under normoxic conditions.\n5. A study published in the journal Radiation Research in 2010 found that amifostine increased HIF-1α expression in mouse brain endothelial cells after exposure to ionizing radiation.",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of protein HIF-1α increases after the administration of the cytoprotective prodrug amifostine (ethyol).",
      "Amifostine is converted into the active compound ethylhydroxylaurate (EHLA) in the body.",
      "EHLA has cytoprotective effects against tissue damage such as oxidative stress, inflammation, and radiation injury.",
      "A study published in the journal Cancer Research in 2003 found that amifostine increased the expression of HIF-1α in human lung cancer cells under normoxic conditions.",
      "A study published in the journal Radiation Research in 2010 found that amifostine increased HIF-1α expression in mouse brain endothelial cells after exposure to ionizing radiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: It is known that the concentration of HIF-1α can increase in response to various protective stimuli, and amifostine is a cytoprotective agent that could potentially cause such an increase.\n2. FALSE [correction]: Amifostine is converted into the active compound WR-1065 in the body, not ethylhydroxylaurate (EHLA).\n3. TRUE: The active metabolite of amifostine, WR-1065, is known to have cytoprotective effects against tissue damage from oxidative stress, inflammation, and radiation injury.\n4. UNKNOWN: Without access to the specific article from the journal Cancer Research in 2003, the truth of this statement cannot be verified.\n5. UNKNOWN: Similarly, without access to the specific article from the journal Radiation Research in 2010, the truth of this statement cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase that deposits the following histone marks:\n* H3K79me3 (histone H3 lysine 79 trimethylation)\nSet7 is specifically involved in the methylation of histone H3 on lysine 79, which is a repressive chromatin mark that plays a role in the regulation of gene expression, particularly during development and cell differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase.\n2. Set7 deposits the histone mark H3K79me3, which stands for histone H3 lysine 79 trimethylation.\n3. Methylation of histone H3 on lysine 79 by Set7 is a repressive chromatin mark.\n4. The histone mark H3K79me3 plays a role in the regulation of gene expression.\n5. H3K79me3 is involved in processes during development and cell differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase.",
      "Set7 deposits the histone mark H3K79me3, which stands for histone H3 lysine 79 trimethylation.",
      "Methylation of histone H3 on lysine 79 by Set7 is a repressive chromatin mark.",
      "The histone mark H3K79me3 plays a role in the regulation of gene expression.",
      "H3K79me3 is involved in processes during development and cell differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 specifically deposits the histone mark H3K4me1, which stands for histone H3 lysine 4 monomethylation, not H3K79me3.\n3. FALSE [correction]: Methylation of histone H3 on lysine 4 by Set7 is generally associated with active transcription, not repression.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "The protein encoded by the gene DNAJC11 (also known as DJ-1) is localized primarily in the cytoplasm, but it can also be found in the nucleus in some cell types. DJ-1 is a small protein that plays a role in the regulation of various cellular processes, including the response to oxidative stress, the maintenance of mitochondrial function, and the regulation of cell proliferation and differentiation. It is also involved in the protection against cancer and neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized primarily in the cytoplasm.\n2. The DNAJC11 protein can also be found in the nucleus in some cell types.\n3. DNAJC11, also known as DJ-1, is involved in the regulation of the response to oxidative stress.\n4. The DNAJC11 protein plays a role in the maintenance of mitochondrial function.\n5. DJ-1 is involved in the protection against cancer and neurodegenerative diseases.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is localized primarily in the cytoplasm.",
      "The DNAJC11 protein can also be found in the nucleus in some cell types.",
      "DNAJC11, also known as DJ-1, is involved in the regulation of the response to oxidative stress.",
      "The DNAJC11 protein plays a role in the maintenance of mitochondrial function.",
      "DJ-1 is involved in the protection against cancer and neurodegenerative diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: DNAJC11 is not the same as DJ-1. DJ-1 is encoded by the PARK7 gene and is involved in the regulation of the response to oxidative stress.\n4. UNKNOWN\n5. FALSE [correction]: DJ-1, not DNAJC11, is involved in the protection against cancer and neurodegenerative diseases. DJ-1 is associated with Parkinson's disease and has been studied for its role in various cellular processes including those related to cancer and neuroprotection.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Yes, ultraconserved elements (UCEs) are often depleted among copy number variants (CNVs). CNVs are genomic regions that contain more or fewer copies of a particular DNA sequence than the typical diploid number, which is two copies in humans. UCEs are sequences that are highly conserved across different species and are often found in regions that are not prone to CNVs.\nStudies have shown that UCEs are enriched in regions that are not commonly affected by CNVs, such as gene-rich regions and regions with high GC content. In contrast, CNVs are more likely to occur in regions that are gene-poor and have low GC content. This is because CNVs are often generated by the duplication or deletion of genomic regions, which can lead to the loss or gain of function of genes in these regions.\nOne study found that UCEs were depleted among CNVs in the human genome, with only 10% of UCEs overlapping with CNVs. Another study found that the number of UCEs in a region was inversely related to the number of CNVs in that region. These findings suggest that UCEs are less likely to be affected by CNVs and are more likely to be conserved across different species.\nHowever, it is important to note that not all UCEs are depleted among CNVs, and some may be preserved even in regions with CNVs. Additionally, the depletion of UCEs among CNVs may not be absolute, and some UCEs may be found in regions with CNVs. Further research is needed to fully understand the relationship between UCEs and CNVs and their potential roles in human genetic variation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UCEs) are often depleted among copy number variants (CNVs).\n2. CNVs are genomic regions that contain more or fewer copies of a particular DNA sequence than the typical diploid number in humans.\n3. UCEs are sequences that are highly conserved across different species.\n4. One study found that only 10% of UCEs overlapped with CNVs in the human genome.\n5. Another study indicated that the number of UCEs in a region was inversely related to the number of CNVs in that region.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UCEs) are often depleted among copy number variants (CNVs).",
      "CNVs are genomic regions that contain more or fewer copies of a particular DNA sequence than the typical diploid number in humans.",
      "UCEs are sequences that are highly conserved across different species.",
      "One study found that only 10% of UCEs overlapped with CNVs in the human genome.",
      "Another study indicated that the number of UCEs in a region was inversely related to the number of CNVs in that region."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Ultraconserved elements (UCEs) are typically regions of the genome that are highly conserved and thus are often depleted among copy number variants (CNVs), which are more variable.\n2. TRUE: CNVs are indeed genomic regions that can have a variable number of copies of a particular DNA sequence compared to the typical two copies (diploid number) found in humans.\n3. TRUE: UCEs are sequences that are highly conserved across different species, indicating their importance and potential function in the genome.\n4. UNKNOWN: Without specific reference to the study mentioned, it is not possible to verify the accuracy of the statement that only 10% of UCEs overlapped with CNVs in the human genome.\n5. UNKNOWN: Similarly, without specific reference to the study, it is not possible to verify the accuracy of the statement that there is an inverse relationship between the number of UCEs and the number of CNVs in a region.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "The substrate of the Haspin kinase during mitosis is the protein Cdc20. Haspin is a protein that is involved in the regulation of the mitotic spindle, which is the structure that separates the chromosomes during cell division. Haspin kinase is activated during mitosis and phosphorylates Cdc20, which is a key regulator of the mitotic spindle. The phosphorylation of Cdc20 by Haspin helps to stabilize the spindle and promote proper chromosome separation during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is the protein Cdc20.\n2. Haspin kinase is involved in the regulation of the mitotic spindle.\n3. The mitotic spindle is the structure that separates chromosomes during cell division.\n4. Haspin kinase is activated during mitosis.\n5. The phosphorylation of Cdc20 by Haspin kinase helps to stabilize the mitotic spindle and promote proper chromosome separation.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is the protein Cdc20.",
      "Haspin kinase is involved in the regulation of the mitotic spindle.",
      "The mitotic spindle is the structure that separates chromosomes during cell division.",
      "Haspin kinase is activated during mitosis.",
      "The phosphorylation of Cdc20 by Haspin kinase helps to stabilize the mitotic spindle and promote proper chromosome separation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The substrate of the Haspin kinase during mitosis is histone H3, not the protein Cdc20.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The phosphorylation of histone H3 by Haspin kinase helps to regulate chromosome behavior and proper chromosome segregation, not the stabilization of the mitotic spindle or the phosphorylation of Cdc20.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate through a unique mechanism that does not involve the standard cellular machinery for protein synthesis and DNA replication. Here is the general mechanism of viroid replication:\n1. Attachment: Viroids attach to the host cell membrane through specific sequences in their RNA molecule.\n2. Endosomal sorting: Once attached, the viroids are endocytosed and sorted into endosomes, where they escape the host cell's immune system.\n3. Acidification: The endosomes containing the viroids become acidified, which triggers a conformational change in the viroid RNA that exposes a ribozyme domain.\n4. RNA-RNA interaction: The exposed ribozyme domain of the viroid RNA interacts with the complementary RNA strand, leading to the cleavage of the RNA molecule.\n5. RNA replication: The cleaved RNA molecule is then replicated by the host cell's RNA polymerase, resulting in the production of new viroid RNA molecules.\n6. Release: The new viroid RNA molecules are released from the host cell through a process called exocytosis, where they can then attach to and infect other host cells.\nIn summary, viroid replication is a complex process that involves the attachment of the viroid to the host cell membrane, endocytosis, acidification, RNA-RNA interaction, RNA replication, and release. This unique mechanism of replication allows viroids to infect a wide range of plant species and to persist in the environment for long periods of time.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules that replicate without the standard cellular machinery for protein synthesis and DNA replication.\n2. Viroids attach to the host cell membrane through specific sequences in their RNA molecule.\n3. The endosomes containing the viroids become acidified, triggering a conformational change in the viroid RNA that exposes a ribozyme domain.\n4. The ribozyme domain of the viroid RNA interacts with the complementary RNA strand, leading to the cleavage of the RNA molecule.\n5. The new viroid RNA molecules are released from the host cell through a process called exocytosis.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules that replicate without the standard cellular machinery for protein synthesis and DNA replication.",
      "Viroids attach to the host cell membrane through specific sequences in their RNA molecule.",
      "The endosomes containing the viroids become acidified, triggering a conformational change in the viroid RNA that exposes a ribozyme domain.",
      "The ribozyme domain of the viroid RNA interacts with the complementary RNA strand, leading to the cleavage of the RNA molecule.",
      "The new viroid RNA molecules are released from the host cell through a process called exocytosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroids do not attach to the host cell membrane through specific sequences in their RNA molecule. Instead, they typically infect plant cells and do not require attachment to the cell membrane for entry.\n3. FALSE [correction]: The statement describes a process similar to that of virus entry and uncoating, which is not applicable to viroids. Viroids do not form endosomes nor require acidification for a conformational change. They function differently, often relying on host cell enzymes for replication.\n4. TRUE: Viroids contain a ribozyme domain that can catalyze the self-cleavage of their RNA molecule.\n5. FALSE [correction]: The mechanism of viroid release from the host cell is not well understood, but it is not typically described as exocytosis. Viroids are known to spread from cell to cell through plasmodesmata in plants.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Fibronectin is a protein that has been suggested as a potential serum biomarker for Duchenne muscular dystrophy (DMD), a severe and progressive genetic disorder that affects muscle strength and function.\nStudies have shown that levels of fibronectin in the bloodstream are significantly elevated in individuals with DMD compared to healthy controls. This increase in fibronectin levels is thought to be due to the excessive muscle damage and inflammation that occurs in DMD, which leads to the release of fibronectin from the muscle tissue into the bloodstream.\nThe elevated levels of fibronectin in the blood of DMD patients can be used as a biomarker for the diagnosis and monitoring of the disease. However, it is important to note that fibronectin levels may not be elevated in all individuals with DMD, particularly in the early stages of the disease. Therefore, the use of fibronectin as a biomarker for DMD should be combined with other diagnostic tests, such as genetic analysis, to confirm the diagnosis.\nAdditionally, fibronectin has been shown to have a role in the pathogenesis of DMD, as it can contribute to the progression of muscle degeneration by promoting inflammation and fibrosis. Therefore, understanding the role of fibronectin in DMD may lead to the development of new therapeutic strategies for the treatment of the disease.\nIn summary, fibronectin constitutes a potential serum biomarker for Duchenne muscular dystrophy, and its elevated levels in the blood of DMD patients can be used for the diagnosis and monitoring of the disease. However, the use of fibronectin as a biomarker should be combined with other diagnostic tests to confirm the diagnosis, and further research is needed to fully understand its role in the pathogenesis of DMD.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin has been suggested as a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Studies have indicated that levels of fibronectin are significantly elevated in individuals with DMD compared to healthy controls.\n3. The increase in fibronectin levels in DMD patients is thought to be due to excessive muscle damage and inflammation.\n4. Elevated levels of fibronectin in the blood can be used for the diagnosis and monitoring of Duchenne muscular dystrophy.\n5. Fibronectin is involved in the pathogenesis of DMD by promoting inflammation and fibrosis.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin has been suggested as a potential serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Studies have indicated that levels of fibronectin are significantly elevated in individuals with DMD compared to healthy controls.",
      "The increase in fibronectin levels in DMD patients is thought to be due to excessive muscle damage and inflammation.",
      "Elevated levels of fibronectin in the blood can be used for the diagnosis and monitoring of Duchenne muscular dystrophy.",
      "Fibronectin is involved in the pathogenesis of DMD by promoting inflammation and fibrosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with scientific understanding regarding the role of fibronectin in Duchenne muscular dystrophy (DMD). Fibronectin is a protein that is involved in cell adhesion and wound healing, and its elevated levels in the serum of individuals with DMD are thought to reflect ongoing muscle damage and inflammation. Elevated fibronectin levels have been suggested as a potential biomarker for the diagnosis and monitoring of DMD, and it is implicated in the pathogenesis of the disease through its role in promoting inflammation and fibrosis. However, it is important to note that while these statements are generally true, the use of fibronectin as a clinical biomarker for DMD would require validation through clinical studies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "The DeepBlue epigenomic data server is a comprehensive resource for epigenomic data from various projects. Here are some of the major epigenome projects whose data are contained in the DeepBlue server:\n1. ENCODE (ENCyclopedia Of DNA Elements): The ENCODE project is a large-scale effort to map all the functional elements in the human genome. The data from this project are included in the DeepBlue server.\n2. Roadmap Epigenomics Project: The Roadmap Epigenomics Project is a collaborative effort to map the epigenetic landscape of various organisms, including humans. The project has generated a wealth of epigenomic data, which are available in the DeepBlue server.\n3. HIPS (Human Epigenome Project): The Human Epigenome Project is a large-scale effort to map the epigenetic marks in human cells. The data from this project are included in the DeepBlue server.\n4. Mouse Epigenome Project: The Mouse Epigenome Project is a comprehensive effort to map the epigenetic marks in mouse cells. The data from this project are also included in the DeepBlue server.\n5. Plant Epigenomics Project: The Plant Epigenomics Project is a large-scale effort to map the epigenetic marks in plant cells. While the majority of the data in the DeepBlue server are from animal genomes, the Plant Epigenomics Project data are also included.\n6. Epigenomics of Human Disease Project: This project aims to identify epigenetic changes associated with various human diseases. The data from this project are included in the DeepBlue server.\n7. Cancer Epigenomics Project: This project aims to identify epigenetic changes in cancer cells. The data from this project are also included in the DeepBlue server.\n8. Epigenomics of Aging Project: This project aims to identify epigenetic changes associated with aging. The data from this project are included in the DeepBlue server.\n9. Epigenomics of Neurological Disorders Project: This project aims to identify epigenetic changes associated with neurological disorders such as Alzheimer's disease and Parkinson's disease. The data from this project are also included in the DeepBlue server.\n10. Ep",
    "llama-2-7b-chat-hf_fact_raw": "1. The ENCODE (ENCyclopedia Of DNA Elements) project data are included in the DeepBlue epigenomic data server.\n2. The Roadmap Epigenomics Project data are available in the DeepBlue epigenomic data server.\n3. Data from the Human Epigenome Project (HIPS) are included in the DeepBlue server.\n4. The Mouse Epigenome Project data are included in the DeepBlue epigenomic data server.\n5. The Plant Epigenomics Project data are also included in the DeepBlue server.",
    "llama-2-7b-chat-hf_fact": [
      "The ENCODE (ENCyclopedia Of DNA Elements) project data are included in the DeepBlue epigenomic data server.",
      "The Roadmap Epigenomics Project data are available in the DeepBlue epigenomic data server.",
      "Data from the Human Epigenome Project (HIPS) are included in the DeepBlue server.",
      "The Mouse Epigenome Project data are included in the DeepBlue epigenomic data server.",
      "The Plant Epigenomics Project data are also included in the DeepBlue server."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There is no widely recognized project called the Human Epigenome Project (HIPS); it might be a confusion with the Human Epigenome Consortium (HEC) or the International Human Epigenome Consortium (IHEC), but without specific information about HIPS being included in DeepBlue, this statement cannot be verified.\n4. UNKNOWN: Without specific information about the inclusion of the Mouse Epigenome Project data in the DeepBlue server, the truth of this statement cannot be determined.\n5. UNKNOWN: Without specific information about the inclusion of the Plant Epigenomics Project data in the DeepBlue server, the truth of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "The tool that employs self-organizing maps (SOM) for analyzing synonymous codon usage is called \"CodonMaps\". This tool uses SOM to visualize and analyze the codon usage patterns in a given DNA sequence, allowing researchers to identify patterns and trends in codon usage that may be associated with specific functional or evolutionary features of the genome. The SOM algorithm creates a lower-dimensional representation of the high-dimensional codon usage data, making it easier to visualize and interpret the results.",
    "llama-2-7b-chat-hf_fact_raw": "1. The tool called \"CodonMaps\" employs self-organizing maps (SOM) for analyzing synonymous codon usage.\n2. \"CodonMaps\" is used to visualize and analyze codon usage patterns in DNA sequences.\n3. The SOM algorithm in \"CodonMaps\" creates a lower-dimensional representation of high-dimensional codon usage data.",
    "llama-2-7b-chat-hf_fact": [
      "The tool called \"CodonMaps\" employs self-organizing maps (SOM) for analyzing synonymous codon usage.",
      "\"CodonMaps\" is used to visualize and analyze codon usage patterns in DNA sequences.",
      "The SOM algorithm in \"CodonMaps\" creates a lower-dimensional representation of high-dimensional codon usage data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 (Microbial Identification and Networks for Drug Discovery and Informatics) is a bioinformatics tool developed by the National Center for Biotechnology Information (NCBI), a part of the National Library of Medicine (NLM) at the National Institutes of Health (NIH). MINDY-1 is a web-based platform that provides a comprehensive framework for the analysis and interpretation of microbial genomic data.\nThe tool offers a range of features and functionalities, including:\n1. Genome assembly and annotation: MINDY-1 can automatically assemble and annotate microbial genomes, including those of bacteria, archaea, and viruses.\n2. Genome comparison: The tool allows users to compare the genomes of different microorganisms to identify similarities and differences, which can be useful in understanding evolutionary relationships and identifying potential drug targets.\n3. Functional genomics analysis: MINDY-1 provides a range of tools for analyzing the functional content of microbial genomes, including gene prediction, functional annotation, and pathway analysis.\n4. Interaction network analysis: The tool can construct and analyze interaction networks between microbial genomes, which can help researchers understand how microorganisms interact with each other and their environment.\n5. Drug target identification: MINDY-1 can identify potential drug targets in microbial genomes by analyzing the structure and function of proteins, lipids, and other biomolecules.\nMINDY-1 is a powerful tool for microbial genomics research, providing a comprehensive framework for analyzing and interpreting microbial genomic data. Its ability to integrate and analyze large amounts of data from different sources makes it a valuable resource for researchers studying microbial genomics, drug discovery, and infectious diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a bioinformatics tool developed by the National Center for Biotechnology Information (NCBI).\n2. The National Center for Biotechnology Information is a part of the National Library of Medicine (NLM) at the National Institutes of Health (NIH).\n3. MINDY-1 is designed for the analysis and interpretation of microbial genomic data.\n4. MINDY-1 can automatically assemble and annotate microbial genomes, including those of bacteria, archaea, and viruses.\n5. The tool allows for the construction and analysis of interaction networks between microbial genomes.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a bioinformatics tool developed by the National Center for Biotechnology Information (NCBI).",
      "The National Center for Biotechnology Information is a part of the National Library of Medicine (NLM) at the National Institutes of Health (NIH).",
      "MINDY-1 is designed for the analysis and interpretation of microbial genomic data.",
      "MINDY-1 can automatically assemble and annotate microbial genomes, including those of bacteria, archaea, and viruses.",
      "The tool allows for the construction and analysis of interaction networks between microbial genomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MINDY-1 is not a bioinformatics tool; it is a hypothetical name and not associated with the National Center for Biotechnology Information (NCBI). There is no widely recognized bioinformatics tool named MINDY-1 developed by NCBI.\n2. TRUE\n3. FALSE [correction]: Since MINDY-1 is not an actual bioinformatics tool developed by NCBI, it is not designed for the analysis and interpretation of microbial genomic data.\n4. FALSE [correction]: MINDY-1, being a hypothetical tool, cannot automatically assemble and annotate microbial genomes.\n5. FALSE [correction]: MINDY-1, as it is not a real tool, does not allow for the construction and analysis of interaction networks between microbial genomes.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, but some popular ones include:\n1. PhyloBayes: PhyloBayes is a Bayesian phylogenetic software package that can be used to identify conserved genomic regions by analyzing multiple alignments of protein or DNA sequences.\n2. PhastCons: PhastCons is a software package that uses a hidden Markov model to identify conserved genomic regions based on multiple alignments of protein or DNA sequences.\n3. ProtScale: ProtScale is a software package that uses a hidden Markov model to identify conserved genomic regions based on multiple alignments of protein sequences.\n4. ConServe: ConServe is a software package that uses a hidden Markov model to identify conserved genomic regions based on multiple alignments of protein or DNA sequences.\n5. GERP: GERP (Genomic Evolutionary Rate Profiling) is a software package that uses a hidden Markov model to identify conserved genomic regions based on multiple alignments of protein or DNA sequences.\n6. MUSCLE: MUSCLE (Multiple Sequence Comparison by Log-Expectation) is a software package that can be used to identify conserved genomic regions by comparing multiple protein or DNA sequences.\n7. MAFFT: MAFFT (Multiple Alignment using Fast Fourier Transform) is a software package that can be used to identify conserved genomic regions by comparing multiple protein or DNA sequences.\n8. RAxML: RAxML (RaxML) is a software package that can be used to identify conserved genomic regions by comparing multiple protein or DNA sequences.\n9. BEAST: BEAST (Bayesian Evolutionary Analysis by Sampling Trees) is a software package that can be used to identify conserved genomic regions by analyzing multiple alignments of protein or DNA sequences.\n10. STRAW: STRAW (Species Tree Reconstruction and Ancestral State Inference) is a software package that can be used to identify conserved genomic regions by analyzing multiple alignments of protein or DNA sequences.\nIt's worth noting that these software packages have different strengths and weaknesses, and the choice of which one to use will depend on the specific research question and the characteristics",
    "llama-2-7b-chat-hf_fact_raw": "1. PhyloBayes is a Bayesian phylogenetic software package used for identifying conserved genomic regions.\n2. PhastCons uses a hidden Markov model to identify conserved genomic regions.\n3. GERP (Genomic Evolutionary Rate Profiling) is a software package designed to identify conserved genomic regions.\n4. MUSCLE (Multiple Sequence Comparison by Log-Expectation) is a software package used for comparing multiple protein or DNA sequences to identify conserved regions.\n5. MAFFT (Multiple Alignment using Fast Fourier Transform) is a software package that assists in identifying conserved genomic regions through multiple sequence comparisons.",
    "llama-2-7b-chat-hf_fact": [
      "PhyloBayes is a Bayesian phylogenetic software package used for identifying conserved genomic regions.",
      "PhastCons uses a hidden Markov model to identify conserved genomic regions.",
      "GERP (Genomic Evolutionary Rate Profiling) is a software package designed to identify conserved genomic regions.",
      "MUSCLE (Multiple Sequence Comparison by Log-Expectation) is a software package used for comparing multiple protein or DNA sequences to identify conserved regions.",
      "MAFFT (Multiple Alignment using Fast Fourier Transform) is a software package that assists in identifying conserved genomic regions through multiple sequence comparisons."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PhyloBayes is a Bayesian phylogenetic software package used for inferring phylogenetic trees, not specifically for identifying conserved genomic regions.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "The PIEZO2 gene is associated with several diseases, including:\n1. PIEZO2-related disorder: This is a rare genetic disorder caused by mutations in the PIEZO2 gene. It is characterized by a range of symptoms including developmental delays, intellectual disability, seizures, and distinctive facial features.\n2. Hypertrophic cardiomyopathy: Mutations in the PIEZO2 gene have been identified as a cause of hypertrophic cardiomyopathy, a condition in which the heart muscle becomes thickened, leading to heart failure and other complications.\n3. Neuropathy, axonal, Charcot-like, and mixed neuropathy, Charcot-Marie-Tooth disease type 2A: Mutations in the PIEZO2 gene have been associated with Charcot-Marie-Tooth disease type 2A, a group of inherited disorders that affect the peripheral nerves. These disorders can cause numbness, weakness, and muscle wasting in the hands and feet, as well as other symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. PIEZO2-related disorder is a genetic disorder caused by mutations in the PIEZO2 gene.\n2. Mutations in the PIEZO2 gene have been identified as a cause of hypertrophic cardiomyopathy.\n3. Mutations in the PIEZO2 gene have been associated with Charcot-Marie-Tooth disease type 2A.",
    "llama-2-7b-chat-hf_fact": [
      "PIEZO2-related disorder is a genetic disorder caused by mutations in the PIEZO2 gene.",
      "Mutations in the PIEZO2 gene have been identified as a cause of hypertrophic cardiomyopathy.",
      "Mutations in the PIEZO2 gene have been associated with Charcot-Marie-Tooth disease type 2A."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in the PIEZO2 gene have not been identified as a cause of hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy is commonly associated with mutations in other genes, such as MYH7 or MYBPC3.\n3. FALSE [correction]: Mutations in the PIEZO2 gene have not been associated with Charcot-Marie-Tooth disease type 2A. Charcot-Marie-Tooth disease type 2A is commonly associated with mutations in the MFN2 gene.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization is involved in the regulation of endoplasmic reticulum (ER) stress response and the unfolded protein response (UPR). The two proteins, ERAP1 and ERAP2, are members of the endoplasmic reticulum aminopeptidase (ERAP) family and are involved in the degradation of misfolded proteins in the ER.\nDimerization of ERAP1 and ERAP2 promotes the degradation of misfolded proteins in the ER by facilitating their recognition and ubiquitination. The ERAP1-ERAP2 dimer acts as a protease complex that can recognize and cleave a variety of substrates, including misfolded proteins, and promote their degradation through the ubiquitin-proteasome pathway.\nIn addition to its role in protein degradation, ERAP1-ERAP2 dimerization also regulates the UPR by modulating the activity of key signaling pathways, including the PERK (PKR-like ER kinase), IRE1 (inositol-requiring enzyme 1), and ATF6 (activating transcription factor 6) pathways. These pathways play critical roles in regulating cellular responses to ER stress, including the upregulation of chaperone proteins, the inhibition of protein synthesis, and the activation of pro-survival pathways.\nIn summary, ERAP1-ERAP2 dimerization promotes the degradation of misfolded proteins in the ER and regulates the UPR by modulating key signaling pathways involved in cellular responses to ER stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization is involved in the regulation of the endoplasmic reticulum stress response and the unfolded protein response.\n2. ERAP1 and ERAP2 are members of the endoplasmic reticulum aminopeptidase family.\n3. The ERAP1-ERAP2 dimer facilitates the recognition and ubiquitination of misfolded proteins in the endoplasmic reticulum.\n4. The ERAP1-ERAP2 dimer acts as a protease complex that can recognize and cleave a variety of substrates, including misfolded proteins.\n5. ERAP1-ERAP2 dimerization regulates the unfolded protein response by modulating the activity of key signaling pathways such as PERK, IRE1, and ATF6.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization is involved in the regulation of the endoplasmic reticulum stress response and the unfolded protein response.",
      "ERAP1 and ERAP2 are members of the endoplasmic reticulum aminopeptidase family.",
      "The ERAP1-ERAP2 dimer facilitates the recognition and ubiquitination of misfolded proteins in the endoplasmic reticulum.",
      "The ERAP1-ERAP2 dimer acts as a protease complex that can recognize and cleave a variety of substrates, including misfolded proteins.",
      "ERAP1-ERAP2 dimerization regulates the unfolded protein response by modulating the activity of key signaling pathways such as PERK, IRE1, and ATF6."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nThe statements about ERAP1 and ERAP2 involve specific biochemical functions and interactions that are subject to ongoing research. While statement 2 is true as ERAP1 and ERAP2 are indeed members of the endoplasmic reticulum aminopeptidase family, the other statements require specific knowledge of current scientific literature to confirm their accuracy. Without access to the latest research or the specific passage from which these statements are extracted, it is not possible to definitively determine the truthfulness of statements 1, 3, and 5. Statement 4 is generally true as ERAP1 and ERAP2 are known to act as a protease complex that can recognize and cleave a variety of substrates, including misfolded proteins.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two proteins that have been implicated in the regulation of gallbladder development and function. While they have been studied primarily in the context of gallbladder disease, they also have important functions in non-damaged gallbladders. Here are some of the functions of R-spondin 1 and Noggin in non-damaged gallbladders:\nR-spondin 1:\n1. Stem cell maintenance: R-spondin 1 has been shown to promote the proliferation and maintenance of stem cells in the gallbladder. It does this by inhibiting the expression of genes that promote differentiation and by promoting the expression of genes that promote stem cell self-renewal.\n2. Cell survival: R-spondin 1 has been shown to promote the survival of gallbladder epithelial cells. It does this by inhibiting the expression of pro-apoptotic genes and by promoting the expression of anti-apoptotic genes.\n3. Cell adhesion and migration: R-spondin 1 has been shown to regulate the adhesion and migration of gallbladder epithelial cells. It does this by controlling the expression of genes involved in cell adhesion and migration.\nNoggin:\n1. Cell signaling: Noggin has been shown to regulate cell signaling pathways in the gallbladder. It does this by inhibiting the activation of certain signaling pathways and by promoting the activation of other pathways.\n2. Cell proliferation: Noggin has been shown to promote the proliferation of gallbladder epithelial cells. It does this by inhibiting the expression of genes that promote cell cycle arrest and by promoting the expression of genes that promote cell cycle progression.\n3. Tissue organization: Noggin has been shown to regulate the organization of the gallbladder tissue. It does this by controlling the expression of genes involved in tissue organization and by promoting the formation of tight junctions between gallbladder epithelial cells.\nIn summary, R-spondin 1 and Noggin play important roles in the regulation",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 promotes the proliferation and maintenance of stem cells in the gallbladder by inhibiting differentiation genes and promoting self-renewal genes.\n2. R-spondin 1 promotes the survival of gallbladder epithelial cells by inhibiting pro-apoptotic genes and promoting anti-apoptotic genes.\n3. R-spondin 1 regulates the adhesion and migration of gallbladder epithelial cells by controlling the expression of genes involved in these processes.\n4. Noggin regulates cell signaling pathways in the gallbladder by inhibiting and promoting the activation of certain pathways.\n5. Noggin promotes the proliferation of gallbladder epithelial cells by inhibiting genes that promote cell cycle arrest and promoting genes that facilitate cell cycle progression.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 promotes the proliferation and maintenance of stem cells in the gallbladder by inhibiting differentiation genes and promoting self-renewal genes.",
      "R-spondin 1 promotes the survival of gallbladder epithelial cells by inhibiting pro-apoptotic genes and promoting anti-apoptotic genes.",
      "R-spondin 1 regulates the adhesion and migration of gallbladder epithelial cells by controlling the expression of genes involved in these processes.",
      "Noggin regulates cell signaling pathways in the gallbladder by inhibiting and promoting the activation of certain pathways.",
      "Noggin promotes the proliferation of gallbladder epithelial cells by inhibiting genes that promote cell cycle arrest and promoting genes that facilitate cell cycle progression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about R-spondin 1 promoting the proliferation and maintenance of stem cells in the gallbladder is specific and would require scientific evidence to confirm its accuracy. Without the context of the specific research or scientific literature, it's not possible to determine the truth of this statement.\n2. UNKNOWN: Similar to the first statement, the claim about R-spondin 1 promoting the survival of gallbladder epithelial cells by regulating gene expression related to apoptosis would need to be supported by scientific research, which is not provided here.\n3. UNKNOWN: The statement regarding R-spondin 1's role in regulating adhesion and migration of gallbladder epithelial cells is also specific and requires scientific evidence to verify its truthfulness.\n4. UNKNOWN: The statement about Noggin regulating cell signaling pathways in the gallbladder is vague and does not specify which pathways it inhibits or promotes. Without additional context or scientific evidence, the truth of this statement cannot be determined.\n5. UNKNOWN: The claim that Noggin promotes the proliferation of gallbladder epithelial cells by influencing genes related to the cell cycle is another specific statement that would need to be backed by scientific research to confirm its validity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) requires a subunit for its function. NOX5 is a heterotetrameric enzyme, meaning it is composed of four subunits: two catalytic subunits (NOX5A and NOX5B) and two regulatory subunits (NOX5R1 and NOX5R2). These subunits work together to form the active enzyme. The catalytic subunits (NOX5A and NOX5B) are responsible for the transfer of electrons from NADPH to oxygen, leading to the production of reactive oxygen species (ROS), while the regulatory subunits (NOX5R1 and NOX5R2) play a role in the regulation of the enzyme's activity. Therefore, NOX5 requires the presence of all four subunits to function properly.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) requires a subunit for its function.\n2. NOX5 is a heterotetrameric enzyme.\n3. NOX5 is composed of four subunits: two catalytic subunits (NOX5A and NOX5B) and two regulatory subunits (NOX5R1 and NOX5R2).\n4. The catalytic subunits (NOX5A and NOX5B) are responsible for the transfer of electrons from NADPH to oxygen.\n5. The regulatory subunits (NOX5R1 and NOX5R2) play a role in the regulation of the enzyme's activity.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) requires a subunit for its function.",
      "NOX5 is a heterotetrameric enzyme.",
      "NOX5 is composed of four subunits: two catalytic subunits (NOX5A and NOX5B) and two regulatory subunits (NOX5R1 and NOX5R2).",
      "The catalytic subunits (NOX5A and NOX5B) are responsible for the transfer of electrons from NADPH to oxygen.",
      "The regulatory subunits (NOX5R1 and NOX5R2) play a role in the regulation of the enzyme's activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) does not require a separate subunit for its function; it is a calcium-dependent enzyme that is activated by binding of calcium ions directly to the enzyme itself.\n2. FALSE [correction]: NOX5 is not a heterotetrameric enzyme; it functions as a single polypeptide without the need for additional subunits.\n3. FALSE [correction]: NOX5 is not composed of four subunits as described; it is a single polypeptide enzyme and does not have separate catalytic and regulatory subunits named NOX5A, NOX5B, NOX5R1, and NOX5R2.\n4. TRUE: The catalytic function of NOX5, as with other NOX enzymes, involves the transfer of electrons from NADPH to oxygen, although NOX5 is not split into separate subunits as stated.\n5. FALSE [correction]: Since NOX5 does not have separate regulatory subunits named NOX5R1 and NOX5R2, this statement is incorrect. NOX5 regulation is instead directly mediated by calcium binding to the enzyme.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are two proteins that are connected in the regulation of iron metabolism.\nHepcidin is a hormone produced in the liver that regulates iron absorption and distribution in the body. It does this by binding to iron-regulatory proteins (IRPs) and ferroportin, a protein that mediates iron efflux from cells. When hepcidin binds to these proteins, it triggers their degradation, leading to a decrease in iron availability to cells and a reduction in iron absorption from the diet.\nFurin, on the other hand, is a protease enzyme that is involved in the processing and activation of many other proteins in the body. In the context of iron metabolism, furin plays a role in the processing and activation of hepcidin. Specifically, furin cleaves hepcidin to produce its active form, which is then able to bind to IRPs and ferroportin and regulate iron efflux from cells.\nIn summary, furin and hepcidin are connected in the regulation of iron metabolism through their respective roles in processing and activating hepcidin, and in the regulation of iron efflux from cells. Dysregulation of either of these proteins can lead to iron overload or iron deficiency, depending on the context.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin is a hormone produced in the liver that regulates iron absorption and distribution in the body.\n2. Hepcidin regulates iron by binding to iron-regulatory proteins (IRPs) and ferroportin, leading to their degradation.\n3. Furin is a protease enzyme involved in the processing and activation of many proteins in the body.\n4. Furin cleaves hepcidin to produce its active form.\n5. Dysregulation of furin or hepcidin can lead to iron overload or iron deficiency.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin is a hormone produced in the liver that regulates iron absorption and distribution in the body.",
      "Hepcidin regulates iron by binding to iron-regulatory proteins (IRPs) and ferroportin, leading to their degradation.",
      "Furin is a protease enzyme involved in the processing and activation of many proteins in the body.",
      "Furin cleaves hepcidin to produce its active form.",
      "Dysregulation of furin or hepcidin can lead to iron overload or iron deficiency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hepcidin regulates iron by binding to the iron exporter protein ferroportin, leading to its internalization and degradation, but it does not bind to iron-regulatory proteins (IRPs).\n3. TRUE\n4. FALSE [correction]: Furin does not cleave hepcidin to produce its active form. Hepcidin is synthesized as a preprohormone, and its maturation involves cleavage by other proteases, but not specifically by furin.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster, also known as the \"phosphoglucose pathway\". This gene cluster contains over 100 genes and is responsible for the breakdown and synthesis of glucose, as well as the production of ATP and other metabolites.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster.\n2. The glycolysis/gluconeogenesis gene cluster is also known as the \"phosphoglucose pathway\".\n3. This gene cluster contains over 100 genes.\n4. It is responsible for the breakdown and synthesis of glucose.\n5. It is involved in the production of ATP and other metabolites.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster.",
      "The glycolysis/gluconeogenesis gene cluster is also known as the \"phosphoglucose pathway\".",
      "This gene cluster contains over 100 genes.",
      "It is responsible for the breakdown and synthesis of glucose.",
      "It is involved in the production of ATP and other metabolites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The glycolysis/gluconeogenesis pathway is commonly known as the glycolytic pathway or gluconeogenesis pathway, but not typically referred to as the \"phosphoglucose pathway\".\n3. FALSE [correction]: The glycolysis/gluconeogenesis gene cluster does not contain over 100 genes. The exact number of genes in the cluster can vary depending on the organism, but it is generally much fewer than 100.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT (Long Non-Coding RNA in Myeloid Lineage Transcription) is a long non-coding RNA (lncRNA) that plays a crucial role in the regulation of myeloid cell development and differentiation. LINCT is specifically expressed in myeloid cells, including granulocytes, monocytes, and macrophages, and plays a key role in the regulation of their proliferation, survival, and differentiation.\nThe main functions of LIMT lncRNA include:\n1. Regulation of myeloid cell proliferation and survival: LIMT lncRNA has been shown to inhibit the proliferation and survival of myeloid cells by suppressing the expression of genes involved in cell cycle progression and apoptosis.\n2. Modulation of myeloid cell differentiation: LIMT lncRNA regulates the differentiation of myeloid cells by controlling the expression of genes involved in the differentiation process. For example, it has been shown to inhibit the differentiation of granulocytes and monocytes.\n3. Regulation of inflammation: LIMT lncRNA has been shown to regulate the expression of genes involved in inflammation, such as NF-κB, a transcription factor that regulates the expression of genes involved in inflammation.\n4. Modulation of immune response: LIMT lncRNA has been shown to regulate the immune response by controlling the expression of genes involved in the immune response, such as T cell activation and cytokine production.\n5. Cancer: LIMT lncRNA has been shown to be involved in the development and progression of cancer, particularly in myeloid malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).\nIn summary, LIMT lncRNA plays a crucial role in the regulation of myeloid cell development, differentiation, and function, and its dysregulation has been implicated in various diseases, including cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT (Long Non-Coding RNA in Myeloid Lineage Transcription) is a long non-coding RNA that is involved in the regulation of myeloid cell development and differentiation.\n2. LIMT lncRNA is specifically expressed in myeloid cells, such as granulocytes, monocytes, and macrophages.\n3. LIMT lncRNA inhibits the proliferation and survival of myeloid cells by suppressing the expression of genes involved in cell cycle progression and apoptosis.\n4. LIMT lncRNA has been shown to inhibit the differentiation of granulocytes and monocytes.\n5. LIMT lncRNA has been implicated in the development and progression of myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).",
    "llama-2-7b-chat-hf_fact": [
      "LIMT (Long Non-Coding RNA in Myeloid Lineage Transcription) is a long non-coding RNA that is involved in the regulation of myeloid cell development and differentiation.",
      "LIMT lncRNA is specifically expressed in myeloid cells, such as granulocytes, monocytes, and macrophages.",
      "LIMT lncRNA inhibits the proliferation and survival of myeloid cells by suppressing the expression of genes involved in cell cycle progression and apoptosis.",
      "LIMT lncRNA has been shown to inhibit the differentiation of granulocytes and monocytes.",
      "LIMT lncRNA has been implicated in the development and progression of myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: LIMT lncRNA is known to promote the proliferation and survival of myeloid cells by enhancing the expression of genes involved in cell cycle progression and inhibiting apoptosis.\n4. FALSE [correction]: LIMT lncRNA has been shown to promote the differentiation of granulocytes and monocytes.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "The R/Bioconductor package that is commonly used for performing SNP (Single Nucleotide Polymorphism) enrichment analysis is called \"SNPsnp\". This package provides a comprehensive set of tools for identifying and interpreting genetic variants in genomic data, including SNPs, insertions, deletions, and copy number variations.\nSNPsnp offers a range of enrichment analysis methods, including:\n1. Hypergeometric test: This method is used to identify overrepresented SNPs in a genomic region or gene.\n2. Fisher's exact test: This method is used to identify overrepresented SNPs in a genomic region or gene.\n3. Randomization test: This method is used to determine whether the observed frequency of SNPs in a genomic region or gene is due to chance or if it is significantly enriched.\n4. Pathway analysis: This method is used to identify overrepresented gene ontology (GO) terms or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in a set of SNPs.\n5. Network analysis: This method is used to identify overrepresented protein-protein interaction networks in a set of SNPs.\nSNPsnp also provides tools for visualizing and interpreting the results of enrichment analysis, including the ability to create heatmaps, network diagrams, and pathway maps.\nIn summary, SNPsnp is a powerful tool for performing SNP enrichment analysis in R/Bioconductor, and it can be used to identify genetic variants that are associated with specific diseases or conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package used for performing SNP enrichment analysis is called \"SNPsnp\".\n2. SNPsnp provides tools for identifying and interpreting genetic variants such as SNPs, insertions, deletions, and copy number variations.\n3. SNPsnp includes a hypergeometric test method for identifying overrepresented SNPs in a genomic region or gene.\n4. SNPsnp includes Fisher's exact test for identifying overrepresented SNPs in a genomic region or gene.\n5. SNPsnp offers a randomization test to determine if the observed frequency of SNPs is significantly enriched or due to chance.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package used for performing SNP enrichment analysis is called \"SNPsnp\".",
      "SNPsnp provides tools for identifying and interpreting genetic variants such as SNPs, insertions, deletions, and copy number variations.",
      "SNPsnp includes a hypergeometric test method for identifying overrepresented SNPs in a genomic region or gene.",
      "SNPsnp includes Fisher's exact test for identifying overrepresented SNPs in a genomic region or gene.",
      "SNPsnp offers a randomization test to determine if the observed frequency of SNPs is significantly enriched or due to chance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The R/Bioconductor package used for performing SNP enrichment analysis is called \"SNPsea\", not \"SNPsnp\".\n2. UNKNOWN (The statement refers to features that could be part of a package like SNPsea, but without the correct package name, the specific features cannot be confirmed for \"SNPsnp\".)\n3. UNKNOWN (As with statement 2, the features described could be part of SNPsea, but the validity of the statement for \"SNPsnp\" cannot be confirmed.)\n4. UNKNOWN (Similar to statements 2 and 3, without the correct package name, the presence of Fisher's exact test in \"SNPsnp\" cannot be confirmed.)\n5. UNKNOWN (The statement could be true for a package designed for SNP enrichment analysis like SNPsea, but it cannot be confirmed for \"SNPsnp\".)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are intermediate progenitors that play a crucial role in the development of the central nervous system (CNS). The specification of radial glial cells to ependymal cells involves a complex interplay of signaling pathways and transcription factors. Here are some of the key players involved in this process:\n1. Notch signaling: Notch is a critical transcription factor that regulates the specification of radial glial cells to ependymal cells. Notch signaling promotes the expression of genes involved in ependymal cell fate and inhibits the expression of genes involved in radial glial cell fate.\n2. Sox2: Sox2 is a transcription factor that is required for the maintenance of stem cell self-renewal and pluripotency in the neural progenitor cells. Sox2 also plays a role in the specification of radial glial cells to ependymal cells by regulating the expression of genes involved in ependymal cell fate.\n3. NeuroD1: NeuroD1 is a transcription factor that is expressed in the neural progenitor cells and plays a role in the specification of radial glial cells to neurons. NeuroD1 also regulates the expression of genes involved in ependymal cell fate and promotes the differentiation of radial glial cells into ependymal cells.\n4. Pax7: Pax7 is a transcription factor that is expressed in the neural progenitor cells and plays a role in the specification of radial glial cells to muscle cells. Pax7 also regulates the expression of genes involved in ependymal cell fate and promotes the differentiation of radial glial cells into ependymal cells.\n5. T-box proteins: T-box proteins, such as T-box 1 (Tbr1) and T-box 2 (Tbr2), are transcription factors that are expressed in the neural progenitor cells and play a role in the specification of radial glial cells to neurons. T-box proteins also regulate the expression of genes involved in ependymal cell fate and promote the differentiation of radial glial cells into ependymal cells.\n6. Eomesodermin (Eomes): Eomes is a transcription factor that is expressed in the",
    "llama-2-7b-chat-hf_fact_raw": "1. Notch signaling is involved in the specification of radial glial cells to ependymal cells, promoting ependymal cell fate gene expression and inhibiting radial glial cell fate gene expression.\n2. Sox2 is a transcription factor required for stem cell self-renewal and pluripotency in neural progenitor cells and plays a role in the specification of radial glial cells to ependymal cells.\n3. NeuroD1 is a transcription factor that contributes to the differentiation of radial glial cells into ependymal cells by regulating gene expression related to ependymal cell fate.\n4. Pax7 is a transcription factor that influences the specification of radial glial cells to muscle cells and also promotes the differentiation of radial glial cells into ependymal cells.\n5. T-box proteins, such as Tbr1 and Tbr2, are involved in the specification of radial glial cells to neurons and also promote the differentiation of radial glial cells into ependymal cells.",
    "llama-2-7b-chat-hf_fact": [
      "Notch signaling is involved in the specification of radial glial cells to ependymal cells, promoting ependymal cell fate gene expression and inhibiting radial glial cell fate gene expression.",
      "Sox2 is a transcription factor required for stem cell self-renewal and pluripotency in neural progenitor cells and plays a role in the specification of radial glial cells to ependymal cells.",
      "NeuroD1 is a transcription factor that contributes to the differentiation of radial glial cells into ependymal cells by regulating gene expression related to ependymal cell fate.",
      "Pax7 is a transcription factor that influences the specification of radial glial cells to muscle cells and also promotes the differentiation of radial glial cells into ependymal cells.",
      "T-box proteins, such as Tbr1 and Tbr2, are involved in the specification of radial glial cells to neurons and also promote the differentiation of radial glial cells into ependymal cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: NeuroD1 is a transcription factor that is involved in neuronal differentiation, not specifically in the differentiation of radial glial cells into ependymal cells.\n4. FALSE [correction]: Pax7 is a transcription factor involved in the specification of muscle progenitor cells and does not promote the differentiation of radial glial cells into ependymal cells.\n5. FALSE [correction]: T-box proteins such as Tbr1 and Tbr2 are involved in the specification of neuronal subtypes during development, not specifically in the differentiation of radial glial cells into ependymal cells.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of brain tumor that is characterized by the absence of certain biomarkers, including:\n1. Tumor marker expression: Triple negative gliomas do not express the markers CD56 (neurofilament intermediate) and CD10 (neuritin).\n2. Ki-67 labeling index: The Ki-67 protein is a marker of cell proliferation, and triple negative gliomas typically have a low Ki-67 labeling index, indicating that the tumor cells are not actively dividing.\n3. EGFR expression: Triple negative gliomas do not express the epidermal growth factor receptor (EGFR), which is a common target for cancer therapy.\nBased on these characteristics, triple negative gliomas are considered to be a distinct subtype of glioma, and they are often more aggressive and difficult to treat than other types of gliomas. Treatment options for triple negative gliomas may include surgery, radiation therapy, and chemotherapy, but the response to these treatments is often limited. Research is ongoing to develop new and more effective treatments for this type of brain tumor.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas do not express the markers CD56 (neurofilament intermediate) and CD10 (neuritin).\n2. Triple negative gliomas typically have a low Ki-67 labeling index.\n3. Triple negative gliomas do not express the epidermal growth factor receptor (EGFR).\n4. Triple negative gliomas are considered to be a distinct subtype of glioma.\n5. Triple negative gliomas are often more aggressive and difficult to treat than other types of gliomas.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas do not express the markers CD56 (neurofilament intermediate) and CD10 (neuritin).",
      "Triple negative gliomas typically have a low Ki-67 labeling index.",
      "Triple negative gliomas do not express the epidermal growth factor receptor (EGFR).",
      "Triple negative gliomas are considered to be a distinct subtype of glioma.",
      "Triple negative gliomas are often more aggressive and difficult to treat than other types of gliomas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Triple negative gliomas typically have a high Ki-67 labeling index, which is indicative of a high proliferation rate.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 (TOPical AZithromycin) is a drug candidate being developed by the biotechnology company, Genentech, for the treatment of various types of cancer, including non-small cell lung cancer (NSCLC), pancreatic cancer, and gastric cancer.\nTOPAZ1 is a novel formulation of the antibiotic azithromycin, which has been shown to have anti-tumor effects in preclinical studies. The drug works by inhibiting the activity of a protein called CD74, which is overexpressed in many types of cancer cells. By blocking the activity of CD74, TOPAZ1 can help to slow the growth and spread of cancer cells, and may also enhance the activity of other cancer therapies.\nGenentech is currently conducting clinical trials of TOPAZ1 in various cancer types, including a Phase 1/2 trial in patients with NSCLC and a Phase 2 trial in patients with pancreatic cancer. The company is also exploring the use of TOPAZ1 in combination with other cancer therapies, such as checkpoint inhibitors, to enhance its anti-tumor effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is a drug candidate being developed by Genentech.\n2. TOPAZ1 is intended for the treatment of various types of cancer, including non-small cell lung cancer, pancreatic cancer, and gastric cancer.\n3. The drug TOPAZ1 is a novel formulation of the antibiotic azithromycin.\n4. TOPAZ1 works by inhibiting the activity of a protein called CD74, which is overexpressed in many types of cancer cells.\n5. Genentech is conducting clinical trials of TOPAZ1, including a Phase 1/2 trial in patients with NSCLC and a Phase 2 trial in patients with pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is a drug candidate being developed by Genentech.",
      "TOPAZ1 is intended for the treatment of various types of cancer, including non-small cell lung cancer, pancreatic cancer, and gastric cancer.",
      "The drug TOPAZ1 is a novel formulation of the antibiotic azithromycin.",
      "TOPAZ1 works by inhibiting the activity of a protein called CD74, which is overexpressed in many types of cancer cells.",
      "Genentech is conducting clinical trials of TOPAZ1, including a Phase 1/2 trial in patients with NSCLC and a Phase 2 trial in patients with pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the drug candidate TOPAZ1 and its development by Genentech, it is not possible to determine the truthfulness of these statements. They could be hypothetical or based on real-world information that is not publicly available or widely known as of my knowledge cutoff date. Therefore, I cannot provide a true or false judgment or corrections for these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "GATA-1 is a transcription factor that plays a crucial role in regulating the expression of genes involved in erythropoiesis, the process of red blood cell production. The expression of GATA-1 isoforms is controlled by several genes, including:\n1. GATA1: The GATA1 gene encodes the full-length GATA-1 protein, which is the primary isoform expressed in erythroid cells. The GATA1 gene is regulated by a complex interplay of transcription factors, including GATA-1 itself, and other factors such as NF-E2 and KLF1.\n2. GATA2: The GATA2 gene encodes a second isoform of GATA-1, which is expressed in a subset of erythroid cells. GATA2 is regulated by a different set of transcription factors than GATA1, including the transcription factor GATA3.\n3. GATA3: The GATA3 gene encodes a transcription factor that regulates the expression of GATA2. GATA3 is itself regulated by a complex interplay of transcription factors, including GATA1 and NF-E2.\nIn summary, the expression of GATA-1 isoforms is controlled by a complex interplay of multiple genes, including GATA1, GATA2, and GATA3, which regulate the expression of these isoforms through a complex network of transcriptional interactions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA1 gene encodes the full-length GATA-1 protein, which is the primary isoform expressed in erythroid cells.\n2. The expression of the GATA1 gene is regulated by transcription factors including GATA-1 itself, NF-E2, and KLF1.\n3. The GATA2 gene encodes a second isoform of GATA-1, which is expressed in a subset of erythroid cells.\n4. The GATA3 gene encodes a transcription factor that regulates the expression of the GATA2 gene.\n5. The expression of GATA-1 isoforms is controlled by a complex interplay of multiple genes, including GATA1, GATA2, and GATA3.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA1 gene encodes the full-length GATA-1 protein, which is the primary isoform expressed in erythroid cells.",
      "The expression of the GATA1 gene is regulated by transcription factors including GATA-1 itself, NF-E2, and KLF1.",
      "The GATA2 gene encodes a second isoform of GATA-1, which is expressed in a subset of erythroid cells.",
      "The GATA3 gene encodes a transcription factor that regulates the expression of the GATA2 gene.",
      "The expression of GATA-1 isoforms is controlled by a complex interplay of multiple genes, including GATA1, GATA2, and GATA3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The GATA2 gene encodes a different transcription factor, GATA-2, which is involved in the regulation of hematopoiesis and is not an isoform of GATA-1.\n4. UNKNOWN (While GATA3 is indeed a transcription factor, without specific context, it is not possible to confirm whether it regulates the expression of the GATA2 gene.)\n5. TRUE (The expression of GATA-1 isoforms and the regulation of hematopoiesis involve a complex interplay of multiple genes, including GATA1, GATA2, and GATA3, among others.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq (Methylation-specific Inverse Regression Assay) is a genomic technique used to measure the epigenetic modification of DNA methylation at a genome-wide scale. Epigenetic modifications, such as DNA methylation, play a crucial role in regulating gene expression and are known to be altered in various diseases, including cancer.\nMIRA-seq is a method that combines the principles of inverse regression and sequencing technology to measure DNA methylation levels at specific CpG sites in a genome-wide manner. The basic idea behind MIRA-seq is to use a reference sample of known methylation levels to estimate the methylation levels of a test sample. The method involves the following steps:\n1. Bisulfite treatment: The test sample and reference sample are treated with bisulfite, which deaminates unmethylated cytosine residues but not methylated ones.\n2. Sequencing: The bisulfite-treated DNA is then sequenced using next-generation sequencing technologies.\n3. Inverse regression: The sequencing data is then used to estimate the methylation levels of each CpG site in the test sample using inverse regression. This involves fitting a statistical model to the sequencing data to estimate the methylation levels of each CpG site.\n4. Normalization and filtering: The estimated methylation levels are then normalized and filtered to remove any low-quality or irrelevant data.\nMIRA-seq has several advantages over other DNA methylation assays, including its high resolution, sensitivity, and specificity. It can be used to analyze a wide range of tissues and cell types, including primary cells, and can be applied to a variety of disease states, including cancer.\nIn summary, MIRA-seq is a powerful tool for measuring DNA methylation at a genome-wide scale, providing valuable insights into the epigenetic regulation of gene expression and its role in disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq stands for Methylation-specific Inverse Regression Assay.\n2. MIRA-seq is used to measure DNA methylation at a genome-wide scale.\n3. DNA methylation is an epigenetic modification that plays a role in regulating gene expression.\n4. MIRA-seq involves bisulfite treatment of DNA, which deaminates unmethylated cytosine residues but not methylated ones.\n5. MIRA-seq uses next-generation sequencing technologies to sequence bisulfite-treated DNA.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq stands for Methylation-specific Inverse Regression Assay.",
      "MIRA-seq is used to measure DNA methylation at a genome-wide scale.",
      "DNA methylation is an epigenetic modification that plays a role in regulating gene expression.",
      "MIRA-seq involves bisulfite treatment of DNA, which deaminates unmethylated cytosine residues but not methylated ones.",
      "MIRA-seq uses next-generation sequencing technologies to sequence bisulfite-treated DNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq stands for Methylated CpG Island Recovery Assay.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: MIRA-seq does not involve bisulfite treatment of DNA; it is a method that enriches methylated DNA fragments using a methyl-CpG binding domain protein complex.\n5. FALSE [correction]: MIRA-seq does not sequence bisulfite-treated DNA; it sequences the enriched methylated DNA fragments using next-generation sequencing technologies.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST (rilonacept) is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS), which are a group of rare genetic disorders that are characterized by recurring episodes of fever, pain, and inflammation. Specifically, ARCALYST is approved for the treatment of:\n* Cryopyrin-associated periodic syndrome (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS)\nARCALYST is also being studied for the treatment of other conditions, including gout and other inflammatory disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST (rilonacept) is used for the treatment of cryopyrin-associated periodic syndromes (CAPS).\n2. CAPS are characterized by recurring episodes of fever, pain, and inflammation.\n3. ARCALYST is specifically approved for the treatment of familial cold autoinflammatory syndrome (FCAS).\n4. ARCALYST is specifically approved for the treatment of Muckle-Wells syndrome (MWS).\n5. ARCALYST is being studied for the treatment of conditions such as gout and other inflammatory disorders.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST (rilonacept) is used for the treatment of cryopyrin-associated periodic syndromes (CAPS).",
      "CAPS are characterized by recurring episodes of fever, pain, and inflammation.",
      "ARCALYST is specifically approved for the treatment of familial cold autoinflammatory syndrome (FCAS).",
      "ARCALYST is specifically approved for the treatment of Muckle-Wells syndrome (MWS).",
      "ARCALYST is being studied for the treatment of conditions such as gout and other inflammatory disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nARCALYST (rilonacept) is indeed used for the treatment of cryopyrin-associated periodic syndromes (CAPS), which are characterized by recurring episodes of fever, pain, and inflammation. It is specifically approved for the treatment of familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). Additionally, ARCALYST has been studied for the treatment of other conditions, including gout and various inflammatory disorders.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Robertsonian translocations are a type of chromosomal abnormality that involve the exchange of genetic material between two acrocentric chromosomes (chromosomes 1, 9, 10, and 11). The following are the human acrocentric chromosomes that can be involved in Robertsonian translocations:\n1. Chromosome 1: This chromosome is involved in approximately 50% of Robertsonian translocations.\n2. Chromosome 9: This chromosome is involved in approximately 30% of Robertsonian translocations.\n3. Chromosome 10: This chromosome is involved in approximately 10% of Robertsonian translocations.\n4. Chromosome 11: This chromosome is involved in approximately 5% of Robertsonian translocations.\nIt's worth noting that Robertsonian translocations can also involve non-acrocentric chromosomes, but acrocentric chromosomes are the most commonly involved.",
    "llama-2-7b-chat-hf_fact_raw": "1. Robertsonian translocations involve the exchange of genetic material between two acrocentric chromosomes.\n2. Chromosomes 1, 9, 10, and 11 are acrocentric chromosomes that can be involved in Robertsonian translocations.\n3. Chromosome 1 is involved in approximately 50% of Robertsonian translocations.\n4. Chromosome 9 is involved in approximately 30% of Robertsonian translocations.\n5. Chromosome 10 is involved in approximately 10% of Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "Robertsonian translocations involve the exchange of genetic material between two acrocentric chromosomes.",
      "Chromosomes 1, 9, 10, and 11 are acrocentric chromosomes that can be involved in Robertsonian translocations.",
      "Chromosome 1 is involved in approximately 50% of Robertsonian translocations.",
      "Chromosome 9 is involved in approximately 30% of Robertsonian translocations.",
      "Chromosome 10 is involved in approximately 10% of Robertsonian translocations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Chromosomes 13, 14, 15, 21, and 22 are acrocentric chromosomes that can be involved in Robertsonian translocations.\n3. FALSE [correction]: Chromosome 1 is not typically involved in Robertsonian translocations; chromosomes 13, 14, 15, 21, and 22 are.\n4. FALSE [correction]: Chromosome 9 is not typically involved in Robertsonian translocations; chromosomes 13, 14, 15, 21, and 22 are.\n5. FALSE [correction]: Chromosome 10 is not typically involved in Robertsonian translocations; chromosomes 13, 14, 15, 21, and 22 are.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, depending on the specific type of analysis and the data available. Here are a few options:\n1. \"brainTumor\": This package provides a comprehensive set of tools for the analysis of brain tumor genomics data, including RNA sequencing (RNA-seq), whole-exome sequencing (WES), and whole-genome sequencing (WGS) data. It includes functions for data preprocessing, mutation calling, and pathway analysis.\n2. \"pediatricTumors\": This package is specifically designed for the analysis of pediatric tumors, including brain tumors. It includes functions for data preprocessing, mutation calling, and survival analysis, as well as visualization tools for exploring the results.\n3. \"TumorGenomics\": This package provides a comprehensive set of tools for the analysis of tumor genomics data, including RNA-seq, WES, and WGS data. It includes functions for data preprocessing, mutation calling, and pathway analysis, as well as tools for identifying potential drug targets and predicting patient outcomes.\n4. \"brainTumorGDC\": This package is a subset of the \"TumorGenomics\" package, and is specifically designed for the analysis of brain tumor genomics data. It includes functions for data preprocessing, mutation calling, and pathway analysis, as well as tools for identifying potential drug targets and predicting patient outcomes.\n5. \"pediatricBrainTumor\": This package is specifically designed for the analysis of pediatric brain tumors, including medulloblastoma, brainstem glioma, and other types of pediatric brain tumors. It includes functions for data preprocessing, mutation calling, and survival analysis, as well as visualization tools for exploring the results.\nThese packages can be used to identify genetic mutations and other genomic alterations in pediatric brain tumors, and to explore their potential role in disease progression and treatment response.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"brainTumor\" R package provides tools for the analysis of brain tumor genomics data, including RNA sequencing, whole-exome sequencing, and whole-genome sequencing.\n2. The \"pediatricTumors\" R package is designed for the analysis of pediatric tumors, including brain tumors, and offers functions for data preprocessing, mutation calling, and survival analysis.\n3. The \"TumorGenomics\" R package includes tools for analyzing tumor genomics data and functions for identifying potential drug targets and predicting patient outcomes.\n4. The \"brainTumorGDC\" R package is a subset of the \"TumorGenomics\" package, tailored for brain tumor genomics data analysis.\n5. The \"pediatricBrainTumor\" R package is specifically for analyzing pediatric brain tumors, including medulloblastoma and brainstem glioma.",
    "llama-2-7b-chat-hf_fact": [
      "The \"brainTumor\" R package provides tools for the analysis of brain tumor genomics data, including RNA sequencing, whole-exome sequencing, and whole-genome sequencing.",
      "The \"pediatricTumors\" R package is designed for the analysis of pediatric tumors, including brain tumors, and offers functions for data preprocessing, mutation calling, and survival analysis.",
      "The \"TumorGenomics\" R package includes tools for analyzing tumor genomics data and functions for identifying potential drug targets and predicting patient outcomes.",
      "The \"brainTumorGDC\" R package is a subset of the \"TumorGenomics\" package, tailored for brain tumor genomics data analysis.",
      "The \"pediatricBrainTumor\" R package is specifically for analyzing pediatric brain tumors, including medulloblastoma and brainstem glioma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific knowledge of these R packages or access to a database of R packages and their descriptions, it is not possible to verify the accuracy of these statements. The names of the packages suggest their purposes, but without further information, the truthfulness of the statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Yes, NEMO (Nuclear Envelope-Associated Protein 1, also known as IκBα) is a zinc finger protein. NEMO is a key component of the IκB kinase (IKK) complex, which plays a crucial role in regulating the expression of genes involved in inflammation and immune responses. NEMO contains multiple zinc fingers, which are motifs that bind to zinc ions and are involved in protein-protein interactions and DNA binding. The zinc fingers in NEMO are thought to be involved in its ability to interact with other proteins and regulate gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO is also known as Nuclear Envelope-Associated Protein 1 and IκBα.\n2. NEMO is a zinc finger protein.\n3. NEMO is a component of the IκB kinase (IKK) complex.\n4. The IKK complex is involved in regulating the expression of genes related to inflammation and immune responses.\n5. NEMO contains multiple zinc fingers that are involved in protein-protein interactions and DNA binding.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO is also known as Nuclear Envelope-Associated Protein 1 and IκBα.",
      "NEMO is a zinc finger protein.",
      "NEMO is a component of the IκB kinase (IKK) complex.",
      "The IKK complex is involved in regulating the expression of genes related to inflammation and immune responses.",
      "NEMO contains multiple zinc fingers that are involved in protein-protein interactions and DNA binding."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NEMO is also known as Nuclear Envelope-Associated Protein 1, but it is not the same as IκBα. IκBα is a different protein that inhibits NF-κB by masking its nuclear localization signals.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: NEMO does not contain multiple zinc fingers. It is involved in protein-protein interactions, but it does not have the zinc finger motif that is typically associated with DNA binding.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (Transcription Factor IIS) has been shown to play a role in nucleosome positioning. TFIIS is a general transcription factor that is involved in the initiation of transcription in eukaryotic cells. It is a component of the RNA polymerase II (RNAPII) complex and helps to recruit the complex to the promoter region of a gene.\nStudies have shown that TFIIS can also influence the positioning of nucleosomes on the DNA template. Nucleosomes are the basic units of chromatin, consisting of a segment of DNA wrapped around a core of eight histone proteins. The positioning of nucleosomes can affect the accessibility of the DNA to transcription factors and other regulatory proteins, and thus play a role in the regulation of gene expression.\nTFIIS has been shown to interact with the histone H3 lysine 9 (H3K9) demethylase KDM4B, which is involved in the removal of methyl groups from histone H3 lysine 9. This interaction leads to the recruitment of KDM4B to the promoter region of actively transcribed genes, where it helps to remove H3K9me3, leading to the relaxation of chromatin structure and the activation of transcription.\nAdditionally, TFIIS has been shown to bind to the nucleosome and help to position it in a more open conformation, allowing for greater accessibility of the DNA to transcription factors. This suggests that TFIIS may play a role in the regulation of nucleosome positioning and the accessibility of the DNA to transcriptional machinery.\nIn summary, TFIIS has been shown to play a role in nucleosome positioning by interacting with histone-modifying enzymes and helping to position nucleosomes in a more open conformation, allowing for greater accessibility of the DNA to transcription factors.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS is involved in the initiation of transcription in eukaryotic cells.\n2. TFIIS is a component of the RNA polymerase II (RNAPII) complex.\n3. Studies have shown that TFIIS can influence the positioning of nucleosomes on the DNA template.\n4. TFIIS interacts with the histone H3 lysine 9 (H3K9) demethylase KDM4B.\n5. TFIIS helps to recruit KDM4B to the promoter region of actively transcribed genes, where it assists in the removal of methyl groups from histone H3 lysine 9.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS is involved in the initiation of transcription in eukaryotic cells.",
      "TFIIS is a component of the RNA polymerase II (RNAPII) complex.",
      "Studies have shown that TFIIS can influence the positioning of nucleosomes on the DNA template.",
      "TFIIS interacts with the histone H3 lysine 9 (H3K9) demethylase KDM4B.",
      "TFIIS helps to recruit KDM4B to the promoter region of actively transcribed genes, where it assists in the removal of methyl groups from histone H3 lysine 9."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TFIIS is involved in the elongation phase of transcription in eukaryotic cells, not the initiation.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe role of TFIIS is primarily associated with the elongation phase of transcription by RNA polymerase II, where it can stimulate the intrinsic cleavage activity of the enzyme to help it overcome transcriptional arrest. The interactions with nucleosomes, specific histone modifications, and recruitment of histone demethylases like KDM4B are more specialized functions that may not be as widely established or may pertain to specific contexts or studies. Without specific references to these studies, the truth of statements 3, 4, and 5 cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Origins of replication in yeast (Saccharomyces cerevisiae) fire late compared to those located far away from centromeres.\nOrigins of replication are the sites where DNA replication begins, and they are essential for cell division. In yeast, there are several origins of replication, and they are typically located near the centromere, which is the region of the chromosome where the spindle fibers attach during cell division.\nStudies have shown that origins of replication located near the centromere in yeast fire later than those located far away from the centromere. This is because the centromere is a highly organized structure that is involved in the regulation of chromosome segregation during cell division. The late firing of origins of replication near the centromere helps to ensure that the chromosomes are properly aligned and separated during cell division, which is essential for genome stability.\nIn contrast, origins of replication located far away from the centromere fire earlier, which allows them to initiate replication before the centromere-associated proteins and the spindle fibers arrive. This ensures that the entire chromosome is replicated before the cell divides, which is important for genome stability and the proper transmission of genetic information to the daughter cells.\nIn summary, origins of replication in yeast fire late near the centromere and early far away from it, which helps to ensure proper chromosome segregation during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication in yeast (Saccharomyces cerevisiae) located near the centromere fire later than those located far away from the centromere.\n2. The centromere is the region of the chromosome where spindle fibers attach during cell division.\n3. Late firing of origins of replication near the centromere in yeast is associated with ensuring proper chromosome alignment and separation during cell division.\n4. Origins of replication located far from the centromere in yeast fire earlier to allow complete replication of the chromosome before cell division.\n5. The timing of the firing of origins of replication in yeast is important for genome stability and proper transmission of genetic information to daughter cells.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication in yeast (Saccharomyces cerevisiae) located near the centromere fire later than those located far away from the centromere.",
      "The centromere is the region of the chromosome where spindle fibers attach during cell division.",
      "Late firing of origins of replication near the centromere in yeast is associated with ensuring proper chromosome alignment and separation during cell division.",
      "Origins of replication located far from the centromere in yeast fire earlier to allow complete replication of the chromosome before cell division.",
      "The timing of the firing of origins of replication in yeast is important for genome stability and proper transmission of genetic information to daughter cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Origins of replication in yeast (Saccharomyces cerevisiae) located near the centromere typically fire earlier than those located far away from the centromere.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences, also known as GATA-binding sites or G-boxes, are specific DNA sequences that are recognized and bound by the transcription factor GATA. These sequences are found in the promoter regions of genes involved in red blood cell-specific gene expression, and play a crucial role in regulating the expression of these genes during erythropoiesis. Here are some properties of mammalian GA-sequences:\n1. Consensus sequence: The consensus sequence of a mammalian GA-sequence is GATA-box, which consists of the following nucleotides: 5'-GATA-3'.\n2. Location: GA-sequences are typically located upstream of the transcription start site of red blood cell-specific genes, and are found in the promoter region of these genes.\n3. Size: GA-sequences are typically around 20-30 nucleotides in length.\n4. Shape: GA-sequences are generally palindromic, meaning they are the same on both strands of the DNA molecule.\n5. GC content: GA-sequences have a high GC content, typically ranging from 50-70%.\n6. Hydrophobicity: GA-sequences are relatively hydrophobic, meaning they are rich in non-polar amino acids.\n7. Evolutionary conservation: GA-sequences are highly conserved across different species, indicating their importance in red blood cell-specific gene expression.\n8. Function: GA-sequences function as a binding site for the GATA transcription factor, which recognizes and binds to these sequences to regulate the expression of red blood cell-specific genes.\n9. Regulation of gene expression: GA-sequences play a crucial role in regulating the expression of red blood cell-specific genes, particularly those involved in hemoglobin synthesis and transport.\n10. Developmental regulation: GA-sequences are also involved in the regulation of red blood cell development, particularly during erythropoiesis.\nIn summary, mammalian GA-sequences are specific DNA sequences that are recognized and bound by the transcription factor GATA",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences, also known as GATA-binding sites or G-boxes, are specific DNA sequences recognized and bound by the transcription factor GATA.\n2. The consensus sequence of a mammalian GA-sequence is GATA-box, which consists of the nucleotides 5'-GATA-3'.\n3. GA-sequences are typically located upstream of the transcription start site of red blood cell-specific genes, in the promoter region of these genes.\n4. GA-sequences are highly conserved across different species, indicating their importance in red blood cell-specific gene expression.\n5. GA-sequences function as a binding site for the GATA transcription factor, which regulates the expression of red blood cell-specific genes.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences, also known as GATA-binding sites or G-boxes, are specific DNA sequences recognized and bound by the transcription factor GATA.",
      "The consensus sequence of a mammalian GA-sequence is GATA-box, which consists of the nucleotides 5'-GATA-3'.",
      "GA-sequences are typically located upstream of the transcription start site of red blood cell-specific genes, in the promoter region of these genes.",
      "GA-sequences are highly conserved across different species, indicating their importance in red blood cell-specific gene expression.",
      "GA-sequences function as a binding site for the GATA transcription factor, which regulates the expression of red blood cell-specific genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The consensus sequence of a mammalian GA-sequence is not referred to as GATA-box. The GATA-box is a particular type of GA-sequence with the consensus sequence 5'-GATAA/G-3'.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "The mouse genome contains 10 Groucho-related genes (GRG). These genes are also known as Groucho-like genes (GRL) or Groucho-related transcription factors (GRTF). The specific GRG genes found in the mouse genome are:\n1. Groucho (Gro)\n2. Groucho-like 1 (Grl1)\n3. Groucho-like 2 (Grl2)\n4. Groucho-like 3 (Grl3)\n5. Groucho-like 4 (Grl4)\n6. Groucho-like 5 (Grl5)\n7. Groucho-like 6 (Grl6)\n8. Groucho-like 7 (Grl7)\n9. Groucho-like 8 (Grl8)\n10. Groucho-like 9 (Grl9)\nEach of these genes encodes a protein that is similar in structure and function to the Groucho protein, which is a transcriptional regulator that plays a role in the regulation of gene expression, particularly in the context of cell fate determination and differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse genome contains 10 Groucho-related genes (GRG).\n2. These genes are also referred to as Groucho-like genes (GRL) or Groucho-related transcription factors (GRTF).\n3. The specific GRG genes in the mouse genome include Groucho (Gro) and Groucho-like 1 through Groucho-like 9 (Grl1-Grl9).\n4. Each of the GRG genes encodes a protein that is similar to the Groucho protein.\n5. The Groucho protein is a transcriptional regulator involved in gene expression regulation, cell fate determination, and differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse genome contains 10 Groucho-related genes (GRG).",
      "These genes are also referred to as Groucho-like genes (GRL) or Groucho-related transcription factors (GRTF).",
      "The specific GRG genes in the mouse genome include Groucho (Gro) and Groucho-like 1 through Groucho-like 9 (Grl1-Grl9).",
      "Each of the GRG genes encodes a protein that is similar to the Groucho protein.",
      "The Groucho protein is a transcriptional regulator involved in gene expression regulation, cell fate determination, and differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II is a complex of two subunits, RNA polymerase IIα (RNAPIIα) and RNA polymerase IIβ (RNAPIIβ). RNAPIIα carries the RNA cleavage activity.\nRNAPIIα is the catalytic subunit of RNA polymerase II and is responsible for transcribing DNA to RNA. It contains an active site that is responsible for cleaving the RNA transcript during transcription elongation. This cleavage event is known as transcription termination.\nIn contrast, RNAPIIβ does not have RNA cleavage activity and is involved in the process of transcription initiation. It helps to recruit RNAPIIα to the promoter region of the gene and facilitates the binding of the transcriptional activators and repressors to the promoter.\nSo, to summarize, RNA polymerase IIα (RNAPIIα) carries the RNA cleavage activity, while RNA polymerase IIβ (RNAPIIβ) does not.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II is composed of two subunits: RNA polymerase IIα (RNAPIIα) and RNA polymerase IIβ (RNAPIIβ).\n2. RNA polymerase IIα (RNAPIIα) carries the RNA cleavage activity.\n3. RNA polymerase IIα (RNAPIIα) is responsible for transcribing DNA to RNA.\n4. RNA polymerase IIβ (RNAPIIβ) is involved in the process of transcription initiation.\n5. RNA polymerase IIβ (RNAPIIβ) does not have RNA cleavage activity.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II is composed of two subunits: RNA polymerase IIα (RNAPIIα) and RNA polymerase IIβ (RNAPIIβ).",
      "RNA polymerase IIα (RNAPIIα) carries the RNA cleavage activity.",
      "RNA polymerase IIα (RNAPIIα) is responsible for transcribing DNA to RNA.",
      "RNA polymerase IIβ (RNAPIIβ) is involved in the process of transcription initiation.",
      "RNA polymerase IIβ (RNAPIIβ) does not have RNA cleavage activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RNA polymerase II is not composed of two subunits named RNA polymerase IIα (RNAPIIα) and RNA polymerase IIβ (RNAPIIβ). It is a complex enzyme composed of multiple subunits, but they are not designated as α and β.\n2. FALSE [correction]: Since RNA polymerase IIα (RNAPIIα) is not a recognized subunit of RNA polymerase II, it does not carry RNA cleavage activity. RNA cleavage during transcription is associated with specific enzymatic activities, not a subunit named RNAPIIα.\n3. FALSE [correction]: RNA polymerase II as a whole is responsible for transcribing DNA to RNA, not a subunit named RNA polymerase IIα (RNAPIIα).\n4. FALSE [correction]: RNA polymerase IIβ (RNAPIIβ) is not a recognized subunit of RNA polymerase II, and therefore it is not involved in transcription initiation. The initiation of transcription is a complex process involving the entire RNA polymerase II enzyme and various other transcription factors.\n5. FALSE [correction]: Since RNA polymerase IIβ (RNAPIIβ) is not a recognized subunit of RNA polymerase II, the statement about its RNA cleavage activity is not applicable.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder that is caused by mutations in the SLC25A17 gene. This gene provides instructions for making a protein called Zellweger spectrum disorder protein (ZSDP) or HAF1. The ZSDP protein plays a critical role in the transport of certain molecules across the inner mitochondrial membrane, which is important for the proper functioning of the mitochondria. Mitochondria are the energy-producing structures within cells, and they are involved in many cellular processes, including energy production, signaling pathways, and the regulation of programmed cell death (apoptosis).\nMutations in the SLC25A17 gene can lead to a deficiency of ZSDP protein, which can disrupt the normal functioning of mitochondria and lead to the characteristic features of Ohdo syndrome, including:\n* Severe intellectual disability\n* Distinctive facial features, such as a small head, narrow eyes, and a short nose\n* Delayed development and growth\n* Hypotonia (low muscle tone)\n* Vision loss or blindness\n* Hearing loss\n* Seizures\n* Heart problems\n* Kidney problems\nOhdo syndrome is an autosomal recessive disorder, which means that a person must inherit two copies of the mutated gene, one from each parent, in order to develop the condition. If a person inherits only one mutated copy of the gene, they will be a carrier of the condition but are unlikely to develop symptoms themselves.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is caused by mutations in the SLC25A17 gene.\n2. The SLC25A17 gene is responsible for making a protein called Zellweger spectrum disorder protein (ZSDP) or HAF1.\n3. The ZSDP protein is involved in the transport of molecules across the inner mitochondrial membrane.\n4. Ohdo syndrome is characterized by features such as severe intellectual disability, distinctive facial features, and delayed development.\n5. Ohdo syndrome is an autosomal recessive disorder, requiring two copies of the mutated gene to develop the condition.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is caused by mutations in the SLC25A17 gene.",
      "The SLC25A17 gene is responsible for making a protein called Zellweger spectrum disorder protein (ZSDP) or HAF1.",
      "The ZSDP protein is involved in the transport of molecules across the inner mitochondrial membrane.",
      "Ohdo syndrome is characterized by features such as severe intellectual disability, distinctive facial features, and delayed development.",
      "Ohdo syndrome is an autosomal recessive disorder, requiring two copies of the mutated gene to develop the condition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome is caused by mutations in several genes, including MED12, KAT6B, and SLC25A24, not SLC25A17.\n2. FALSE [correction]: The SLC25A17 gene is responsible for making a protein called peroxisomal membrane protein 34 (PMP34), not Zellweger spectrum disorder protein (ZSDP) or HAF1.\n3. TRUE: Proteins like PMP34, which is encoded by the SLC25A17 gene, are indeed involved in the transport of molecules across the inner mitochondrial membrane.\n4. TRUE: Ohdo syndrome is characterized by such features, although the severity of intellectual disability and other symptoms can vary.\n5. FALSE [correction]: Ohdo syndrome can be inherited in different patterns, including autosomal dominant for some forms caused by mutations in the MED12 or KAT6B genes. Autosomal recessive inheritance is not the only pattern for Ohdo syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "There are several R/Bioconductor packages that have been developed for the analysis of psychiatric disease genes. Some of the popular packages include:\n1. \"psychgen\": This package provides a comprehensive framework for the analysis of genetic data in psychiatric disorders. It includes tools for genome-wide association study (GWAS) analysis, gene-set enrichment analysis, and pathway analysis.\n2. \"psychbioma\": This package is focused on the analysis of genomic data in psychiatric disorders, particularly in the context of genome-wide association studies (GWAS). It includes tools for quality control, genotyping, and imputation, as well as methods for identifying genetic variants associated with psychiatric disorders.\n3. \"psychgenetics\": This package provides a comprehensive framework for the analysis of genetic data in psychiatric disorders, including GWAS, gene-set enrichment analysis, and pathway analysis. It also includes tools for visualizing and interpreting genetic data.\n4. \"mentalgen\": This package is focused on the analysis of genetic data in mental disorders, including GWAS, gene-set enrichment analysis, and pathway analysis. It also includes tools for visualizing and interpreting genetic data.\n5. \"psychgwas\": This package provides a comprehensive framework for the analysis of GWAS data in psychiatric disorders. It includes tools for quality control, genotyping, and imputation, as well as methods for identifying genetic variants associated with psychiatric disorders.\n6. \"psychbiomarker\": This package is focused on the analysis of genomic data in psychiatric disorders, particularly in the context of biomarker discovery. It includes tools for quality control, genotyping, and imputation, as well as methods for identifying genetic variants associated with psychiatric disorders.\n7. \"psychgenome\": This package provides a comprehensive framework for the analysis of genomic data in psychiatric disorders, including GWAS, gene-set enrichment analysis, and pathway analysis. It also includes tools for visualizing and interpreting genetic data.\n8. \"psychgenomics\": This package is focused on the analysis of genomic data in",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"psychgen\" R/Bioconductor package provides tools for GWAS analysis, gene-set enrichment analysis, and pathway analysis in psychiatric disorders.\n2. The \"psychbioma\" R/Bioconductor package includes tools for quality control, genotyping, and imputation in the context of GWAS for psychiatric disorders.\n3. The \"psychgenetics\" R/Bioconductor package offers a framework for analyzing genetic data in psychiatric disorders, including visualization and interpretation tools.\n4. The \"mentalgen\" R/Bioconductor package is designed for analyzing genetic data in mental disorders and includes GWAS, gene-set enrichment analysis, and pathway analysis tools.\n5. The \"psychgwas\" R/Bioconductor package provides a framework for analyzing GWAS data in psychiatric disorders, including methods for identifying genetic variants associated with these disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The \"psychgen\" R/Bioconductor package provides tools for GWAS analysis, gene-set enrichment analysis, and pathway analysis in psychiatric disorders.",
      "The \"psychbioma\" R/Bioconductor package includes tools for quality control, genotyping, and imputation in the context of GWAS for psychiatric disorders.",
      "The \"psychgenetics\" R/Bioconductor package offers a framework for analyzing genetic data in psychiatric disorders, including visualization and interpretation tools.",
      "The \"mentalgen\" R/Bioconductor package is designed for analyzing genetic data in mental disorders and includes GWAS, gene-set enrichment analysis, and pathway analysis tools.",
      "The \"psychgwas\" R/Bioconductor package provides a framework for analyzing GWAS data in psychiatric disorders, including methods for identifying genetic variants associated with these disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe truthfulness of these statements cannot be determined without specific knowledge of the R/Bioconductor packages and their contents. The names of the packages suggest a focus on psychiatric genetics and GWAS analysis, but without documentation or a reliable source confirming the features of each package, it is not possible to verify the accuracy of the statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "The swirl sign is a clinical sign that is often observed in patients with intracerebral hemorrhage (ICH), which is bleeding in the brain tissue. It is characterized by a swirling or spiral pattern of blood in the affected area of the brain, which can be seen on a computed tomography (CT) scan or magnetic resonance imaging (MRI) scan.\nThe swirl sign is caused by the movement of blood within the affected brain tissue due to the hemorrhage. The blood flows in a spiral pattern, creating a swirling motion that can be visualized on imaging studies. The sign is more commonly seen on CT scans than on MRI scans, as it is more sensitive to the density of the blood.\nThe swirl sign can be an important diagnostic indicator of ICH, as it can help doctors identify the location and extent of the bleeding in the brain. It can also provide information about the severity of the hemorrhage and the potential risk of further bleeding or complications.\nIn addition to the swirl sign, other signs of ICH may include:\n1. Elevated intracranial pressure: This can cause headache, confusion, and loss of consciousness.\n2. Hydrocephalus: This is the accumulation of cerebrospinal fluid in the brain, which can cause increased intracranial pressure and symptoms such as headache, nausea, and vomiting.\n3. Brain edema: This is the swelling of brain tissue due to the accumulation of fluid, which can cause increased intracranial pressure and symptoms such as headache, confusion, and loss of consciousness.\n4. Cerebral infarction: This is the death of brain tissue due to lack of blood supply, which can cause symptoms such as weakness or numbness in the face, arm, or leg on one side of the body.\n5. Seizures: These can occur in some cases of ICH, particularly if the bleeding is severe or if there is a history of seizure disorder.\nIt is important to note that the swirl sign is not specific to ICH and can also be seen in other conditions such as subarachnoid hemorrhage, cerebral contusion, and brain tumors",
    "llama-2-7b-chat-hf_fact_raw": "1. The swirl sign is a clinical sign observed in patients with intracerebral hemorrhage (ICH).\n2. The swirl sign is characterized by a swirling or spiral pattern of blood on a CT or MRI scan.\n3. The swirl sign is more commonly seen on CT scans than on MRI scans.\n4. The swirl sign can help doctors identify the location and extent of bleeding in the brain.\n5. The swirl sign is not specific to ICH and can also be seen in conditions such as subarachnoid hemorrhage, cerebral contusion, and brain tumors.",
    "llama-2-7b-chat-hf_fact": [
      "The swirl sign is a clinical sign observed in patients with intracerebral hemorrhage (ICH).",
      "The swirl sign is characterized by a swirling or spiral pattern of blood on a CT or MRI scan.",
      "The swirl sign is more commonly seen on CT scans than on MRI scans.",
      "The swirl sign can help doctors identify the location and extent of bleeding in the brain.",
      "The swirl sign is not specific to ICH and can also be seen in conditions such as subarachnoid hemorrhage, cerebral contusion, and brain tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The swirl sign is specific to intracerebral hemorrhage and is not typically used to describe findings in subarachnoid hemorrhage, cerebral contusion, or brain tumors. However, similar patterns may be seen in other types of hemorrhages or lesions, but they are not referred to as the \"swirl sign.\"",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA polymerase II-associated factor 1) is a transcriptional elongation factor that plays a crucial role in regulating gene expression in response to various environmental stimuli. The expression of ROF1 in Arabidopsis is induced by a variety of factors, including:\n1. Light: ROF1 expression is increased in response to light, particularly blue light. This is mediated by the photoreceptor cryptochrome, which triggers a signaling cascade that leads to the activation of ROF1 transcription.\n2. Temperature: ROF1 expression is also temperature-sensitive, with high temperatures inducing its expression. This is thought to be a response to the increased demand for transcriptional machinery at elevated temperatures.\n3. Abiotic stress: ROF1 expression is induced by a range of abiotic stresses, including drought, salinity, and oxidative stress. This is thought to be a response to the increased demand for transcriptional machinery in response to stress.\n4. Hormones: ROF1 expression is also regulated by plant hormones, including auxin and ethylene. For example, auxin has been shown to induce ROF1 expression in roots, while ethylene has been shown to repress ROF1 expression in shoots.\n5. Developmental cues: ROF1 expression is also regulated by developmental cues, including the transition from the vegetative to reproductive phase.\n6. Microbial interactions: ROF1 expression is also regulated by interactions with microorganisms, including bacteria and fungi. For example, the bacterial signal molecule, lipopolysaccharide, has been shown to induce ROF1 expression in Arabidopsis.\n7. Reactive oxygen species (ROS): ROF1 expression is also regulated by ROS, which can induce its expression by activating signaling pathways that lead to its transcriptional activation.\n8. miRNAs: ROF1 expression is also regulated by miRNAs, which can bind to specific mRNA sequences and repress their translation.\n9. Transcription factors: ROF1 expression is also regulated by other transcription factors, including MYB and WRKY, which can",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is increased in response to light, particularly blue light.\n2. High temperatures induce the expression of ROF1 in Arabidopsis.\n3. Arabidopsis ROF1 expression is induced by abiotic stresses such as drought, salinity, and oxidative stress.\n4. Plant hormones like auxin and ethylene regulate the expression of ROF1 in Arabidopsis.\n5. The transition from the vegetative to reproductive phase is a developmental cue that regulates ROF1 expression in Arabidopsis.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is increased in response to light, particularly blue light.",
      "High temperatures induce the expression of ROF1 in Arabidopsis.",
      "Arabidopsis ROF1 expression is induced by abiotic stresses such as drought, salinity, and oxidative stress.",
      "Plant hormones like auxin and ethylene regulate the expression of ROF1 in Arabidopsis.",
      "The transition from the vegetative to reproductive phase is a developmental cue that regulates ROF1 expression in Arabidopsis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe responses to statements 1 and 5 are marked as UNKNOWN because, without specific scientific references, it is difficult to confirm or deny these statements. The responses to statements 2, 3, and 4 are based on common knowledge about plant stress responses and hormone regulation in plants, but specific details about ROF1 expression in response to these factors would require access to specialized scientific literature.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "The most common cause of hereditary renal amyloidosis is the protein alpha-2-macroglobulin (A2M). Hereditary renal amyloidosis, also known as familial amyloid nephropathy (FAN), is a rare genetic disorder that leads to the accumulation of abnormal protein deposits, called amyloid, in the kidneys. These deposits can cause progressive damage to the kidneys and lead to kidney failure.\nThe A2M protein is produced in the liver and is normally present in the bloodstream. However, in people with hereditary renal amyloidosis, the A2M protein is misfolded and accumulates in the kidneys, where it forms the amyloid deposits that cause damage to the kidney tissue.\nOther proteins, such as transthyretin (TTR) and apolipoprotein A-I (APOA1), can also cause hereditary renal amyloidosis, but A2M is the most common cause.",
    "llama-2-7b-chat-hf_fact_raw": "1. Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.\n2. Hereditary renal amyloidosis is also known as familial amyloid nephropathy (FAN).\n3. Hereditary renal amyloidosis leads to the accumulation of amyloid deposits in the kidneys.\n4. The A2M protein is produced in the liver.\n5. Transthyretin (TTR) and apolipoprotein A-I (APOA1) can also cause hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_fact": [
      "Alpha-2-macroglobulin (A2M) is the most common cause of hereditary renal amyloidosis.",
      "Hereditary renal amyloidosis is also known as familial amyloid nephropathy (FAN).",
      "Hereditary renal amyloidosis leads to the accumulation of amyloid deposits in the kidneys.",
      "The A2M protein is produced in the liver.",
      "Transthyretin (TTR) and apolipoprotein A-I (APOA1) can also cause hereditary renal amyloidosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Alpha-2-macroglobulin (A2M) is not the most common cause of hereditary renal amyloidosis. The most common cause is mutations in the gene encoding for transthyretin (TTR).\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed. The hippocampus is a region of the brain that plays a critical role in memory and spatial navigation, and it has been the focus of numerous studies on protein expression and function.\nSome of the key findings from these studies include:\n1. Identification of proteins involved in synaptic plasticity and neurotransmission: The hippocampus contains a large number of synapses, which are the sites of communication between neurons. Studies have identified a number of proteins that are involved in synaptic plasticity and neurotransmission, including N-methyl-D-aspartate (NMDA) receptors, AMPA receptors, and glutamate decarboxylase.\n2. Analysis of protein expression changes in response to learning and memory tasks: Researchers have used proteomics techniques to study the changes in protein expression that occur in the hippocampus in response to learning and memory tasks. For example, one study found that the expression of the protein CREB (cAMP response element-binding protein) increases in the hippocampus after spatial learning.\n3. Identification of proteins involved in the regulation of the hippocampal circuitry: The hippocampus is a complex circuit that involves multiple types of neurons and synapses. Studies have identified a number of proteins that are involved in the regulation of this circuitry, including ion channels, neurotransmitter receptors, and scaffolding proteins.\n4. Analysis of protein expression changes in Alzheimer's disease: Alzheimer's disease is a neurodegenerative disorder that is characterized by the deposition of amyloid-β plaques and neurofibrillary tangles in the brain, including the hippocampus. Studies have used proteomics techniques to identify changes in protein expression in the hippocampus of Alzheimer's disease patients compared to controls. For example, one study found that the expression of the protein tau is increased in the hippocampus of Alzheimer's disease patients.\n5. Identification of proteins involved in the regulation of the hippocampal stem cell niche: The hipp",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been extensively analyzed.\n2. Proteins involved in synaptic plasticity and neurotransmission, such as NMDA receptors, AMPA receptors, and glutamate decarboxylase, have been identified in the hippocampus.\n3. Proteomic studies have shown that protein expression in the hippocampus changes in response to learning and memory tasks, with an example being the increased expression of CREB after spatial learning.\n4. Proteins that regulate hippocampal circuitry, including ion channels, neurotransmitter receptors, and scaffolding proteins, have been identified.\n5. Proteomic analysis has revealed changes in protein expression in the hippocampus of Alzheimer's disease patients, including an increase in the expression of the protein tau.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been extensively analyzed.",
      "Proteins involved in synaptic plasticity and neurotransmission, such as NMDA receptors, AMPA receptors, and glutamate decarboxylase, have been identified in the hippocampus.",
      "Proteomic studies have shown that protein expression in the hippocampus changes in response to learning and memory tasks, with an example being the increased expression of CREB after spatial learning.",
      "Proteins that regulate hippocampal circuitry, including ion channels, neurotransmitter receptors, and scaffolding proteins, have been identified.",
      "Proteomic analysis has revealed changes in protein expression in the hippocampus of Alzheimer's disease patients, including an increase in the expression of the protein tau."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Yes, mouse chromosomes are acrocentric. Acrocentric chromosomes are a type of chromosome where the centromere, the region where the chromosome is attached to the spindle fibers during cell division, is located near the center of the chromosome. In contrast, centromeric chromosomes, which are found in some other organisms, have their centromere located closer to one of the ends of the chromosome.\nIn mice, each chromosome is acrocentric, meaning that the centromere is located near the center of the chromosome. This is in contrast to many other organisms, including humans, where the chromosomes are centromeric. The acrocentric structure of mouse chromosomes is thought to be an adaptation that allows for more efficient chromosome segregation during cell division.\nIt's worth noting that while the term \"acrocentric\" refers specifically to the location of the centromere, it is sometimes used more broadly to refer to any chromosome that has a relatively small number of genes compared to its overall length. In this sense, mouse chromosomes are not the only acrocentric chromosomes in the animal kingdom, as many other organisms also have acrocentric chromosomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are acrocentric.\n2. Acrocentric chromosomes have the centromere located near the center of the chromosome.\n3. Centromeric chromosomes have their centromere located closer to one of the ends of the chromosome.\n4. Humans have centromeric chromosomes, in contrast to mice.\n5. The acrocentric structure of mouse chromosomes is thought to be an adaptation for more efficient chromosome segregation during cell division.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are acrocentric.",
      "Acrocentric chromosomes have the centromere located near the center of the chromosome.",
      "Centromeric chromosomes have their centromere located closer to one of the ends of the chromosome.",
      "Humans have centromeric chromosomes, in contrast to mice.",
      "The acrocentric structure of mouse chromosomes is thought to be an adaptation for more efficient chromosome segregation during cell division."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Acrocentric chromosomes have the centromere located near one end of the chromosome, not near the center.\n3. FALSE [correction]: The term \"centromeric chromosomes\" is not accurate; chromosomes have centromeres, but the correct term for chromosomes with the centromere closer to one end is \"acrocentric\" or \"telocentric\" depending on the exact position. \"Centromeric\" refers to the region of the chromosome, not a type of chromosome.\n4. FALSE [correction]: Humans have both metacentric and acrocentric chromosomes, not centromeric. Metacentric chromosomes have the centromere near the center, making the arms of the chromosome approximately equal in length.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "The siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer is called ONC201. It is being developed by OncoGenex Pharmaceuticals and is currently in Phase 2 clinical trials for the treatment of pancreatic cancer. ONC201 works by selectively targeting and inhibiting the expression of the gene that encodes the protein P53, which is mutated in many cases of pancreatic cancer. By inhibiting the expression of P53, ONC201 may help to slow the growth and progression of pancreatic cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. The siRNA-based drug in clinical trials for the treatment of pancreatic cancer is called ONC201.\n2. ONC201 is being developed by OncoGenex Pharmaceuticals.\n3. ONC201 is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.\n4. ONC201 targets and inhibits the expression of the gene that encodes the protein P53.\n5. The protein P53 is mutated in many cases of pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "The siRNA-based drug in clinical trials for the treatment of pancreatic cancer is called ONC201.",
      "ONC201 is being developed by OncoGenex Pharmaceuticals.",
      "ONC201 is currently in Phase 2 clinical trials for the treatment of pancreatic cancer.",
      "ONC201 targets and inhibits the expression of the gene that encodes the protein P53.",
      "The protein P53 is mutated in many cases of pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The siRNA-based drug in clinical trials for the treatment of pancreatic cancer is not called ONC201. ONC201 is a small molecule, not an siRNA-based drug.\n2. FALSE [correction]: ONC201 is being developed by Oncoceutics, not OncoGenex Pharmaceuticals.\n3. UNKNOWN: Without current data, it is not possible to confirm the phase of clinical trials for ONC201 without up-to-date information.\n4. FALSE [correction]: ONC201 does not target and inhibit the expression of the gene that encodes the protein P53. Instead, it is known to target the dopamine receptor D2 (DRD2) and perhaps other related receptors.\n5. TRUE: The protein P53 is indeed mutated in many cases of pancreatic cancer, as well as in a wide variety of other cancers.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG (H+/proton-coupled ATPase) pore is a type of ion channel that is found in the plasma membrane of many cells, including those in the nervous system. It is also known as the VGluT1 pore or the VGAT pore.\nThe HPG pore is a proton-gated ion channel that is responsible for the uptake of glutamate from the extracellular space into the presynaptic neuron. The channel is composed of four subunits, each of which is composed of six transmembrane domains. The channel is opened when the pH of the extracellular space is lowered, allowing positively charged protons to flow through the channel and allowing glutamate to enter the cell.\nThe HPG pore plays a critical role in the release of neurotransmitters from presynaptic neurons. When an action potential reaches the presynaptic neuron, the HPG pore opens, allowing glutamate to flow out of the neuron and into the synapse. This leads to the activation of postsynaptic receptors and the transmission of the signal.\nDysfunction of the HPG pore has been implicated in a number of neurological disorders, including epilepsy, chronic pain, and neurodegenerative diseases such as Alzheimer's and Parkinson's.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore is found in the plasma membrane of many cells, including those in the nervous system.\n2. The HPG pore is also known as the VGluT1 pore or the VGAT pore.\n3. It is a proton-gated ion channel responsible for the uptake of glutamate from the extracellular space into the presynaptic neuron.\n4. The HPG pore is composed of four subunits, each with six transmembrane domains.\n5. Dysfunction of the HPG pore has been implicated in neurological disorders such as epilepsy, chronic pain, and neurodegenerative diseases like Alzheimer's and Parkinson's.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore is found in the plasma membrane of many cells, including those in the nervous system.",
      "The HPG pore is also known as the VGluT1 pore or the VGAT pore.",
      "It is a proton-gated ion channel responsible for the uptake of glutamate from the extracellular space into the presynaptic neuron.",
      "The HPG pore is composed of four subunits, each with six transmembrane domains.",
      "Dysfunction of the HPG pore has been implicated in neurological disorders such as epilepsy, chronic pain, and neurodegenerative diseases like Alzheimer's and Parkinson's."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The term \"HPG pore\" is not a standard term in cellular biology. It is possible that this is a fictional or a highly specialized term not widely recognized in scientific literature. Without additional context, the truth of this statement cannot be determined.\n\n2. FALSE [correction]: VGluT1 (Vesicular Glutamate Transporter 1) and VGAT (Vesicular GABA Transporter) are not pores but are transporters involved in the uptake of neurotransmitters into synaptic vesicles. VGluT1 is responsible for the uptake of glutamate, and VGAT is responsible for the uptake of GABA and glycine into vesicles.\n\n3. FALSE [correction]: If HPG pore is meant to refer to a proton-gated ion channel, it would not be responsible for the uptake of glutamate into the presynaptic neuron. Proton-gated ion channels typically respond to changes in proton concentration and are involved in various cellular processes, but the uptake of neurotransmitters like glutamate is usually mediated by specific transporters, not ion channels.\n\n4. UNKNOWN: Without a clear reference to what the HPG pore is, it is impossible to confirm the structural details of such a pore. Ion channels can be composed of multiple subunits with transmembrane domains, but without specific information, the structure of the HPG pore cannot be verified.\n\n5. UNKNOWN: Since the existence and function of the HPG pore are not established, any claims about its dysfunction and implications in neurological disorders cannot be confirmed. However, it is true that dysfunction in various ion channels and transporters can be implicated in neurological disorders such as epilepsy, chronic pain, and neurodegenerative diseases.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a large-scale effort to sequence the genomes of 959 species of nematodes, which are a group of microscopic worms that are found in almost every environment on Earth. The initiative is led by the University of California, Riverside (UCR) and involves a collaboration of researchers from over 100 institutions around the world.\nNematodes are important model organisms in biology and play a crucial role in many ecosystems, including agricultural systems. They are also important for human health, as some species are parasitic and can cause diseases in humans and animals. However, despite their importance, the genomes of most nematode species have been poorly studied, and there is a lack of genomic resources available for many species.\nThe goal of the 959 Nematode Genomes initiative is to change this by sequencing the genomes of as many nematode species as possible and making the data and resources available to the scientific community. The initiative is focused on species that are important for agriculture, human health, and the environment, and it aims to generate high-quality genomes for these species.\nThe initiative is using a variety of sequencing technologies, including Illumina and PacBio, to generate long-read genomes for the nematode species. The data is being analyzed using a variety of bioinformatic tools and methods, including assembly, annotation, and comparative genomics. The goal is to generate high-quality genomes that can be used for a variety of applications, including understanding the evolution of nematode genomes, identifying genes that are important for parasitism and disease, and developing new pest management strategies.\nOverall, the 959 Nematode Genomes initiative is an ambitious effort to generate a comprehensive understanding of the genomes of nematode species and their role in ecosystems and human health. The data and resources generated by the initiative will be available to the scientific community and will help to advance our understanding of these important organisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence the genomes of 959 species of nematodes.\n2. The initiative is led by the University of California, Riverside (UCR).\n3. The initiative involves collaboration from researchers at over 100 institutions worldwide.\n4. The initiative focuses on nematode species that are important for agriculture, human health, and the environment.\n5. Sequencing technologies such as Illumina and PacBio are being used in the initiative to generate long-read genomes.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence the genomes of 959 species of nematodes.",
      "The initiative is led by the University of California, Riverside (UCR).",
      "The initiative involves collaboration from researchers at over 100 institutions worldwide.",
      "The initiative focuses on nematode species that are important for agriculture, human health, and the environment.",
      "Sequencing technologies such as Illumina and PacBio are being used in the initiative to generate long-read genomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The 959 Nematode Genomes initiative, also known as the 959 Nematode Genomes Project or WormBase ParaSite project, is not specifically led by the University of California, Riverside (UCR). It is a collaborative effort involving multiple institutions.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Some of the popular ones include:\n1. \"NIPT\": This package provides a set of functions for analyzing NIPT data, including quality control, data cleaning, and statistical analysis.\n2. \"Prenatix\": This package provides a comprehensive set of tools for NIPT data analysis, including data preprocessing, feature selection, and machine learning algorithms.\n3. \"PrenatalGenomics\": This package provides functions for NIPT data analysis, including data cleaning, quality control, and statistical analysis.\n4. \"PrenatalTesting\": This package provides functions for NIPT data analysis, including data cleaning, quality control, and statistical analysis.\n5. \"NIPT-Analysis\": This package provides a set of functions for NIPT data analysis, including data cleaning, quality control, and statistical analysis.\n6. \"PrenatalGenomics-R\": This package provides functions for NIPT data analysis, including data cleaning, quality control, and statistical analysis.\n7. \"PrenatalTesting-R\": This package provides functions for NIPT data analysis, including data cleaning, quality control, and statistical analysis.\n8. \"NIPT-Tools\": This package provides a set of functions for NIPT data analysis, including data cleaning, quality control, and statistical analysis.\n9. \"PrenatalGenomics-Bioconductor\": This package provides functions for NIPT data analysis, including data cleaning, quality control, and statistical analysis.\n10. \"PrenatalTesting-Bioconductor\": This package provides functions for NIPT data analysis, including data cleaning, quality control, and statistical analysis.\nIt's worth noting that these packages are constantly being updated and new packages are being developed, so it's always a good idea to check the latest packages and their documentation for the most up-to-date information.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"NIPT\" R package provides functions for analyzing Non-invasive prenatal testing data, including quality control, data cleaning, and statistical analysis.\n2. The \"Prenatix\" R package offers tools for NIPT data analysis, including data preprocessing, feature selection, and machine learning algorithms.\n3. The \"PrenatalGenomics\" R package includes functions for NIPT data analysis, such as data cleaning, quality control, and statistical analysis.\n4. The \"NIPT-Analysis\" R package provides a set of functions for NIPT data analysis, including data cleaning, quality control, and statistical analysis.\n5. The \"PrenatalGenomics-Bioconductor\" R package provides functions for NIPT data analysis, including data cleaning, quality control, and statistical analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The \"NIPT\" R package provides functions for analyzing Non-invasive prenatal testing data, including quality control, data cleaning, and statistical analysis.",
      "The \"Prenatix\" R package offers tools for NIPT data analysis, including data preprocessing, feature selection, and machine learning algorithms.",
      "The \"PrenatalGenomics\" R package includes functions for NIPT data analysis, such as data cleaning, quality control, and statistical analysis.",
      "The \"NIPT-Analysis\" R package provides a set of functions for NIPT data analysis, including data cleaning, quality control, and statistical analysis.",
      "The \"PrenatalGenomics-Bioconductor\" R package provides functions for NIPT data analysis, including data cleaning, quality control, and statistical analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific knowledge of the \"NIPT\" R package and its functions, it is not possible to confirm the accuracy of this statement.\n2. UNKNOWN: Without specific knowledge of the \"Prenatix\" R package and its functions, it is not possible to confirm the accuracy of this statement.\n3. UNKNOWN: Without specific knowledge of the \"PrenatalGenomics\" R package and its functions, it is not possible to confirm the accuracy of this statement.\n4. UNKNOWN: Without specific knowledge of the \"NIPT-Analysis\" R package and its functions, it is not possible to confirm the accuracy of this statement.\n5. UNKNOWN: Without specific knowledge of the \"PrenatalGenomics-Bioconductor\" R package and its functions, it is not possible to confirm the accuracy of this statement.\n\nNote: The truthfulness of these statements would require specific knowledge about the mentioned R packages, which would involve looking up each package's documentation or having prior knowledge of them. If these packages do not exist or do not provide the functions as described, the statements would be false. However, without access to current databases or repositories to verify the existence and features of these R packages, the truthfulness of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome, also known as Achenbach's triad or Achenbach's complex, is a rare neurological disorder characterized by a combination of three distinct symptoms:\n1. Oculomotor dysfunction: Achenbach's syndrome is often associated with abnormalities in the control of eye movements, including difficulty moving the eyes, double vision, and a tendency to drift outward.\n2. Dysarthria: The syndrome can also cause slurred or slow speech, which can make it difficult for others to understand what the individual is saying.\n3. Cerebellar ataxia: Affected individuals may experience coordination problems, including difficulty with balance, gait, and fine motor movements. They may also experience tremors, rigidity, and other signs of cerebellar dysfunction.\nThe exact cause of Achenbach's syndrome is not fully understood, but it is believed to be related to damage to the cerebellum and brainstem. The disorder can be caused by a variety of factors, including genetic mutations, infections, and traumatic brain injury.\nAchenbach's syndrome is a rare disorder, and the prevalence is not well established. However, it is estimated to affect approximately 1 in 100,000 to 1 in 50,000 individuals. The disorder can occur at any age, but it is most commonly diagnosed in adulthood.\nThere is no cure for Achenbach's syndrome, but various treatments can help manage the symptoms. These may include physical therapy, speech therapy, and medications to control tremors and other movement disorders. In some cases, surgery may be necessary to relieve compression on the brainstem or cerebellum.\nOverall, Achenbach's syndrome is a complex and rare disorder that can significantly impact an individual's quality of life. Early diagnosis and appropriate treatment can help manage the symptoms and improve the individual's functional abilities.",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is characterized by oculomotor dysfunction, dysarthria, and cerebellar ataxia.\n2. The syndrome is believed to be related to damage to the cerebellum and brainstem.\n3. Achenbach's syndrome can be caused by genetic mutations, infections, and traumatic brain injury.\n4. The estimated prevalence of Achenbach's syndrome is approximately 1 in 100,000 to 1 in 50,000 individuals.\n5. Treatments for Achenbach's syndrome may include physical therapy, speech therapy, medications, and possibly surgery.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is characterized by oculomotor dysfunction, dysarthria, and cerebellar ataxia.",
      "The syndrome is believed to be related to damage to the cerebellum and brainstem.",
      "Achenbach's syndrome can be caused by genetic mutations, infections, and traumatic brain injury.",
      "The estimated prevalence of Achenbach's syndrome is approximately 1 in 100,000 to 1 in 50,000 individuals.",
      "Treatments for Achenbach's syndrome may include physical therapy, speech therapy, medications, and possibly surgery."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is characterized by spontaneous bruising, primarily in the hands or fingers.\n2. FALSE [correction]: Achenbach's syndrome is not related to damage to the cerebellum and brainstem; it is a benign condition involving paroxysmal hematoma of the hand.\n3. FALSE [correction]: Achenbach's syndrome is not typically caused by genetic mutations, infections, or traumatic brain injury. The exact cause is often unknown, but it may be related to minor traumas or spontaneous bleeding.\n4. UNKNOWN: The prevalence of Achenbach's syndrome is not well-documented, so an accurate estimate is difficult to determine.\n5. TRUE: While the specific treatments for Achenbach's syndrome may vary, management may include conservative measures such as rest and observation, and in some cases, pain relief medications. Physical therapy, speech therapy, and surgery are not typically associated with the treatment of Achenbach's syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "There are several algorithms that can be used for the detection of long repeat expansions, including:\n1. RepeatMasker: This is a widely used algorithm for detecting repeat expansions in DNA sequences. It uses a combination of heuristics and statistical models to identify repeat elements and predict their lengths.\n2. LINE-SRAF: This algorithm is specifically designed for detecting long repeat expansions in the LINE (Long Interspersed Nuclear Elements) class of repeat elements. It uses a combination of sequence alignment and statistical modeling to identify LINE elements and predict their lengths.\n3. GATA-W: This algorithm is similar to RepeatMasker, but it is specifically designed for detecting repeat expansions in the GATA (GATA-binding site) class of repeat elements. It uses a combination of heuristics and statistical models to identify GATA elements and predict their lengths.\n4. REDS: This algorithm is a more recent approach to repeat expansion detection that uses a combination of machine learning and statistical modeling. It can be used to detect a wide range of repeat classes, including LINE, SINE, and DNA transposons.\n5. DeepRepeats: This is a deep learning-based approach to repeat expansion detection that uses a convolutional neural network (CNN) to identify repeat elements in DNA sequences. It can be used to detect a wide range of repeat classes, including LINE, SINE, and DNA transposons.\n6. RepeatHunter: This is a web-based tool that uses a combination of heuristics and statistical models to detect repeat expansions in DNA sequences. It can be used to detect a wide range of repeat classes, including LINE, SINE, and DNA transposons.\n7. RepetitionFinder: This is a web-based tool that uses a combination of heuristics and statistical models to detect repeat expansions in DNA sequences. It can be used to detect a wide range of repeat classes, including LINE, SINE, and DNA transposons.\n8. RepeatAnalyzer: This is a web-based tool that uses a combination of heuristics and statistical models to detect repeat expansions in DNA sequences. It can be used to detect a wide range of repeat classes, including LINE, SINE, and DNA transposons.\n9. RepeatSc",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm used for detecting repeat expansions in DNA sequences.\n2. LINE-SRAF is an algorithm designed for detecting long repeat expansions in the LINE class of repeat elements.\n3. GATA-W is an algorithm designed for detecting repeat expansions in the GATA class of repeat elements.\n4. REDS is an algorithm that uses machine learning and statistical modeling for repeat expansion detection.\n5. DeepRepeats is a deep learning-based algorithm that uses a convolutional neural network to identify repeat elements in DNA sequences.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is an algorithm used for detecting repeat expansions in DNA sequences.",
      "LINE-SRAF is an algorithm designed for detecting long repeat expansions in the LINE class of repeat elements.",
      "GATA-W is an algorithm designed for detecting repeat expansions in the GATA class of repeat elements.",
      "REDS is an algorithm that uses machine learning and statistical modeling for repeat expansion detection.",
      "DeepRepeats is a deep learning-based algorithm that uses a convolutional neural network to identify repeat elements in DNA sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 has been shown to promote the growth and progression of certain types of brain tumors, including:\n1. Medulloblastoma: Neuroligin-3 is overexpressed in medulloblastoma, a type of pediatric brain cancer that originates in the cerebellum. Overexpression of neuroligin-3 has been linked to more aggressive tumor behavior and poorer prognosis.\n2. Glioblastoma: Neuroligin-3 is also overexpressed in glioblastoma, the most common and aggressive form of adult brain cancer. High levels of neuroligin-3 have been associated with a higher risk of recurrence and poorer overall survival.\n3. Astrocytoma: Neuroligin-3 is also overexpressed in some types of astrocytoma, a type of brain cancer that originates in the supportive tissue of the brain.\nIn summary, neuroligin-3 promotes the growth and progression of certain types of brain tumors, including medulloblastoma, glioblastoma, and astrocytoma.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 is overexpressed in medulloblastoma, a pediatric brain cancer.\n2. Overexpression of neuroligin-3 in medulloblastoma is linked to more aggressive tumor behavior and poorer prognosis.\n3. Neuroligin-3 is overexpressed in glioblastoma, the most common and aggressive form of adult brain cancer.\n4. High levels of neuroligin-3 in glioblastoma are associated with a higher risk of recurrence and poorer overall survival.\n5. Neuroligin-3 is overexpressed in some types of astrocytoma, a brain cancer originating in the supportive tissue of the brain.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 is overexpressed in medulloblastoma, a pediatric brain cancer.",
      "Overexpression of neuroligin-3 in medulloblastoma is linked to more aggressive tumor behavior and poorer prognosis.",
      "Neuroligin-3 is overexpressed in glioblastoma, the most common and aggressive form of adult brain cancer.",
      "High levels of neuroligin-3 in glioblastoma are associated with a higher risk of recurrence and poorer overall survival.",
      "Neuroligin-3 is overexpressed in some types of astrocytoma, a brain cancer originating in the supportive tissue of the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Neuroligin-3 has been reported to be overexpressed in medulloblastoma, which is a type of pediatric brain cancer.\n2. TRUE: Studies have suggested that the overexpression of neuroligin-3 in medulloblastoma is associated with more aggressive tumor behavior and a poorer prognosis.\n3. UNKNOWN: While neuroligin-3 has been studied in various types of brain cancers, the statement's specificity regarding its overexpression in glioblastoma requires access to specific scientific research that confirms this claim.\n4. UNKNOWN: Similar to the previous statement, the association of high levels of neuroligin-3 with the risk of recurrence and overall survival in glioblastoma patients would need to be confirmed by specific scientific studies.\n5. UNKNOWN: Astrocytomas are a diverse group of brain tumors, and while neuroligin-3 may be overexpressed in some cases, this statement would require validation through scientific research specific to astrocytomas.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles are small, membrane-bound structures found in some bacteria and archaea that are used for buoyancy and movement. The size of gas vesicles can vary depending on the species of bacteria or archaea, but they are generally in the range of 10-100 nanometers (nm) in diameter.\nFor example, in the bacterium Vibrio cholerae, gas vesicles are typically around 20-30 nm in diameter, while in the archaeon Halorubrum sodomense, they are around 50-70 nm in diameter. In some cases, gas vesicles can be larger, up to 100-200 nm in diameter.\nIt's worth noting that the size of gas vesicles can also vary depending on the stage of growth and development of the bacteria or archaea. For example, gas vesicles may be larger in younger cells that are actively growing and dividing, and smaller in older cells that are no longer actively growing.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles are membrane-bound structures found in some bacteria and archaea.\n2. Gas vesicles are generally in the range of 10-100 nanometers in diameter.\n3. In the bacterium Vibrio cholerae, gas vesicles are typically around 20-30 nm in diameter.\n4. In the archaeon Halorubrum sodomense, gas vesicles are around 50-70 nm in diameter.\n5. The size of gas vesicles can vary depending on the stage of growth and development of the bacteria or archaea.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles are membrane-bound structures found in some bacteria and archaea.",
      "Gas vesicles are generally in the range of 10-100 nanometers in diameter.",
      "In the bacterium Vibrio cholerae, gas vesicles are typically around 20-30 nm in diameter.",
      "In the archaeon Halorubrum sodomense, gas vesicles are around 50-70 nm in diameter.",
      "The size of gas vesicles can vary depending on the stage of growth and development of the bacteria or archaea."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Gas vesicles are generally in the range of 45-200 nanometers in diameter.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that play a crucial role in regulating gene expression by modifying chromatin structure. Here are the five BET proteins:\n1. BRD2 (Bromodomain-Containing Protein 2): BRD2 is the most well-studied BET protein and is involved in various cellular processes, including transcriptional activation, DNA repair, and cell proliferation.\n2. BRD3 (Bromodomain-Containing Protein 3): BRD3 is similar to BRD2 in function and is also involved in transcriptional activation and chromatin remodeling.\n3. BRDT (Bromodomain-Containing Protein T): BRDT is a member of the BET family that is primarily expressed in the testis and is involved in the regulation of spermatogenesis.\n4. BRDM2 (Bromodomain-Containing Protein 2-Like 2): BRDM2 is a BET protein that is similar to BRD2 and is involved in the regulation of gene expression, particularly in the context of cancer.\n5. BRDTL1 (Bromodomain-Containing Protein T-Like 1): BRDTL1 is a BET protein that is similar to BRDT and is involved in the regulation of gene expression, particularly in the context of cancer.\nBET proteins are known to bind to acetylated histone proteins and recognize specific DNA sequences, leading to changes in chromatin structure and gene expression. Dysregulation of BET proteins has been implicated in various diseases, including cancer, and BET inhibitors are being developed as potential therapeutics for cancer treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRD2 (Bromodomain-Containing Protein 2) is involved in transcriptional activation, DNA repair, and cell proliferation.\n2. BRD3 (Bromodomain-Containing Protein 3) functions similarly to BRD2 and is involved in transcriptional activation and chromatin remodeling.\n3. BRDT (Bromodomain-Containing Protein T) is primarily expressed in the testis and regulates spermatogenesis.\n4. BRDM2 (Bromodomain-Containing Protein 2-Like 2) is involved in the regulation of gene expression, particularly in the context of cancer.\n5. Dysregulation of BET proteins has been implicated in various diseases, including cancer.",
    "llama-2-7b-chat-hf_fact": [
      "BRD2 (Bromodomain-Containing Protein 2) is involved in transcriptional activation, DNA repair, and cell proliferation.",
      "BRD3 (Bromodomain-Containing Protein 3) functions similarly to BRD2 and is involved in transcriptional activation and chromatin remodeling.",
      "BRDT (Bromodomain-Containing Protein T) is primarily expressed in the testis and regulates spermatogenesis.",
      "BRDM2 (Bromodomain-Containing Protein 2-Like 2) is involved in the regulation of gene expression, particularly in the context of cancer.",
      "Dysregulation of BET proteins has been implicated in various diseases, including cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: There is no commonly known protein with the abbreviation BRDM2. The correct abbreviation for Bromodomain-Containing Protein 2-Like 2 is BRD2L2 or BRD2-like 2, and it is involved in the regulation of gene expression, but its specific role in cancer is not well-defined without additional context.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning algorithms that have been developed for predicting protein subcellular localization. Some of the most popular ones include:\n1. DeepLoc: This algorithm uses a deep learning model to predict the subcellular localization of proteins based on their sequence features. It was developed by the University of California, San Diego and has been shown to be highly accurate in predicting localization for a wide range of organisms.\n2. LocNet: This algorithm uses a deep learning model to predict the localization of proteins in the endoplasmic reticulum (ER), Golgi apparatus, and mitochondria. It was developed by the University of California, Los Angeles and has been shown to be highly accurate in predicting localization for these organelles.\n3. PredictProteinLoc: This algorithm uses a deep learning model to predict the subcellular localization of proteins based on their sequence features and structural information. It was developed by the University of California, San Francisco and has been shown to be highly accurate in predicting localization for a wide range of organisms.\n4. DeepSEA: This algorithm uses a deep learning model to predict the subcellular localization of proteins based on their sequence features and structural information. It was developed by the University of California, Berkeley and has been shown to be highly accurate in predicting localization for a wide range of organisms.\n5. SEA-based deep learning model: This algorithm uses a deep learning model to predict the subcellular localization of proteins based on their sequence features and structural information. It was developed by the University of Texas Southwestern Medical Center and has been shown to be highly accurate in predicting localization for a wide range of organisms.\n6. Locus-based deep learning model: This algorithm uses a deep learning model to predict the subcellular localization of proteins based on their sequence features and structural information. It was developed by the University of California, San Diego and has been shown to be highly accurate in predicting localization for a wide range of organisms.\n7. Graph convolutional network (GCN)-based model: This algorithm uses a GCN to predict the subcellular localization of proteins based on their sequence features and structural information. It was developed by the University of California, Los Angeles and has been shown to be highly accurate in predicting localization for a wide",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepLoc is an algorithm that predicts the subcellular localization of proteins based on their sequence features and was developed by the University of California, San Diego.\n2. LocNet is an algorithm that predicts the localization of proteins in the endoplasmic reticulum, Golgi apparatus, and mitochondria, developed by the University of California, Los Angeles.\n3. PredictProteinLoc is an algorithm that predicts the subcellular localization of proteins using sequence features and structural information, developed by the University of California, San Francisco.\n4. DeepSEA is an algorithm that predicts the subcellular localization of proteins based on sequence features and structural information, developed by the University of California, Berkeley.\n5. A SEA-based deep learning model for predicting protein subcellular localization was developed by the University of Texas Southwestern Medical Center.",
    "llama-2-7b-chat-hf_fact": [
      "DeepLoc is an algorithm that predicts the subcellular localization of proteins based on their sequence features and was developed by the University of California, San Diego.",
      "LocNet is an algorithm that predicts the localization of proteins in the endoplasmic reticulum, Golgi apparatus, and mitochondria, developed by the University of California, Los Angeles.",
      "PredictProteinLoc is an algorithm that predicts the subcellular localization of proteins using sequence features and structural information, developed by the University of California, San Francisco.",
      "DeepSEA is an algorithm that predicts the subcellular localization of proteins based on sequence features and structural information, developed by the University of California, Berkeley.",
      "A SEA-based deep learning model for predicting protein subcellular localization was developed by the University of Texas Southwestern Medical Center."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: DeepSEA is an algorithm designed to predict the effects of noncoding variants on sequence features, chromatin effects, and transcription factor binding, not for predicting the subcellular localization of proteins. It was developed by researchers at the University of California, San Francisco, and the New York Genome Center.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "I apologize, but I'm not familiar with the term \"MULTOVL\". It's possible that it's a misspelling or a term that is not widely used in the scientific community. Can you please provide more context or information about where you encountered this term? This will help me better understand and provide a more accurate answer.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Yes, GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment in various types of cancer, including breast, lung, and colon cancer. Metformin is a commonly used medication for type 2 diabetes, but it has also been shown to have anti-tumor effects and is being investigated as a potential treatment for various types of cancer.\nStudies have shown that GDF15 levels are significantly increased in cancer cells and are inversely correlated with the expression of the AMP-activated protein kinase (AMPK) pathway, which is activated by metformin. Therefore, GDF15 has been proposed as a potential biomarker for the effectiveness of metformin treatment in cancer.\nOne study published in the journal Cancer Research in 2017 found that GDF15 levels were significantly lower in breast cancer patients who responded to metformin treatment compared to those who did not respond. Another study published in the journal Oncogene in 2018 found that GDF15 levels were significantly higher in lung cancer patients who were resistant to metformin treatment compared to those who were sensitive to the drug.\nOverall, these studies suggest that GDF15 may be a useful biomarker for predicting the effectiveness of metformin treatment in cancer, and further research is needed to confirm these findings and to determine the clinical utility of GDF15 as a biomarker for metformin treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment in various types of cancer.\n2. Metformin is a medication commonly used for type 2 diabetes and has been shown to have anti-tumor effects.\n3. GDF15 levels are significantly increased in cancer cells and inversely correlated with the expression of the AMP-activated protein kinase (AMPK) pathway.\n4. A study published in the journal Cancer Research in 2017 found that GDF15 levels were significantly lower in breast cancer patients who responded to metformin treatment compared to non-responders.\n5. Another study published in the journal Oncogene in 2018 found that GDF15 levels were significantly higher in lung cancer patients resistant to metformin treatment compared to those sensitive to the drug.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment in various types of cancer.",
      "Metformin is a medication commonly used for type 2 diabetes and has been shown to have anti-tumor effects.",
      "GDF15 levels are significantly increased in cancer cells and inversely correlated with the expression of the AMP-activated protein kinase (AMPK) pathway.",
      "A study published in the journal Cancer Research in 2017 found that GDF15 levels were significantly lower in breast cancer patients who responded to metformin treatment compared to non-responders.",
      "Another study published in the journal Oncogene in 2018 found that GDF15 levels were significantly higher in lung cancer patients resistant to metformin treatment compared to those sensitive to the drug."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GDF15 levels are significantly increased in response to metformin treatment and are positively correlated with the activation of the AMP-activated protein kinase (AMPK) pathway.\n4. FALSE [correction]: A study published in the journal Cancer Research in 2017 found that GDF15 levels were significantly higher in breast cancer patients who responded to metformin treatment compared to non-responders.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Yes, recursive splicing is more common in short introns. Recursive splicing, also known as intron retention, occurs when the splicing machinery removes the intron but then re-binds to the remaining exon and removes it again, resulting in a shorter mRNA molecule. This process can lead to the production of different isoforms of the protein.\nShort introns are typically defined as those that are shorter than 100 nucleotides in length, and they are more prone to recursive splicing than longer introns. This is because the splicing machinery has a harder time recognizing the intron-exon boundaries in short introns, leading to more errors and the formation of alternative splicing patterns.\nIn fact, studies have shown that the majority of recursive splicing events occur in short introns, and that the frequency of recursive splicing increases as the length of the intron decreases. This is likely due to the fact that the splicing machinery has a harder time recognizing the intron-exon boundaries in short introns, leading to more errors and the formation of alternative splicing patterns.\nIn contrast, longer introns are less prone to recursive splicing, as the splicing machinery is better able to recognize the intron-exon boundaries and accurately splice the pre-mRNA. However, longer introns can still undergo alternative splicing, but this is typically through a process called non-recursive splicing, where the intron is removed in a single step.\nOverall, the shorter the intron, the more likely it is to undergo recursive splicing, and the more diverse the resulting isoforms will be.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns than in longer ones.\n2. Short introns are typically defined as those shorter than 100 nucleotides in length.\n3. The frequency of recursive splicing increases as the length of the intron decreases.\n4. Studies have shown that the majority of recursive splicing events occur in short introns.\n5. Longer introns are less prone to recursive splicing due to better recognition of intron-exon boundaries by the splicing machinery.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns than in longer ones.",
      "Short introns are typically defined as those shorter than 100 nucleotides in length.",
      "The frequency of recursive splicing increases as the length of the intron decreases.",
      "Studies have shown that the majority of recursive splicing events occur in short introns.",
      "Longer introns are less prone to recursive splicing due to better recognition of intron-exon boundaries by the splicing machinery."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing is more common in long introns than in shorter ones.\n2. TRUE\n3. FALSE [correction]: The frequency of recursive splicing increases with the length of the intron, not decreases.\n4. FALSE [correction]: Studies have shown that the majority of recursive splicing events occur in long introns.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "TALE-iD is a method used in genomics and molecular biology to identify the genomic locations of specific DNA sequences, such as transcriptional enhancers, using Chromatin Conformation Capture (3C) data.\nThe TALE-iD method is used to identify the genomic locations of specific DNA sequences, such as transcriptional enhancers, by analyzing Chromatin Conformation Capture (3C) data. 3C is a technique that captures the interactions between chromatin fragments in a genomic region, providing information on the three-dimensional structure of chromatin. TALE-iD takes advantage of this information to identify the genomic locations of specific DNA sequences, such as enhancers, by analyzing the patterns of chromatin interactions around these sequences.\nThe method works by using a computational algorithm to identify regions of the genome where the chromatin interactions are more likely to be associated with specific DNA sequences. These regions are then further analyzed to identify the specific sequences that are responsible for the observed chromatin interactions.\nTALE-iD is particularly useful for identifying enhancers, which are short sequences that can be located far away from their target genes and are often difficult to identify using traditional genomic approaches. By using TALE-iD to identify enhancers, researchers can gain insights into the regulation of gene expression and the role of non-coding RNAs in the cell.\nIn summary, TALE-iD is a computational method used to identify the genomic locations of specific DNA sequences, such as transcriptional enhancers, by analyzing Chromatin Conformation Capture (3C) data. It is a powerful tool for understanding the regulation of gene expression and the role of non-coding RNAs in the cell.",
    "llama-2-7b-chat-hf_fact_raw": "1. TALE-iD is a method used in genomics and molecular biology.\n2. TALE-iD identifies the genomic locations of specific DNA sequences using Chromatin Conformation Capture (3C) data.\n3. Chromatin Conformation Capture (3C) is a technique that captures interactions between chromatin fragments to provide information on the three-dimensional structure of chromatin.\n4. TALE-iD is used to identify enhancers, which are short sequences that can regulate gene expression from a distance.\n5. TALE-iD employs a computational algorithm to identify regions of the genome associated with specific DNA sequences.",
    "llama-2-7b-chat-hf_fact": [
      "TALE-iD is a method used in genomics and molecular biology.",
      "TALE-iD identifies the genomic locations of specific DNA sequences using Chromatin Conformation Capture (3C) data.",
      "Chromatin Conformation Capture (3C) is a technique that captures interactions between chromatin fragments to provide information on the three-dimensional structure of chromatin.",
      "TALE-iD is used to identify enhancers, which are short sequences that can regulate gene expression from a distance.",
      "TALE-iD employs a computational algorithm to identify regions of the genome associated with specific DNA sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TALE-iD identifies the genomic locations of specific DNA sequences using transcription activator-like effectors (TALEs), not Chromatin Conformation Capture (3C) data.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing, including:\n1. CL-Image: This is a Lisp library for image processing that provides a set of functions for reading, writing, and manipulating images. It supports various image formats, including PNG, JPEG, and TIFF.\n2. ImageTk: This is a Lisp interface to the Tk image processing toolkit, which provides a wide range of image processing functions, including filtering, resizing, and color manipulation.\n3. Lisp-Image: This is a Lisp library for image processing that provides a simple and efficient way to manipulate images. It includes functions for reading and writing images, as well as functions for performing common image processing tasks, such as resizing, cropping, and thresholding.\n4. Image-Lisp: This is a Lisp library for image processing that provides a comprehensive set of functions for working with images. It includes functions for reading and writing images, as well as functions for performing advanced image processing tasks, such as edge detection, morphology, and color manipulation.\n5. Lisp-Image-JPEG: This is a Lisp library for image processing that provides a set of functions for working with JPEG images. It includes functions for reading and writing JPEG images, as well as functions for performing common image processing tasks, such as resizing, cropping, and thresholding.\nThese are some of the popular Lisp frameworks for image processing, but there are many others available, each with their own strengths and weaknesses. The choice of which one to use will depend on the specific requirements of the project and the preferences of the developer.",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-Image is a Lisp library for image processing that supports various image formats, including PNG, JPEG, and TIFF.\n2. ImageTk is a Lisp interface to the Tk image processing toolkit.\n3. Lisp-Image is a Lisp library that includes functions for reading, writing, and performing common image processing tasks.\n4. Image-Lisp provides a comprehensive set of functions for advanced image processing tasks.\n5. Lisp-Image-JPEG is a Lisp library focused on working with JPEG images, including reading, writing, and common processing tasks.",
    "llama-2-7b-chat-hf_fact": [
      "CL-Image is a Lisp library for image processing that supports various image formats, including PNG, JPEG, and TIFF.",
      "ImageTk is a Lisp interface to the Tk image processing toolkit.",
      "Lisp-Image is a Lisp library that includes functions for reading, writing, and performing common image processing tasks.",
      "Image-Lisp provides a comprehensive set of functions for advanced image processing tasks.",
      "Lisp-Image-JPEG is a Lisp library focused on working with JPEG images, including reading, writing, and common processing tasks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: ImageTk is not a Lisp interface; it is a Python interface to the Tk GUI toolkit that allows displaying images in a Tkinter canvas.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding Lisp libraries are difficult to verify without specific knowledge about these libraries or access to a database of Lisp libraries. The correction for statement 2 is based on the known Python library ImageTk, which is part of the Python Imaging Library (PIL) and is not related to Lisp.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "The yeast species Saccharomyces cerevisiae (baker's yeast) has undergone a whole genome duplication event in its evolutionary history. This event, which occurred around 100-200 million years ago, resulted in the duplication of approximately 100-150 genes. These genes are known as \"ancient duplications\" or \"pre-existing genes\" and are thought to have been preserved in the genome through evolutionary time due to their functional importance.\nIt's worth noting that the exact number of ancient duplications in S. cerevisiae is still a matter of debate and can vary depending on the method used to identify them. Some studies have estimated that around 100-150 genes are the result of this ancient whole genome duplication, while others have suggested that the number could be higher or lower. However, most studies agree that the majority of these genes are involved in metabolic processes, particularly those related to carbon metabolism and stress response.",
    "llama-2-7b-chat-hf_fact_raw": "1. Saccharomyces cerevisiae (baker's yeast) has experienced a whole genome duplication event in its evolutionary history.\n2. The whole genome duplication event in Saccharomyces cerevisiae occurred around 100-200 million years ago.\n3. Approximately 100-150 genes in Saccharomyces cerevisiae are the result of this ancient whole genome duplication.\n4. The genes resulting from the ancient whole genome duplication in Saccharomyces cerevisiae are often involved in metabolic processes.\n5. The genes from the ancient duplication in Saccharomyces cerevisiae are particularly related to carbon metabolism and stress response.",
    "llama-2-7b-chat-hf_fact": [
      "Saccharomyces cerevisiae (baker's yeast) has experienced a whole genome duplication event in its evolutionary history.",
      "The whole genome duplication event in Saccharomyces cerevisiae occurred around 100-200 million years ago.",
      "Approximately 100-150 genes in Saccharomyces cerevisiae are the result of this ancient whole genome duplication.",
      "The genes resulting from the ancient whole genome duplication in Saccharomyces cerevisiae are often involved in metabolic processes.",
      "The genes from the ancient duplication in Saccharomyces cerevisiae are particularly related to carbon metabolism and stress response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The number of genes retained from the whole genome duplication event in Saccharomyces cerevisiae is much higher. Estimates suggest that about 10% of the yeast genome, which would be approximately 600 genes, are the result of this ancient whole genome duplication.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor β (Esrrb) is a nuclear receptor that is activated by estrogenic ligands, including estradiol (E2). Esrrb is bound by a complex of ligands that includes:\n1. Estradiol (E2): The most well-known and well-studied ligand of Esrrb, E2 is the most potent and selective activator of Esrrb.\n2. 4-Hydroxyestradiol (4-OHE2): A metabolite of E2, 4-OHE2 is also a potent and selective activator of Esrrb.\n3. Estetrol (Et): A naturally occurring estrogen in the fetal and neonatal period, Et is a weak activator of Esrrb.\n4. Selective estrogen receptor modulators (SERMs): A class of compounds that bind to both Esrrb and the estrogen receptor alpha (ERα), SERMs can act as agonists or antagonists of Esrrb depending on the specific compound and the cellular context. Examples of SERMs include tamoxifen, raloxifene, and lasofoxifene.\n5. Phytoestrogens: Plant-derived compounds that exhibit estrogenic activity, phytoestrogens can bind to Esrrb and modulate its activity. Examples of phytoestrogens include isoflavones (e.g., genistein, daidzein) and lignans (e.g., enterolactone).",
    "llama-2-7b-chat-hf_fact_raw": "1. Estradiol (E2) is a ligand that activates the estrogen-related receptor β (Esrrb).\n2. 4-Hydroxyestradiol (4-OHE2) is a metabolite of estradiol and a potent activator of Esrrb.\n3. Estetrol (Et) is a naturally occurring estrogen that can weakly activate Esrrb.\n4. Selective estrogen receptor modulators (SERMs) can bind to both Esrrb and estrogen receptor alpha (ERα) and can act as agonists or antagonists.\n5. Phytoestrogens, such as isoflavones and lignans, can bind to Esrrb and modulate its activity.",
    "llama-2-7b-chat-hf_fact": [
      "Estradiol (E2) is a ligand that activates the estrogen-related receptor β (Esrrb).",
      "4-Hydroxyestradiol (4-OHE2) is a metabolite of estradiol and a potent activator of Esrrb.",
      "Estetrol (Et) is a naturally occurring estrogen that can weakly activate Esrrb.",
      "Selective estrogen receptor modulators (SERMs) can bind to both Esrrb and estrogen receptor alpha (ERα) and can act as agonists or antagonists.",
      "Phytoestrogens, such as isoflavones and lignans, can bind to Esrrb and modulate its activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Estradiol (E2) is a ligand that activates the estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), not specifically the estrogen-related receptor β (Esrrb).\n2. UNKNOWN: Without specific scientific evidence provided, it is difficult to confirm whether 4-Hydroxyestradiol (4-OHE2) is a potent activator of Esrrb.\n3. UNKNOWN: The specific activity of Estetrol (E4) on Esrrb is not provided, so its ability to weakly activate Esrrb cannot be confirmed without additional context.\n4. TRUE: Selective estrogen receptor modulators (SERMs) can indeed bind to both Esrrb and estrogen receptor alpha (ERα) and can act as agonists or antagonists depending on the target tissue.\n5. TRUE: Phytoestrogens, such as isoflavones and lignans, can bind to estrogen receptors including Esrrb and modulate their activity.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17, also known as Zinc finger CCHC-type zinc finger protein 17, is a protein that plays a crucial role in the regulation of gene expression, particularly in the context of stem cells and development. It is a transcriptional repressor that is involved in the control of cell fate decisions, proliferation, and differentiation.\nZCCHC17 is a member of the CCHC-type zinc finger protein family, which are characterized by the presence of a conserved zinc finger domain that is involved in DNA binding and protein-protein interactions. The ZCCHC17 protein contains multiple zinc fingers, which are responsible for its ability to recognize and bind to specific DNA sequences.\nStudies have shown that ZCCHC17 plays a critical role in regulating the expression of genes involved in stem cell self-renewal and differentiation, particularly in the context of embryonic development. It has been shown to repress the expression of genes involved in cell fate determination and to promote the maintenance of stem cell self-renewal.\nIn addition to its role in stem cell biology, ZCCHC17 has also been implicated in the development and progression of cancer. It has been shown to be overexpressed in a variety of cancer types, including breast, lung, and colon cancer, and to promote the growth and proliferation of cancer cells.\nOverall, the role of ZCCHC17 is to regulate the expression of genes involved in cell fate decisions, proliferation, and differentiation, particularly in the context of stem cells and development. Its dysregulation has been implicated in a variety of diseases, including cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is involved in the regulation of gene expression, particularly in stem cells and development.\n2. ZCCHC17 functions as a transcriptional repressor controlling cell fate decisions, proliferation, and differentiation.\n3. The ZCCHC17 protein is a member of the CCHC-type zinc finger protein family and contains multiple zinc fingers for DNA binding.\n4. ZCCHC17 regulates the expression of genes involved in stem cell self-renewal and differentiation, especially during embryonic development.\n5. ZCCHC17 has been found to be overexpressed in various cancer types and is associated with the promotion of cancer cell growth and proliferation.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is involved in the regulation of gene expression, particularly in stem cells and development.",
      "ZCCHC17 functions as a transcriptional repressor controlling cell fate decisions, proliferation, and differentiation.",
      "The ZCCHC17 protein is a member of the CCHC-type zinc finger protein family and contains multiple zinc fingers for DNA binding.",
      "ZCCHC17 regulates the expression of genes involved in stem cell self-renewal and differentiation, especially during embryonic development.",
      "ZCCHC17 has been found to be overexpressed in various cancer types and is associated with the promotion of cancer cell growth and proliferation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about ZCCHC17 involve specific scientific information that would require access to current and reliable scientific resources to verify. Without such resources or a specific context confirming these statements, it is not possible to accurately determine the truthfulness of statements 1, 2, 4, and 5. However, statement 3 is generally true for proteins that are members of the CCHC-type zinc finger protein family, as they characteristically contain zinc finger motifs that are involved in DNA binding.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is a large protein structure that spans the nuclear envelope and regulates the transport of molecules between the nucleus and the cytoplasm in eukaryotic cells. The proteins that form the nuclear pore basket in human cells include:\n1. Nucleoporin 1 (Nup1): This protein is one of the most abundant components of the NPC and forms the central channel of the structure.\n2. Nucleoporin 2 (Nup2): This protein is also a major component of the NPC and helps to regulate the transport of molecules across the nuclear envelope.\n3. Nucleoporin 3 (Nup3): This protein is involved in the assembly and maintenance of the NPC and helps to regulate the transport of molecules between the nucleus and the cytoplasm.\n4. Nucleoporin 4 (Nup4): This protein is a minor component of the NPC, but plays a critical role in regulating the transport of certain molecules.\n5. Nucleoporin 5 (Nup5): This protein is also a minor component of the NPC and helps to regulate the transport of molecules between the nucleus and the cytoplasm.\n6. Nucleoporin 6 (Nup6): This protein is involved in the assembly and maintenance of the NPC and helps to regulate the transport of molecules between the nucleus and the cytoplasm.\n7. Nucleoporin 7 (Nup7): This protein is a minor component of the NPC and helps to regulate the transport of certain molecules.\n8. Nucleoporin 8 (Nup8): This protein is involved in the assembly and maintenance of the NPC and helps to regulate the transport of molecules between the nucleus and the cytoplasm.\n9. Nucleoporin 9 (Nup9): This protein is a minor component of the NPC and helps to regulate the transport of certain molecules.\n10. Nucleoporin 10 (Nup10): This protein is involved in the assembly and maintenance of the NPC and helps to regulate the transport of molecules between the",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore complex (NPC) is a large protein structure that spans the nuclear envelope in eukaryotic cells.\n2. Nucleoporin 1 (Nup1) is one of the most abundant components of the NPC and forms the central channel of the structure.\n3. Nucleoporin 2 (Nup2) is a major component of the NPC and helps to regulate the transport of molecules across the nuclear envelope.\n4. Nucleoporin 3 (Nup3) is involved in the assembly and maintenance of the NPC.\n5. Nucleoporin 4 (Nup4) plays a critical role in regulating the transport of certain molecules within the NPC.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore complex (NPC) is a large protein structure that spans the nuclear envelope in eukaryotic cells.",
      "Nucleoporin 1 (Nup1) is one of the most abundant components of the NPC and forms the central channel of the structure.",
      "Nucleoporin 2 (Nup2) is a major component of the NPC and helps to regulate the transport of molecules across the nuclear envelope.",
      "Nucleoporin 3 (Nup3) is involved in the assembly and maintenance of the NPC.",
      "Nucleoporin 4 (Nup4) plays a critical role in regulating the transport of certain molecules within the NPC."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no specific nucleoporin known as Nucleoporin 1 (Nup1) that is identified as one of the most abundant components of the NPC forming the central channel. The central channel is formed by multiple nucleoporins, and the nomenclature for nucleoporins typically involves numbers, but not in a simple sequential order like Nup1, Nup2, etc.\n3. UNKNOWN: Without specific scientific literature or context, it's unclear whether a Nucleoporin 2 (Nup2) exists and what its role might be. Nucleoporins are indeed major components of the NPC and regulate transport across the nuclear envelope, but the statement is too vague to be verified as true or false.\n4. UNKNOWN: Similar to the previous statement, without specific context, it's unclear whether a Nucleoporin 3 (Nup3) exists and what its role might be. While nucleoporins are involved in the assembly and maintenance of the NPC, the specific role of a Nup3 cannot be confirmed without additional information.\n5. UNKNOWN: As with the other nucleoporin statements, without specific context, it's unclear whether a Nucleoporin 4 (Nup4) exists and what its role might be. Nucleoporins do play roles in regulating transport within the NPC, but the statement is too vague to be verified as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a topoisomerase II inhibitor. Specifically, it is a topoisomerase II alpha (Topo IIα) inhibitor, which means it selectively binds to and inhibits the activity of the Topo IIα enzyme. Topo IIα is involved in the replication and repair of DNA, and is overexpressed in many types of cancer, including breast, ovarian, and lung cancers. By inhibiting Topo IIα, gepotidacin can slow down or stop the growth of cancer cells, making it a potential anticancer drug.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase II inhibitor.\n2. It specifically inhibits the topoisomerase II alpha (Topo IIα) enzyme.\n3. Topo IIα is involved in the replication and repair of DNA.\n4. Topo IIα is overexpressed in many types of cancer, including breast, ovarian, and lung cancers.\n5. By inhibiting Topo IIα, gepotidacin can slow down or stop the growth of cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase II inhibitor.",
      "It specifically inhibits the topoisomerase II alpha (Topo IIα) enzyme.",
      "Topo IIα is involved in the replication and repair of DNA.",
      "Topo IIα is overexpressed in many types of cancer, including breast, ovarian, and lung cancers.",
      "By inhibiting Topo IIα, gepotidacin can slow down or stop the growth of cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is not a topoisomerase II inhibitor; it is a novel bacterial topoisomerase inhibitor that targets bacterial type II topoisomerases, specifically DNA gyrase and topoisomerase IV, and is being developed for the treatment of bacterial infections.\n2. FALSE [correction]: Gepotidacin does not specifically inhibit the topoisomerase II alpha (Topo IIα) enzyme in humans; it targets bacterial DNA gyrase and topoisomerase IV.\n3. TRUE: Topo IIα is indeed involved in the replication and repair of DNA in human cells.\n4. TRUE: Topo IIα is overexpressed in many types of cancer, including breast, ovarian, and lung cancers.\n5. FALSE [correction]: By inhibiting bacterial DNA gyrase and topoisomerase IV, gepotidacin is intended to treat bacterial infections, not to slow down or stop the growth of cancer cells. The statement incorrectly attributes the effect on cancer cells to gepotidacin, which is not designed for cancer treatment.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Single-Cell Protein Wash) is a technique used in single-cell analysis to isolate and analyze the protein content of individual cells. It is a modification of the traditional Protein Wash (PW) method, which was developed for bulk tissue analysis.\nIn Canvas SPW, cells are first isolated using microfluidics or other methods, and then subjected to a series of washing steps to remove any excess RNA or other contaminants. The cells are then lysed, and the protein content is extracted and concentrated using a series of centrifugation steps.\nThe protein extract is then mixed with a buffer that contains a fluorescent dye, such as SYBR Green, which intercalates into the protein structure and emits a fluorescent signal that can be detected using a microplate reader. The amount of protein in each cell is proportional to the intensity of the fluorescent signal, allowing researchers to quantify the protein content of individual cells.\nCanvas SPW offers several advantages over traditional PW methods, including improved resolution, increased sensitivity, and reduced sample consumption. It can be used to analyze a wide range of cell types, including rare and precious cells, and can be applied to a variety of biological samples, including blood, tissue, and cell cultures.\nIn summary, Canvas SPW is a powerful tool for single-cell protein analysis that allows researchers to quantify the protein content of individual cells with high resolution and sensitivity. It has a wide range of applications in biology and medicine, including the study of cellular heterogeneity, cell signaling, and drug response.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW (Single-Cell Protein Wash) is a technique used for isolating and analyzing the protein content of individual cells.\n2. The traditional Protein Wash (PW) method was developed for bulk tissue analysis.\n3. In Canvas SPW, cells are isolated and then subjected to a series of washing steps to remove excess RNA or other contaminants.\n4. The protein content in Canvas SPW is extracted and concentrated using centrifugation steps.\n5. Canvas SPW uses a fluorescent dye, such as SYBR Green, to emit a fluorescent signal that can be detected using a microplate reader for quantifying protein content.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW (Single-Cell Protein Wash) is a technique used for isolating and analyzing the protein content of individual cells.",
      "The traditional Protein Wash (PW) method was developed for bulk tissue analysis.",
      "In Canvas SPW, cells are isolated and then subjected to a series of washing steps to remove excess RNA or other contaminants.",
      "The protein content in Canvas SPW is extracted and concentrated using centrifugation steps.",
      "Canvas SPW uses a fluorescent dye, such as SYBR Green, to emit a fluorescent signal that can be detected using a microplate reader for quantifying protein content."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The term \"Canvas SPW\" does not correspond to a widely recognized technique in cell biology or biochemistry. It is possible that \"Canvas SPW\" is a term from a specific study or a proprietary method not widely known. Without additional context, the truth of this statement cannot be determined.\n\n2. TRUE: The traditional Protein Wash (PW) method is indeed developed for bulk tissue analysis, where proteins are extracted from a large number of cells or from tissue samples to analyze their collective protein content.\n\n3. UNKNOWN: While the description of isolating cells and washing them to remove contaminants is a plausible step in single-cell protein analysis, the specific term \"Canvas SPW\" is not recognized, and without further context, the accuracy of this statement cannot be confirmed.\n\n4. UNKNOWN: Centrifugation is a common technique used to extract and concentrate proteins in various biochemical methods. However, without specific information about the \"Canvas SPW\" technique, it is not possible to confirm if this statement is true or false.\n\n5. UNKNOWN: Fluorescent dyes like SYBR Green are commonly used to detect nucleic acids, not proteins. They bind to DNA and, upon excitation with light, emit fluorescence that can be measured. However, for protein quantification, other dyes such as Coomassie Brilliant Blue or fluorescent dyes that specifically bind to proteins are typically used. Without additional context about the \"Canvas SPW\" method, the use of SYBR Green for protein quantification in this context cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "STING (Stimulator of Interferon Genes) is a protein that plays a crucial role in the innate immune response to viral infections. STING agonists are molecules that activate the STING protein and trigger an immune response. Here are some examples of STING agonists:\n1. Poly(I:C): Poly(I:C) is a synthetic analog of viral double-stranded RNA that activates STING and triggers an interferon response.\n2. CpG DNA: CpG DNA is a type of bacterial DNA that contains the dinucleotide CpG, which is highly conserved in bacterial DNA but rare in mammalian DNA. CpG DNA activates STING and triggers an immune response.\n3. DNA-based vaccines: Some DNA-based vaccines, such as the HPV vaccine, contain STING agonists that activate the immune system and trigger an immune response against specific pathogens.\n4. Small molecule agonists: Some small molecules, such as cyclic dinucleotides (CDNs), have been identified as STING agonists and can activate the immune response through the STING pathway.\n5. Peptidoglycan (PGN): PGN is a component of bacterial cell walls that activates STING and triggers an immune response.\n6. Lipid II: Lipid II is a component of the bacterial cell wall that activates STING and triggers an immune response.\n7. Flagellin: Flagellin is a protein component of bacterial flagella that activates STING and triggers an immune response.\n8. Virus-like particles (VLPs): VLPs are non-infectious particles that mimic the structure of a virus and can activate STING and trigger an immune response.\n9. Toll-like receptor (TLR) agonists: Some TLR agonists, such as lipopolysaccharide (LPS), can activate STING and trigger an immune response.\n10. Imidazoquinoline compounds: Some imidazoquinoline compounds, such as imiquimod, have been",
    "llama-2-7b-chat-hf_fact_raw": "1. Poly(I:C) is a synthetic analog of viral double-stranded RNA that activates STING.\n2. CpG DNA contains the dinucleotide CpG and activates STING.\n3. Some DNA-based vaccines contain STING agonists that activate the immune system.\n4. Cyclic dinucleotides (CDNs) are small molecules identified as STING agonists.\n5. Peptidoglycan (PGN) is a component of bacterial cell walls that activates STING.",
    "llama-2-7b-chat-hf_fact": [
      "Poly(I:C) is a synthetic analog of viral double-stranded RNA that activates STING.",
      "CpG DNA contains the dinucleotide CpG and activates STING.",
      "Some DNA-based vaccines contain STING agonists that activate the immune system.",
      "Cyclic dinucleotides (CDNs) are small molecules identified as STING agonists.",
      "Peptidoglycan (PGN) is a component of bacterial cell walls that activates STING."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Poly(I:C) is a synthetic analog of viral double-stranded RNA that activates immune responses typically through pattern recognition receptors like TLR3, MDA5, and RIG-I, not STING, which is primarily activated by cyclic dinucleotides.\n2. FALSE [correction]: CpG DNA contains the dinucleotide CpG and is known to activate immune responses through TLR9, not STING.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Peptidoglycan (PGN) is a component of bacterial cell walls that is recognized by pattern recognition receptors like NOD-like receptors in the immune system, not by STING.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Sparse Linear Inverse Covariance Estimation with CAGG) is a computational method used to estimate the inverse of the covariance matrix of a set of data, particularly in the context of high-dimensional data. It is a type of non-parametric method, meaning it does not make any assumptions about the functional form of the covariance matrix.\nThe SLIC-CAGE algorithm was developed as an improvement over traditional methods of estimating the inverse of the covariance matrix, such as the sample covariance matrix, which can be sensitive to outliers and may not provide accurate estimates for high-dimensional data.\nThe SLIC-CAGE algorithm works by first transforming the data into a lower-dimensional space using a sparse representation, such as the CAGG (Common Ancestral Granger Graph) representation. This transformation reduces the dimensionality of the data while preserving the pairwise covariance structure.\nOnce the data has been transformed, the SLIC-CAGE algorithm estimates the inverse of the covariance matrix using a sparse linear regression model. This model is fit to the transformed data, and the resulting estimate of the inverse of the covariance matrix is obtained by solving a linear system of equations.\nOne of the key advantages of the SLIC-CAGE algorithm is that it can handle high-dimensional data with a small number of observations, which is a common problem in many applications. It is also robust to outliers and can provide accurate estimates even when the data is noisy or corrupted with errors.\nSLIC-CAGE has been applied in a variety of fields, including finance, biology, and engineering, and has been shown to be effective in estimating the inverse of the covariance matrix in these contexts. It is a powerful tool for analyzing and modeling complex data sets, and can be used for a wide range of applications, such as portfolio optimization, gene expression analysis, and signal processing.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is used to estimate the inverse of the covariance matrix of a set of data, especially in high-dimensional contexts.\n2. The SLIC-CAGE algorithm is a non-parametric method, which means it does not assume a specific functional form for the covariance matrix.\n3. The algorithm involves transforming data into a lower-dimensional space using a sparse representation like CAGG (Common Ancestral Granger Graph).\n4. SLIC-CAGE estimates the inverse covariance matrix using a sparse linear regression model and solving a linear system of equations.\n5. The SLIC-CAGE method has been applied in various fields such as finance, biology, and engineering.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is used to estimate the inverse of the covariance matrix of a set of data, especially in high-dimensional contexts.",
      "The SLIC-CAGE algorithm is a non-parametric method, which means it does not assume a specific functional form for the covariance matrix.",
      "The algorithm involves transforming data into a lower-dimensional space using a sparse representation like CAGG (Common Ancestral Granger Graph).",
      "SLIC-CAGE estimates the inverse covariance matrix using a sparse linear regression model and solving a linear system of equations.",
      "The SLIC-CAGE method has been applied in various fields such as finance, biology, and engineering."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The algorithm involves transforming data into a lower-dimensional space using a sparse representation, but the correct term is CAGE (Covariance Assisted Graph Estimation), not CAGG.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (LEM-domain-containing protein 3) is a protein that plays a crucial role in various cellular processes, including transcriptional regulation, RNA metabolism, and cell signaling. Here are some of the key roles of LEM-3:\n1. Transcriptional regulation: LEM-3 is a transcriptional coactivator that plays a role in the regulation of gene expression by interacting with transcription factors and modulating their activity.\n2. RNA metabolism: LEM-3 has been shown to be involved in the processing and stability of RNA molecules, including miRNAs and mRNAs. It can also affect the localization and stability of RNA-binding proteins.\n3. Cell signaling: LEM-3 can interact with and modulate the activity of various signaling proteins, including the NF-κB transcription factor, which is involved in inflammation and immune responses.\n4. Cell adhesion and migration: LEM-3 has been implicated in cell adhesion and migration, with studies suggesting that it may play a role in the regulation of cell spreading, migration, and invasion.\n5. Cancer: LEM-3 has been shown to be overexpressed in various types of cancer, including breast, lung, and colon cancer. Overexpression of LEM-3 has been linked to cancer progression and poor prognosis.\n6. Neurodegeneration: LEM-3 has been implicated in the regulation of neurodegeneration, with studies suggesting that it may play a role in the protection of neurons against oxidative stress and neurodegenerative diseases such as Alzheimer's disease.\nIn summary, LEM-3 is a multifunctional protein that plays a complex role in various cellular processes, including transcriptional regulation, RNA metabolism, cell signaling, cell adhesion and migration, cancer, and neurodegeneration. Its dysregulation has been implicated in various diseases, highlighting its potential as a therapeutic target for the treatment of these diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in transcriptional regulation by interacting with transcription factors and modulating their activity.\n2. LEM-3 is implicated in the processing and stability of RNA molecules, including miRNAs and mRNAs.\n3. LEM-3 can modulate the activity of various signaling proteins, including the NF-κB transcription factor.\n4. LEM-3 has been implicated in cell adhesion and migration, potentially affecting cell spreading, migration, and invasion.\n5. LEM-3 has been shown to be overexpressed in various types of cancer, such as breast, lung, and colon cancer, and its overexpression has been linked to cancer progression and poor prognosis.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in transcriptional regulation by interacting with transcription factors and modulating their activity.",
      "LEM-3 is implicated in the processing and stability of RNA molecules, including miRNAs and mRNAs.",
      "LEM-3 can modulate the activity of various signaling proteins, including the NF-κB transcription factor.",
      "LEM-3 has been implicated in cell adhesion and migration, potentially affecting cell spreading, migration, and invasion.",
      "LEM-3 has been shown to be overexpressed in various types of cancer, such as breast, lung, and colon cancer, and its overexpression has been linked to cancer progression and poor prognosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided pertain to the functions and implications of LEM-3, which is likely a specific protein or gene. Without specific scientific context or references, it is not possible to accurately determine the truthfulness of these statements. They require specialized knowledge in molecular biology, particularly in the study of LEM-3, which is not common knowledge and would need to be verified with scientific literature.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "TmVar is a tool for visualizing and exploring time-series data. Here are some of the releases of TmVar:\n1. TmVar 1.0: This was the initial release of TmVar, which provided a basic interface for visualizing and exploring time-series data.\n2. TmVar 1.2: This release added several new features, including the ability to import data from external sources, such as CSV files, and the ability to create custom visualizations using the TmVar API.\n3. TmVar 2.0: This major release introduced a completely revised user interface, making it easier to use and more intuitive for users. It also added several new features, including the ability to create interactive visualizations and to share them with others.\n4. TmVar 2.2: This release improved the performance of TmVar, making it faster and more responsive when working with large datasets. It also added several new visualization types, including a new type of scatter plot and a new type of bar chart.\n5. TmVar 3.0: This release introduced a new, more powerful architecture for TmVar, making it easier to add new features and to customize the tool for specific use cases. It also added several new features, including the ability to create custom data models and to use TmVar with other tools and platforms.\n6. TmVar 3.2: This release improved the performance of TmVar, making it faster and more responsive when working with large datasets. It also added several new visualization types, including a new type of heatmap and a new type of tree map.\n7. TmVar 4.0: This release introduced a completely revised user interface, making it easier to use and more intuitive for users. It also added several new features, including the ability to create interactive visualizations and to share them with others.\n8. TmVar 4.2: This release improved the performance of TmVar, making it faster and more responsive when working with large datasets. It also added several new visualization types, including a new type of scatter plot and a new type of bar chart.\n9. TmVar 5.0: This release introduced a new, more powerful architecture for TmVar, making it easier to add new features and to customize the tool for specific use cases.",
    "llama-2-7b-chat-hf_fact_raw": "1. TmVar 1.0 was the initial release of TmVar, which provided a basic interface for visualizing and exploring time-series data.\n2. TmVar 2.0 introduced a completely revised user interface and the ability to create interactive visualizations.\n3. TmVar 3.0 introduced a new, more powerful architecture for TmVar.\n4. TmVar 4.0 introduced a completely revised user interface and added new features for creating interactive visualizations.\n5. TmVar 5.0 introduced a new, more powerful architecture for TmVar.",
    "llama-2-7b-chat-hf_fact": [
      "TmVar 1.0 was the initial release of TmVar, which provided a basic interface for visualizing and exploring time-series data.",
      "TmVar 2.0 introduced a completely revised user interface and the ability to create interactive visualizations.",
      "TmVar 3.0 introduced a new, more powerful architecture for TmVar.",
      "TmVar 4.0 introduced a completely revised user interface and added new features for creating interactive visualizations.",
      "TmVar 5.0 introduced a new, more powerful architecture for TmVar."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are about the version history and features of a software named TmVar. Without specific knowledge about the software's release notes or version history, it is not possible to verify the accuracy of these statements. Therefore, the truthfulness of these statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There are several databases that contain information on somatic mutations in normal cells. Here are a few examples:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. While the primary focus of TCGA is on cancer, the project also includes analysis of normal tissue samples, which can be used to identify somatic mutations in normal cells.\n2. The 1000 Genomes Project: The 1000 Genomes Project is a large-scale effort to catalogue the genetic variation in a diverse set of individuals. While the project primarily focuses on coding regions of the genome, it also includes analysis of non-coding regions, such as introns and intergenic regions, which can be used to identify somatic mutations in normal cells.\n3. The Genome Aggregation Database (GAD): GAD is a database that aggregates genomic data from a variety of sources, including TCGA and the 1000 Genomes Project. It includes information on both coding and non-coding regions of the genome, and can be used to identify somatic mutations in normal cells.\n4. The ClinVar database: ClinVar is a database that catalogues genetic variants, including somatic mutations, that have been associated with human disease. While the primary focus of ClinVar is on disease-associated variants, it also includes information on somatic mutations in normal cells.\n5. The Mutational Load database: Mutational Load is a database that catalogues somatic mutations in normal tissues, including those found in blood and saliva samples. The database includes information on the frequency and distribution of mutations in different tissues and cell types.\n6. The Cancer Cell Line Encyclopedia (CCLE): CCLE is a database that catalogues the genomic and transcriptomic information of a large collection of cancer cell lines. While the primary focus of CCLE is on cancer cells, it also includes information on normal cell lines, which can be used to identify somatic mutations in normal cells.\n7. The National Center for Biotechnology Information's (NCBI) GenBank: GenBank is",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n2. The 1000 Genomes Project is a large-scale effort to catalogue genetic variation in a diverse set of individuals.\n3. The Genome Aggregation Database (GAD) aggregates genomic data from various sources, including TCGA and the 1000 Genomes Project.\n4. The ClinVar database catalogues genetic variants, including somatic mutations, that have been associated with human disease.\n5. The Mutational Load database catalogues somatic mutations in normal tissues, including those found in blood and saliva samples.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The 1000 Genomes Project is a large-scale effort to catalogue genetic variation in a diverse set of individuals.",
      "The Genome Aggregation Database (GAD) aggregates genomic data from various sources, including TCGA and the 1000 Genomes Project.",
      "The ClinVar database catalogues genetic variants, including somatic mutations, that have been associated with human disease.",
      "The Mutational Load database catalogues somatic mutations in normal tissues, including those found in blood and saliva samples."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Genome Aggregation Database (gnomAD) aggregates genomic data from various sources, but it is not specifically known to aggregate data from TCGA and the 1000 Genomes Project. gnomAD aims to collect and aggregate data from a wide range of large-scale sequencing projects to provide a comprehensive resource to the scientific community.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available that have been implemented in Java. Here are a few examples:\n1. JGraphT: JGraphT is a Java library for graph theory that provides a simple and efficient way to create, manipulate, and analyze graphs. It supports a wide range of graph algorithms and is highly customizable.\n2. GraphCrunch: GraphCrunch is a Java library for graph processing that provides a simple and efficient way to perform graph computations. It supports a wide range of graph algorithms and can be used for a variety of applications, including social network analysis, recommendation systems, and fraud detection.\n3. GraphBLAS: GraphBLAS is a Java library for graph computing that provides a set of highly optimized graph kernels. It is designed to be used in conjunction with the Java Native Interface (JNI) and can be used to accelerate graph computations on CPUs and GPUs.\n4. JGraph: JGraph is a Java library for graph theory that provides a simple and efficient way to create, manipulate, and analyze graphs. It supports a wide range of graph algorithms and is highly customizable.\n5. GraphMol: GraphMol is a Java library for molecular graph analysis that provides a simple and efficient way to perform graph computations on molecular graphs. It supports a wide range of graph algorithms and can be used for a variety of applications, including drug discovery and materials science.\nThese libraries are widely used in various fields such as social network analysis, recommendation systems, fraud detection, drug discovery, and materials science.\nIt's worth noting that these libraries are not limited to graph kernel, they also provide other functionalities such as graph data structures, graph algorithms, and graph visualization.",
    "llama-2-7b-chat-hf_fact_raw": "1. JGraphT is a Java library for graph theory that includes a range of graph algorithms and customization options.\n2. GraphCrunch is a Java library for graph processing that can be applied to social network analysis, recommendation systems, and fraud detection.\n3. GraphBLAS is a Java library that offers optimized graph kernels and is designed to work with the Java Native Interface (JNI) for graph computations on CPUs and GPUs.\n4. JGraph is a Java library for graph theory that supports the creation, manipulation, and analysis of graphs with a variety of graph algorithms.\n5. GraphMol is a Java library for molecular graph analysis that is used in drug discovery and materials science.",
    "llama-2-7b-chat-hf_fact": [
      "JGraphT is a Java library for graph theory that includes a range of graph algorithms and customization options.",
      "GraphCrunch is a Java library for graph processing that can be applied to social network analysis, recommendation systems, and fraud detection.",
      "GraphBLAS is a Java library that offers optimized graph kernels and is designed to work with the Java Native Interface (JNI) for graph computations on CPUs and GPUs.",
      "JGraph is a Java library for graph theory that supports the creation, manipulation, and analysis of graphs with a variety of graph algorithms.",
      "GraphMol is a Java library for molecular graph analysis that is used in drug discovery and materials science."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GraphCrunch is not specifically a Java library. It is a software tool for graph-theoretic analysis of biological networks, but it is not limited to Java and can be used with other programming languages.\n3. FALSE [correction]: GraphBLAS is not a Java library. It is a specification for building graph algorithms in the language of linear algebra. Implementations of GraphBLAS can be used with various programming languages, and it is not designed specifically for Java or the Java Native Interface (JNI).\n4. TRUE\n5. FALSE [correction]: GraphMol is not a Java library. RDKit is a collection of cheminformatics and machine learning tools that includes GraphMol for molecular graph analysis, but RDKit is primarily implemented in C++ and Python, not Java.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "SHERLOCKv2 is a next-generation sequencing (NGS) platform that has been integrated with several advances to improve its performance and capabilities. The four main advances integrated into the SHERLOCKv2 platform are:\n1. Single-molecule real-time (SMRT) sequencing: SHERLOCKv2 uses SMRT sequencing technology, which allows for the direct visualization of individual DNA molecules during sequencing. This results in longer read lengths and higher accuracy compared to other NGS technologies.\n2. Parallel sequencing: SHERLOCKv2 enables parallel sequencing of multiple samples, allowing for faster turnaround times and increased throughput.\n3. Improved data analysis: SHERLOCKv2 includes advanced data analysis software that can handle large amounts of data generated by the platform. This software can perform tasks such as base calling, read trimming, and assembly, and can also be used to identify and correct errors in the data.\n4. Enhanced data visualization: SHERLOCKv2 includes a range of data visualization tools that can be used to explore and interpret the data generated by the platform. These tools can be used to visualize the sequencing data in 3D, identify patterns and anomalies, and compare data from different samples.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 uses Single-molecule real-time (SMRT) sequencing technology.\n2. SHERLOCKv2 allows for parallel sequencing of multiple samples.\n3. SHERLOCKv2 includes advanced data analysis software for tasks such as base calling, read trimming, and assembly.\n4. SHERLOCKv2 provides tools for enhanced data visualization, including the ability to visualize sequencing data in 3D.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 uses Single-molecule real-time (SMRT) sequencing technology.",
      "SHERLOCKv2 allows for parallel sequencing of multiple samples.",
      "SHERLOCKv2 includes advanced data analysis software for tasks such as base calling, read trimming, and assembly.",
      "SHERLOCKv2 provides tools for enhanced data visualization, including the ability to visualize sequencing data in 3D."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SHERLOCKv2 is not a sequencing technology; it is an acronym for Specific High-sensitivity Enzymatic Reporter unLOCKing version 2, which is a CRISPR-based diagnostic tool, not related to SMRT sequencing technology.\n2. TRUE: SHERLOCKv2, as a CRISPR-based diagnostic tool, allows for the detection of multiple targets, which can be considered a form of parallel analysis of multiple samples for different genetic sequences.\n3. FALSE [correction]: SHERLOCKv2 does not include advanced data analysis software for sequencing tasks such as base calling, read trimming, and assembly, as it is not a sequencing technology. It is a diagnostic tool that uses CRISPR technology for the detection of nucleic acid sequences.\n4. FALSE [correction]: SHERLOCKv2 does not provide tools for enhanced data visualization like the ability to visualize sequencing data in 3D, as it is not a sequencing platform but a diagnostic method based on CRISPR technology.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender algorithm is a heuristic search algorithm used in artificial intelligence and robotics to find the shortest path to a goal in a weighted graph or network. It was first introduced by John Laird in 1995. The algorithm is called \"Bartender\" because it is inspired by the way a bartender might recommend a drink to a customer based on their preferences.\nThe Bartender algorithm works by maintaining a set of \"favorite\" nodes in the graph, which are nodes that are closer to the goal than any other node in the set. The algorithm starts by selecting a node that is close to the goal and adding it to the set of favorite nodes. It then iteratively selects the next node from the set of favorite nodes and adds it to the set of favorite nodes if it is closer to the goal than any other node in the set. The algorithm continues to iterate until the goal node is reached or the set of favorite nodes is empty.\nThe key insight behind the Bartender algorithm is that the algorithm can use the set of favorite nodes to prune the search space and avoid exploring nodes that are unlikely to lead to the goal. By focusing on the nodes that are closest to the goal, the algorithm can reduce the number of nodes it needs to explore, making the search more efficient.\nThe Bartender algorithm has been shown to be effective in a variety of applications, including robotics, game playing, and natural language processing. It is particularly useful in situations where the search space is large and complex, and the algorithm needs to find a solution efficiently.\nHere is a high-level description of the Bartender algorithm:\n1. Initialize the set of favorite nodes to an empty set.\n2. Select the node that is closest to the goal from the set of nodes that have not been visited.\n3. Add the selected node to the set of favorite nodes.\n4. Iteratively select the next node from the set of favorite nodes and add it to the set of favorite nodes if it is closer to the goal than any other node in the set.\n5. Repeat step 4 until the goal node is reached or the set of favorite nodes is empty.\n6. When the goal node is reached, return the path from the starting node to the goal node.\nThe Bartender algorithm is a simple and efficient algorithm for finding the shortest path to a goal in a weighted graph or network. It is particularly useful in",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm is a heuristic search algorithm used in artificial intelligence and robotics.\n2. It was introduced by John Laird in 1995.\n3. The algorithm is designed to find the shortest path to a goal in a weighted graph or network.\n4. The Bartender algorithm maintains a set of \"favorite\" nodes, which are closer to the goal than any other node in the set.\n5. The algorithm has been applied in various fields including robotics, game playing, and natural language processing.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm is a heuristic search algorithm used in artificial intelligence and robotics.",
      "It was introduced by John Laird in 1995.",
      "The algorithm is designed to find the shortest path to a goal in a weighted graph or network.",
      "The Bartender algorithm maintains a set of \"favorite\" nodes, which are closer to the goal than any other node in the set.",
      "The algorithm has been applied in various fields including robotics, game playing, and natural language processing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There is no widely recognized heuristic search algorithm known as the \"Bartender algorithm\" in artificial intelligence and robotics. It's possible that this is a confusion with another algorithm or it might be a fictional or less-known algorithm not widely acknowledged in the field.\n2. FALSE [correction]: Since the \"Bartender algorithm\" is not a recognized algorithm in the field of artificial intelligence and robotics, it cannot be attributed to John Laird in 1995 or any other time.\n3. UNKNOWN: Without accurate information on the \"Bartender algorithm,\" it is not possible to confirm whether it is designed to find the shortest path in a weighted graph or network.\n4. UNKNOWN: Similarly, without proper information on the \"Bartender algorithm,\" we cannot confirm the details of how it operates, including whether it maintains a set of \"favorite\" nodes.\n5. UNKNOWN: As the \"Bartender algorithm\" is not established in the field, we cannot verify its applications in robotics, game playing, and natural language processing.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "There are several web-based pedigree editors available, including:\n1. Pedigree.io: This is a popular web-based tool that allows users to create and edit family trees. It offers a user-friendly interface and includes features such as automatic source citations and the ability to import data from other genealogy software.\n2. FamilySearch: This is a free online tool provided by the Church of Jesus Christ of Latter-day Saints. It allows users to create and edit family trees, as well as search for and connect with other researchers.\n3. MyHeritage: This is a commercial genealogy website that offers a web-based pedigree editor. It includes features such as automatic source citations, photo sharing, and the ability to connect with other researchers.\n4. Ancestry.com: This is a popular genealogy website that offers a web-based pedigree editor. It includes features such as automatic source citations, photo sharing, and the ability to connect with other researchers.\n5. GenoPro: This is a web-based genealogy software that allows users to create and edit family trees. It includes features such as automatic source citations, photo sharing, and the ability to connect with other researchers.\n6. Legacy Family Tree: This is a web-based genealogy software that allows users to create and edit family trees. It includes features such as automatic source citations, photo sharing, and the ability to connect with other researchers.\n7. FamilyTreeWebinars: This is a web-based platform that offers a variety of genealogy webinars and courses. It also includes a pedigree editor that allows users to create and edit family trees.\n8. GenealogyBank: This is a web-based genealogy research platform that includes a pedigree editor. It allows users to create and edit family trees, as well as search for and access historical records.\n9. Findmypast: This is a web-based genealogy research platform that includes a pedigree editor. It allows users to create and edit family trees, as well as search for and access historical records.\n10. BillionGraves: This is a web-based platform that allows users to create and edit family trees, as well as search for and access historical records. It also includes a",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree.io is a web-based tool designed for creating and editing family trees.\n2. FamilySearch is a free online tool provided by the Church of Jesus Christ of Latter-day Saints for creating and editing family trees.\n3. MyHeritage is a commercial genealogy website that offers a web-based pedigree editor.\n4. Ancestry.com is a genealogy website that provides a web-based pedigree editor.\n5. GenoPro is a web-based genealogy software that allows users to create and edit family trees.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree.io is a web-based tool designed for creating and editing family trees.",
      "FamilySearch is a free online tool provided by the Church of Jesus Christ of Latter-day Saints for creating and editing family trees.",
      "MyHeritage is a commercial genealogy website that offers a web-based pedigree editor.",
      "Ancestry.com is a genealogy website that provides a web-based pedigree editor.",
      "GenoPro is a web-based genealogy software that allows users to create and edit family trees."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: GenoPro is not a web-based genealogy software; it is a downloadable software application that allows users to create and edit family trees.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases available for spider-venom toxins, including:\n1. ToxinDB: This is a comprehensive database of toxins from various sources, including spider venom. It contains information on the structure, function, and pharmacology of toxins, as well as their potential therapeutic applications.\n2. Spider Toxin Database (SpTox): This database contains information on the venom peptides and proteins from various spider species, including their sequences, structures, and functional properties. It also provides information on the pharmacological activities of these toxins and their potential applications in medicine.\n3. Venom-DB: This is a comprehensive database of venom peptides and proteins from various sources, including spiders, snakes, and scorpions. It contains information on the structure, function, and pharmacology of these toxins, as well as their potential therapeutic applications.\n4. ToxinTDB: This is a database of toxins from various sources, including spider venom. It contains information on the structure, function, and pharmacology of toxins, as well as their potential therapeutic applications.\n5. Natural Products Database (NPDB): This database contains information on natural products, including spider-venom toxins, their structures, and their pharmacological activities. It also provides information on the sources of these compounds and their potential therapeutic applications.\n6. Toxin Ontology (TOX): This is a database of toxins from various sources, including spider venom. It contains information on the structure, function, and pharmacology of toxins, as well as their potential therapeutic applications.\n7. Spider Venom Toxin Database (SVTD): This database contains information on the venom peptides and proteins from various spider species, including their sequences, structures, and functional properties. It also provides information on the pharmacological activities of these toxins and their potential applications in medicine.\n8. Venom Peptide Database (VePDB): This database contains information on the venom peptides from various sources, including spider venom. It contains information on the",
    "llama-2-7b-chat-hf_fact_raw": "1. ToxinDB is a database that includes information on toxins from various sources, including spider venom.\n2. The Spider Toxin Database (SpTox) provides information on venom peptides and proteins from various spider species.\n3. Venom-DB is a comprehensive database of venom peptides and proteins from sources such as spiders, snakes, and scorpions.\n4. The Natural Products Database (NPDB) includes information on natural products like spider-venom toxins and their pharmacological activities.\n5. The Spider Venom Toxin Database (SVTD) contains information on venom peptides and proteins from various spider species, including their pharmacological activities.",
    "llama-2-7b-chat-hf_fact": [
      "ToxinDB is a database that includes information on toxins from various sources, including spider venom.",
      "The Spider Toxin Database (SpTox) provides information on venom peptides and proteins from various spider species.",
      "Venom-DB is a comprehensive database of venom peptides and proteins from sources such as spiders, snakes, and scorpions.",
      "The Natural Products Database (NPDB) includes information on natural products like spider-venom toxins and their pharmacological activities.",
      "The Spider Venom Toxin Database (SVTD) contains information on venom peptides and proteins from various spider species, including their pharmacological activities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are about specific databases that include information on toxins and venoms from various sources, including spiders. Without additional context, it's not possible to verify the existence or contents of the Natural Products Database (NPDB) or the Spider Venom Toxin Database (SVTD), hence the response \"UNKNOWN\" for statements 4 and 5.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "There is currently limited evidence to suggest that Axitinib, a tyrosine kinase inhibitor, prolongs survival in patients with pancreatic cancer.\nA phase II clinical trial published in the Journal of Clinical Oncology in 2018 found that Axitinib did not meet the primary endpoint of overall survival in patients with advanced pancreatic cancer who had progressed after previous treatment with gemcitabine. The study found that the median overall survival was 8.2 months in the Axitinib arm compared to 6.8 months in the placebo arm, which was not a statistically significant difference.\nAnother phase II clinical trial published in the Journal of Clinical Oncology in 2020 found that Axitinib plus chemotherapy (gemcitabine and nab-paclitaxel) improved overall survival in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) compared to chemotherapy alone. The median overall survival was 13.6 months in the Axitinib arm compared to 10.7 months in the chemotherapy alone arm.\nIt is important to note that these studies were small and had limited sample sizes, so more research is needed to confirm these findings and establish the efficacy of Axitinib in prolonging survival in pancreatic cancer patients. Additionally, Axitinib has been approved by the FDA for the treatment of advanced renal cell carcinoma, not pancreatic cancer.\nIn summary, while there is some evidence to suggest that Axitinib may have a potential role in the treatment of pancreatic cancer, more research is needed to confirm these findings and establish its efficacy in prolonging survival in these patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. A phase II clinical trial published in the Journal of Clinical Oncology in 2018 found that Axitinib did not meet the primary endpoint of overall survival in patients with advanced pancreatic cancer.\n2. In the 2018 study, the median overall survival was 8.2 months in the Axitinib arm compared to 6.8 months in the placebo arm.\n3. A phase II clinical trial published in the Journal of Clinical Oncology in 2020 found that Axitinib plus chemotherapy improved overall survival in patients with metastatic pancreatic ductal adenocarcinoma compared to chemotherapy alone.\n4. The median overall survival was 13.6 months in the Axitinib plus chemotherapy arm compared to 10.7 months in the chemotherapy alone arm, according to the 2020 study.\n5. Axitinib has been approved by the FDA for the treatment of advanced renal cell carcinoma, not pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "A phase II clinical trial published in the Journal of Clinical Oncology in 2018 found that Axitinib did not meet the primary endpoint of overall survival in patients with advanced pancreatic cancer.",
      "In the 2018 study, the median overall survival was 8.2 months in the Axitinib arm compared to 6.8 months in the placebo arm.",
      "A phase II clinical trial published in the Journal of Clinical Oncology in 2020 found that Axitinib plus chemotherapy improved overall survival in patients with metastatic pancreatic ductal adenocarcinoma compared to chemotherapy alone.",
      "The median overall survival was 13.6 months in the Axitinib plus chemotherapy arm compared to 10.7 months in the chemotherapy alone arm, according to the 2020 study.",
      "Axitinib has been approved by the FDA for the treatment of advanced renal cell carcinoma, not pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Microtubule-associated protein) regulates F-actin dynamics through its interaction with the F-actin-binding protein, cofilin.\nCofilin is a small actin-binding protein that is involved in the dynamics of F-actin filaments. It can depolymerize F-actin filaments by breaking the interactions between actin monomers, leading to the loss of F-actin mass. MLP can bind to cofilin and inhibit its actin-depolymerizing activity, thereby promoting the accumulation of F-actin filaments.\nThe interaction between MLP and cofilin is thought to be mediated by the MLP's ability to bind to the cofilin's actin-binding domain. This binding leads to a conformational change in cofilin that inhibits its actin-depolymerizing activity. As a result, F-actin filaments are stabilized, leading to the accumulation of F-actin mass.\nIn addition to regulating F-actin dynamics, MLP has been shown to play a role in regulating the organization of the actin cytoskeleton in cells. For example, MLP has been shown to promote the formation of actin bundles and filopodial structures, which are important for cell migration and invasion.\nOverall, the interaction between MLP and cofilin is an important mechanism by which MLP regulates F-actin dynamics and contributes to the organization of the actin cytoskeleton in cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP (Microtubule-associated protein) regulates F-actin dynamics through its interaction with the F-actin-binding protein, cofilin.\n2. Cofilin can depolymerize F-actin filaments by breaking the interactions between actin monomers.\n3. MLP can bind to cofilin and inhibit its actin-depolymerizing activity.\n4. The interaction between MLP and cofilin leads to a conformational change in cofilin that inhibits its actin-depolymerizing activity.\n5. MLP promotes the formation of actin bundles and filopodial structures, which are important for cell migration and invasion.",
    "llama-2-7b-chat-hf_fact": [
      "MLP (Microtubule-associated protein) regulates F-actin dynamics through its interaction with the F-actin-binding protein, cofilin.",
      "Cofilin can depolymerize F-actin filaments by breaking the interactions between actin monomers.",
      "MLP can bind to cofilin and inhibit its actin-depolymerizing activity.",
      "The interaction between MLP and cofilin leads to a conformational change in cofilin that inhibits its actin-depolymerizing activity.",
      "MLP promotes the formation of actin bundles and filopodial structures, which are important for cell migration and invasion."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement is specific to molecular biology, and without the proper context or reference, it's difficult to verify the role of MLP (Microtubule-associated protein) in regulating F-actin dynamics or its interaction with cofilin.\n2. TRUE: Cofilin is known to bind to F-actin filaments and can depolymerize them by severing the filaments and disassembling actin monomers at the minus end.\n3. UNKNOWN: The interaction between MLP and cofilin and the specific effect of MLP on cofilin's actin-depolymerizing activity would require specific scientific evidence or context to verify.\n4. UNKNOWN: Similar to statement 3, the effect of the interaction between MLP and cofilin on cofilin's conformation and activity would need to be supported by specific scientific studies or data.\n5. UNKNOWN: The role of MLP in promoting the formation of actin bundles and filopodial structures, as well as its importance for cell migration and invasion, would need to be confirmed with relevant biological research or literature.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "The human kinome contains approximately 100 pseudokinases.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human kinome contains approximately 100 pseudokinases.",
    "llama-2-7b-chat-hf_fact": [
      "The human kinome contains approximately 100 pseudokinases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "ApoE mimetics are compounds that mimic the structure and function of apolipoprotein E (apoE), a protein that plays a crucial role in lipid metabolism and inflammation. Here are three examples of apoE mimetics:\n1. ApoEMimetic-101: This is a small molecule apoE mimetic that has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of non-alcoholic fatty liver disease (NAFLD). ApoEMimetic-101 works by mimicking the structure and function of apoE, which is involved in the transport of cholesterol and other lipids in the bloodstream.\n2. AZD-7207: This is a small molecule apoE mimetic that has been developed as a potential treatment for atherosclerosis and other cardiovascular diseases. AZD-7207 has been shown to reduce inflammation and improve endothelial function in animal models of atherosclerosis.\n3. GS-99730: This is a small molecule apoE mimetic that has been shown to reduce inflammation and improve insulin sensitivity in animal models of NAFLD. GS-99730 works by mimicking the structure and function of apoE, which is involved in the transport of cholesterol and other lipids in the bloodstream.\nIt's worth noting that these are just a few examples of apoE mimetics, and there are many other compounds that have been developed as potential treatments for various diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoEMimetic-101 is a small molecule apoE mimetic that has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of non-alcoholic fatty liver disease (NAFLD).\n2. AZD-7207 is a small molecule apoE mimetic developed as a potential treatment for atherosclerosis and other cardiovascular diseases.\n3. AZD-7207 has been shown to reduce inflammation and improve endothelial function in animal models of atherosclerosis.\n4. GS-99730 is a small molecule apoE mimetic that has been shown to reduce inflammation and improve insulin sensitivity in animal models of NAFLD.\n5. ApoE mimetics are compounds that mimic the structure and function of apolipoprotein E (apoE), which is involved in lipid metabolism and inflammation.",
    "llama-2-7b-chat-hf_fact": [
      "ApoEMimetic-101 is a small molecule apoE mimetic that has been shown to reduce liver inflammation and improve insulin sensitivity in animal models of non-alcoholic fatty liver disease (NAFLD).",
      "AZD-7207 is a small molecule apoE mimetic developed as a potential treatment for atherosclerosis and other cardiovascular diseases.",
      "AZD-7207 has been shown to reduce inflammation and improve endothelial function in animal models of atherosclerosis.",
      "GS-99730 is a small molecule apoE mimetic that has been shown to reduce inflammation and improve insulin sensitivity in animal models of NAFLD.",
      "ApoE mimetics are compounds that mimic the structure and function of apolipoprotein E (apoE), which is involved in lipid metabolism and inflammation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe statements about ApoEMimetic-101, AZD-7207, and GS-99730 are specific claims about the effects of these compounds in animal models. Without access to the specific research studies or data, it is not possible to verify these claims. Therefore, the truthfulness of statements 1, 2, 3, and 4 cannot be determined from the information provided.\n\nStatement 5 is a general description of apoE mimetics, which is accurate. ApoE mimetics are indeed designed to mimic the structure and function of apolipoprotein E, a protein that plays a key role in lipid metabolism and has anti-inflammatory properties.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (SAM and HD-like protein 1) is an enzyme that plays a crucial role in regulating the innate immune response to viral infections. It is a deacetylase that targets and deacetylates the histone H3 lysine 9 (H3K9) residue, leading to the repression of viral gene expression.\nSex differences in SAMHD1 activity have been observed in various studies. Here are some of the key findings:\n1. Expression levels: SAMHD1 expression levels are generally higher in females than in males, particularly in the brain and other tissues. This may contribute to the observed sex differences in SAMHD1 activity.\n2. Deacetylase activity: Studies have shown that SAMHD1 has higher deacetylase activity in females than in males, which may also contribute to the observed sex differences in its activity.\n3. Viral infection: During viral infection, SAMHD1 activity is upregulated in females compared to males. This is thought to be due to the higher expression levels of SAMHD1 in females, which leads to increased deacetylase activity and a stronger innate immune response.\n4. HIV-1 infection: In HIV-1-infected individuals, SAMHD1 activity is higher in females than in males, which may contribute to the observed differences in the progression of the disease between the sexes.\n5. Chronic HBV infection: In chronic hepatitis B virus (HBV) infection, SAMHD1 activity is higher in females than in males, which may contribute to the observed differences in the progression of the disease between the sexes.\n6. Autoimmune diseases: Sex differences in SAMHD1 activity have also been observed in autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. In these diseases, SAMHD1 activity is higher in females than in males, which may contribute to the observed sex differences in disease severity and progression.\nIn summary, sex differences in SAMHD1 activity have been observed in various studies, with higher activity in females compared to males. These differences may contribute to the observed sex differences in the innate immune response to viral infe",
    "llama-2-7b-chat-hf_fact_raw": "1. SAMHD1 expression levels are generally higher in females than in males, particularly in the brain and other tissues.\n2. SAMHD1 has higher deacetylase activity in females than in males.\n3. During viral infection, SAMHD1 activity is upregulated in females compared to males.\n4. In HIV-1-infected individuals, SAMHD1 activity is higher in females than in males.\n5. In chronic hepatitis B virus (HBV) infection, SAMHD1 activity is higher in females than in males.",
    "llama-2-7b-chat-hf_fact": [
      "SAMHD1 expression levels are generally higher in females than in males, particularly in the brain and other tissues.",
      "SAMHD1 has higher deacetylase activity in females than in males.",
      "During viral infection, SAMHD1 activity is upregulated in females compared to males.",
      "In HIV-1-infected individuals, SAMHD1 activity is higher in females than in males.",
      "In chronic hepatitis B virus (HBV) infection, SAMHD1 activity is higher in females than in males."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: SAMHD1 does not have deacetylase activity; it is known for its deoxynucleoside triphosphate triphosphohydrolase activity, which can degrade deoxynucleoside triphosphates (dNTPs) and restrict the availability of these nucleotides for viral DNA synthesis.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding SAMHD1 expression and activity levels in females versus males, and its specific response to various viral infections, would require specific scientific evidence to confirm. Without the context of the passage or access to relevant studies, it is not possible to accurately determine the truthfulness of these statements. The correction for statement 2 is based on the known enzymatic function of SAMHD1.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Yes, RUNX2 (Runt-related transcription factor 2) has been shown to inhibit astrocyte differentiation.\nAstrocytes are a type of glial cell that play a crucial role in the central nervous system (CNS), and their differentiation is tightly regulated during brain development. RUNX2 is a transcription factor that has been implicated in the regulation of astrocyte differentiation.\nStudies have shown that RUNX2 can repress the expression of genes involved in astrocyte differentiation, such as GFAP (glial fibrillary acidic protein) and A2B5 (amyloid beta-peptide 2B5), and inhibit the process of astrocyte differentiation in vitro and in vivo.\nFor example, one study found that overexpression of RUNX2 in mouse neural progenitor cells inhibited their differentiation into astrocytes, as evidenced by decreased expression of GFAP and A2B5, and decreased ability to produce the astrocyte-specific marker, glial fibrillary acidic protein (GFAP) (1). Another study found that RUNX2 knockdown in human astrocytes led to increased expression of GFAP and A2B5, and increased astrocyte differentiation (2).\nThese findings suggest that RUNX2 plays a negative role in astrocyte differentiation, and may be involved in the regulation of astrocyte development and function in the CNS.\nReferences:\n1. Kim, J. et al. (2010). Runx2 inhibits astrocyte differentiation in neural progenitor cells. Developmental Dynamics, 239(10), 2470-2478.\n2. Li, X. et al. (2013). Runx2 regulates the expression of genes involved in astrocyte differentiation in human astrocytes. Molecular Brain Research, 121(1-2), 107-117.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 (Runt-related transcription factor 2) inhibits astrocyte differentiation.\n2. Astrocytes are a type of glial cell important in the central nervous system.\n3. RUNX2 represses the expression of genes involved in astrocyte differentiation, such as GFAP and A2B5.\n4. Overexpression of RUNX2 in mouse neural progenitor cells resulted in decreased expression of GFAP and A2B5 and inhibited their differentiation into astrocytes.\n5. Knockdown of RUNX2 in human astrocytes led to increased expression of GFAP and A2B5, and increased astrocyte differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 (Runt-related transcription factor 2) inhibits astrocyte differentiation.",
      "Astrocytes are a type of glial cell important in the central nervous system.",
      "RUNX2 represses the expression of genes involved in astrocyte differentiation, such as GFAP and A2B5.",
      "Overexpression of RUNX2 in mouse neural progenitor cells resulted in decreased expression of GFAP and A2B5 and inhibited their differentiation into astrocytes.",
      "Knockdown of RUNX2 in human astrocytes led to increased expression of GFAP and A2B5, and increased astrocyte differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the known roles of RUNX2 in inhibiting astrocyte differentiation by repressing the expression of genes such as GFAP and A2B5. Overexpression leading to decreased expression of these genes and inhibition of differentiation, as well as knockdown leading to increased expression and increased differentiation, are logical outcomes based on the role of RUNX2. However, without specific experimental data or a reference to validate these claims, the responses are based on the general understanding of RUNX2's function in the context provided.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "The Cobb-Stainsby excision arthroplasty is a surgical procedure that is typically performed on the knee joint. It is a type of arthroplasty, which means it involves replacing a damaged or arthritic joint with an artificial one. The procedure involves removing a portion of the bone on the inside of the knee, called the medial femoral condyle, and replacing it with a prosthetic implant. This is done to relieve pain and improve mobility in the knee joint. The Cobb-Stainsby excision arthroplasty is typically performed on the knee joint, specifically the medial compartment of the knee, which is the compartment on the inside of the knee.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.\n2. It involves replacing a damaged or arthritic joint with an artificial one.\n3. The procedure includes removing a portion of the bone called the medial femoral condyle.\n4. The medial femoral condyle is located on the inside of the knee.\n5. The goal of the procedure is to relieve pain and improve mobility in the knee joint.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.",
      "It involves replacing a damaged or arthritic joint with an artificial one.",
      "The procedure includes removing a portion of the bone called the medial femoral condyle.",
      "The medial femoral condyle is located on the inside of the knee.",
      "The goal of the procedure is to relieve pain and improve mobility in the knee joint."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the hip joint, not the knee joint.\n2. FALSE [correction]: It does not involve replacing the joint with an artificial one; instead, it involves the removal of the femoral head and neck and the interposition of soft tissues to create a pseudoarthrosis.\n3. FALSE [correction]: The procedure does not include removing a portion of the bone called the medial femoral condyle, as it is a hip procedure, not a knee procedure.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Yes, over-expression of GRHL2 (Growth Hormone-Releasing Hormone 2) has been shown to lead to Epithelial-to-Mesenchymal Transition (EMT). EMT is a process by which epithelial cells lose their cell-cell adhesion and acquire mesenchymal characteristics, such as increased migration and invasiveness, and is often associated with cancer progression.\nGRHL2 is a member of the Growth Hormone-Releasing Hormone (GHRH) family of peptide hormones, which play a key role in regulating growth hormone secretion and metabolism. In addition to its role in GH secretion, GRHL2 has been shown to have a variety of other biological functions, including the regulation of cell proliferation, differentiation, and survival.\nStudies have shown that GRHL2 over-expression is associated with EMT in various types of cancer, including breast, lung, and colon cancer. For example, one study found that GRHL2 over-expression in breast cancer cells led to increased migration and invasion, as well as a loss of epithelial markers and gain of mesenchymal markers. Another study found that GRHL2 over-expression in lung cancer cells led to EMT and increased tumor growth and metastasis.\nThe mechanisms by which GRHL2 over-expression leads to EMT are not fully understood, but it is thought to involve the activation of key transcription factors, such as ZEB1 and Snail, which are known to promote EMT. GRHL2 has been shown to interact with these transcription factors and enhance their activity, leading to the repression of epithelial genes and the activation of mesenchymal genes.\nOverall, the evidence suggests that GRHL2 over-expression is a key player in the process of EMT, and that targeting GRHL2 may be a promising strategy for the prevention and treatment of cancer metastasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Over-expression of GRHL2 has been shown to lead to Epithelial-to-Mesenchymal Transition (EMT).\n2. GRHL2 is a member of the Growth Hormone-Releasing Hormone (GHRH) family of peptide hormones.\n3. GRHL2 over-expression is associated with EMT in various types of cancer, including breast, lung, and colon cancer.\n4. A study found that GRHL2 over-expression in breast cancer cells led to increased migration and invasion, as well as a loss of epithelial markers and gain of mesenchymal markers.\n5. Another study indicated that GRHL2 over-expression in lung cancer cells resulted in EMT and increased tumor growth and metastasis.",
    "llama-2-7b-chat-hf_fact": [
      "Over-expression of GRHL2 has been shown to lead to Epithelial-to-Mesenchymal Transition (EMT).",
      "GRHL2 is a member of the Growth Hormone-Releasing Hormone (GHRH) family of peptide hormones.",
      "GRHL2 over-expression is associated with EMT in various types of cancer, including breast, lung, and colon cancer.",
      "A study found that GRHL2 over-expression in breast cancer cells led to increased migration and invasion, as well as a loss of epithelial markers and gain of mesenchymal markers.",
      "Another study indicated that GRHL2 over-expression in lung cancer cells resulted in EMT and increased tumor growth and metastasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GRHL2 is not a member of the Growth Hormone-Releasing Hormone (GHRH) family of peptide hormones. It is a transcription factor involved in the regulation of epithelial cell differentiation and has been implicated in cancer progression.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "T-UCRs (Transcribed Ultraconserved Regions) are a class of non-coding RNAs that have been implicated in various cancers, including lung cancer. Here are some T-UCRs that have been linked to lung cancer:\n1. T-UCR-1: T-UCR-1 is one of the most well-studied T-UCRs in lung cancer. It is overexpressed in many lung cancer cell lines and primary tumors, and its overexpression is associated with poor prognosis.\n2. T-UCR-2: T-UCR-2 is another T-UCR that has been implicated in lung cancer. It is overexpressed in lung cancer cell lines and primary tumors, and its overexpression is associated with aggressive tumor phenotypes.\n3. T-UCR-3: T-UCR-3 is a T-UCR that is overexpressed in lung cancer, particularly in adenocarcinoma subtype. Its overexpression is associated with poor prognosis and resistance to chemotherapy.\n4. T-UCR-4: T-UCR-4 is a T-UCR that is overexpressed in lung cancer, particularly in squamous cell carcinoma subtype. Its overexpression is associated with poor prognosis and aggressive tumor phenotypes.\n5. T-UCR-5: T-UCR-5 is a T-UCR that is overexpressed in lung cancer, particularly in adenocarcinoma subtype. Its overexpression is associated with poor prognosis and resistance to chemotherapy.\nThese T-UCRs are known to play a role in the development and progression of lung cancer by regulating various cellular processes, including cell proliferation, migration, and apoptosis. They may also play a role in the development of resistance to chemotherapy and radiation therapy.\nIt is important to note that the expression of these T-UCRs in lung cancer is complex and can vary depending on the subtype of lung cancer, the stage of disease, and the individual patient. Further research is needed to fully understand the role of these T-UCRs in lung cancer and to identify potential therapeutic targets for the treatment of this disease",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCR-1 is overexpressed in many lung cancer cell lines and primary tumors, and its overexpression is associated with poor prognosis.\n2. T-UCR-2 is overexpressed in lung cancer cell lines and primary tumors, and its overexpression is associated with aggressive tumor phenotypes.\n3. T-UCR-3 is overexpressed in lung cancer, particularly in the adenocarcinoma subtype, and is associated with poor prognosis and resistance to chemotherapy.\n4. T-UCR-4 is overexpressed in lung cancer, particularly in the squamous cell carcinoma subtype, and is associated with poor prognosis and aggressive tumor phenotypes.\n5. T-UCR-5 is overexpressed in lung cancer, particularly in the adenocarcinoma subtype, and is associated with poor prognosis and resistance to chemotherapy.",
    "llama-2-7b-chat-hf_fact": [
      "T-UCR-1 is overexpressed in many lung cancer cell lines and primary tumors, and its overexpression is associated with poor prognosis.",
      "T-UCR-2 is overexpressed in lung cancer cell lines and primary tumors, and its overexpression is associated with aggressive tumor phenotypes.",
      "T-UCR-3 is overexpressed in lung cancer, particularly in the adenocarcinoma subtype, and is associated with poor prognosis and resistance to chemotherapy.",
      "T-UCR-4 is overexpressed in lung cancer, particularly in the squamous cell carcinoma subtype, and is associated with poor prognosis and aggressive tumor phenotypes.",
      "T-UCR-5 is overexpressed in lung cancer, particularly in the adenocarcinoma subtype, and is associated with poor prognosis and resistance to chemotherapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided refer to T-UCR (Transcribed Ultra-Conserved Regions) and their expression in lung cancer. Without specific scientific research or data to reference, it is not possible to verify the accuracy of these statements. The role of T-UCRs in cancer is a topic of ongoing research, and their associations with prognosis, tumor phenotypes, and resistance to chemotherapy can vary depending on the specific T-UCR and the context of the study. Therefore, without additional context or sources, the truthfulness of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151 is an orphan G protein-coupled receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. The gene encoding GPR151 was first identified in the early 1990s, and since then, a significant amount of research has been conducted to understand its function and potential therapeutic applications. Here are some key findings about GPR151:\n1. Tissue distribution: GPR151 is expressed in a wide range of tissues, including the brain, heart, liver, and immune cells.\n2. Ligand binding: GPR151 has been shown to bind a variety of ligands, including fatty acids, retinoids, and steroids. However, the most well-studied ligand for GPR151 is the fatty acid 12-oxo-phytoderoxin (12-oxo-Ptx).\n3. Signal transduction: Activation of GPR151 triggers a G protein-mediated signaling cascade that leads to the activation of downstream effectors, such as adenylate cyclase and ion channels. This activation can lead to changes in intracellular calcium levels, cAMP levels, and other second messenger systems.\n4. Physiological functions: GPR151 has been implicated in a variety of physiological processes, including inflammation, immune response, and cardiovascular function. For example, GPR151 activation has been shown to reduce inflammation in models of arthritis and atherosclerosis.\n5. Disease associations: GPR151 has been implicated in a number of diseases, including cardiovascular disease, metabolic disorders, and cancer. For example, GPR151 has been shown to be overexpressed in certain types of cancer, and inhibition of GPR151 has been shown to inhibit tumor growth.\n6. Therapeutic potential: GPR151 has been identified as a potential target for the treatment of a variety of diseases, including cardiovascular disease, metabolic disorders, and cancer. For example, GPR151",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an orphan G protein-coupled receptor without a well-defined endogenous ligand or clear physiological function.\n2. The gene encoding GPR151 was first identified in the early 1990s.\n3. GPR151 is expressed in a range of tissues, including the brain, heart, liver, and immune cells.\n4. Activation of GPR151 triggers a G protein-mediated signaling cascade that can lead to changes in intracellular calcium levels and cAMP levels.\n5. GPR151 has been implicated in various physiological processes such as inflammation, immune response, and cardiovascular function.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an orphan G protein-coupled receptor without a well-defined endogenous ligand or clear physiological function.",
      "The gene encoding GPR151 was first identified in the early 1990s.",
      "GPR151 is expressed in a range of tissues, including the brain, heart, liver, and immune cells.",
      "Activation of GPR151 triggers a G protein-mediated signaling cascade that can lead to changes in intracellular calcium levels and cAMP levels.",
      "GPR151 has been implicated in various physiological processes such as inflammation, immune response, and cardiovascular function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The gene encoding GPR151 was first identified in the early 2000s, not the early 1990s.\n3. FALSE [correction]: GPR151 is primarily expressed in the central nervous system, particularly in the brain, with limited expression in peripheral tissues.\n4. UNKNOWN\n5. FALSE [correction]: Since GPR151 is an orphan receptor with no well-defined endogenous ligand or clear physiological function, it has not been definitively implicated in physiological processes such as inflammation, immune response, and cardiovascular function.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "The Fluzone intradermal quadrivalent vaccine contains the following attenuated live viruses:\n1. A/H1N1: This strain is a type A influenza virus that is similar to the H1N1 subtype that caused the 2009 pandemic.\n2. A/H3N2: This strain is a type A influenza virus that is similar to the H3N2 subtype that is commonly found in the Northern Hemisphere.\n3. B/Victoria: This strain is a type B influenza virus that is commonly found in the Northern Hemisphere.\n4. B/Yamagata: This strain is a type B influenza virus that is commonly found in the Northern Hemisphere.\nIt's important to note that the Fluzone intradermal quadrivalent vaccine is not a trivalent vaccine, meaning it contains four strains of the virus, rather than three. The \"quadrivalent\" name reflects this.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains an A/H1N1 strain similar to the subtype that caused the 2009 pandemic.\n2. The Fluzone intradermal quadrivalent vaccine contains an A/H3N2 strain similar to the subtype commonly found in the Northern Hemisphere.\n3. The Fluzone intradermal quadrivalent vaccine contains a B/Victoria strain commonly found in the Northern Hemisphere.\n4. The Fluzone intradermal quadrivalent vaccine contains a B/Yamagata strain commonly found in the Northern Hemisphere.\n5. The Fluzone intradermal quadrivalent vaccine is not a trivalent vaccine but contains four strains of the virus.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains an A/H1N1 strain similar to the subtype that caused the 2009 pandemic.",
      "The Fluzone intradermal quadrivalent vaccine contains an A/H3N2 strain similar to the subtype commonly found in the Northern Hemisphere.",
      "The Fluzone intradermal quadrivalent vaccine contains a B/Victoria strain commonly found in the Northern Hemisphere.",
      "The Fluzone intradermal quadrivalent vaccine contains a B/Yamagata strain commonly found in the Northern Hemisphere.",
      "The Fluzone intradermal quadrivalent vaccine is not a trivalent vaccine but contains four strains of the virus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The Fluzone intradermal quadrivalent vaccine does contain an A/H1N1 strain similar to the subtype that caused the 2009 pandemic, as quadrivalent vaccines are designed to protect against four different flu viruses, including an influenza A H1N1 virus.\n2. TRUE: The Fluzone intradermal quadrivalent vaccine also contains an A/H3N2 strain, which is another subtype commonly found in the Northern Hemisphere.\n3. TRUE: The Fluzone intradermal quadrivalent vaccine includes a B/Victoria strain, which is one of the influenza B strains commonly found in the Northern Hemisphere.\n4. UNKNOWN: Without current and specific information about the composition of the Fluzone intradermal quadrivalent vaccine for a specific flu season, it is not possible to confirm whether it contains a B/Yamagata strain. The strains in the vaccine can change from year to year based on World Health Organization recommendations.\n5. TRUE: The Fluzone intradermal quadrivalent vaccine is not a trivalent vaccine; it is a quadrivalent vaccine, meaning it contains four different strains of the influenza virus.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that is caused by a combination of genetic and environmental factors. The TNFR2 (Tumor Necrosis Factor Receptor 2) gene has been identified as a genetic risk factor for SLE.\nThe most well-established genetic association with SLE is a single nucleotide polymorphism (SNP) in the TNFR2 gene, specifically the -308G/C polymorphism. This SNP is located in the 5' untranslated region of the TNFR2 gene and is associated with increased expression of the TNFR2 protein.\nStudies have shown that individuals with the -308C allele have an increased risk of developing SLE, particularly in certain ethnic groups such as African Americans. The -308C allele is also associated with a higher disease severity and a higher risk of organ damage in SLE patients.\nIn addition to the -308G/C polymorphism, other SNPs in the TNFR2 gene have also been associated with SLE, including the -262A/G and -169C/T polymorphisms. However, the -308G/C polymorphism is the most well-established and widely studied.\nOverall, genetic variations in the TNFR2 gene contribute to the risk of developing SLE and may play a role in the pathogenesis of the disease. However, it is important to note that the genetic contribution to SLE is complex and involves multiple genetic and environmental factors.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 (Tumor Necrosis Factor Receptor 2) gene has been identified as a genetic risk factor for Systemic Lupus Erythematosus (SLE).\n2. A single nucleotide polymorphism (SNP) in the TNFR2 gene, specifically the -308G/C polymorphism, is associated with SLE.\n3. The -308G/C polymorphism is located in the 5' untranslated region of the TNFR2 gene.\n4. Individuals with the -308C allele have an increased risk of developing SLE, particularly in certain ethnic groups such as African Americans.\n5. The -308C allele is associated with a higher disease severity and a higher risk of organ damage in SLE patients.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 (Tumor Necrosis Factor Receptor 2) gene has been identified as a genetic risk factor for Systemic Lupus Erythematosus (SLE).",
      "A single nucleotide polymorphism (SNP) in the TNFR2 gene, specifically the -308G/C polymorphism, is associated with SLE.",
      "The -308G/C polymorphism is located in the 5' untranslated region of the TNFR2 gene.",
      "Individuals with the -308C allele have an increased risk of developing SLE, particularly in certain ethnic groups such as African Americans.",
      "The -308C allele is associated with a higher disease severity and a higher risk of organ damage in SLE patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The TNFR2 gene has been studied in the context of autoimmune diseases, including Systemic Lupus Erythematosus (SLE), and has been identified as a potential genetic risk factor.\n2. FALSE [correction]: The -308G/A polymorphism is associated with SLE, not the -308G/C polymorphism. It is a well-known SNP in the TNF-alpha promoter region, which can affect gene expression.\n3. TRUE: The -308G/A polymorphism is indeed located in the 5' untranslated region (5' UTR) of the TNF-alpha gene, which is upstream of the coding sequence and can influence gene expression.\n4. UNKNOWN: While certain alleles of genetic polymorphisms can be associated with increased risk of developing SLE in some ethnic groups, without specific evidence or studies, it is not possible to confirm the association of the -308C allele with SLE risk in African Americans or any other ethnic group.\n5. UNKNOWN: The association of the -308C allele with disease severity and risk of organ damage in SLE patients would require specific studies to confirm. Without such evidence, the statement remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "There is currently no licensed vaccine available for the prevention of peanut allergy. Peanut allergy is an immune-mediated reaction to proteins found in peanuts, and there is no known way to prevent it through vaccination.\nHowever, researchers are actively working on developing a vaccine for peanut allergy, and several clinical trials are currently underway. These trials are testing different approaches to induce immune tolerance to peanut proteins, including:\n1. Oral immunotherapy: This involves gradually increasing the dose of peanut protein consumed over time to build up tolerance to the allergy.\n2. Epicutaneous immunotherapy: This involves applying a small amount of peanut protein to the skin, which can help the immune system build up tolerance to the allergen.\n3. mRNA-based vaccines: These vaccines use a piece of genetic material called messenger RNA (mRNA) to instruct cells to produce a specific protein. In the case of peanut allergy, mRNA vaccines are being developed to produce a protein that can help the immune system recognize and tolerate peanut proteins.\nWhile these vaccines show promise, it is important to note that they are still in the experimental stage and have not yet been proven to be effective in preventing peanut allergy. If you or someone you know has a peanut allergy, it is important to follow the advice of medical professionals and avoid consuming peanuts or peanut products to prevent an allergic reaction.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no licensed vaccine available for the prevention of peanut allergy.\n2. Peanut allergy is an immune-mediated reaction to proteins found in peanuts.\n3. Researchers are actively working on developing a vaccine for peanut allergy.\n4. Clinical trials for peanut allergy vaccines are currently underway.\n5. Approaches being tested in clinical trials include oral immunotherapy, epicutaneous immunotherapy, and mRNA-based vaccines.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no licensed vaccine available for the prevention of peanut allergy.",
      "Peanut allergy is an immune-mediated reaction to proteins found in peanuts.",
      "Researchers are actively working on developing a vaccine for peanut allergy.",
      "Clinical trials for peanut allergy vaccines are currently underway.",
      "Approaches being tested in clinical trials include oral immunotherapy, epicutaneous immunotherapy, and mRNA-based vaccines."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE (As of my knowledge cutoff in early 2023, there is no licensed vaccine available for the prevention of peanut allergy.)\n2. TRUE (Peanut allergy is indeed an immune-mediated reaction to proteins found in peanuts.)\n3. TRUE (Researchers are actively working on developing various treatments and potentially vaccines for peanut allergies.)\n4. TRUE (Clinical trials for different approaches to treat or prevent peanut allergy, including vaccines, have been underway.)\n5. TRUE (Approaches such as oral immunotherapy, epicutaneous immunotherapy, and exploration of mRNA-based vaccines are among the methods being tested in clinical trials for peanut allergy.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The Fxy gene in mice is located on the X chromosome at position Xq13.3. This means that the Fxy gene is located on the long (q) arm of the X chromosome at position 13.3 from the centromere.\nIn mammals, including mice, the X chromosome is one of the two sex chromosomes, and it plays a crucial role in determining the sex of an individual. Females have two X chromosomes, one inherited from each parent, while males have one X chromosome inherited from their mother and one Y chromosome inherited from their father.\nThe Fxy gene is one of the genes located on the X chromosome that is involved in the regulation of X-chromosome inactivation, a process that occurs in female mammals to avoid a doubling of gene expression due to the presence of two X chromosomes. The Fxy gene is one of the genes that is inactivated in a random manner in each cell of the female body, resulting in a mosaic pattern of X-chromosome inactivation.\nIn summary, the Fxy gene in mice is located on the X chromosome at position Xq13.3, which is a specific location on the long arm of the X chromosome that is involved in the regulation of X-chromosome inactivation in female mammals.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fxy gene in mice is located on the X chromosome at position Xq13.3.\n2. The X chromosome is one of the two sex chromosomes in mammals.\n3. Female mammals have two X chromosomes, while male mammals have one X and one Y chromosome.\n4. The Fxy gene is involved in the regulation of X-chromosome inactivation in female mammals.\n5. X-chromosome inactivation occurs in female mammals to prevent doubling of gene expression due to having two X chromosomes.",
    "llama-2-7b-chat-hf_fact": [
      "The Fxy gene in mice is located on the X chromosome at position Xq13.3.",
      "The X chromosome is one of the two sex chromosomes in mammals.",
      "Female mammals have two X chromosomes, while male mammals have one X and one Y chromosome.",
      "The Fxy gene is involved in the regulation of X-chromosome inactivation in female mammals.",
      "X-chromosome inactivation occurs in female mammals to prevent doubling of gene expression due to having two X chromosomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "Methylation-specific PCR (MSP) is a method used to detect and quantify DNA methylation at specific CpG sites. MPE-seq is a modification of the MSP method that uses a different type of probe, called a methylation-specific primer extension (MPE) probe, which is designed to detect methylation at specific CpG sites.\nThe basis of the MPE-seq method is as follows:\n1. Sample preparation: The sample is first treated with bisulfite to deaminate unmethylated cytosine residues, leaving only methylated cytosine residues intact.\n2. PCR amplification: The bisulfite-treated DNA is then subjected to PCR amplification using MPE primers that are specific to the CpG site of interest.\n3. MPE probe hybridization: After PCR amplification, the MPE probes are hybridized to the amplified DNA. The MPE probes are designed to be complementary to the methylated CpG site, and they contain a fluorescent label that can be detected using a fluorescence-based detection system.\n4. Detection: The fluorescent signal from the MPE probes is measured using a fluorescence-based detection system, such as a microarray or a next-generation sequencing platform. The intensity of the signal is proportional to the amount of methylation at the CpG site.\nMPE-seq is a sensitive and specific method for detecting and quantifying DNA methylation at specific CpG sites. It can be used to analyze a wide range of samples, including whole blood, tissue, and cell cultures, and it can be used to study the effects of DNA methylation on gene expression and cellular differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Methylation-specific PCR (MSP) is used to detect and quantify DNA methylation at specific CpG sites.\n2. MPE-seq is a modification of MSP that uses methylation-specific primer extension (MPE) probes.\n3. In MPE-seq, the sample is treated with bisulfite to deaminate unmethylated cytosine residues, leaving methylated cytosine residues intact.\n4. The bisulfite-treated DNA is subjected to PCR amplification using MPE primers specific to the CpG site of interest.\n5. The intensity of the fluorescent signal from the MPE probes in MPE-seq is proportional to the amount of methylation at the CpG site.",
    "llama-2-7b-chat-hf_fact": [
      "Methylation-specific PCR (MSP) is used to detect and quantify DNA methylation at specific CpG sites.",
      "MPE-seq is a modification of MSP that uses methylation-specific primer extension (MPE) probes.",
      "In MPE-seq, the sample is treated with bisulfite to deaminate unmethylated cytosine residues, leaving methylated cytosine residues intact.",
      "The bisulfite-treated DNA is subjected to PCR amplification using MPE primers specific to the CpG site of interest.",
      "The intensity of the fluorescent signal from the MPE probes in MPE-seq is proportional to the amount of methylation at the CpG site."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: The bisulfite-treated DNA is subjected to PCR amplification using primers specific to the CpG site of interest, but the term \"MPE primers\" is not standard and may be incorrect. The correct term is usually \"methylation-specific primers.\"\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR (Genome-Wide Association Study) is typically implemented using a programming language that is well-suited for bioinformatics and genomics analysis. Some popular programming languages for GWAS analysis include:\n1. Python: Python is a popular language for bioinformatics and genomics analysis due to its simplicity, flexibility, and extensive libraries for genomics analysis. Popular Python libraries for GWAS analysis include scikit-learn, GWASpy, and PLINK.\n2. R: R is a popular language for statistical computing and graphics, and is widely used in bioinformatics and genomics analysis. R has a large number of packages available for GWAS analysis, including PLINK, GWASpy, and MASS.\n3. MATLAB: MATLAB is a high-level programming language that is widely used in bioinformatics and genomics analysis. It has a number of built-in functions and toolboxes for GWAS analysis, including the Bioinformatics Toolbox and the Genomics Toolbox.\n4. Java: Java is a popular language for bioinformatics and genomics analysis due to its platform independence and ability to run on any Java Virtual Machine (JVM). Popular Java libraries for GWAS analysis include Weka and GWAS Java.\n5. C++: C++ is a powerful programming language that is commonly used for bioinformatics and genomics analysis due to its performance and flexibility. Popular C++ libraries for GWAS analysis include GWAS-C++ and C++ Genome Toolkit.\nIt's worth noting that the choice of programming language will depend on the specific requirements of the analysis and the user's familiarity with the language.",
    "llama-2-7b-chat-hf_fact_raw": "1. Python is used for bioinformatics and genomics analysis and has libraries such as scikit-learn, GWASpy, and PLINK for GWAS analysis.\n2. R is used for statistical computing and graphics in bioinformatics and genomics analysis, with packages like PLINK, GWASpy, and MASS for GWAS analysis.\n3. MATLAB is used in bioinformatics and genomics analysis and offers toolboxes like the Bioinformatics Toolbox and the Genomics Toolbox for GWAS analysis.\n4. Java is used for bioinformatics and genomics analysis and has libraries like Weka and GWAS Java for GWAS analysis.\n5. C++ is used for bioinformatics and genomics analysis and includes libraries such as GWAS-C++ and C++ Genome Toolkit for GWAS analysis.",
    "llama-2-7b-chat-hf_fact": [
      "Python is used for bioinformatics and genomics analysis and has libraries such as scikit-learn, GWASpy, and PLINK for GWAS analysis.",
      "R is used for statistical computing and graphics in bioinformatics and genomics analysis, with packages like PLINK, GWASpy, and MASS for GWAS analysis.",
      "MATLAB is used in bioinformatics and genomics analysis and offers toolboxes like the Bioinformatics Toolbox and the Genomics Toolbox for GWAS analysis.",
      "Java is used for bioinformatics and genomics analysis and has libraries like Weka and GWAS Java for GWAS analysis.",
      "C++ is used for bioinformatics and genomics analysis and includes libraries such as GWAS-C++ and C++ Genome Toolkit for GWAS analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: R is used for statistical computing and graphics in bioinformatics and genomics analysis, with packages like Bioconductor, and MASS, but not PLINK and GWASpy, which are not R packages.\n3. TRUE\n4. UNKNOWN (While Java is used in bioinformatics, \"GWAS Java\" is not a well-known library. Weka is a machine learning library but is not specifically for GWAS analysis.)\n5. UNKNOWN (C++ is used in bioinformatics, but \"GWAS-C++\" and \"C++ Genome Toolkit\" are not standard or well-known libraries for GWAS analysis. However, there are C++ libraries and tools used in bioinformatics for various analyses.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "There is currently no scientific evidence to support the use of xaliproden (also known as P7C3) for the treatment of amyotrophic lateral sclerosis (ALS). Xaliproden is an experimental drug that has been studied for its potential to slow or halt the progression of ALS, but it has not been approved by regulatory authorities for this use.\nWhile some early-stage clinical trials have suggested that xaliproden may have some beneficial effects on ALS progression, these findings have not been consistently replicated in larger, more rigorous studies. As a result, the scientific community has not yet established a clear consensus on the efficacy of xaliproden for ALS treatment.\nTherefore, it is important to note that xaliproden is not a proven or recommended treatment for ALS, and its use for this purpose is considered experimental and off-label. Patients with ALS should consult with their healthcare providers regarding available treatment options and the latest scientific evidence on their effectiveness.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden is an experimental drug that has been studied for its potential to slow or halt the progression of amyotrophic lateral sclerosis (ALS).\n2. Xaliproden has not been approved by regulatory authorities for the treatment of ALS.\n3. Some early-stage clinical trials have suggested that xaliproden may have beneficial effects on ALS progression.\n4. Larger, more rigorous studies have not consistently replicated the beneficial effects of xaliproden on ALS progression.\n5. The use of xaliproden for the treatment of ALS is considered experimental and off-label.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden is an experimental drug that has been studied for its potential to slow or halt the progression of amyotrophic lateral sclerosis (ALS).",
      "Xaliproden has not been approved by regulatory authorities for the treatment of ALS.",
      "Some early-stage clinical trials have suggested that xaliproden may have beneficial effects on ALS progression.",
      "Larger, more rigorous studies have not consistently replicated the beneficial effects of xaliproden on ALS progression.",
      "The use of xaliproden for the treatment of ALS is considered experimental and off-label."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "The LiPS-A3S line is a transgenic line of mice in which transgenes are inserted into chromosome 17.",
    "llama-2-7b-chat-hf_fact_raw": "1. The LiPS-A3S line is a transgenic line of mice.\n2. In the LiPS-A3S line, transgenes are inserted into chromosome 17.",
    "llama-2-7b-chat-hf_fact": [
      "The LiPS-A3S line is a transgenic line of mice.",
      "In the LiPS-A3S line, transgenes are inserted into chromosome 17."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several tools and methods that exist for predicting drug synergy with deep learning. Here are some of the most popular ones:\n1. DeepSynth: This is a deep learning-based tool for predicting drug synergy. It uses a convolutional neural network (CNN) to analyze the chemical structures of drugs and predict their synergy.\n2. Drug2Drug: This tool uses a deep learning approach to predict drug-drug interactions, including synergy. It takes two drugs as input and predicts their potential interaction.\n3. DrugSynth: This tool uses a deep learning model to predict drug synergy by analyzing the chemical structures of drugs. It can predict both positive and negative synergy.\n4. Synergizer: This tool uses a deep learning approach to predict drug synergy by analyzing the genomic and transcriptomic data of drug-treated cells. It can predict both drug-drug and drug-gene interactions.\n5. DeepChem: This is a deep learning framework for predicting chemical properties and reactions. It can be used to predict drug synergy by analyzing the chemical structures of drugs.\n6. Chem2Drug: This tool uses a deep learning approach to predict drug-drug interactions, including synergy. It takes two drugs as input and predicts their potential interaction.\n7. DrugDiscovery: This tool uses a deep learning approach to predict drug-drug interactions, including synergy. It takes two drugs as input and predicts their potential interaction.\n8. DrugCombinator: This tool uses a deep learning approach to predict drug combinations that are likely to be effective. It takes two drugs as input and predicts their potential synergy.\n9. DrugSynergizer: This tool uses a deep learning approach to predict drug synergy by analyzing the genomic and transcriptomic data of drug-treated cells. It can predict both drug-drug and drug-gene interactions.\n10. SynergyMiner: This tool uses a deep learning approach to predict drug synergy by analyzing the chemical structures of drugs. It can predict both positive and negative synergy.\nThese are just a few examples of the many tools available for predicting drug",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepSynth is a tool that uses a convolutional neural network to predict drug synergy based on the chemical structures of drugs.\n2. Drug2Drug is a tool designed to predict drug-drug interactions, including synergy, by taking two drugs as input.\n3. Synergizer predicts drug synergy by analyzing genomic and transcriptomic data of drug-treated cells.\n4. DeepChem is a deep learning framework that can predict drug synergy among other chemical properties and reactions.\n5. DrugCombinator predicts effective drug combinations by taking two drugs as input and assessing their potential synergy.",
    "llama-2-7b-chat-hf_fact": [
      "DeepSynth is a tool that uses a convolutional neural network to predict drug synergy based on the chemical structures of drugs.",
      "Drug2Drug is a tool designed to predict drug-drug interactions, including synergy, by taking two drugs as input.",
      "Synergizer predicts drug synergy by analyzing genomic and transcriptomic data of drug-treated cells.",
      "DeepChem is a deep learning framework that can predict drug synergy among other chemical properties and reactions.",
      "DrugCombinator predicts effective drug combinations by taking two drugs as input and assessing their potential synergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: DeepChem is a deep learning framework for drug discovery, quantum chemistry, materials science, and biology, but it is not specifically designed to predict drug synergy.\n5. UNKNOWN\n\nNote: The truth value of statements 1, 2, 3, and 5 cannot be determined without additional context or information about these specific tools, as they may or may not exist or function as described.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "The cloud-based platform that has been developed for comparing GWAS (Genome-Wide Association Studies) is called \"GWAS Central\". GWAS Central is a web-based platform that allows researchers to compare and integrate genetic association signals across different GWAS datasets. It provides a user-friendly interface for uploading and analyzing GWAS data, and for identifying novel associations and replication opportunities. GWAS Central also includes tools for visualizing and interpreting the results, and for identifying potential biological pathways and mechanisms underlying the associations. The platform is designed to facilitate collaboration and data sharing among researchers, and to accelerate the discovery of new genetic associations and their translation into clinical practice.",
    "llama-2-7b-chat-hf_fact_raw": "1. GWAS Central is a cloud-based platform developed for comparing Genome-Wide Association Studies (GWAS).\n2. GWAS Central provides a user-friendly interface for uploading and analyzing GWAS data.\n3. The platform includes tools for visualizing and interpreting GWAS results.\n4. GWAS Central is designed to facilitate collaboration and data sharing among researchers.\n5. The platform aims to accelerate the discovery of new genetic associations and their translation into clinical practice.",
    "llama-2-7b-chat-hf_fact": [
      "GWAS Central is a cloud-based platform developed for comparing Genome-Wide Association Studies (GWAS).",
      "GWAS Central provides a user-friendly interface for uploading and analyzing GWAS data.",
      "The platform includes tools for visualizing and interpreting GWAS results.",
      "GWAS Central is designed to facilitate collaboration and data sharing among researchers.",
      "The platform aims to accelerate the discovery of new genetic associations and their translation into clinical practice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GWAS Central is not specifically described as a cloud-based platform; it is a database and online resource for genome-wide association studies.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "CMB305 is a monoclonal antibody that is currently being studied for the treatment of various types of cancer, including sarcomas. Sarcomas are a type of cancer that develops in the connective tissue of the body, such as bone, cartilage, and fat.\nCMB305 works by targeting a protein called CD47, which is found on the surface of many cancer cells. By binding to CD47, CMB305 can help to trigger the body's immune system to attack and destroy cancer cells.\nSeveral early-stage clinical trials have been conducted to evaluate the safety and efficacy of CMB305 in patients with various types of cancer, including sarcomas. These trials have shown that CMB305 can be well-tolerated and may be effective in shrinking or stabilizing tumors in some patients. However, more research is needed to confirm these findings and to determine the optimal dosing and administration schedule for CMB305 in the treatment of sarcomas.\nIt is important to note that CMB305 is not currently approved by the FDA for the treatment of sarcomas or any other type of cancer. It is still in the experimental stage, and more research is needed to determine its long-term safety and effectiveness. If you have sarcoma or any other type of cancer, it is important to discuss your treatment options with your doctor and to enroll in clinical trials if eligible.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a monoclonal antibody being studied for the treatment of various types of cancer, including sarcomas.\n2. Sarcomas are a type of cancer that develops in the connective tissue of the body.\n3. CMB305 targets a protein called CD47 found on the surface of many cancer cells.\n4. Early-stage clinical trials have been conducted to evaluate the safety and efficacy of CMB305 in patients with various types of cancer, including sarcomas.\n5. CMB305 is not currently approved by the FDA for the treatment of sarcomas or any other type of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a monoclonal antibody being studied for the treatment of various types of cancer, including sarcomas.",
      "Sarcomas are a type of cancer that develops in the connective tissue of the body.",
      "CMB305 targets a protein called CD47 found on the surface of many cancer cells.",
      "Early-stage clinical trials have been conducted to evaluate the safety and efficacy of CMB305 in patients with various types of cancer, including sarcomas.",
      "CMB305 is not currently approved by the FDA for the treatment of sarcomas or any other type of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: CMB305 is a cancer vaccine that targets the NY-ESO-1 cancer antigen, not CD47.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the triad of St. Vitus, is a group of three symptoms that are commonly associated with certain neurological conditions, particularly those that affect the nervous system. The three symptoms of the Saint's Triad are:\n1. Chorea: This is a type of involuntary movement that can affect the arms, legs, or face. It is characterized by quick, jerky movements that can be irregular and unpredictable.\n2. Athetosis: This is a slow, writhing movement of the hands and feet that can make it difficult to perform coordinated movements.\n3. Ataxia: This is a loss of coordination and balance that can make it difficult to walk or stand. It can also cause problems with speech and swallowing.\nThe Saint's Triad is often associated with conditions such as Huntington's disease, Sydenham's chorea, and other neurodegenerative disorders. It is important to note that the Saint's Triad is not a specific diagnosis, but rather a collection of symptoms that can be caused by a variety of underlying conditions. A proper diagnosis can only be made by a qualified medical professional after a thorough evaluation of the individual's symptoms and medical history.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Saint's Triad is associated with certain neurological conditions that affect the nervous system.\n2. Chorea, characterized by quick, jerky movements, is one of the symptoms of the Saint's Triad.\n3. Athetosis, involving slow, writhing movements of the hands and feet, is a symptom of the Saint's Triad.\n4. Ataxia, which includes a loss of coordination and balance, is a symptom of the Saint's Triad.\n5. The Saint's Triad can be associated with conditions such as Huntington's disease and Sydenham's chorea.",
    "llama-2-7b-chat-hf_fact": [
      "The Saint's Triad is associated with certain neurological conditions that affect the nervous system.",
      "Chorea, characterized by quick, jerky movements, is one of the symptoms of the Saint's Triad.",
      "Athetosis, involving slow, writhing movements of the hands and feet, is a symptom of the Saint's Triad.",
      "Ataxia, which includes a loss of coordination and balance, is a symptom of the Saint's Triad.",
      "The Saint's Triad can be associated with conditions such as Huntington's disease and Sydenham's chorea."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The term \"Saint's Triad\" is not a recognized medical term associated with neurological conditions. The correct term might be \"Saint Vitus' dance,\" which is associated with Sydenham's chorea, or the term could be a confusion with \"Charcot's triad,\" which is associated with multiple sclerosis.\n2. FALSE [correction]: Since the term \"Saint's Triad\" is incorrect or not recognized, the statement about chorea being one of its symptoms is also false. However, chorea is a symptom of neurological conditions such as Huntington's disease and Sydenham's chorea.\n3. FALSE [correction]: Similar to the previous statement, since \"Saint's Triad\" is not a recognized term, the statement about athetosis being a symptom is false. Athetosis is a symptom that can occur in various neurological disorders, but it is not associated with a \"Saint's Triad.\"\n4. FALSE [correction]: Again, as \"Saint's Triad\" is not a recognized medical term, the statement about ataxia being a symptom is false. Ataxia is a symptom of many neurological disorders, including cerebellar ataxia, but not associated with a \"Saint's Triad.\"\n5. FALSE [correction]: The statement is false because \"Saint's Triad\" is not a recognized term. However, Huntington's disease and Sydenham's chorea are indeed associated with neurological symptoms such as chorea.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "There is some evidence to suggest that overexpression of the protein LY6K is associated with a better prognosis for non-small cell lung cancer (NSCLC) patients.\nLY6K, also known as CD155, is a transmembrane glycoprotein that has been implicated in various cellular processes, including cell adhesion, migration, and signaling. In recent years, LY6K has been found to be overexpressed in several types of cancer, including NSCLC.\nSeveral studies have investigated the prognostic value of LY6K expression in NSCLC. A meta-analysis of 12 studies published in the journal Oncotarget found that high levels of LY6K expression were associated with improved overall survival and disease-free survival in NSCLC patients. Another study published in the journal Clinical Cancer Research found that LY6K expression was associated with a lower risk of disease progression and death in NSCLC patients.\nThe mechanisms by which LY6K promotes a better prognosis in NSCLC are not fully understood, but it is thought to involve its role in regulating cellular processes such as cell adhesion, migration, and signaling. LY6K has been shown to promote the epithelial-to-mesenchymal transition (EMT), a process that is associated with increased cancer cell migration and invasiveness. It has also been shown to inhibit the activity of the PI3K/Akt signaling pathway, which is commonly activated in cancer and promotes cell survival and proliferation.\nOverall, the evidence suggests that overexpression of LY6K is associated with a better prognosis in NSCLC patients. However, further research is needed to fully understand the mechanisms underlying this association and to determine the potential clinical applications of LY6K as a prognostic marker or therapeutic target in NSCLC.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is associated with a better prognosis for non-small cell lung cancer (NSCLC) patients according to some evidence.\n2. LY6K, also known as CD155, is a transmembrane glycoprotein involved in cell adhesion, migration, and signaling.\n3. A meta-analysis published in the journal Oncotarget found that high levels of LY6K expression were associated with improved overall survival and disease-free survival in NSCLC patients.\n4. A study in the journal Clinical Cancer Research found that LY6K expression was associated with a lower risk of disease progression and death in NSCLC patients.\n5. LY6K has been shown to promote the epithelial-to-mesenchymal transition (EMT) and inhibit the activity of the PI3K/Akt signaling pathway.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is associated with a better prognosis for non-small cell lung cancer (NSCLC) patients according to some evidence.",
      "LY6K, also known as CD155, is a transmembrane glycoprotein involved in cell adhesion, migration, and signaling.",
      "A meta-analysis published in the journal Oncotarget found that high levels of LY6K expression were associated with improved overall survival and disease-free survival in NSCLC patients.",
      "A study in the journal Clinical Cancer Research found that LY6K expression was associated with a lower risk of disease progression and death in NSCLC patients.",
      "LY6K has been shown to promote the epithelial-to-mesenchymal transition (EMT) and inhibit the activity of the PI3K/Akt signaling pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is generally associated with a poor prognosis for non-small cell lung cancer (NSCLC) patients.\n2. FALSE [correction]: LY6K, also known as Lymphocyte Antigen 6 Complex, Locus K, is not the same as CD155. CD155 is also known as the Poliovirus Receptor (PVR) and is a different protein.\n3. FALSE [correction]: A meta-analysis published in the journal Oncotarget would likely find that high levels of LY6K expression are associated with poor overall survival and disease-free survival in NSCLC patients, given that LY6K overexpression is generally linked to a poor prognosis.\n4. UNKNOWN: Without specific details from the study in the journal Clinical Cancer Research, the association between LY6K expression and the risk of disease progression and death in NSCLC patients cannot be confirmed.\n5. UNKNOWN: The statement about LY6K promoting the epithelial-to-mesenchymal transition (EMT) and inhibiting the activity of the PI3K/Akt signaling pathway requires specific scientific evidence to confirm its accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "During cytokinesis, the cell undergoes a series of events that lead to the separation of the daughter cells. One of the key events is the dephosphorylation of various cyclin-dependent kinase (Cdk) targets, which plays a crucial role in the progression of cytokinesis. Here are some of the Cdk targets that are dephosphorylated during cytokinesis:\n1. Cyclin-dependent kinase 1 (Cdk1): Cdk1 is a key regulator of the cell cycle and is inactivated during cytokinesis through the dephosphorylation of its substrates.\n2. Cyclin B: Cyclin B is a substrate of Cdk1 and is dephosphorylated during cytokinesis, leading to its inactivation and the release of Cdk1.\n3. Cyclin D: Cyclin D is also a substrate of Cdk1 and is dephosphorylated during cytokinesis, leading to its inactivation.\n4. Polo-like kinase 1 (Plk1): Plk1 is a Cdk9-regulated kinase that is involved in the regulation of the cell cycle and is dephosphorylated during cytokinesis.\n5. Aurora A: Aurora A is a Cdk1 substrate that is involved in the regulation of the spindle checkpoint and is dephosphorylated during cytokinesis.\n6. Aurora B: Aurora B is also a Cdk1 substrate and is involved in the regulation of the spindle checkpoint and the separation of the daughter cells during cytokinesis.\n7. Boreal: Boreal is a Cdk1 substrate that is involved in the regulation of the spindle checkpoint and is dephosphorylated during cytokinesis.\n8. Spindle-associated protein 1 (SAP1): SAP1 is a Cdk1 substrate that is involved in the regulation of the spindle checkpoint and is dephosphorylated during cytokinesis.\n9. Kinesin-like protein 1 (KLP1): KLP1 is a Cdk1 substrate that is involved in the regulation of the spind",
    "llama-2-7b-chat-hf_fact_raw": "1. Cyclin-dependent kinase 1 (Cdk1) is inactivated during cytokinesis through the dephosphorylation of its substrates.\n2. Cyclin B is dephosphorylated during cytokinesis, leading to its inactivation.\n3. Cyclin D is dephosphorylated during cytokinesis, leading to its inactivation.\n4. Polo-like kinase 1 (Plk1) is dephosphorylated during cytokinesis.\n5. Aurora A and Aurora B are substrates of Cdk1 that are dephosphorylated during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Cyclin-dependent kinase 1 (Cdk1) is inactivated during cytokinesis through the dephosphorylation of its substrates.",
      "Cyclin B is dephosphorylated during cytokinesis, leading to its inactivation.",
      "Cyclin D is dephosphorylated during cytokinesis, leading to its inactivation.",
      "Polo-like kinase 1 (Plk1) is dephosphorylated during cytokinesis.",
      "Aurora A and Aurora B are substrates of Cdk1 that are dephosphorylated during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cyclin-dependent kinase 1 (Cdk1) is inactivated during mitosis through the degradation of its activating partner cyclin B, not through the dephosphorylation of its substrates.\n2. FALSE [correction]: Cyclin B is not dephosphorylated during cytokinesis; it is targeted for degradation by the anaphase-promoting complex/cyclosome (APC/C), leading to its inactivation and the inactivation of Cdk1.\n3. UNKNOWN: The statement about Cyclin D is not directly related to the common knowledge about cell cycle regulation, and without specific context, it's unclear whether Cyclin D is dephosphorylated during cytokinesis.\n4. UNKNOWN: The statement about Polo-like kinase 1 (Plk1) being dephosphorylated during cytokinesis is not a well-established fact and would require specific context or evidence to confirm its accuracy.\n5. FALSE [correction]: Aurora A and Aurora B are not substrates of Cdk1. Aurora B is a part of the chromosomal passenger complex and plays a role in cytokinesis, but it is not dephosphorylated by Cdk1 during cytokinesis. Aurora A is involved in mitotic entry and spindle assembly, and its regulation is not primarily through Cdk1-mediated dephosphorylation during cytokinesis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a brand name for a medication called midazolam, which is a type of benzodiazepine. It is used to treat a variety of conditions, including anxiety, insomnia, and seizures. Xanamem is typically administered intravenously or by injection, and its effects can last for several hours. It works by slowing down the activity of the nervous system, which can help to calm anxiety and promote relaxation. However, it can also cause drowsiness, confusion, and memory problems, so it is important to use it only as directed by a healthcare professional.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is a brand name for the medication midazolam.\n2. Midazolam is a type of benzodiazepine.\n3. Xanamem is used to treat anxiety, insomnia, and seizures.\n4. Xanamem can be administered intravenously or by injection.\n5. Xanamem works by slowing down the activity of the nervous system.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is a brand name for the medication midazolam.",
      "Midazolam is a type of benzodiazepine.",
      "Xanamem is used to treat anxiety, insomnia, and seizures.",
      "Xanamem can be administered intravenously or by injection.",
      "Xanamem works by slowing down the activity of the nervous system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Xanamem is not a brand name for midazolam; it is a proposed brand name for a different drug, xanameline, which is being investigated for the treatment of Alzheimer's disease.\n2. TRUE\n3. FALSE [correction]: Since Xanamem is not midazolam, it is not used to treat anxiety, insomnia, and seizures. Those are uses for midazolam. Xanamem (xanameline) is being investigated for the treatment of Alzheimer's disease.\n4. UNKNOWN (The statement is likely intended for midazolam, which can be administered intravenously or by injection, but since Xanamem is not midazolam, the administration method for Xanamem is not specified here.)\n5. UNKNOWN (The statement likely refers to the mechanism of action of midazolam, which works by slowing down the activity of the nervous system. However, since Xanamem is not midazolam, the mechanism of action for Xanamem is not specified in this statement.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Hof1 and Cyk3 are two proteins that play important roles in the regulation of various cellular processes in yeast, including cell cycle progression, DNA repair, and stress response. The interaction between Hof1 and Cyk3 is crucial for the proper functioning of these processes.\nHof1 (Hofh1-interacting protein 1) is a protein that was first identified as a binding partner of the DNA damage response protein, Hofh1. Hof1 is a negative regulator of the cell cycle and is involved in the G1/S checkpoint, which is a control point that ensures that cells are ready to enter the S phase of the cell cycle. Hof1 also plays a role in the repair of DNA double-strand breaks (DSBs) and interacts with the DNA repair protein, Mre11.\nCyk3 (Cyk3-like protein 1) is a protein that is involved in the regulation of various cellular processes, including cell cycle progression, DNA repair, and stress response. Cyk3 is a member of the Cyk (Cyk1-like protein) family of proteins, which are structurally related to the mammalian protein, CK1. Cyk3 is a key regulator of the G1/S checkpoint and is involved in the regulation of the expression of genes involved in DNA repair and cell cycle progression.\nThe interaction between Hof1 and Cyk3 is crucial for the proper functioning of the G1/S checkpoint and the regulation of DNA repair. Hof1 binds to Cyk3 and inhibits its activity, preventing it from phosphorylating and activating key regulators of the cell cycle. This interaction also affects the expression of genes involved in DNA repair, as Cyk3 is required for the expression of some DNA repair genes.\nIn summary, the interaction between Hof1 and Cyk3 is essential for the proper regulation of the G1/S checkpoint and the DNA repair process in yeast. Hof1 inhibits the activity of Cyk3, preventing it from activating key regulators of the cell cycle and affecting the expression of genes involved in DNA repair.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hof1 and Cyk3 are proteins involved in cell cycle progression, DNA repair, and stress response in yeast.\n2. Hof1 is a negative regulator of the cell cycle and is involved in the G1/S checkpoint.\n3. Hof1 plays a role in the repair of DNA double-strand breaks and interacts with the DNA repair protein Mre11.\n4. Cyk3 is a member of the Cyk family of proteins and is structurally related to the mammalian protein CK1.\n5. The interaction between Hof1 and Cyk3 inhibits Cyk3's activity, which is crucial for the proper functioning of the G1/S checkpoint and the regulation of DNA repair in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "Hof1 and Cyk3 are proteins involved in cell cycle progression, DNA repair, and stress response in yeast.",
      "Hof1 is a negative regulator of the cell cycle and is involved in the G1/S checkpoint.",
      "Hof1 plays a role in the repair of DNA double-strand breaks and interacts with the DNA repair protein Mre11.",
      "Cyk3 is a member of the Cyk family of proteins and is structurally related to the mammalian protein CK1.",
      "The interaction between Hof1 and Cyk3 inhibits Cyk3's activity, which is crucial for the proper functioning of the G1/S checkpoint and the regulation of DNA repair in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hof1 is not a negative regulator of the cell cycle; it is involved in cytokinesis, the final stage of the cell cycle.\n3. UNKNOWN\n4. FALSE [correction]: Cyk3 is not structurally related to the mammalian protein CK1; it is involved in cytokinesis in yeast. The Cyk family of proteins is not a recognized family, and CK1 refers to Casein Kinase 1, which is unrelated.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "T-UCRs (Transcribed Ultraconserved Regions) are a class of non-coding RNAs that have been implicated in various cancers, including gastric cancer. Here are some T-UCRs that have been studied in gastric cancer:\n1. T-UCR-1: T-UCR-1 is one of the most well-studied T-UCRs in gastric cancer. It is overexpressed in many gastric cancer tissues and cell lines, and its overexpression is associated with poor prognosis. T-UCR-1 has been shown to promote the proliferation and migration of gastric cancer cells and to inhibit the apoptosis of cancer cells.\n2. T-UCR-2: T-UCR-2 is another T-UCR that has been implicated in gastric cancer. It is overexpressed in many gastric cancer tissues and cell lines, and its overexpression is associated with poor prognosis. T-UCR-2 has been shown to promote the proliferation and migration of gastric cancer cells and to inhibit the apoptosis of cancer cells.\n3. T-UCR-3: T-UCR-3 is a T-UCR that has been implicated in gastric cancer. It is overexpressed in many gastric cancer tissues and cell lines, and its overexpression is associated with poor prognosis. T-UCR-3 has been shown to promote the proliferation and migration of gastric cancer cells and to inhibit the apoptosis of cancer cells.\n4. T-UCR-4: T-UCR-4 is a T-UCR that has been implicated in gastric cancer. It is overexpressed in many gastric cancer tissues and cell lines, and its overexpression is associated with poor prognosis. T-UCR-4 has been shown to promote the proliferation and migration of gastric cancer cells and to inhibit the apoptosis of cancer cells.\n5. T-UCR-5: T-UCR-5 is a T-UCR that has been implicated in gastric cancer. It is overexpressed in many gastric cancer tissues and cell lines, and its",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCRs (Transcribed Ultraconserved Regions) have been implicated in various cancers, including gastric cancer.\n2. T-UCR-1 is overexpressed in many gastric cancer tissues and cell lines, and its overexpression is associated with poor prognosis.\n3. T-UCR-2 is overexpressed in many gastric cancer tissues and cell lines, and its overexpression is associated with poor prognosis.\n4. T-UCR-3 is overexpressed in many gastric cancer tissues and cell lines, and its overexpression is associated with poor prognosis.\n5. T-UCR-4 is overexpressed in many gastric cancer tissues and cell lines, and its overexpression is associated with poor prognosis.",
    "llama-2-7b-chat-hf_fact": [
      "T-UCRs (Transcribed Ultraconserved Regions) have been implicated in various cancers, including gastric cancer.",
      "T-UCR-1 is overexpressed in many gastric cancer tissues and cell lines, and its overexpression is associated with poor prognosis.",
      "T-UCR-2 is overexpressed in many gastric cancer tissues and cell lines, and its overexpression is associated with poor prognosis.",
      "T-UCR-3 is overexpressed in many gastric cancer tissues and cell lines, and its overexpression is associated with poor prognosis.",
      "T-UCR-4 is overexpressed in many gastric cancer tissues and cell lines, and its overexpression is associated with poor prognosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Transcribed Ultraconserved Regions (T-UCRs) have been implicated in various cancers, including gastric cancer, due to their high level of conservation and regulatory functions.\n2. UNKNOWN: Without specific information on T-UCR-1, it is not possible to confirm whether it is overexpressed in gastric cancer tissues and cell lines or if its overexpression is associated with poor prognosis.\n3. UNKNOWN: Without specific information on T-UCR-2, it is not possible to confirm whether it is overexpressed in gastric cancer tissues and cell lines or if its overexpression is associated with poor prognosis.\n4. UNKNOWN: Without specific information on T-UCR-3, it is not possible to confirm whether it is overexpressed in gastric cancer tissues and cell lines or if its overexpression is associated with poor prognosis.\n5. UNKNOWN: Without specific information on T-UCR-4, it is not possible to confirm whether it is overexpressed in gastric cancer tissues and cell lines or if its overexpression is associated with poor prognosis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects various parts of the body, including the skin, joints, and organs. The LSI is a standardized measure that takes into account various clinical and laboratory parameters to provide a comprehensive assessment of the disease activity.\nThe LSI was developed by the Lupus Assessment in Rheumatology (LAR) Group and consists of 11 components:\n1. Skin: The presence and severity of malar rash, discoid rash, and photosensitivity.\n2. Joints: The number of swollen and tender joints.\n3. Serositis: The presence and severity of pleuritis and pericarditis.\n4. Renal: The presence and severity of kidney involvement, including proteinuria, hematuria, and serum creatinine level.\n5. Neurology: The presence and severity of neurological symptoms, such as headache, confusion, seizures, and psychosis.\n6. Haematology: The presence and severity of anemia, leukopenia, and thrombocytopenia.\n7. Immunology: The presence and severity of autoantibodies, including antinuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA), and anti-SjÖgren's syndrome antigen A (anti-SjSG).\n8. Inflammatory markers: The level of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).\n9. Functional status: The patient's ability to perform daily activities, measured using the Patient's Global Assessment (PGA) score.\n10. Quality of life: The patient's subjective assessment of their quality of life, measured using the Short Form-36 (SF-36) questionnaire.\n11. Treatment: The number and type of medications used to treat the patient's SLE.\nEach component is assigned a score, and the total score ranges from 0 to",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI takes into account various clinical and laboratory parameters to provide a comprehensive assessment of disease activity.\n3. The Lupus Assessment in Rheumatology (LAR) Group developed the LSI.\n4. The LSI consists of 11 components, including assessments of skin, joints, serositis, renal function, neurology, haematology, immunology, inflammatory markers, functional status, quality of life, and treatment.\n5. The LSI includes the Patient's Global Assessment (PGA) score and the Short Form-36 (SF-36) questionnaire as measures of functional status and quality of life, respectively.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI takes into account various clinical and laboratory parameters to provide a comprehensive assessment of disease activity.",
      "The Lupus Assessment in Rheumatology (LAR) Group developed the LSI.",
      "The LSI consists of 11 components, including assessments of skin, joints, serositis, renal function, neurology, haematology, immunology, inflammatory markers, functional status, quality of life, and treatment.",
      "The LSI includes the Patient's Global Assessment (PGA) score and the Short Form-36 (SF-36) questionnaire as measures of functional status and quality of life, respectively."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe Lupus Severity Index (LSI) is indeed a tool used to assess the severity of systemic lupus erythematosus (SLE), and it does take into account various clinical and laboratory parameters. However, without specific information about the development of the LSI or its components, it is not possible to confirm the accuracy of statements 3, 4, and 5. These details would require access to specific medical literature or guidelines that outline the development and components of the LSI.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "De novo mutations in the ZSWIM6 gene have been associated with several rare genetic disorders, including:\n1. Zellweger Syndrome Spectrum Disorders: These are a group of rare genetic disorders that are characterized by a range of symptoms including vision loss, hearing loss, seizures, and developmental delays. De novo mutations in the ZSWIM6 gene have been identified in some individuals with Zellweger syndrome spectrum disorders.\n2. Neuronal Ceroid Lipofuscinoses (NCLs): These are a group of rare genetic disorders that are characterized by progressive loss of nervous system function, seizures, and vision loss. De novo mutations in the ZSWIM6 gene have been identified in some individuals with NCLs.\n3. Batten Disease: This is a rare genetic disorder that is characterized by progressive loss of vision, seizures, and developmental delays. De novo mutations in the ZSWIM6 gene have been identified in some individuals with Batten disease.\n4. Other rare genetic disorders: De novo mutations in the ZSWIM6 gene have also been identified in other rare genetic disorders, including intellectual disability, autism spectrum disorder, and congenital disorders.\nIt is important to note that the frequency and distribution of de novo mutations in ZSWIM6 may vary depending on the population being studied and the specific disorder being investigated. Further research is needed to fully understand the role of de novo mutations in ZSWIM6 in the development of these disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in the ZSWIM6 gene have been associated with Zellweger Syndrome Spectrum Disorders.\n2. Individuals with Zellweger Syndrome Spectrum Disorders may exhibit symptoms such as vision loss, hearing loss, seizures, and developmental delays.\n3. De novo mutations in the ZSWIM6 gene have been identified in some individuals with Neuronal Ceroid Lipofuscinoses (NCLs).\n4. Batten Disease, characterized by progressive loss of vision, seizures, and developmental delays, has been associated with de novo mutations in the ZSWIM6 gene.\n5. De novo mutations in the ZSWIM6 gene have been identified in individuals with other rare genetic disorders, including intellectual disability and autism spectrum disorder.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in the ZSWIM6 gene have been associated with Zellweger Syndrome Spectrum Disorders.",
      "Individuals with Zellweger Syndrome Spectrum Disorders may exhibit symptoms such as vision loss, hearing loss, seizures, and developmental delays.",
      "De novo mutations in the ZSWIM6 gene have been identified in some individuals with Neuronal Ceroid Lipofuscinoses (NCLs).",
      "Batten Disease, characterized by progressive loss of vision, seizures, and developmental delays, has been associated with de novo mutations in the ZSWIM6 gene.",
      "De novo mutations in the ZSWIM6 gene have been identified in individuals with other rare genetic disorders, including intellectual disability and autism spectrum disorder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: De novo mutations in the ZSWIM6 gene have been associated with Acromelic Frontonasal Dysostosis, not Zellweger Syndrome Spectrum Disorders.\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: Batten Disease, which is a form of Neuronal Ceroid Lipofuscinoses (NCLs), is typically associated with mutations in other genes, such as CLN3, not the ZSWIM6 gene.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is used to classify Vestibular Schwannomas, also known as Acoustic Neuromas, which are benign tumors that develop on the nerve that controls balance and hearing. The Koos Classification system helps to determine the size and location of the tumor, which can guide treatment decisions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify Vestibular Schwannomas.\n2. Vestibular Schwannomas are also known as Acoustic Neuromas.\n3. Vestibular Schwannomas are benign tumors.\n4. These tumors develop on the nerve that controls balance and hearing.\n5. The Koos Classification system is used to determine the size and location of the tumor.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify Vestibular Schwannomas.",
      "Vestibular Schwannomas are also known as Acoustic Neuromas.",
      "Vestibular Schwannomas are benign tumors.",
      "These tumors develop on the nerve that controls balance and hearing.",
      "The Koos Classification system is used to determine the size and location of the tumor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a small molecule inhibitor of the enzyme phosphatidylinositol 3-kinase (PI3K). PI3K is a key regulator of cell survival and signaling pathways, and AZD8601 has been shown to have a range of in vivo effects, including:\n1. Inhibition of tumor growth: AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, both in vitro and in vivo.\n2. Induction of apoptosis: AZD8601 has been shown to induce apoptosis (programmed cell death) in cancer cells, which can lead to a reduction in tumor volume.\n3. Inhibition of angiogenesis: AZD8601 has been shown to inhibit the formation of new blood vessels, which are necessary for tumor growth and survival.\n4. Enhancement of immune response: AZD8601 has been shown to enhance the immune response against cancer cells, which can lead to a more effective anti-tumor response.\n5. Reduction of cancer stem cell population: AZD8601 has been shown to reduce the population of cancer stem cells, which are thought to be responsible for the initiation and progression of cancer.\n6. Inhibition of metastasis: AZD8601 has been shown to inhibit the migration and invasion of cancer cells, which can reduce the likelihood of metastasis.\n7. Improved cardiovascular function: AZD8601 has been shown to improve cardiovascular function in animal models of cancer, which can reduce the risk of cardiotoxicity associated with cancer treatment.\n8. Reduction of cancer-associated fibrosis: AZD8601 has been shown to reduce the formation of scar tissue in the tumor microenvironment, which can improve the efficacy of cancer treatment.\n9. Enhancement of chemotherapy: AZD8601 has been shown to enhance the efficacy of chemotherapy in animal models of cancer, which can improve treatment outcomes.\n1",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is a small molecule inhibitor of the enzyme phosphatidylinositol 3-kinase (PI3K).\n2. AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer.\n3. AZD8601 has been shown to induce apoptosis in cancer cells.\n4. AZD8601 has been shown to inhibit the formation of new blood vessels necessary for tumor growth and survival.\n5. AZD8601 has been shown to enhance the immune response against cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is a small molecule inhibitor of the enzyme phosphatidylinositol 3-kinase (PI3K).",
      "AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer.",
      "AZD8601 has been shown to induce apoptosis in cancer cells.",
      "AZD8601 has been shown to inhibit the formation of new blood vessels necessary for tumor growth and survival.",
      "AZD8601 has been shown to enhance the immune response against cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not a small molecule inhibitor of PI3K. It is actually an mRNA-based therapy that encodes for vascular endothelial growth factor A (VEGF-A), which is intended to stimulate the growth of blood vessels.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction for statement 1 is based on the known information about AZD8601 as of my knowledge cutoff date. The other statements about the effects of AZD8601 on tumor growth, apoptosis, blood vessel formation, and immune response are not verifiable without specific data or research findings, hence the response \"UNKNOWN\" for statements 2 through 5.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFs (Sperm Associated Histone Fragments) are created through a process called histone modification. Histones are proteins that make up the nucleosome, the basic unit of DNA packaging in eukaryotic cells. Histone modifications are chemical modifications that can be added to the histone proteins, altering their structure and function.\nThere are several types of histone modifications, but one of the most well-known is histone acetylation. When a histone is acetylated, it becomes more accessible to the DNA-binding proteins, allowing for more efficient gene expression. SAHFs are created when a histone is acetylated on a specific lysine residue, typically lysine 5 or lysine 14. This creates a histone fragment that is associated with the sperm tail and can be transported to the egg during fertilization.\nThe process of creating SAHFs involves several steps:\n1. Histone modification: The histone is first modified by adding an acetyl group to the lysine residue. This is done by enzymes called histone acetyltransferases.\n2. Fragmentation: The modified histone is then fragmented into smaller pieces, including the SAHF. This is done by enzymes called histone-processing enzymes.\n3. Association with sperm tail: The SAHFs are then associated with the sperm tail through a process called protein-protein interaction. This allows the SAHFs to be transported to the egg during fertilization.\n4. Transport to the egg: During fertilization, the sperm penetrates the egg and the SAHFs are delivered to the egg cytoplasm, where they can interact with the egg's DNA.\n5. Gene expression: Once the SAHFs are in the egg cytoplasm, they can interact with the egg's DNA and influence gene expression. This can lead to changes in the expression of genes involved in embryonic development and cell differentiation.\nIt's worth noting that the exact mechanisms of SAHF creation and transport are still not fully understood and are the subject of ongoing research.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFs (Sperm Associated Histone Fragments) are created through a process called histone modification.\n2. Histones are proteins that make up the nucleosome, the basic unit of DNA packaging in eukaryotic cells.\n3. Histone acetylation is a type of histone modification where an acetyl group is added to a histone protein, typically on lysine 5 or lysine 14.\n4. Histone acetyltransferases are enzymes that add acetyl groups to histones during histone modification.\n5. SAHFs are associated with the sperm tail and can be transported to the egg during fertilization.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFs (Sperm Associated Histone Fragments) are created through a process called histone modification.",
      "Histones are proteins that make up the nucleosome, the basic unit of DNA packaging in eukaryotic cells.",
      "Histone acetylation is a type of histone modification where an acetyl group is added to a histone protein, typically on lysine 5 or lysine 14.",
      "Histone acetyltransferases are enzymes that add acetyl groups to histones during histone modification.",
      "SAHFs are associated with the sperm tail and can be transported to the egg during fertilization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SAHFs (Sperm Associated Histone Fragments) are not created through histone modification. They are actually DNA fragments that are associated with the histones in sperm. The term \"SAHF\" is more commonly used to refer to Senescence-Associated Heterochromatin Foci, which are structures formed by condensed chromatin in senescent cells.\n2. TRUE\n3. FALSE [correction]: Histone acetylation typically occurs on lysine residues, but not specifically on lysine 5 or lysine 14. Common sites of acetylation on histones include lysine 9, lysine 14, lysine 18, and lysine 27 on histone H3, and lysine 5, lysine 8, lysine 12, and lysine 16 on histone H4.\n4. TRUE\n5. FALSE [correction]: SAHFs, if referring to Sperm Associated Histone Fragments, are not associated with the sperm tail. Instead, they would be associated with the DNA in the sperm head. If SAHF is taken to mean Senescence-Associated Heterochromatin Foci, then this statement is also incorrect as SAHFs are related to cellular senescence and not sperm function.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "SATB1 (Sex-determining region, Y-box 1) is a transcription factor that plays a crucial role in the regulation of gene expression during embryonic development and cell differentiation. SATB1 contains multiple domains, including an N-terminal PDZ (PSD-95/Discs-large/ZO-1) domain.\nThe PDZ domain of SATB1 is involved in protein-protein interactions and is responsible for the binding of SATB1 to specific ligands, such as the extracellular matrix protein fibronectin. The PDZ domain can also interact with other proteins, including the cytoskeleton, to modulate the localization and activity of SATB1.\nStudies have shown that the PDZ domain of SATB1 is important for its ability to regulate gene expression, particularly in the context of cell adhesion and migration. The PDZ domain can recruit SATB1 to specific genomic loci, where it can activate or repress transcription in response to changes in the cellular environment.\nIn addition, the PDZ domain of SATB1 has been implicated in the regulation of stem cell maintenance and differentiation. SATB1 is known to be involved in the maintenance of stem cell self-renewal and pluripotency, and the PDZ domain may play a role in these processes by modulating the interactions between SATB1 and other transcription factors.\nOverall, the PDZ domain of SATB1 is a critical component of its function as a transcription factor, and its interactions with other proteins and the cytoskeleton play a key role in regulating gene expression and cellular behavior.",
    "llama-2-7b-chat-hf_fact_raw": "1. SATB1 is a transcription factor involved in the regulation of gene expression during embryonic development and cell differentiation.\n2. The PDZ domain of SATB1 is involved in protein-protein interactions.\n3. The PDZ domain is responsible for the binding of SATB1 to specific ligands, such as fibronectin.\n4. The PDZ domain of SATB1 can recruit the transcription factor to specific genomic loci to activate or repress transcription.\n5. The PDZ domain of SATB1 has been implicated in the regulation of stem cell maintenance and differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "SATB1 is a transcription factor involved in the regulation of gene expression during embryonic development and cell differentiation.",
      "The PDZ domain of SATB1 is involved in protein-protein interactions.",
      "The PDZ domain is responsible for the binding of SATB1 to specific ligands, such as fibronectin.",
      "The PDZ domain of SATB1 can recruit the transcription factor to specific genomic loci to activate or repress transcription.",
      "The PDZ domain of SATB1 has been implicated in the regulation of stem cell maintenance and differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The PDZ domain is generally known for mediating protein-protein interactions, but it is not responsible for the binding of SATB1 to specific ligands such as fibronectin. SATB1 typically binds to DNA at base-unpairing regions (BURs) to regulate gene expression.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The BLISS (Bayesian Linear Inverse Scattering) technique is a statistical method used to estimate the parameters of a linear inverse problem, such as the parameters of a linear regression model. The basis of the BLISS technique is Bayesian inference, which is a statistical framework for making probabilistic predictions based on prior knowledge or beliefs about a system or process.\nIn the context of the BLISS technique, the linear inverse problem is formulated as a Bayesian inference problem, where the goal is to estimate the parameters of a linear regression model that best explains a set of observations. The BLISS technique uses a Bayesian approach to estimate the parameters of the linear regression model by maximizing the posterior probability of the model given the observations.\nThe BLISS technique is based on the following assumptions:\n1. The observations are independent and identically distributed random variables.\n2. The observations are normally distributed with a mean equal to the expected value of the linear regression model and a variance equal to the variance of the observations.\n3. The parameters of the linear regression model are normally distributed with known mean and variance.\n4. The prior distribution of the parameters of the linear regression model is known.\nBy using these assumptions, the BLISS technique can estimate the parameters of the linear regression model by maximizing the posterior probability of the model given the observations. The technique is particularly useful when the number of observations is large and the observations are noisy, as it can provide accurate estimates of the parameters of the linear regression model in these cases.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is used to estimate parameters of a linear inverse problem.\n2. Bayesian inference is the statistical framework upon which the BLISS technique is based.\n3. The BLISS technique formulates the linear inverse problem as a Bayesian inference problem to estimate parameters of a linear regression model.\n4. The BLISS technique assumes that observations are independent and identically distributed random variables.\n5. The BLISS technique assumes that the parameters of the linear regression model are normally distributed with known mean and variance.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is used to estimate parameters of a linear inverse problem.",
      "Bayesian inference is the statistical framework upon which the BLISS technique is based.",
      "The BLISS technique formulates the linear inverse problem as a Bayesian inference problem to estimate parameters of a linear regression model.",
      "The BLISS technique assumes that observations are independent and identically distributed random variables.",
      "The BLISS technique assumes that the parameters of the linear regression model are normally distributed with known mean and variance."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are consistent with a Bayesian approach to solving linear inverse problems, where BLISS (Bayesian Linear Inverse System Solver) could be a technique used for such problems. However, without specific details about the BLISS technique, it is not possible to confirm the assumptions about the distribution of observations and parameters (statements 4 and 5). These details are not standard for all Bayesian techniques and can vary.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "NK3R (Neuromedin K receptor) antagonists are a class of drugs that target the NK3R receptor and are used to treat various conditions, including nausea and vomiting, migraine, and gastrointestinal disorders. Here are three NK3R antagonists:\n1. Alogliptin: Alogliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor that also acts as an NK3R antagonist. It is used to treat type 2 diabetes and has been shown to reduce nausea and vomiting in patients with diabetes.\n2. Tesofensine: Tesofensine is an oral NK3R antagonist that is used to treat nausea and vomiting associated with chemotherapy in patients with cancer. It works by blocking the action of NK3R on the vagus nerve, which is responsible for causing nausea and vomiting.\n3. Oncesecret: Oncesecret is an oral NK3R antagonist that is currently being investigated for the treatment of gastroparesis, a condition characterized by delayed gastric emptying. It has also shown promise in reducing nausea and vomiting in patients with gastroparesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Alogliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor that acts as an NK3R antagonist.\n2. Tesofensine is an oral NK3R antagonist used to treat nausea and vomiting associated with chemotherapy in cancer patients.\n3. Oncesecret is an oral NK3R antagonist being investigated for the treatment of gastroparesis.",
    "llama-2-7b-chat-hf_fact": [
      "Alogliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor that acts as an NK3R antagonist.",
      "Tesofensine is an oral NK3R antagonist used to treat nausea and vomiting associated with chemotherapy in cancer patients.",
      "Oncesecret is an oral NK3R antagonist being investigated for the treatment of gastroparesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Alogliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used to treat type 2 diabetes; it is not an NK3R antagonist.\n2. FALSE [correction]: Tesofensine is not an NK3R antagonist; it is a serotonin-noradrenaline-dopamine reuptake inhibitor primarily investigated for the treatment of obesity. It is not used to treat nausea and vomiting associated with chemotherapy in cancer patients.\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is called BMS-986177. It was developed by Bristol-Myers Squibb and was studied in a phase 1 clinical trial in 2009. The trial was designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of BMS-986177 in healthy subjects, and it showed that the drug was well-tolerated and had a predictable pharmacokinetic profile. However, further development of BMS-986177 was discontinued due to disappointing efficacy results in subsequent clinical trials for the treatment of obesity.",
    "llama-2-7b-chat-hf_fact_raw": "1. BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. BMS-986177 was developed by Bristol-Myers Squibb.\n3. A phase 1 clinical trial for BMS-986177 was conducted in 2009.\n4. The phase 1 clinical trial was designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of BMS-986177 in healthy subjects.\n5. Further development of BMS-986177 was discontinued due to disappointing efficacy results in subsequent clinical trials for the treatment of obesity.",
    "llama-2-7b-chat-hf_fact": [
      "BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "BMS-986177 was developed by Bristol-Myers Squibb.",
      "A phase 1 clinical trial for BMS-986177 was conducted in 2009.",
      "The phase 1 clinical trial was designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of BMS-986177 in healthy subjects.",
      "Further development of BMS-986177 was discontinued due to disappointing efficacy results in subsequent clinical trials for the treatment of obesity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nWithout specific information on the development timeline of BMS-986177, the year of the phase 1 clinical trial (statement 3), and the reasons for discontinuation of its development (statement 5), it is not possible to verify these statements as true or false.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora, also known as Shanchol, is a cholera vaccine approved for use in adults 18 years of age and older for the prevention of cholera caused by Vibrio cholerae serogroup A in adults who are traveling to or living in areas where cholera is common. The protective efficacy of Vaxchora against moderate to severe cholera has been demonstrated in clinical trials.\nIn a phase 3 clinical trial conducted in Bangladesh, Vaxchora was shown to provide 60% protection against moderate to severe cholera in adults who received the vaccine 2-12 months before potential exposure to cholera. The trial included 1,000 participants who were randomly assigned to receive either Vaxchora or a placebo. The participants were then exposed to a cholera outbreak in their community, and the incidence of cholera was compared between the vaccinated and placebo groups.\nAnother phase 3 clinical trial conducted in Africa also demonstrated the protective efficacy of Vaxchora against moderate to severe cholera. In this trial, 1,500 adults were randomly assigned to receive either Vaxchora or a placebo, and the incidence of cholera was compared between the two groups after potential exposure to cholera. The results showed that Vaxchora provided 53% protection against moderate to severe cholera.\nIt is important to note that while Vaxchora has been shown to provide protection against moderate to severe cholera, it is not 100% effective, and it is still possible to contract cholera even after vaccination. Therefore, it is important to continue practicing good hygiene and sanitation practices, such as drinking safe water and food, and properly disposing of human waste, to reduce the risk of cholera infection.\nOverall, the protective efficacy of Vaxchora against moderate to severe cholera is around 50-60%, which is considered moderate to good. However, the exact level of protection may vary depending on the specific population being studied and the circumstances of the cholera outbreak.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is a cholera vaccine approved for use in adults 18 years and older for the prevention of cholera caused by Vibrio cholerae serogroup A.\n2. In a phase 3 clinical trial in Bangladesh, Vaxchora provided 60% protection against moderate to severe cholera in adults who received the vaccine 2-12 months before exposure.\n3. The phase 3 clinical trial in Bangladesh included 1,000 participants who were randomly assigned to receive either Vaxchora or a placebo.\n4. Another phase 3 clinical trial in Africa showed that Vaxchora provided 53% protection against moderate to severe cholera.\n5. Vaxchora is not 100% effective in preventing cholera, and good hygiene and sanitation practices are still recommended to reduce the risk of infection.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is a cholera vaccine approved for use in adults 18 years and older for the prevention of cholera caused by Vibrio cholerae serogroup A.",
      "In a phase 3 clinical trial in Bangladesh, Vaxchora provided 60% protection against moderate to severe cholera in adults who received the vaccine 2-12 months before exposure.",
      "The phase 3 clinical trial in Bangladesh included 1,000 participants who were randomly assigned to receive either Vaxchora or a placebo.",
      "Another phase 3 clinical trial in Africa showed that Vaxchora provided 53% protection against moderate to severe cholera.",
      "Vaxchora is not 100% effective in preventing cholera, and good hygiene and sanitation practices are still recommended to reduce the risk of infection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Vaxchora is a cholera vaccine approved for use in adults 18 years and older for the prevention of cholera caused by Vibrio cholerae serogroup O1.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the United States was Shanchol (cholera vaccine, live, oral, strain Bsub37). It was approved by the U.S. Food and Drug Administration (FDA) in 2016 for the prevention of cholera in adults 18 through 64 years of age who are traveling to areas where cholera is common.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the United States was Shanchol.\n2. Shanchol is a live, oral cholera vaccine.\n3. The vaccine strain used in Shanchol is Bsub37.\n4. The U.S. Food and Drug Administration (FDA) approved Shanchol in 2016.\n5. Shanchol was approved for the prevention of cholera in adults aged 18 through 64 who are traveling to cholera-affected areas.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the United States was Shanchol.",
      "Shanchol is a live, oral cholera vaccine.",
      "The vaccine strain used in Shanchol is Bsub37.",
      "The U.S. Food and Drug Administration (FDA) approved Shanchol in 2016.",
      "Shanchol was approved for the prevention of cholera in adults aged 18 through 64 who are traveling to cholera-affected areas."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The first cholera vaccine approved in the United States was Vaxchora, not Shanchol.\n2. FALSE [correction]: Shanchol is an inactivated, oral cholera vaccine, not a live vaccine.\n3. UNKNOWN\n4. FALSE [correction]: The U.S. Food and Drug Administration (FDA) approved Shanchol in 2022, not 2016.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a mutation in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T-cell receptor (TCR) beta chain. These genes are located on the X chromosome and play a critical role in the development and function of the adaptive immune system.\nThe most common mutations associated with CVID are found in the IGH gene, specifically in the CDR3 region, which is responsible for the diversity of the antibody repertoire. These mutations can result in a reduced number of functional B cells and impaired antibody production, leading to recurrent infections and other immunological abnormalities characteristic of CVID.\nThe prevalence of X-linked IGH mutations in CVID varies among different populations, but it is estimated to be around 70-80% in European populations. Other genetic causes of CVID, such as mutations in the TCR beta chain gene or other genes involved in the immune system, are less common and may occur in combination with X-linked mutations.",
    "llama-2-7b-chat-hf_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a mutation in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T-cell receptor (TCR) beta chain.\n2. These genes are located on the X chromosome.\n3. The most common mutations associated with CVID in the IGH gene are found in the CDR3 region.\n4. These mutations can lead to a reduced number of functional B cells and impaired antibody production.\n5. The prevalence of X-linked IGH mutations in CVID is estimated to be around 70-80% in European populations.",
    "llama-2-7b-chat-hf_fact": [
      "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a mutation in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T-cell receptor (TCR) beta chain.",
      "These genes are located on the X chromosome.",
      "The most common mutations associated with CVID in the IGH gene are found in the CDR3 region.",
      "These mutations can lead to a reduced number of functional B cells and impaired antibody production.",
      "The prevalence of X-linked IGH mutations in CVID is estimated to be around 70-80% in European populations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is not a mutation in the X-linked genes encoding the immunoglobulin heavy chain (IGH) or the T-cell receptor (TCR) beta chain. Instead, mutations in genes like ICOS, TNFRSF13B (TACI), and TNFRSF13C (BAFFR) are more commonly associated with CVID.\n2. FALSE [correction]: Since the statement about the most common monogenic cause of CVID being X-linked IGH or TCR mutations is incorrect, the location of these genes on the X chromosome is irrelevant to the cause of CVID.\n3. UNKNOWN: Without the correct context of which genes are most commonly mutated in CVID, it is not possible to confirm if mutations in the IGH gene associated with CVID are found in the CDR3 region.\n4. TRUE: Mutations that affect the function of B cells can lead to a reduced number of functional B cells and impaired antibody production, which is characteristic of CVID.\n5. FALSE [correction]: The prevalence of X-linked IGH mutations in CVID is not estimated to be around 70-80% in European populations. Monogenic causes are relatively rare, and the majority of CVID cases are considered to be complex and multifactorial, with only a small percentage attributed to single-gene defects.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene has been found to play a role in the development and progression of Systemic Lupus Erythematosus (SLE), an autoimmune disease that affects multiple organ systems. Here are some of the ways in which the IFIT1 gene is involved in SLE:\n1. IFIT1 is a negative regulator of type I interferons: SLE is characterized by an imbalance in the immune response, leading to an overproduction of type I interferons. The IFIT1 gene encodes a protein that inhibits the production of these interferons, which can help to reduce the severity of the disease.\n2. IFIT1 is downregulated in SLE patients: Studies have shown that the expression of the IFIT1 gene is reduced in the peripheral blood mononuclear cells of SLE patients compared to healthy controls. This reduction in IFIT1 expression may contribute to the overproduction of type I interferons and the development of SLE.\n3. IFIT1 regulates the expression of genes involved in the immune response: The IFIT1 gene can bind to specific DNA sequences and regulate the expression of genes involved in the immune response, such as those involved in the production of cytokines and chemokines. In SLE, the IFIT1 gene may play a role in regulating the expression of genes that contribute to the development of the disease.\n4. IFIT1 may play a role in the pathogenesis of SLE: The IFIT1 gene has been shown to be involved in the pathogenesis of SLE in animal models of the disease. For example, mice lacking the Ifit1 gene are more susceptible to the development of SLE-like disease.\nIn summary, the IFIT1 gene plays a critical role in regulating the immune response and preventing the overproduction of type I interferons, which are involved in the development of Systemic Lupus Erythematosus (SLE). The downregulation of IFIT1 expression in SLE patients may contribute to the development of the disease, and the IFIT1 gene may play a role in the pathogenesis of SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene is a negative regulator of type I interferons, which are overproduced in Systemic Lupus Erythematosus (SLE).\n2. The expression of the IFIT1 gene is reduced in the peripheral blood mononuclear cells of SLE patients compared to healthy controls.\n3. The IFIT1 gene can regulate the expression of genes involved in the immune response, including those related to cytokines and chemokines production.\n4. Mice lacking the Ifit1 gene are more susceptible to the development of SLE-like disease, indicating a role in the pathogenesis of SLE.\n5. The IFIT1 gene encodes a protein that inhibits the production of type I interferons, which can help to reduce the severity of SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene is a negative regulator of type I interferons, which are overproduced in Systemic Lupus Erythematosus (SLE).",
      "The expression of the IFIT1 gene is reduced in the peripheral blood mononuclear cells of SLE patients compared to healthy controls.",
      "The IFIT1 gene can regulate the expression of genes involved in the immune response, including those related to cytokines and chemokines production.",
      "Mice lacking the Ifit1 gene are more susceptible to the development of SLE-like disease, indicating a role in the pathogenesis of SLE.",
      "The IFIT1 gene encodes a protein that inhibits the production of type I interferons, which can help to reduce the severity of SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The IFIT1 gene is not a negative regulator of type I interferons; it is induced by type I interferons and has antiviral activities.\n2. UNKNOWN: Without specific data or research findings, it is not possible to confirm the expression levels of the IFIT1 gene in SLE patients compared to healthy controls.\n3. TRUE: The IFIT1 gene can regulate the expression of genes involved in the immune response, including those related to cytokines and chemokines production, as part of the interferon-stimulated gene family.\n4. UNKNOWN: The role of the Ifit1 gene in the development of SLE-like disease in mice would require specific experimental evidence to confirm.\n5. FALSE [correction]: The IFIT1 gene encodes a protein that is involved in the antiviral response and is not known to inhibit the production of type I interferons. Instead, it is typically upregulated in response to interferon signaling.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a clinical assessment tool used to evaluate the severity of elbow pain and stiffness in patients with elbow injuries or conditions, such as tennis elbow (lateral epicondylitis) or golfer's elbow (medial epicondylitis). The score is used to assess the patient's level of function and disability, and to monitor the effectiveness of treatment interventions.\nThe LES is a simple and quick assessment tool that consists of 5 items that evaluate the patient's symptoms and function in the following areas:\n1. Pain: The patient is asked to rate their elbow pain on a numerical rating scale (NRS) from 0 (no pain) to 10 (worst possible pain).\n2. Stiffness: The patient is asked to rate their elbow stiffness on a NRS from 0 (no stiffness) to 10 (maximum stiffness).\n3. Grip strength: The patient's grip strength is measured using a dynamometer.\n4. Functional ability: The patient is asked to perform a series of functional activities, such as bending and straightening their elbow, and the examiner assesses the patient's ability to perform these tasks.\n5. Quality of life: The patient is asked to complete a questionnaire that evaluates their overall quality of life and their ability to perform daily activities.\nThe scores from each of these items are added up to give a total LES score, which can range from 0 to 50. A higher score indicates greater severity of elbow symptoms and disability.\nThe LES has been shown to be a reliable and valid measure of elbow function and disability, and it has been used in numerous research studies and clinical trials to evaluate the effectiveness of different treatments for elbow injuries and conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to evaluate the severity of elbow pain and stiffness in patients with elbow injuries or conditions.\n2. The LES assesses the patient's level of function and disability and monitors the effectiveness of treatment interventions.\n3. The LES consists of 5 items that evaluate symptoms and function in areas including pain, stiffness, grip strength, functional ability, and quality of life.\n4. The total LES score can range from 0 to 50, with a higher score indicating greater severity of elbow symptoms and disability.\n5. The LES has been shown to be a reliable and valid measure of elbow function and disability.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to evaluate the severity of elbow pain and stiffness in patients with elbow injuries or conditions.",
      "The LES assesses the patient's level of function and disability and monitors the effectiveness of treatment interventions.",
      "The LES consists of 5 items that evaluate symptoms and function in areas including pain, stiffness, grip strength, functional ability, and quality of life.",
      "The total LES score can range from 0 to 50, with a higher score indicating greater severity of elbow symptoms and disability.",
      "The LES has been shown to be a reliable and valid measure of elbow function and disability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Liverpool Elbow Score (LES) consists of 10 items, not 5, that evaluate symptoms and function in areas including pain, stiffness, grip strength, functional ability, and quality of life.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project was a large-scale genomics project launched in 2012 in the UK with the goal of analyzing the genomes of 100,000 individuals, including those with rare and undiagnosed diseases, in order to improve our understanding of the genetic basis of disease and to develop new diagnostic and therapeutic approaches.\nSarcoma is a rare and complex cancer that affects connective tissue, including bone, cartilage, and fat. The 100,000 Genomes Project has made significant efforts to better understand the genetic landscape of sarcoma through whole-genome sequencing of sarcoma tumors. Here are some key findings and insights from these efforts:\n1. Identification of novel sarcoma subtypes: The 100,000 Genomes Project has identified several novel subtypes of sarcoma, including a new subtype of osteosarcoma, which is the most common type of primary bone cancer. These subtypes have distinct genetic mutations and may require different treatment approaches.\n2. Mutational analysis of sarcoma-specific genes: The project has analyzed the mutational status of genes known to be involved in sarcoma, such as TP53, PTEN, and MDM2. These analyses have identified novel mutations and variations in these genes that may play a role in sarcoma development and progression.\n3. Identification of driver mutations: The project has identified specific driver mutations in sarcoma tumors, which are likely to be responsible for the development and progression of the disease. These driver mutations may be targeted with specific therapies to improve treatment outcomes.\n4. Development of personalized treatment strategies: The 100,000 Genomes Project has the potential to develop personalized treatment strategies for sarcoma patients based on the specific genetic mutations present in their tumors. This may involve using targeted therapies or clinical trials of new drugs that are tailored to the specific genetic mutations present in the patient's tumor.\n5. Improved understanding of sarcoma genetic heterogeneity: The project has provided insights into the gen",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in 2012 in the UK with the goal of analyzing the genomes of 100,000 individuals.\n2. The project includes efforts to understand the genetic basis of rare and undiagnosed diseases, including sarcoma.\n3. The 100,000 Genomes Project has identified several novel subtypes of sarcoma, including a new subtype of osteosarcoma.\n4. The project has analyzed the mutational status of genes known to be involved in sarcoma, such as TP53, PTEN, and MDM2.\n5. The 100,000 Genomes Project has identified specific driver mutations in sarcoma tumors that may be targeted with specific therapies.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in 2012 in the UK with the goal of analyzing the genomes of 100,000 individuals.",
      "The project includes efforts to understand the genetic basis of rare and undiagnosed diseases, including sarcoma.",
      "The 100,000 Genomes Project has identified several novel subtypes of sarcoma, including a new subtype of osteosarcoma.",
      "The project has analyzed the mutational status of genes known to be involved in sarcoma, such as TP53, PTEN, and MDM2.",
      "The 100,000 Genomes Project has identified specific driver mutations in sarcoma tumors that may be targeted with specific therapies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project was launched in 2013 in the UK with the goal of analyzing the genomes of 100,000 individuals.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nThe 100,000 Genomes Project indeed aims to understand the genetic basis of rare diseases and cancer, including sarcomas, and would likely analyze known genes involved in these conditions. However, without specific information from the passage regarding the identification of novel subtypes of sarcoma or specific driver mutations, the truth of statements 3 and 5 cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Yes, the protein ALEX1 (Armadillo-like homeobox 1) contains armadillo repeats. ALEX1 is a transcription factor that plays a crucial role in regulating cell fate decisions, including cell proliferation, differentiation, and survival. It is composed of 10 armadillo repeats, which are a type of structural motif that is involved in protein-protein interactions and DNA binding. The armadillo repeats in ALEX1 are responsible for its ability to recognize and bind to specific DNA sequences and regulate gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains armadillo repeats.\n2. ALEX1 is a transcription factor involved in regulating cell fate decisions.\n3. ALEX1 plays a role in cell proliferation, differentiation, and survival.\n4. ALEX1 is composed of 10 armadillo repeats.\n5. The armadillo repeats in ALEX1 are involved in protein-protein interactions and DNA binding.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains armadillo repeats.",
      "ALEX1 is a transcription factor involved in regulating cell fate decisions.",
      "ALEX1 plays a role in cell proliferation, differentiation, and survival.",
      "ALEX1 is composed of 10 armadillo repeats.",
      "The armadillo repeats in ALEX1 are involved in protein-protein interactions and DNA binding."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ALEX1 is not a transcription factor; it is a cytoplasmic protein that may be involved in various cellular processes, but it is not directly involved in regulating gene transcription.\n3. UNKNOWN\n4. FALSE [correction]: ALEX1 is composed of 11 armadillo repeats, not 10.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "There are several enzymes that remove histone modifications, including:\n1. Histone demethylases: These enzymes remove methyl groups from histone proteins, leading to a loss of repressive chromatin marks. Examples of histone demethylases include KDM4B, KDM5A, and JMJD2A.\n2. Histone acetyltransferases (HATs): These enzymes add acetyl groups to histone proteins, leading to a gain of active chromatin marks. Examples of HATs include p300 and CBP (CREB-binding protein).\n3. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histone proteins, leading to a loss of active chromatin marks. Examples of HDACs include HDAC1, HDAC2, and HDAC6.\n4. Lysine-specific demethylase 1 (LSD1): This enzyme removes methyl groups from histone H3 lysine 4 (H3K4), leading to a loss of repressive chromatin marks.\n5. Lysine-specific demethylase 2A (LSD2A): This enzyme removes methyl groups from histone H3 lysine 9 (H3K9), leading to a loss of repressive chromatin marks.\n6. JMJD2B: This enzyme removes methyl groups from histone H3 lysine 27 (H3K27), leading to a loss of repressive chromatin marks.\n7. KDM6A: This enzyme removes methyl groups from histone H3 lysine 56 (H3K56), leading to a loss of repressive chromatin marks.\n8. KDM5B: This enzyme removes methyl groups from histone H3 lysine 79 (H3K79), leading to a loss of repressive chromatin marks.\n9. SUV39H1: This enzyme removes methyl groups from histone H3 lysine 9 (H3K9) and histone H4 lysine 20 (H4K20",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases are enzymes that remove methyl groups from histone proteins.\n2. Histone acetyltransferases (HATs) add acetyl groups to histone proteins.\n3. Histone deacetylases (HDACs) remove acetyl groups from histone proteins.\n4. Lysine-specific demethylase 1 (LSD1) removes methyl groups from histone H3 lysine 4 (H3K4).\n5. Lysine-specific demethylase 2A (LSD2A) removes methyl groups from histone H3 lysine 9 (H3K9).",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases are enzymes that remove methyl groups from histone proteins.",
      "Histone acetyltransferases (HATs) add acetyl groups to histone proteins.",
      "Histone deacetylases (HDACs) remove acetyl groups from histone proteins.",
      "Lysine-specific demethylase 1 (LSD1) removes methyl groups from histone H3 lysine 4 (H3K4).",
      "Lysine-specific demethylase 2A (LSD2A) removes methyl groups from histone H3 lysine 9 (H3K9)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Lysine-specific demethylase 2A (LSD2A) is not a recognized enzyme. The correct enzyme is Lysine-specific demethylase 1A (LSD1A), also known as KDM1A, which is known to demethylate H3K4 and H3K9. However, Lysine-specific demethylase 2 (LSD2), also known as KDM1B, does demethylate H3K9.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Head CT scans are commonly used to diagnose and monitor various conditions affecting the brain, such as traumatic brain injury, stroke, and brain tumors. However, there is some evidence to suggest that head CT scans may increase the risk of developing a brain tumor, particularly in children and young adults.\nThe possible link between head CT scans and brain tumors is due to the exposure to ionizing radiation that occurs during the imaging process. Ionizing radiation has been shown to increase the risk of cancer, including brain tumors, in some studies. However, the risk is generally considered to be low, and the benefits of using a head CT scan to diagnose and monitor brain conditions often outweigh the potential risks.\nSeveral studies have investigated the potential link between head CT scans and brain tumors, and the results have been mixed. Some studies have found a small increase in the risk of brain tumors in individuals who have undergone frequent head CT scans, particularly in children and young adults. However, other studies have found no association between head CT scans and brain tumors.\nA 2011 study published in the journal Radiology found that children and young adults who underwent frequent head CT scans had a higher risk of developing a brain tumor compared to those who did not undergo as many scans. The study found that the risk increased with the number of head CT scans performed, and the risk was highest in children under the age of 5.\nA 2018 study published in the journal Neurology found that adults who underwent head CT scans for the evaluation of headaches had a small increased risk of developing a brain tumor. The study found that the risk was higher in those who had a history of previous head trauma.\nIt is important to note that the risk of developing a brain tumor from a head CT scan is still very low, and the benefits of using a head CT scan to diagnose and monitor brain conditions often outweigh the potential risks. However, individuals who are concerned about the potential risks of head CT scans can discuss their concerns with their healthcare provider and consider alternative imaging tests, such as MRI, when appropriate.\nIn summary, while there is some evidence to suggest that head CT scans may increase the risk of developing a brain tumor, particularly in children and young adult",
    "llama-2-7b-chat-hf_fact_raw": "1. Head CT scans are used to diagnose and monitor conditions like traumatic brain injury, stroke, and brain tumors.\n2. Ionizing radiation from head CT scans has been shown to increase the risk of cancer, including brain tumors, in some studies.\n3. A 2011 study in the journal Radiology found that children and young adults who underwent frequent head CT scans had a higher risk of developing a brain tumor.\n4. The same study indicated that the risk of brain tumors increased with the number of head CT scans, especially in children under the age of 5.\n5. A 2018 study in the journal Neurology found that adults who underwent head CT scans for headache evaluation had a small increased risk of developing a brain tumor.",
    "llama-2-7b-chat-hf_fact": [
      "Head CT scans are used to diagnose and monitor conditions like traumatic brain injury, stroke, and brain tumors.",
      "Ionizing radiation from head CT scans has been shown to increase the risk of cancer, including brain tumors, in some studies.",
      "A 2011 study in the journal Radiology found that children and young adults who underwent frequent head CT scans had a higher risk of developing a brain tumor.",
      "The same study indicated that the risk of brain tumors increased with the number of head CT scans, especially in children under the age of 5.",
      "A 2018 study in the journal Neurology found that adults who underwent head CT scans for headache evaluation had a small increased risk of developing a brain tumor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The study mentioned does not exist in the journal Neurology for the year 2018. It is important to verify the existence of the study and its findings from a reliable source before confirming this statement as true.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is associated with neural pluripotency. Specifically, Otx2 is a transcription factor that is expressed in the neural progenitor cells and is involved in the maintenance of neural progenitor cell fate and the regulation of neural stem cell self-renewal. Otx2 is also important for the proper formation of the cerebral cortex and the development of the nervous system.\nIn addition, Otx2 has been shown to be involved in the regulation of pluripotency in embryonic stem cells, and it is thought to play a role in the maintenance of pluripotency in these cells. However, the exact mechanisms by which Otx2 regulates pluripotency are not yet fully understood.\nIn summary, Otx2 is associated with neural pluripotency and plays a role in the regulation of pluripotency in embryonic stem cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with neural pluripotency.\n2. Otx2 is a transcription factor expressed in neural progenitor cells.\n3. Otx2 is involved in maintaining neural progenitor cell fate.\n4. Otx2 plays a role in the regulation of neural stem cell self-renewal.\n5. Otx2 is important for the proper formation of the cerebral cortex and the development of the nervous system.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with neural pluripotency.",
      "Otx2 is a transcription factor expressed in neural progenitor cells.",
      "Otx2 is involved in maintaining neural progenitor cell fate.",
      "Otx2 plays a role in the regulation of neural stem cell self-renewal.",
      "Otx2 is important for the proper formation of the cerebral cortex and the development of the nervous system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Otx2 is associated with neural development, but it is not directly associated with pluripotency. Pluripotency is a characteristic of undifferentiated stem cells, such as embryonic stem cells, which can differentiate into any cell type.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta globin locus region is marked by several DNaseI hypersensitive sites (DHS). The exact number of DHS sites in the beta globin locus region can vary depending on the specific strain of mouse and the method used to identify them. However, several studies have reported the following number of DHS sites in the beta globin locus region of mice:\n* 10-15 DHS sites were identified in the beta globin locus region of C57BL/6J mice using a combination of DNaseI hypersensitivity and chromatin immunoprecipitation sequencing (ChIP-seq) (Kim et al., 2010)\n* 12-15 DHS sites were identified in the beta globin locus region of B6.CBA-Tg(HBB-M)1Marr/J mice, which are transgenic mice expressing human beta globin under the control of the mouse beta globin promoter (Kim et al., 2010)\n* 17-20 DHS sites were identified in the beta globin locus region of mouse embryonic stem cells (ESCs) using ChIP-seq (Wang et al., 2012)\n* 19-22 DHS sites were identified in the beta globin locus region of adult mouse liver using ChIP-seq (Wang et al., 2012)\nIt is important to note that the number of DHS sites in the beta globin locus region can vary depending on the specific method used to identify them and the strain of mouse being studied. However, these studies suggest that there are at least several dozen DHS sites in the beta globin locus region of mice.",
    "llama-2-7b-chat-hf_fact_raw": "1. 10-15 DNaseI hypersensitive sites were identified in the beta globin locus region of C57BL/6J mice using DNaseI hypersensitivity and chromatin immunoprecipitation sequencing (ChIP-seq) according to Kim et al., 2010.\n2. 12-15 DNaseI hypersensitive sites were identified in the beta globin locus region of B6.CBA-Tg(HBB-M)1Marr/J mice as reported by Kim et al., 2010.\n3. 17-20 DNaseI hypersensitive sites were found in the beta globin locus region of mouse embryonic stem cells using ChIP-seq, as stated by Wang et al., 2012.\n4. 19-22 DNaseI hypersensitive sites were identified in the beta globin locus region of adult mouse liver using ChIP-seq, according to Wang et al., 2012.",
    "llama-2-7b-chat-hf_fact": [
      "10-15 DNaseI hypersensitive sites were identified in the beta globin locus region of C57BL/6J mice using DNaseI hypersensitivity and chromatin immunoprecipitation sequencing (ChIP-seq) according to Kim et al., 2010.",
      "12-15 DNaseI hypersensitive sites were identified in the beta globin locus region of B6.CBA-Tg(HBB-M)1Marr/J mice as reported by Kim et al., 2010.",
      "17-20 DNaseI hypersensitive sites were found in the beta globin locus region of mouse embryonic stem cells using ChIP-seq, as stated by Wang et al., 2012.",
      "19-22 DNaseI hypersensitive sites were identified in the beta globin locus region of adult mouse liver using ChIP-seq, according to Wang et al., 2012."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout access to the specific scientific articles by Kim et al., 2010, and Wang et al., 2012, it is not possible to verify the exact number of DNaseI hypersensitive sites identified in the beta globin locus region of the specified mouse strains and tissues. Therefore, the truthfulness of these statements cannot be determined from the information provided.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "There are several European influenza vaccines available in the market. Here are some of them:\n1. Fluad: This is a quadrivalent influenza vaccine developed by GlaxoSmithKline (GSK) and is approved for use in adults aged 65 years and older.\n2. Fluarix Tetra: This is a quadrivalent influenza vaccine developed by BioNTech and is approved for use in individuals aged 6 months and older.\n3. Fluaxess: This is a quadrivalent influenza vaccine developed by Novartis and is approved for use in individuals aged 6 months and older.\n4. Fluvirin: This is a trivalent influenza vaccine developed by Novartis and is approved for use in individuals aged 6 months and older.\n5. Fluzone: This is a trivalent influenza vaccine developed by Sanofi Pasteur and is approved for use in individuals aged 6 months and older.\n6. FluMist: This is a quadrivalent influenza vaccine developed by MedImmune and is approved for use in individuals aged 2-49 years.\n7. Vaxigrip: This is a trivalent influenza vaccine developed by Sanofi Pasteur and is approved for use in individuals aged 6 months and older.\n8. Aflunax: This is a quadrivalent influenza vaccine developed by Novartis and is approved for use in individuals aged 6 months and older.\n9. Fluad Quad: This is a quadrivalent influenza vaccine developed by GSK and is approved for use in adults aged 65 years and older.\n10. Flu-Egri: This is a quadrivalent influenza vaccine developed by Egis and is approved for use in individuals aged 18-64 years.\nPlease note that this is not an exhaustive list and there may be other influenza vaccines available in Europe that are not listed here. Additionally, the availability and approval status of these vaccines may vary by country.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluad is a quadrivalent influenza vaccine developed by GlaxoSmithKline (GSK) and is approved for use in adults aged 65 years and older.\n2. Fluarix Tetra is a quadrivalent influenza vaccine developed by BioNTech and is approved for use in individuals aged 6 months and older.\n3. Fluaxess is a quadrivalent influenza vaccine developed by Novartis and is approved for use in individuals aged 6 months and older.\n4. Fluvirin is a trivalent influenza vaccine developed by Novartis and is approved for use in individuals aged 6 months and older.\n5. Fluzone is a trivalent influenza vaccine developed by Sanofi Pasteur and is approved for use in individuals aged 6 months and older.",
    "llama-2-7b-chat-hf_fact": [
      "Fluad is a quadrivalent influenza vaccine developed by GlaxoSmithKline (GSK) and is approved for use in adults aged 65 years and older.",
      "Fluarix Tetra is a quadrivalent influenza vaccine developed by BioNTech and is approved for use in individuals aged 6 months and older.",
      "Fluaxess is a quadrivalent influenza vaccine developed by Novartis and is approved for use in individuals aged 6 months and older.",
      "Fluvirin is a trivalent influenza vaccine developed by Novartis and is approved for use in individuals aged 6 months and older.",
      "Fluzone is a trivalent influenza vaccine developed by Sanofi Pasteur and is approved for use in individuals aged 6 months and older."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Fluad is a trivalent influenza vaccine developed by Seqirus, not GlaxoSmithKline (GSK), and is approved for use in adults aged 65 years and older.\n2. FALSE [correction]: Fluarix Tetra is a quadrivalent influenza vaccine developed by GlaxoSmithKline (GSK), not BioNTech, and is approved for use in individuals aged 6 months and older.\n3. UNKNOWN: Without current information, the status of a vaccine named \"Fluaxess\" cannot be verified, nor can the details of its development and approval.\n4. TRUE: Fluvirin is indeed a trivalent influenza vaccine developed by Novartis and is approved for use in individuals aged 6 months and older.\n5. FALSE [correction]: Fluzone is a quadrivalent influenza vaccine developed by Sanofi Pasteur and is approved for use in individuals aged 6 months and older, although trivalent formulations have also been available.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the geneome of Paramyxovirus is segmented, negative-sense RNA. Paramyxoviruses are a family of viruses that include the viruses that cause measles, mumps, and respiratory diseases in humans and animals. The genome of these viruses is composed of several segments of RNA, each of which encodes a different protein.\nThe genome of Paramyxovirus is negative-sense RNA, meaning that the RNA molecule has a complementary sequence to the messenger RNA (mRNA) that it encodes. This is in contrast to positive-sense RNA viruses, such as HIV, which have a continuous reading frame and do not require the presence of a complementary RNA molecule for replication.\nEach segment of the Paramyxovirus genome is transcribed into mRNA, which is then translated into protein. The proteins encoded by these mRNAs are then assembled into viral particles, which are released from infected cells and go on to infect other cells.\nThe segmented nature of the Paramyxovirus genome allows for the coordinated regulation of gene expression, as different segments of the genome can be transcribed at different times and in different cells. This can help the virus to optimize its replication and spread within the host organism.",
    "llama-2-7b-chat-hf_fact_raw": "1. The genome of Paramyxovirus is segmented.\n2. Paramyxoviruses include viruses that cause measles, mumps, and respiratory diseases in humans and animals.\n3. The genome of Paramyxovirus is negative-sense RNA.\n4. Negative-sense RNA has a complementary sequence to the messenger RNA it encodes.\n5. Each segment of the Paramyxovirus genome is transcribed into mRNA and then translated into protein.",
    "llama-2-7b-chat-hf_fact": [
      "The genome of Paramyxovirus is segmented.",
      "Paramyxoviruses include viruses that cause measles, mumps, and respiratory diseases in humans and animals.",
      "The genome of Paramyxovirus is negative-sense RNA.",
      "Negative-sense RNA has a complementary sequence to the messenger RNA it encodes.",
      "Each segment of the Paramyxovirus genome is transcribed into mRNA and then translated into protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The genome of Paramyxovirus is non-segmented.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Since the Paramyxovirus genome is non-segmented, it does not have segments. The entire genome is transcribed into a single, continuous mRNA and then translated into proteins.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is effective for the treatment of plaque psoriasis, a chronic skin condition characterized by red, scaly patches on the skin. It works by reducing inflammation and slowing down the growth of skin cells, which helps to improve the appearance of the skin and relieve symptoms such as itching and burning.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used for the treatment of plaque psoriasis.\n2. Plaque psoriasis is characterized by red, scaly patches on the skin.\n3. Roflumilast cream works by reducing inflammation.\n4. Roflumilast cream helps to slow down the growth of skin cells.\n5. The cream is used to improve the appearance of the skin and relieve symptoms like itching and burning.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used for the treatment of plaque psoriasis.",
      "Plaque psoriasis is characterized by red, scaly patches on the skin.",
      "Roflumilast cream works by reducing inflammation.",
      "Roflumilast cream helps to slow down the growth of skin cells.",
      "The cream is used to improve the appearance of the skin and relieve symptoms like itching and burning."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Roflumilast is available as a tablet for the treatment of chronic obstructive pulmonary disease (COPD). There is a topical form of roflumilast that may be used for psoriasis, but it is not typically referred to as \"roflumilast cream.\"\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Several tools have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are some of the commonly used tools:\n1. RNAhybrid: This tool uses a combination of sequence alignment and molecular dynamics simulations to predict the secondary and tertiary structure of ncRNA molecules. It can also predict the promoter regions of ncRNAs.\n2. PrognoseR: This tool uses a machine learning approach to predict the promoter regions of ncRNAs based on their sequence features. It can also predict the strength of the promoter and the orientation of the transcript.\n3. RNApromoter: This tool uses a combination of sequence analysis and machine learning to predict the promoter regions of ncRNAs. It can also predict the strength of the promoter and the orientation of the transcript.\n4. CpG Island Finder: This tool identifies CpG islands in the genome, which are known to be enriched in ncRNA promoters.\n5. ChromHMM: This tool uses a hidden Markov model to predict the chromatin structure of the genome, including the location of ncRNA promoters.\n6. DeepSEA: This tool uses a deep learning approach to predict the promoter regions of ncRNAs based on their sequence features. It can also predict the strength of the promoter and the orientation of the transcript.\n7. RNAProfiler: This tool uses a combination of sequence analysis and machine learning to predict the promoter regions of ncRNAs. It can also predict the strength of the promoter and the orientation of the transcript.\n8. NCRNApro: This tool uses a combination of sequence analysis and machine learning to predict the promoter regions of ncRNAs. It can also predict the strength of the promoter and the orientation of the transcript.\n9. RNApromoter2: This tool uses a combination of sequence analysis and machine learning to predict the promoter regions of ncRNAs. It can also predict the strength of the promoter and the orientation of the transcript.\n10. Prognosticate: This tool uses a machine learning approach to predict the promoter regions of ncRNAs based on",
    "llama-2-7b-chat-hf_fact_raw": "1. RNAhybrid is a tool that predicts the secondary and tertiary structure of ncRNA molecules and their promoter regions.\n2. PrognoseR is a machine learning tool designed to predict ncRNA promoter regions, their strength, and transcript orientation.\n3. CpG Island Finder is a tool that identifies CpG islands, which are often associated with ncRNA promoters.\n4. ChromHMM uses a hidden Markov model to predict chromatin structure, including ncRNA promoter locations.\n5. DeepSEA is a deep learning tool that predicts ncRNA promoter regions, their strength, and transcript orientation based on sequence features.",
    "llama-2-7b-chat-hf_fact": [
      "RNAhybrid is a tool that predicts the secondary and tertiary structure of ncRNA molecules and their promoter regions.",
      "PrognoseR is a machine learning tool designed to predict ncRNA promoter regions, their strength, and transcript orientation.",
      "CpG Island Finder is a tool that identifies CpG islands, which are often associated with ncRNA promoters.",
      "ChromHMM uses a hidden Markov model to predict chromatin structure, including ncRNA promoter locations.",
      "DeepSEA is a deep learning tool that predicts ncRNA promoter regions, their strength, and transcript orientation based on sequence features."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RNAhybrid is a tool that predicts the minimum free energy hybridization of a long and a short RNA molecule, not the secondary and tertiary structure of ncRNA molecules and their promoter regions.\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: ChromHMM uses a hidden Markov model to predict chromatin states, not specifically ncRNA promoter locations.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "The SWIM tool is a computational pipeline for identifying novel cancer-specific transcripts and genes that are down-regulated in cancer. Here are some examples of genes that SWIM has identified as down-regulated in glioblastoma:\n1. TP53INP1: TP53-induced nuclear protein 1 (TP53INP1) is a tumor suppressor gene that is down-regulated in many types of cancer, including glioblastoma.\n2. PTEN: Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene that is down-regulated in many types of cancer, including glioblastoma.\n3. CDKN2A: Cyclin-dependent kinase inhibitor 2A (CDKN2A) is a tumor suppressor gene that is down-regulated in many types of cancer, including glioblastoma.\n4. STK11: Serine/threonine kinase 11 (STK11) is a tumor suppressor gene that is down-regulated in many types of cancer, including glioblastoma.\n5. PML: Promyelocytic leukemia (PML) is a tumor suppressor gene that is down-regulated in many types of cancer, including glioblastoma.\n6. TARDBP: TAR DNA-binding protein (TARDBP) is a tumor suppressor gene that is down-regulated in many types of cancer, including glioblastoma.\n7. SLC9A2: Solute carrier family 9, subfamily A, member 2 (SLC9A2) is a gene that is down-regulated in many types of cancer, including glioblastoma.\n8. GOLM1: GOLM1 is a gene that is down-regulated in many types of cancer, including glioblastoma.\n9. MTUS1: Membrane-associated guanylate kinase-like protein 1 (MTUS1) is a gene that is down-regulated in many types of cancer, including glioblastoma.\n10. RHNO1: Rhomboid protein 1 (RHNO1) is a gene that is down-",
    "llama-2-7b-chat-hf_fact_raw": "1. TP53-induced nuclear protein 1 (TP53INP1) is identified by SWIM as down-regulated in glioblastoma.\n2. Phosphatase and tensin homolog (PTEN) is identified by SWIM as down-regulated in glioblastoma.\n3. Cyclin-dependent kinase inhibitor 2A (CDKN2A) is identified by SWIM as down-regulated in glioblastoma.\n4. Serine/threonine kinase 11 (STK11) is identified by SWIM as down-regulated in glioblastoma.\n5. Promyelocytic leukemia (PML) is identified by SWIM as down-regulated in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "TP53-induced nuclear protein 1 (TP53INP1) is identified by SWIM as down-regulated in glioblastoma.",
      "Phosphatase and tensin homolog (PTEN) is identified by SWIM as down-regulated in glioblastoma.",
      "Cyclin-dependent kinase inhibitor 2A (CDKN2A) is identified by SWIM as down-regulated in glioblastoma.",
      "Serine/threonine kinase 11 (STK11) is identified by SWIM as down-regulated in glioblastoma.",
      "Promyelocytic leukemia (PML) is identified by SWIM as down-regulated in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific context or results from the SWIM (which could be a specific study, database, or analysis tool), it is not possible to verify the accuracy of these statements regarding the regulation of these genes in glioblastoma.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for studying Transcriptional Activity Domains (TADs), which are regions of the genome where gene expression is actively regulated. Here are some of the popular R packages for studying TADs:\n1. TADbit: This package provides a comprehensive set of tools for the analysis of TADs, including the ability to identify TADs, quantify their expression levels, and infer their regulatory interactions.\n2. TADeley: This package provides a simple and efficient way to identify TADs in a genome, as well as to analyze their expression levels and regulatory interactions.\n3. TADtrack: This package provides a comprehensive set of tools for the analysis of TADs, including the ability to identify TADs, quantify their expression levels, and infer their regulatory interactions.\n4. TADseq: This package provides a simple and efficient way to identify TADs in a genome, as well as to analyze their expression levels and regulatory interactions.\n5. TADR: This package provides a comprehensive set of tools for the analysis of TADs, including the ability to identify TADs, quantify their expression levels, and infer their regulatory interactions.\n6. TAD-seq: This package provides a simple and efficient way to identify TADs in a genome, as well as to analyze their expression levels and regulatory interactions.\n7. TAD-tools: This package provides a comprehensive set of tools for the analysis of TADs, including the ability to identify TADs, quantify their expression levels, and infer their regulatory interactions.\n8. TAD-workflow: This package provides a comprehensive set of tools for the analysis of TADs, including the ability to identify TADs, quantify their expression levels, and infer their regulatory interactions.\nThese packages provide a wide range of tools and methods for studying TADs, including the ability to identify TADs, quantify their expression levels, and infer their regulatory interactions. They can be used to analyze large-scale genomic data sets, such as those generated by next-generation sequencing technologies, and can be used to identify novel TADs and regulatory elements.",
    "llama-2-7b-chat-hf_fact_raw": "1. TADbit is an R package developed for the analysis of Transcriptional Activity Domains (TADs).\n2. TADeley is an R package that provides tools to identify TADs and analyze their expression levels and regulatory interactions.\n3. TADtrack is an R package designed for the analysis of TADs, including identification and quantification of their expression levels.\n4. TADseq is an R package that offers methods to identify TADs and analyze their expression levels and regulatory interactions.\n5. TADR is an R package that includes tools for the analysis of TADs, such as identification and quantification of expression levels.",
    "llama-2-7b-chat-hf_fact": [
      "TADbit is an R package developed for the analysis of Transcriptional Activity Domains (TADs).",
      "TADeley is an R package that provides tools to identify TADs and analyze their expression levels and regulatory interactions.",
      "TADtrack is an R package designed for the analysis of TADs, including identification and quantification of their expression levels.",
      "TADseq is an R package that offers methods to identify TADs and analyze their expression levels and regulatory interactions.",
      "TADR is an R package that includes tools for the analysis of TADs, such as identification and quantification of expression levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TADbit is a Python library, not an R package, developed for the analysis of 3D genomic data and the identification of Topologically Associating Domains (TADs).\n2. UNKNOWN: There is no widely recognized R package named TADeley. It is possible that this is a fictional or less-known package, or the name might be misspelled.\n3. UNKNOWN: Similar to TADeley, there is no widely recognized R package named TADtrack. This could be a fictional or less-known package, or the name might be incorrect.\n4. UNKNOWN: TADseq does not appear to be a recognized R package for the analysis of TADs. This could be a fictional name, a less-known package, or a mistake in the name.\n5. UNKNOWN: TADR is not a known R package for TAD analysis in the bioinformatics community. This could be a fictional package, a less-known package, or the name might be incorrect.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "The Bioconductor tool that has been developed for accessing bacterial regulatory networks is called \"BioCyc\". BioCyc is a comprehensive database of genomic and proteomic information for bacteria, including regulatory networks, metabolic pathways, and gene expression data. It provides a user-friendly interface for exploring and analyzing the regulatory networks of various bacterial species, including E. coli, B. subtilis, and S. aureus. BioCyc uses a combination of machine learning and statistical methods to predict the interactions between transcription factors, regulatory genes, and their target genes, and it also includes tools for visualizing and analyzing the resulting networks.",
    "llama-2-7b-chat-hf_fact_raw": "1. BioCyc is a Bioconductor tool developed for accessing bacterial regulatory networks.\n2. BioCyc is a database that includes genomic and proteomic information for bacteria.\n3. The database provides information on regulatory networks, metabolic pathways, and gene expression data.\n4. BioCyc offers a user-friendly interface for exploring bacterial species such as E. coli, B. subtilis, and S. aureus.\n5. BioCyc employs machine learning and statistical methods to predict interactions in regulatory networks.",
    "llama-2-7b-chat-hf_fact": [
      "BioCyc is a Bioconductor tool developed for accessing bacterial regulatory networks.",
      "BioCyc is a database that includes genomic and proteomic information for bacteria.",
      "The database provides information on regulatory networks, metabolic pathways, and gene expression data.",
      "BioCyc offers a user-friendly interface for exploring bacterial species such as E. coli, B. subtilis, and S. aureus.",
      "BioCyc employs machine learning and statistical methods to predict interactions in regulatory networks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: BioCyc is not a Bioconductor tool; it is a collection of pathway/genome databases.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The end products of the shikimate pathway are a group of aromatic amino acids, including:\n1. Phenylalanine: This is the first committed step in the shikimate pathway and is converted into other aromatic amino acids through a series of reactions.\n2. Tyrosine: This amino acid is produced from phenylalanine through a series of enzyme-catalyzed reactions.\n3. Tryptophan: This amino acid is synthesized from tyrosine through a series of reactions involving the enzyme aromatic amino acid decarboxylase.\n4. Tryptophan-3-monooxygenase: This enzyme catalyzes the conversion of tryptophan into 3-hydroxytryptophan (serotonin), which is involved in various physiological processes, including mood regulation and appetite.\n5. Quinolinic acid: This amino acid is produced from tryptophan through a series of enzyme-catalyzed reactions.\n6. Kynurenine: This amino acid is synthesized from quinolinic acid through a series of reactions involving the enzyme kynurenine hydroxylase.\n7. Anthranilic acid: This amino acid is produced from kynurenine through a series of enzyme-catalyzed reactions.\n8. 3-Hydroxyanthranilic acid: This amino acid is synthesized from anthranilic acid through a series of enzyme-catalyzed reactions.\n9. 3-Hydroxybenzoic acid: This amino acid is produced from 3-hydroxyanthranilic acid through a series of enzyme-catalyzed reactions.\nThese end products of the shikimate pathway are important for various physiological processes in the body, including the synthesis of neurotransmitters, hormones, and other biomolecules.",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway produces a group of aromatic amino acids.\n2. Phenylalanine is one of the end products of the shikimate pathway.\n3. Tyrosine is produced from phenylalanine through a series of enzyme-catalyzed reactions.\n4. Tryptophan is synthesized from intermediates in the shikimate pathway.\n5. Quinolinic acid is produced from tryptophan through a series of enzyme-catalyzed reactions.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway produces a group of aromatic amino acids.",
      "Phenylalanine is one of the end products of the shikimate pathway.",
      "Tyrosine is produced from phenylalanine through a series of enzyme-catalyzed reactions.",
      "Tryptophan is synthesized from intermediates in the shikimate pathway.",
      "Quinolinic acid is produced from tryptophan through a series of enzyme-catalyzed reactions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome, which is a rare condition that can occur after treatment with certain types of hormone-sensitive tumors, such as pituitary tumors. Cabergoline is a dopamine receptor agonist that can help to reduce the growth of tumors in the pituitary gland and surrounding tissues, which can help to relieve symptoms of Nelson's syndrome.\nCabergoline has been shown to be effective in reducing the size of tumors in the pituitary gland and improving symptoms such as headache, visual disturbances, and hormonal imbalances. However, it is important to note that cabergoline is not a cure for Nelson's syndrome, and it may not completely eliminate all symptoms.\nIt's worth noting that cabergoline is not FDA-approved for the treatment of Nelson's syndrome, and it is typically used off-label for this purpose. Therefore, it's important to discuss the potential benefits and risks of cabergoline with a qualified healthcare professional before starting treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is sometimes used to treat Nelson's syndrome.\n2. Nelson's syndrome is a rare condition that can occur after treatment for hormone-sensitive tumors, such as pituitary tumors.\n3. Cabergoline is a dopamine receptor agonist.\n4. Cabergoline has been shown to be effective in reducing the size of tumors in the pituitary gland.\n5. Cabergoline is not FDA-approved for the treatment of Nelson's syndrome and is used off-label for this purpose.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is sometimes used to treat Nelson's syndrome.",
      "Nelson's syndrome is a rare condition that can occur after treatment for hormone-sensitive tumors, such as pituitary tumors.",
      "Cabergoline is a dopamine receptor agonist.",
      "Cabergoline has been shown to be effective in reducing the size of tumors in the pituitary gland.",
      "Cabergoline is not FDA-approved for the treatment of Nelson's syndrome and is used off-label for this purpose."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used to treat Nelson's syndrome. Nelson's syndrome involves the growth of a pituitary tumor after the removal of the adrenal glands, and cabergoline is not a standard treatment for this condition.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare genetic disorder that primarily affects the nervous system. The main manifestation of Liebenberg syndrome is a combination of symptoms that include:\n1. Seizures: The most common symptom of Liebenberg syndrome is the occurrence of seizures, which can be of various types such as tonic-clonic, atypical absence, or myoclonic seizures. The seizures usually begin in childhood and can continue throughout life.\n2. Intellectual disability: Individuals with Liebenberg syndrome often have intellectual disability, which can range from mild to severe. This can affect their ability to learn and adapt to new situations.\n3. Autism spectrum disorder: Many individuals with Liebenberg syndrome also have autism spectrum disorder (ASD), which can manifest as difficulties with social interaction, communication, and repetitive behaviors.\n4. Sleep disturbances: People with Liebenberg syndrome may experience sleep disturbances, including insomnia, sleepwalking, and night terrors.\n5. Vision problems: Some individuals with Liebenberg syndrome may have vision problems, including nystagmus (involuntary eye movements), strabismus (crossed eyes), and visual field defects.\n6. Hearing loss: Some people with Liebenberg syndrome may experience hearing loss or decreased hearing sensitivity.\n7. Other symptoms: Other symptoms that may be present in Liebenberg syndrome include delayed speech and language development, coordination problems, and motor skill delays.\nIt's important to note that the severity and combination of these symptoms can vary widely among individuals with Liebenberg syndrome. A thorough medical evaluation and genetic testing can help confirm the diagnosis and guide appropriate management and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder that primarily affects the nervous system.\n2. The most common symptom of Liebenberg syndrome is the occurrence of seizures.\n3. Individuals with Liebenberg syndrome often have intellectual disability.\n4. Many individuals with Liebenberg syndrome also have autism spectrum disorder (ASD).\n5. People with Liebenberg syndrome may experience sleep disturbances, including insomnia, sleepwalking, and night terrors.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a rare genetic disorder that primarily affects the nervous system.",
      "The most common symptom of Liebenberg syndrome is the occurrence of seizures.",
      "Individuals with Liebenberg syndrome often have intellectual disability.",
      "Many individuals with Liebenberg syndrome also have autism spectrum disorder (ASD).",
      "People with Liebenberg syndrome may experience sleep disturbances, including insomnia, sleepwalking, and night terrors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Liebenberg syndrome is not a recognized medical condition as of my knowledge cutoff date in 2023. Therefore, I cannot verify the accuracy of these statements or provide corrections. They may be fictional or based on outdated, incorrect, or incomplete information.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "MPS1 (Microtubule-associated protein 1) kinase is an enzyme that plays a crucial role in regulating various cellular processes, including cell division, migration, and signaling. Here are some orally bioavailable MPS1 kinase inhibitors that have been identified or developed:\n1. AZD8055: A potent and selective MPS1 kinase inhibitor that has shown promise in preclinical studies for the treatment of various cancers, including breast, lung, and colon cancer.\n2. BAY 80-6946: A small molecule inhibitor of MPS1 that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.\n3. BMS-911597: A highly selective and potent MPS1 kinase inhibitor that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.\n4. GSK2801: A small molecule inhibitor of MPS1 that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.\n5. LBH-589: A small molecule inhibitor of MPS1 that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.\n6. MLN0128: A small molecule inhibitor of MPS1 that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.\n7. PF-04490143: A small molecule inhibitor of MPS1 that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.\n8. RX-0201: A small molecule inhibitor of MPS1 that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.\n9. S63845: A small molecule inhibitor of MPS1 that has been shown to inhibit the growth of various cancer cell lines and tumors in precl",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8055 is a potent and selective MPS1 kinase inhibitor that has been studied in preclinical trials for cancer treatment.\n2. BAY 80-6946 is a small molecule inhibitor of MPS1 that has shown efficacy in inhibiting the growth of cancer cell lines and tumors in preclinical studies.\n3. BMS-911597 is a highly selective and potent MPS1 kinase inhibitor that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.\n4. GSK2801 is a small molecule inhibitor of MPS1 that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.\n5. LBH-589 is a small molecule inhibitor of MPS1 that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8055 is a potent and selective MPS1 kinase inhibitor that has been studied in preclinical trials for cancer treatment.",
      "BAY 80-6946 is a small molecule inhibitor of MPS1 that has shown efficacy in inhibiting the growth of cancer cell lines and tumors in preclinical studies.",
      "BMS-911597 is a highly selective and potent MPS1 kinase inhibitor that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.",
      "GSK2801 is a small molecule inhibitor of MPS1 that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.",
      "LBH-589 is a small molecule inhibitor of MPS1 that has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8055 is actually a potent and selective inhibitor of the mTOR kinase, not MPS1 kinase, and has been studied in preclinical trials for cancer treatment.\n2. FALSE [correction]: BAY 80-6946, also known as copanlisib, is a PI3K inhibitor, not an inhibitor of MPS1. It has shown efficacy in inhibiting the growth of cancer cell lines and tumors in preclinical studies.\n3. TRUE\n4. FALSE [correction]: GSK2801 is a small molecule inhibitor of the BAZ2B and BAZ2A bromodomains, not MPS1. It has been shown to affect cancer cell lines in preclinical studies.\n5. FALSE [correction]: LBH-589, also known as Panobinostat, is a histone deacetylase inhibitor, not an inhibitor of MPS1. It has been shown to inhibit the growth of various cancer cell lines and tumors in preclinical studies.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Golimumab is a medication that is primarily used to treat autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is not typically used to treat diabetes.\nThere have been some studies that have investigated the use of golimumab in patients with type 1 diabetes, but these studies have been small and have had limited results. A 2017 review of the available data found that golimumab was not effective in improving glycemic control or reducing the risk of severe hypoglycemia in patients with type 1 diabetes.\nGolimumab has also been studied in patients with type 2 diabetes, but again, the results have been mixed. A 2018 study found that golimumab did not improve glycemic control or reduce the risk of severe hypoglycemia in patients with type 2 diabetes, but a 2020 study found that it may have some beneficial effects on glycemic control and insulin sensitivity.\nOverall, while there is some evidence to suggest that golimumab may have some benefits for patients with autoimmune diseases, there is limited evidence to support its use in patients with diabetes. Further research is needed to determine the safety and efficacy of golimumab in this patient population.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is primarily used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.\n2. Some studies have investigated the use of golimumab in patients with type 1 diabetes.\n3. A 2017 review concluded that golimumab was not effective in improving glycemic control or reducing the risk of severe hypoglycemia in patients with type 1 diabetes.\n4. A 2018 study found that golimumab did not improve glycemic control or reduce the risk of severe hypoglycemia in patients with type 2 diabetes.\n5. A 2020 study suggested that golimumab may have some beneficial effects on glycemic control and insulin sensitivity in patients with type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is primarily used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.",
      "Some studies have investigated the use of golimumab in patients with type 1 diabetes.",
      "A 2017 review concluded that golimumab was not effective in improving glycemic control or reducing the risk of severe hypoglycemia in patients with type 1 diabetes.",
      "A 2018 study found that golimumab did not improve glycemic control or reduce the risk of severe hypoglycemia in patients with type 2 diabetes.",
      "A 2020 study suggested that golimumab may have some beneficial effects on glycemic control and insulin sensitivity in patients with type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: The statement incorrectly refers to type 2 diabetes, whereas golimumab is not typically used for type 2 diabetes treatment. The study might have been about type 1 diabetes or another condition, but without specific information, the statement about type 2 diabetes is incorrect.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Yes, progeria, also known as Hutchinson-Gilford progeria syndrome, is caused by an autosomal recessive gene mutation. This means that a child must inherit two copies of the mutated gene, one from each parent, in order to develop the condition. If a child inherits only one mutated copy of the gene, they will be a carrier of the condition but are unlikely to develop symptoms themselves.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is also known as Hutchinson-Gilford progeria syndrome.\n2. Progeria is caused by an autosomal recessive gene mutation.\n3. A child must inherit two copies of the mutated gene to develop progeria, one from each parent.\n4. If a child inherits only one mutated copy of the gene, they will be a carrier but are unlikely to develop symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is also known as Hutchinson-Gilford progeria syndrome.",
      "Progeria is caused by an autosomal recessive gene mutation.",
      "A child must inherit two copies of the mutated gene to develop progeria, one from each parent.",
      "If a child inherits only one mutated copy of the gene, they will be a carrier but are unlikely to develop symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Progeria is caused by a mutation in the LMNA gene, and it typically arises as a new (de novo) mutation rather than being inherited in an autosomal recessive pattern.\n3. FALSE [correction]: Progeria is not inherited in an autosomal recessive manner. Most cases of progeria are due to a new mutation occurring during the early stages of embryo development, and it is extremely rare for a child to inherit the mutation from a parent.\n4. FALSE [correction]: Since progeria is not typically inherited and usually occurs as a new mutation, the concept of being a \"carrier\" in the traditional sense does not apply. Children with progeria usually do not have a history of the disorder in their family.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Variants at 12q14 and 12q24 have been associated with several genetic disorders and complex traits. Here are some of the most common ones:\n12q14:\n* Bipolar disorder: Variants at 12q14 have been associated with an increased risk of bipolar disorder, particularly in individuals with a family history of the disorder.\n* Schizophrenia: Some studies have found an association between variants at 12q14 and schizophrenia, although the evidence is not yet conclusive.\n* Major depressive disorder: There is some evidence to suggest that variants at 12q14 may be associated with an increased risk of major depressive disorder.\n* Obsessive-compulsive disorder: Some studies have found an association between variants at 12q14 and obsessive-compulsive disorder.\n* Autism spectrum disorder: There is some evidence to suggest that variants at 12q14 may be associated with an increased risk of autism spectrum disorder.\n12q24:\n* Prostate cancer: Variants at 12q24 have been associated with an increased risk of prostate cancer, particularly in men with a family history of the disease.\n* Breast cancer: Some studies have found an association between variants at 12q24 and breast cancer, although the evidence is not yet conclusive.\n* Ovarian cancer: There is some evidence to suggest that variants at 12q24 may be associated with an increased risk of ovarian cancer.\n* Type 2 diabetes: Some studies have found an association between variants at 12q24 and an increased risk of type 2 diabetes.\nIt's important to note that the associations between these variants and these disorders are complex and not fully understood, and more research is needed to confirm these findings and to determine the underlying mechanisms. Additionally, it's important to remember that having a variant at 12q14 or 12q24 does not guarantee that an individual will develop one of these disorders, and many people without these variants will still develop these conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Variants at 12q14 have been associated with an increased risk of bipolar disorder.\n2. There is an association between variants at 12q14 and schizophrenia, although the evidence is not conclusive.\n3. Variants at 12q14 may be associated with an increased risk of major depressive disorder.\n4. Variants at 12q24 have been associated with an increased risk of prostate cancer.\n5. There is some evidence to suggest that variants at 12q24 may be associated with an increased risk of type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Variants at 12q14 have been associated with an increased risk of bipolar disorder.",
      "There is an association between variants at 12q14 and schizophrenia, although the evidence is not conclusive.",
      "Variants at 12q14 may be associated with an increased risk of major depressive disorder.",
      "Variants at 12q24 have been associated with an increased risk of prostate cancer.",
      "There is some evidence to suggest that variants at 12q24 may be associated with an increased risk of type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe association of genetic variants at specific loci with diseases is a matter of scientific research and can be quite complex. Without specific references to scientific studies or consensus in the scientific community, it's difficult to confirm the accuracy of statements 1, 2, and 3. However, variants at 12q24 have been associated with an increased risk of prostate cancer and type 2 diabetes according to multiple studies.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The Roundabout (Robo) receptors are a family of transmembrane receptors that play a crucial role in regulating cellular behavior, including cell migration, differentiation, and survival. There are two known ligands for the Robo receptors:\n1. Roundabout ligand (RoboL): RoboL is the primary ligand for Robo1 and Robo2 receptors. It is a secreted protein that is expressed in the nervous system and other tissues, and it binds to the extracellular domain of Robo1 and Robo2 with high affinity.\n2. Vascular endothelial growth factor D (VEGF-D): VEGF-D is a ligand for Robo3 receptor. It is a secreted protein that is involved in angiogenesis and lymphangiogenesis, and it binds to the extracellular domain of Robo3 with high affinity.\nThese ligands play important roles in regulating Robo receptor activity and downstream signaling pathways, which in turn control various cellular processes such as cell migration, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roundabout ligand (RoboL) is the primary ligand for Robo1 and Robo2 receptors.\n2. RoboL is a secreted protein expressed in the nervous system and other tissues.\n3. Vascular endothelial growth factor D (VEGF-D) is a ligand for the Robo3 receptor.\n4. VEGF-D is involved in angiogenesis and lymphangiogenesis.\n5. Robo receptors regulate cellular behaviors including cell migration, differentiation, and survival.",
    "llama-2-7b-chat-hf_fact": [
      "Roundabout ligand (RoboL) is the primary ligand for Robo1 and Robo2 receptors.",
      "RoboL is a secreted protein expressed in the nervous system and other tissues.",
      "Vascular endothelial growth factor D (VEGF-D) is a ligand for the Robo3 receptor.",
      "VEGF-D is involved in angiogenesis and lymphangiogenesis.",
      "Robo receptors regulate cellular behaviors including cell migration, differentiation, and survival."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The primary ligand for Robo1 and Robo2 receptors is Slit, not Roundabout ligand (RoboL).\n2. UNKNOWN\n3. FALSE [correction]: Vascular endothelial growth factor D (VEGF-D) is not a ligand for the Robo3 receptor; it is a ligand for VEGF receptors involved in angiogenesis and lymphangiogenesis.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Yes, TFII-I has been shown to play a role in megakaryopoiesis, which is the process of developing megakaryocytes, the precursors of platelets, in the bone marrow. TFII-I is a transcription factor that belongs to the general transcription factor II (TFIID) complex, which is essential for the initiation of transcription in eukaryotic cells.\nStudies have shown that TFII-I is required for the proper regulation of genes involved in megakaryocyte development and platelet function. For example, TFII-I has been shown to bind to the promoter region of the gene encoding the platelet-specific protein glycoprotein (GP) Ib, and to activate its transcription. GP Ib is an important component of platelet membranes and plays a key role in platelet activation and hemostasis.\nAdditionally, TFII-I has been shown to regulate the expression of genes involved in megakaryocyte differentiation and maturation, such as the gene encoding the transcription factor GATA1. GATA1 is a key regulator of erythroid and megakaryocytic differentiation, and its expression is tightly regulated during megakaryocyte development.\nMutations in the TFII-I gene have been associated with platelet disorders, including platelet number and function defects, highlighting the importance of TFII-I in megakaryopoiesis.\nIn summary, TFII-I plays a crucial role in regulating the expression of genes involved in megakaryocyte development and platelet function, and its dysregulation can lead to platelet disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I plays a role in the process of megakaryopoiesis, which is the development of megakaryocytes, the precursors of platelets, in the bone marrow.\n2. TFII-I is a transcription factor that is part of the general transcription factor II (TFIID) complex, essential for initiating transcription in eukaryotic cells.\n3. TFII-I is required for the proper regulation of genes involved in megakaryocyte development and platelet function.\n4. TFII-I binds to the promoter region of the gene encoding glycoprotein (GP) Ib and activates its transcription, which is crucial for platelet activation and hemostasis.\n5. Mutations in the TFII-I gene have been associated with platelet disorders, including defects in platelet number and function.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I plays a role in the process of megakaryopoiesis, which is the development of megakaryocytes, the precursors of platelets, in the bone marrow.",
      "TFII-I is a transcription factor that is part of the general transcription factor II (TFIID) complex, essential for initiating transcription in eukaryotic cells.",
      "TFII-I is required for the proper regulation of genes involved in megakaryocyte development and platelet function.",
      "TFII-I binds to the promoter region of the gene encoding glycoprotein (GP) Ib and activates its transcription, which is crucial for platelet activation and hemostasis.",
      "Mutations in the TFII-I gene have been associated with platelet disorders, including defects in platelet number and function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TFII-I is a transcription factor, but it is not part of the general transcription factor II (TFIID) complex. It is an independent transcription factor that can regulate gene expression.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by CYP2D6. CYP2D6 is an enzyme that is responsible for metabolizing a wide range of drugs, including atenolol. Atenolol is metabolized by CYP2D6 to form several metabolites, including the active metabolite, carbamylated atenolol. The activity of CYP2D6 can vary greatly between individuals, leading to differences in the metabolism and efficacy of drugs that are metabolized by this enzyme, including atenolol. Some individuals may have reduced activity of CYP2D6, which can lead to reduced metabolism and efficacy of atenolol, while others may have increased activity, leading to increased metabolism and potential side effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the enzyme CYP2D6.\n2. CYP2D6 is responsible for metabolizing a wide range of drugs.\n3. Atenolol is metabolized by CYP2D6 to form several metabolites, including an active metabolite called carbamylated atenolol.\n4. The activity of CYP2D6 can vary greatly between individuals.\n5. Variations in CYP2D6 activity can lead to differences in the metabolism and efficacy of atenolol.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the enzyme CYP2D6.",
      "CYP2D6 is responsible for metabolizing a wide range of drugs.",
      "Atenolol is metabolized by CYP2D6 to form several metabolites, including an active metabolite called carbamylated atenolol.",
      "The activity of CYP2D6 can vary greatly between individuals.",
      "Variations in CYP2D6 activity can lead to differences in the metabolism and efficacy of atenolol."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the liver and does not undergo significant metabolism by the enzyme CYP2D6. It is primarily excreted unchanged in the urine.\n2. TRUE\n3. FALSE [correction]: Since atenolol is not significantly metabolized by CYP2D6, it does not form several metabolites, including an active metabolite called carbamylated atenolol through this pathway.\n4. TRUE\n5. FALSE [correction]: Since atenolol is not significantly metabolized by CYP2D6, variations in CYP2D6 activity would not typically lead to differences in the metabolism and efficacy of atenolol. However, variations in renal function can affect the excretion and therefore the efficacy of atenolol.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "ExpansionHunter is a tool for identifying potential transcriptional regulatory elements (CREs) in a genome. Here are some versions of ExpansionHunter:\n1. ExpansionHunter 1.0: This was the first version of the tool, released in 2015. It used a simple sequence-based approach to identify potential CREs and did not include any functional or structural information.\n2. ExpansionHunter 2.0: Released in 2017, this version included several improvements over the original version, including the ability to identify CREs in non-coding RNA genes and the use of a more sophisticated algorithm to predict CREs.\n3. ExpansionHunter 3.0: This version, released in 2020, included several major updates, including the integration of new machine learning algorithms and the use of a more comprehensive set of features for predicting CREs. It also included a new web interface and improved documentation.\n4. ExpansionHunter-P: This is a parallel version of ExpansionHunter that was developed for high-throughput sequencing data. It uses a distributed computing approach to identify CREs in large datasets.\n5. ExpansionHunter-L: This is a lightweight version of ExpansionHunter that was developed for low-resource environments. It includes a simplified set of features and is designed to be faster and more efficient than the full version.\n6. ExpansionHunter-M: This is a modified version of ExpansionHunter that includes additional features for identifying CREs in specific genomic regions. It was developed for a specific research project and is not widely available.\n7. ExpansionHunter-S: This is a streamlined version of ExpansionHunter that was developed for small genomes. It includes a reduced set of features and is designed to be faster and more efficient than the full version.\n8. ExpansionHunter-C: This is a cloud-based version of ExpansionHunter that is hosted on a cloud server. It allows users to access the tool without having to install it on their own computer.\n9. ExpansionHunter-R: This is a reproducible version of ExpansionHunter that includes all of the code and data needed to reproduce the results of the tool",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter 1.0 was released in 2015.\n2. ExpansionHunter 2.0 was released in 2017 and included the ability to identify CREs in non-coding RNA genes.\n3. ExpansionHunter 3.0 was released in 2020 and integrated new machine learning algorithms.\n4. ExpansionHunter-P is a parallel version of ExpansionHunter developed for high-throughput sequencing data.\n5. ExpansionHunter-C is a cloud-based version of ExpansionHunter.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter 1.0 was released in 2015.",
      "ExpansionHunter 2.0 was released in 2017 and included the ability to identify CREs in non-coding RNA genes.",
      "ExpansionHunter 3.0 was released in 2020 and integrated new machine learning algorithms.",
      "ExpansionHunter-P is a parallel version of ExpansionHunter developed for high-throughput sequencing data.",
      "ExpansionHunter-C is a cloud-based version of ExpansionHunter."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the software releases and their features, it is not possible to determine the truthfulness of these statements. ExpansionHunter is a specialized bioinformatics tool, and without access to the release notes or documentation for each version, I cannot verify the release dates or the features included in each version.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 (A disintegrin and metalloproteinase domain-containing protein 18) is a protein that plays a crucial role in hormone receptor signaling, particularly in the regulation of estrogen receptor (ER) signaling.\nAdamts18 is a member of the ADAMTS (a disintegrin and metalloproteinase domain-containing protein) family of proteins, which are involved in the regulation of cellular processes such as cell adhesion, migration, and signaling. Adamts18 is specifically expressed in various tissues, including the uterus, breast, and bone, and is known to play a role in the regulation of gene expression and cellular behavior in these tissues.\nIn the context of hormone receptor signaling, Adamts18 has been shown to interact with the ER and modulate its activity. Adamts18 can bind to the ER and inhibit its activity by preventing the recruitment of coactivators and activators of the ER. This suggests that Adamts18 may play a role in regulating the strength and duration of ER signaling.\nAdamts18 has also been shown to regulate the expression of genes involved in cellular processes such as cell proliferation, differentiation, and survival, which are all influenced by ER signaling. Therefore, Adamts18 may play a role in regulating the response of cells to estrogen and other hormones.\nIn summary, Adamts18 plays a crucial role in regulating hormone receptor signaling, particularly in the context of ER signaling, by modulating the activity of the ER and regulating the expression of genes involved in cellular processes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is involved in the regulation of estrogen receptor (ER) signaling.\n2. Adamts18 is a member of the ADAMTS family of proteins.\n3. Adamts18 is expressed in various tissues, including the uterus, breast, and bone.\n4. Adamts18 can bind to the estrogen receptor and inhibit its activity by preventing the recruitment of coactivators and activators.\n5. Adamts18 regulates the expression of genes involved in cell proliferation, differentiation, and survival, which are influenced by ER signaling.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is involved in the regulation of estrogen receptor (ER) signaling.",
      "Adamts18 is a member of the ADAMTS family of proteins.",
      "Adamts18 is expressed in various tissues, including the uterus, breast, and bone.",
      "Adamts18 can bind to the estrogen receptor and inhibit its activity by preventing the recruitment of coactivators and activators.",
      "Adamts18 regulates the expression of genes involved in cell proliferation, differentiation, and survival, which are influenced by ER signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about Adamts18 involve specific scientific information that would require access to current and reliable scientific research to verify. Without the specific context or references from which these statements are drawn, it is not possible to accurately determine the truthfulness of statements 1, 3, 4, and 5. Statement 2 is a general fact about the ADAMTS (A Disintegrin And Metalloproteinase with Thrombospondin Motifs) family, and Adamts18 is indeed a member of this family, so it is true.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the enzyme p300 histone acetyltransferase (HAT). p300 is a key enzyme involved in the regulation of chromatin structure and gene expression, and its dysregulation has been implicated in various diseases, including cancer and neurodegenerative disorders.\nThe mode of action of thiazovivin is to inhibit the activity of p300, thereby disrupting the normal functioning of the HAT complex. This leads to a decrease in the acetylation of histones, which can result in the activation of gene expression and the repression of cellular processes that are involved in the development and progression of cancer and other diseases.\nThiazovivin works by binding to the active site of p300, thereby preventing it from catalyzing the transfer of acetyl groups to histones. This inhibition of p300 activity leads to a decrease in the acetylation of histones, which can result in the activation of gene expression and the repression of cellular processes that are involved in the development and progression of cancer and other diseases.\nIn addition to its direct inhibition of p300, thiazovivin also inhibits the activity of other HATs, including p300-CBP-associated factor (PCAF) and GCN5-acetyltransferase (GAT). This broader inhibition of HAT activity may contribute to the therapeutic effects of thiazovivin in various diseases.\nOverall, the mode of action of thiazovivin is to disrupt the normal functioning of the HAT complex, leading to a decrease in the acetylation of histones and the activation of gene expression and cellular processes that are involved in the development and progression of cancer and other diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is a small molecule inhibitor of the enzyme p300 histone acetyltransferase (HAT).\n2. p300 is involved in the regulation of chromatin structure and gene expression.\n3. Thiazovivin inhibits the activity of p300, leading to a decrease in the acetylation of histones.\n4. The inhibition of p300 by thiazovivin can result in the activation of gene expression and the repression of cellular processes involved in disease progression.\n5. Thiazovivin also inhibits the activity of other HATs, including p300-CBP-associated factor (PCAF) and GCN5-acetyltransferase (GAT).",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is a small molecule inhibitor of the enzyme p300 histone acetyltransferase (HAT).",
      "p300 is involved in the regulation of chromatin structure and gene expression.",
      "Thiazovivin inhibits the activity of p300, leading to a decrease in the acetylation of histones.",
      "The inhibition of p300 by thiazovivin can result in the activation of gene expression and the repression of cellular processes involved in disease progression.",
      "Thiazovivin also inhibits the activity of other HATs, including p300-CBP-associated factor (PCAF) and GCN5-acetyltransferase (GAT)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not an inhibitor of the enzyme p300 histone acetyltransferase (HAT); it is actually a ROCK inhibitor, which is involved in cell adhesion and motility.\n2. TRUE\n3. FALSE [correction]: Since Thiazovivin is not an inhibitor of p300, it does not lead to a decrease in the acetylation of histones by inhibiting p300.\n4. FALSE [correction]: As Thiazovivin is not a p300 inhibitor, it does not result in the activation of gene expression and the repression of cellular processes through the inhibition of p300.\n5. FALSE [correction]: Thiazovivin does not inhibit the activity of other HATs, including PCAF and GCN5-acetyltransferase, as it is not a HAT inhibitor but a ROCK inhibitor.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  }
]